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CHAPTER 1 
INTRODUCTION 
1.1  Antimicrobials 
Antibiotics have been variously defined as molecules created by a microbe, or more 
generally any organism, which are inhibitory towards another microbe’s or organism’s growth or 
replication.  The broader rubric, antimicrobials, encompasses any molecule that kills or inhibits 
the growth of microbes (bacteria or eukaraya) and whose origin need not be natural.  The 20th 
century saw a remarkable decline in mortality due to infectious disease.  The inception of this 
decline predates the discovery and use of antibiotics or vaccines indicating improvements in 
nutrition and sanitation due to western industrialization were the cause.1  However, a second 
down leg, beginning in 1937 with the discovery of sulfonamides, began a period (1938-1953) of 
four-fold decrease in infectious disease mortality.  This encompassed the mass use of the 
antibiotic penicillin derived from the mold Penicillium notatum in 1945 and the utilization of 
streptomycin against Mycobacterium tuberculosis infections, starting in 1944.2  Thus, the golden 
age of antimicrobial discovery dawned (Figure 1.1) and it was believed that the scourge of 
bacterial infectious disease would be eradicated in the near future.   
Antimicrobials are categorized by chemical structure.  As structure dictates function, 
groups with similar structures have similar effects on a given target molecule (Table 1.1).  The 
antimicrobial peptide (AMP) group is an exception of antimicrobials grouped on their 
fundamental molecular makeup, but whose structure and function vary from peptide to peptide.  
They will be discussed more in depth later.  Antimicrobials created by nature, which includes the 
progenitors of every major group except the fluoroquinolones, sulfonamides and oxazolidinones, 
target a small range of targets with the ribosome being the most common.  Below are 
summarized the more popular classes of antimicrobials that have been employed medically. 
2 
 
 
 
 
 
 
Figure 1.1:  Timeline of notable antibiotic development and the rise of resistance.  The golden 
age of antibiotic discovery (red line), between the years 1944-1972, encompassed the discovery 
and implementation of most antibiotic classes.  Antibiotics developed since 1972, with exception 
of linezolid and daptomycin, are derivatives of previously identified antibiotics. 
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Table 1.1:  Common therapeutic antibiotics classified by molecular structure. 
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1.1.1 Antimicrobial Targets 
1.1.1.1 Cell Wall 
1.1.1.1.1  β-lactams 
The β-lactams comprise one of the most popular and plentiful groups of antimicrobials 
including penicillin and related antibiotics, cephalosporins, carbapenems and monobactams 
(Figure 1.2). All members contain the β-lactam ring that mimics D-alanyl-D-alanine, the 
substrate of transpeptidases required for the production of peptidoglycan, an essential 
component of Gram-positive and Gram-negative cell walls.3  By inhibiting the expansion of the 
cell wall, β-lactams cause an imbalance between the environment and the intracellular pressure 
of the cell, inducing cell lysis. 
 
 
Figure 1.2:  Molecular structures of the β-lactam antibiotics.  The structures represent each 
sub-class of the β-lactams: ampicillin4 (penicillins), cefalexin5 (cephalosporins), imipenem6 
(carbapenems), and aztreonam7 (monobactams).  All sub-classes share the same β-lactam ring 
that mimics the structure of D-alanyl-D-alanine, an essential component of peptidoglycan. 
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1.1.1.1.2  Glycopeptides & Lipoglycopeptides 
As the name implies, glycopeptides, such as vancomycin (Figure 1.3), and their 
derivatives, the lipoglycopeptides8 consist of sugar-amino acid hybrids that inhibit the formation 
of peptidoglycan.  They bind to the terminal D-alanyl-D-alanine of the peptidoglycan precursors 
and block transpeptidases and transglycosylases from cross-linking them to neighboring 
molecules.9  This creates holes in the cell wall, similar to β-lactams, causing cell lysis. 
 
 
 
Figure 1.3:  The molecular structure of the glycopeptide, vancomycin,10 a non-ribosomally 
synthesized sugar-amino acid antibiotic that disrupts peptidoglycan synthesis by binding acyl-D-
alanyl-D-alanine. 
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1.1.1.1.3  Lipopeptides 
Lipopeptides, such as daptomycin (Figure 1.4), have a positive charge that displaces 
magnesium and calcium cations and bind lipid A, an outer membrane component11 of Gram-
negative bacteria.  This results in the increased permeability of the inner and outer membranes.  
Due to the nature of lipopeptides’ target, they only exhibit antimicrobial activity against Gram-
negative bacteria that possess outer membranes composed of lipopolysaccharides, including 
lipid A.12 
 
 
 
 
Figure 1.4:  The molecular structure of the lipopeptide, daptomycin,13 a non-ribosomally 
synthesized lipid-amino acid antibiotic that disrupts outer membrane integrity by binding lipid A. 
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1.1.1.2 Ribosome  
1.1.1.2.1  Tetracyclines 
Tetracycline (Figure 1.5) and structurally related antibiotics bind helices 31 and 34 of the 
16S rRNA of the 30S ribosomal subunit preventing the binding of new charged aminoacyl-
tRNAs to the A site during elongation of translation.14  
 
 
Figure 1.5:  Molecular structures of antibiotic classes that inhibit translation by binding the 16S 
rRNA of the 30S ribosomal subunit including streptomycin15 (aminoglycosides) and 
tetracycline16 (tetracyclines). 
 
1.1.1.2.2  Aminoglycosides 
Aminoglycosides are a large class of antibiotics with several generations of modified 
antimicrobials, including streptomycin (Figure 1.5), neomycin and kanamycin.  They bind to the 
tRNA acceptor site or A site of the 16S rRNA of the 30S ribosomal subunit interfering with 
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translation.17  They cause the ribosome to have a high error rate in amino acid incorporation, 
leading to mistranslated membrane proteins that increase permeability of the membrane, killing 
the bacterium.18 
 
1.1.1.2.3  Amphenicols 
Amphenicols are lipid-soluble molecules, containing phenylpropanoid components that 
bind to the peptidyl-transferase center of the 23S rRNA of the 50S ribosomal subunit inhibiting 
peptide elongation during translation.19; 20  Chloramphenicol (Figure 1.6.A) was the first and 
only amphenicol isolated from nature for use and has served as a template for the generation of 
other viable derivatives. 
 
 
 
 
Figure 1.6.A:  Molecular structures of antibiotic classes that inhibit translation by binding the 
23S rRNA of the 50S ribosomal subunit including chloramphenicol21 (amphenicols), 
erythromycin22 (macrolides, MLS), and clindamycin23 (lincosaminides, MLS). 
 
 
9 
 
 
 
1.1.1.2.4  Marcolides, Lincosaminides and Streptogramins (MLS) 
The chemical structures of the MLS antibiotics differ significantly, but they are often 
grouped together because they have similar binding sites, mechanisms of inhibition, and 
common resistance mechanisms.  Like amphenicols, macrolides, such as erythromycin, and 
lincosaminides, including clindamycin (Figure 1.6.A), bind to the 23S rRNA or the 50S 
ribosomal subunit in close proximity to the peptidyl transferase center and disrupt elongation by 
inhibiting peptide bond formation.24  They have a broad spectrum of activity and have been used 
heavily as antimicrobials of first recourse.  Streptogramins, such as quinupristin (Figure 1.6.B), 
also bind near the peptidyl transferase center but do not disrupt peptide bond formation.  
Instead, they block the tunnel through which nascent peptides exit the ribosome.  This stunts 
elongation as the ribosome stalls and cannot proceed down the mRNA.24 
 
 
Figure 1.6.B:  Molecular structures of antibiotic classes that inhibit translation by binding the 
23S rRNA of the 50S ribosomal subunit including quinupristin25 (streptogramins, MLS) and 
linezolid26 (oxazolidinones). 
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1.1.1.2.5  Oxazolidinones 
The wholly synthetic oxazolidinones were originally developed in 1978 but shelved due 
to toxicity concerns.27  In the past decade interest has been revitalized by the rise of 
antimicrobial resistance.  Oxazolidinones, such as linezolid (Figure 1.6.B), inhibit translation by 
a different mechanism than those previously described.  While they bind near the peptidyl 
transferase center of the 23S rRNA, a location they compete for binding with chloramphenicol 
and lincomycin, it appears that they sterically inhibit ribosome assembly during which the 50S 
subunit binds to the 30S subunit-mRNA complex, preventing the formation of the 70S initiation 
complex.28 
 
1.1.1.3  Miscellaneous 
1.1.1.3.1  Sulfonamides & Diaminopyrimidines 
Sulfonamides or sulpha drugs, another synthetic antibiotic class, were the first class to 
enjoy mass appeal for the treatment of a wide variety of bacterial infections.  Sulfadiazine 
(Figure 1.7), and related antibiotics, are named after the sulfonamide group that is the 
cornerstone of their ability to competitively inhibit dihydropteroate synthetase (DHPS), disrupting 
the cellular production of folate.29  Trimethoprim (Figure 1.7), a diaminopyrimidine, also blocks 
metabolism of folate, but, unlike sulfonamides, it inhibits the enzyme dihydrofolate reductase 
(DHFR).30 
 
1.1.1.3.2  Fluoroquinolones 
Fluoroquinolones, such as norflaxacin (Figure 1.7) are a completely synthetic 
antimicrobial class.3  They inhibit DNA gyrase, an enzyme responsible for separating DNA 
strands prior to DNA replication.  Fluoroquinolones bind the DNA gyrase-DNA complex 
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preventing further melting of the DNA helix and preventing the advance of the replication fork.  
The resultant inhibition of DNA replication leads to cell death.31 
 
 
Figure 1.7:  Molecular structures of antibiotics targeting various processes by binding different 
targets.  Sulfadiazine32 (sulfonamides) and trimethoprim33 (diaminopyrimidines) inhibit folate 
synthesis by targeting different enzymes (DHPS and DHFR, repectively) in the folate metabolic 
pathway.  Norfloxacin34 (fluoroquinolones) inhibits enzymes responsible for supercoiling 
chromosomal DNA, blocking DNA replication.  Rifampicin35 (rifamycin) inhibits RNA transcripting 
by targeting DNA-dependent RNA polymerase (RNAP). 
 
1.1.1.3.3  Rifamycins 
Rifamycins, including the antibiotic rifampicin (Figure 1.7), target another essential 
enzyme that differs radically from its eukaryotic counterparts, DNA-dependent RNA polymerase 
(RNAP).  Rifamycins bind to the β subunit of RNAP and sterically inhibit initiation of RNA 
transcription.3 
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1.1.2   Antimicrobial Phenotypes 
Chemistry is not the only way antimicrobials are classified.  The definition of 
antimicrobials dictates that they must stop cells from growing, but there are three phenotypes 
that equate to the disruption of reproduction and growth.  Phenotypes of antimicrobials can also 
depend on the treated microbe’s characteristics.  A common determinant is the cell envelope, 
for example, the phenotype of rifampicin is bactericidal against Gram-positive bacteria and 
bacteriostatic against Gram-negative bacteria.  The difference is believed to be due to 
differences in drug uptake, not rifampicin’s binding affinity.36 
 
1.1.2.1 Bactericidal    
A bactericidal agent causes the irreversible arrest of the reproduction or growth of a 
bacterial cell in which the removal of the antimicrobial does not alleviate the condition (Figure 
1.8).  Examples of bactericidal antimicrobials include the fluoroquinolones and the 
aminoglycosides. 
 
1.1.2.2 Bacteriostatic 
A bacteriostatic agent causes the reversible arrest of bacterial reproduction or growth 
(Figure 1.9).  Here, the process can be reversed if the antimicrobial’s concentration is not 
maintained at its minimum inhibitory concentration (MIC).  Bacteriostatic agents are equally 
efficient as antimicrobials as bactericidal when operating in conjunction with an unimpaired 
immune system that given time can clear an infection.37  Examples of bacteriostatic 
antimicrobials include the macrolides and sulfonamides. 
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Figure 1.8:  The effect of a bactericidal agent on a culture’s optical density and viable cell 
count.  The effects are irreversible. 
 
 
Figure 1.9:  The effect of a bacteriostatic agent on a culture’s optical density and viable cell 
count.  The effects are reversible.  Upon the removal of the bacteriostatic agent growth of the 
culture resumes. 
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1.1.2.3 Bacteriolytic 
This phenotype is typically related to the disruption of cell wall synthesis or membrane 
integrity in both Gram-positive and Gram-negative cells leading to instability between the 
environment’s pressure and that of the interior of the cell (Figure 1.10).  This causes the cell to 
lyse.  Lysis can be elicited by the all sub-classes of the β-lactams. 
 
 
Figure 1.10:  The effect of a bacteriolytic agent on a culture’s optical density and viable cell 
count.  The reduction in optical density correlates to the dissolution of whole cells resulting in 
less scattering of light. 
 
1.2  Antimicrobial Resistance 
Unfortunately, a pathogen’s persistence is not so easily extinguished.  By the late 1930’s 
resistance to the sulfonamides was reported and in 1940, two years before its mass production, 
in what must have been a disheartening development, resistance to penicillin via the first 
human-observed penicillinase was discovered.38  Flash forward to the present and we find 
ourselves increasingly in the world of our grandfathers, surrounded by ‘superbugs,’ bacteria that 
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have become resistant to multiple antimicrobials and threaten to overwhelm the medical 
industry.  A total of $26.5 billion was spent on antimicrobials in 2008 compared to the market 
leading cardiovascular drugs which earned $95 billion.39 The market is not small, yet the cost of 
research and development and the loss of sales due to antimicrobial resistance cannibalize any 
revenues making the pharmaceutical industry skittish.40  In 2002 it is estimated that there were 
1.7 million hospital-acquired infections (HAIs) of which 99,000 were fatal.41  Compared to 2008 
morbidity statistics, HAIs would be the 6th leading cause of death in the United States.42  In 
2006-2007 50% of the HAI Staphylococcus aureus infections were methicillin resistant and 
56.5% of Enterococcus faecium were vancomycin resistant.43  The International Nosocomial 
Infection Control Consortium, a worldwide HAI surveillance group demonstrates that resistance 
rates are even higher in the developing world with a 50% greater incidence of methicillin-
resistant S. aureus (MRSA).44   
 
1.2.1 Gram-negative Bacteria 
Resistance varies from species to species.  Gram-positive and Gram-negative bacteria 
are two large branches of bacteria distinguished primarily on the structure of their cell 
envelopes.  Gram-negative bacteria (including such pathogens and opportunists as Escherichia 
coli, Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumonia) have more 
complex cell envelopes composed of a small peptidoglycan layer and an outer membrane of 
lipopolysaccharides (Figures 1.11.A-B).45  The outer membrane decreases the overall 
permeability of the cell for extracellular molecules including antimicrobials.  This imbues Gram-
negative cells an innate resistance to hydrophobic antimicrobials (Figure 1.12). 46; 47; 48 
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Figures 1.11.A-B:  Comparison of the cell walls of Gram-negative (A) and Gram-positive (B) 
bacteria.  Gram-negative cell walls are composed of three parts: the inner membrane, the 
periplasm (including the peptidoglycan) and the outer membrane that decreases the 
permeability of hydrophobic antimicrobials.  Gram-positive cell walls, however, have no outer 
membrane and a greater peptidoglycan component making them more sensitive to antibiotics 
due to increased permeability.  
A 
B 
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The spread of MRSA49 has garnered the attention of the pharmaceutical industry costing 
huge sums of money and numerous man-hours of research.39  While the industry was busying 
itself with tepid results on MRSA, they left the backdoor open for Gram-negative opportunists.50  
Roughly 70% of intensive care unit infections are attributed to Gram-negative bacteria.51  And 
Gram-negative opportunists such as P. aeruginosa, A. baumannii, and members of the 
Enterobacteriaceae are the dominating cause of hospital-acquired pneumonia,52 infecting 10-
20% of all patients on ventilators over 48 hours.51  While there has been a connection between 
the rise of hospital-acquired infections and the cleanliness of hospitals,53  the prevalence of 
antimicrobial-resistance among Gram-negative bacteria has contributed enormously.  In recent 
surveys on the prevalence of resistance by the National Healthcare Safety Network it was 
reported that notable increases in the representation of multi-drug resistant (MDR) organisms in 
nosocomial infections caused by Gram-positive MRSA and E. faecium accounted for 8 and 4%, 
respectively, while Gram-negatives carbapenem-resistant Pseudomonas aeruginosa accounted 
for 1%, and extended-spectrum cephalosporin-resistant Klebsiella pneumonia 1% among a host 
of others comprising an additional 2%.43  Thus, infections due to MDR Gram-negative 
organisms comprise 33% of all MDR infections.  The pharmaceutical pipeline for therapeutics 
against the most problematic MDR Gram-negative organisms, such as P. aeruginosa, A. 
baumannii, K. pneumoniae, and Stenotrophomonas maltophilia, has been reduced to rehashed 
antimicrobials with limited prospects for new developments.54  The appearance of carbapenem–
resistant K. pneumoniae (CRKP)55 is causing alarm similar to the advent of MRSA, especially 
after the recent dissemination of resistance to E. coli.56  Thus, there is a dire need for new 
antimicrobials that can target Gram-negative pathogens.57 
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1.2.2 Mechanisms 
Antimicrobial resistance has manifested in several disparate ways in bacterial 
pathogens.  This collection of resistance mechanisms has recently been labeled the resistome58; 
59; 60 to represent the fluidity that exists between the resistant and the susceptible.  Resistance 
mechanisms generally fall into five categories. 
 
Figure 1.12:  Common antibiotic resistance mechanisms including A) antibiotic modification via 
an enzyme, B) target modification via an enzyme, C) non-permeability of the cell wall, D) 
lowering of antibiotic intracellular concentration via efflux pumps, and E) enzymatic degradation. 
 
1.2.2.1 Target Modification 
Target modification resistance comes in two varieties: 1) The spontaneous mutation of 
the target to reduce susceptibility by destabilizing the interaction with the antimicrobial while 
maintaining some necessary level of target function61 and 2) the enlistment of a third party, 
typically an enzyme, to modify the target, lowering its susceptibility to the antimicrobial.62  There 
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are numerous examples of each and both can exist at the same time to increase resistance 
levels in one bacterium.  It has been observed that mutation resistance can exert a high fitness 
cost on the host63 but that it can be countered by a third party modification in the resistome.64 
 
1.2.2.1.1 Mutation 
Spontaneous mutation is a classic ribosome target resistance mechanism, but it has 
been observed with other targets as well.  The mutation of G2032 in the 23S rRNA in E. coli to 
an A, U or C confers oxazolidinone resistance.65  Or similarly, mutations proximal to the peptidyl 
transferase center in Mycobacterium smegmatis conferred cross-resistance to chloramphenicol 
and clindamycin.66  Linezolid resistance is facilitated by the P site mutation of position 2576 and 
positions 2032 and 2447 near the A site in the 23S rRNA.67  Macrolide resistance has arisen 
from mutations in the 23S rRNA at position A2058 and its neighboring bases67 as well as 
mutations in ribosomal proteins L4 and L22 of the large subunit in Streptococcus pneumoniae68 
and E. coli.69  Aminoglycoside resistance is frequently due to mutations in the 16S ribosomal 
protein S1270 or mutations in 16S rRNA at the A site.67   
Fluoroquinolones are negated in a phylum-specific manner.  They target both DNA 
gyrase and topoisomerase IV and prevent their function, but in Gram-negative bacteria 
resistance is associated with mutations of the GyrA subunit of DNA gyrase, while in Gram-
positive bacteria resistance is conferred by mutations in topoisomerase IV.31  Rifampicin targets 
the β-subunit of DNA dependent RNA polymerase.  It is commonly used in the treatment of M. 
tuberculosis in combination with other antimicrobials due to a variety of point mutations, 
deletions and insertions in a 100 base pair region that can give rise to resistance.71  A single 
amino acid substitution in the dhfr gene encoding dihydrofolate reductase renders trimethoprim 
ineffective.67  Sulfonamide resistance is brought about by numerous mutations to the target 
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enzyme dihydropteroate synthase.72  Radical changes in the target, as is the case with 
sulfonamide resistance, cannot occur by spontaneous mutation requiring horizontal gene 
transfer. 
 
1.2.2.1.2 Post-transcriptional Modification 
Another method of target modification, commonly observed with ribosome-targeting 
antimicrobials is post-transcriptional modification by an enzyme (Figure 1.12).  In clinical 
isolates of S. aureus the enzyme ErmC N-methyltransferase specifically methylates residue 
A2058 of the 23S ribosomal subunit preventing the binding of the macrolide, lincosamide and 
strepogramin B (MLS) antibiotics, preserving ribosome function.69  The Cfr rRNA 
methyltransferase, which was recently transferred to S. aureus and E. coli, casts a much larger 
net than ErmC.  Its methylation of residue A2503 near the peptidyl transferase center of the 23S 
rRNA negates the efficacy of amphenicols, lincosamides, oxazolidinones, pleuromutilins and 
streptogramin A antibiotics.73  Cfr rRNA methyltransferase is the most efficacious methylase, 
successfully negating five chemically disparate classes of antimicrobials.   
Lipopeptide resistance has arisen in Gram-negative bacteria11 via alterations in the outer 
membrane.  Specifically, 4-amino-4-deoxy-L-arabinose is added to a phosphate group on lipid 
A, a member of the LPS moiety.  The modification increases the charge of lipid A thereby 
repulsing the positively-charged lipopeptides.74  Glycopeptide resistance, long feared with 
vancomycin occupying the vaunted ‘antimicrobial of last resort’ status, has also come to pass.  
Initially, vancomycin susceptibility was observed to be lessened in isolates termed vancomycin-
intermediate S. aureus (GISA) whose cell walls were notably thicker than standard S. aureus 
strains and contained more binding sites for vancomycin.75  It was shown that this phenotype 
trapped vancomycin preventing it from reaching its target in the peptidoglycan.76  Vancomycin 
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resistance has arisen in E. faecium and E. faecalis and recently disseminated to S. aureus.  
Gene clusters, VanA and VanB, encode for enzymes that alter the normal peptidoglycan 
component D-alanyl-D-alanine to D-alanyl-D-lactate which has a much lower binding affinity for 
the glcopeptides.77 
In 1961 the first methicillin-resistant S. aureus isolate was identified in the United 
Kingdom.78  The mecA gene, encoding PBP2a, was found to be the culprit maintaining integrity 
of staphylococcal cell wall synthesis in the presence of the β-lactam methicillin.79  PBP2a 
disrupts the ability of β-lactam antibiotics to modify covalently the active site serine residue by 
lowering the rate of acetylation and increasing the rate of dissociation.80  
 
1.2.2.2 Target Protection 
An uncommon method of antimicrobial resistance is illustrated in the panoply of 
tetracycline resistance mechanisms.  In the intestinal pathogen Campylobacter jejuni a protein, 
TetO,81 a homologue of other numerous proteins thought to fulfill the same purpose,82 belongs 
to a group called ribosomal protection proteins.  It has been shown that TetO’s binding to the 
50S ribosomal subunit during elongation causes a conformational change that may be 
responsible for removing any bound tetracycline that may have been inhibiting translation.83 
Another example is the curious case of the protein QnrA.  Resistance to quinolones, 
high-level to nalidixic acid and low-level to other fluoroquinolones, is mediated by QnrA.  The 
protein is part of the a pentapeptide repeat family that includes the resistance protein, McbG, 
utilized by producers of the antimicrobial peptide microcin B17 that targets DNA gyrase and 
topoisomerase IV.84 The mechanism is not fully understood, but studies show that QnrA is able 
to bind DNA gyrase and topoisomerase IV before the enzymes form a complex with DNA 
suggesting target protection.85   
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1.2.2.3 Efflux Pumps 
First associated with tetracycline resistance in E. coli, efflux pumps were the last type of 
general resistance mechanism to be discovered.86  Through efflux, the pumps lower the 
concentration of the antibiotic below the minimal level for inhibition (Figure 1.12). Found 
throughout a variety of species, including Gram-positive and Gram-negative bacteria, it is more 
prevalent and pervasive in MDR Gram-negative species87 greatly contributing to the 
consternation over MDR P. aeruginosa88 and A. baumannii.89  Pumps can be antibiotic-specific 
(e.g. tetracycline), class-specific (e.g. marcolides) or capable of removing multiple antibiotic 
classes and have been broken into five classes based on homology including 1) the major 
facilitator (MF) superfamily, 2) the ATP binding cassette (ABC) family, 3) the resistance-
nodulation-division (RND) family, 4) the small multi-drug resistance (SMR) family, and 5) the 
multidrug and toxic compound extrusion (MATE) family.90  The RND family, represented by 
AcrAB-TolC pump complex in E. coli, provides multidrug resistance to numerous Gram-negative 
bacteria.91  It is a two protein complex with AcrAB spanning the inner membrane and TolC the 
outer membrane.39  It and its homologues in numerous other Gram-negative bacteria confer 
resistance to fluoroquinolones,92 macrolides,93 lincosamides, tetracyclines, β-lactams, 
aminoglycosides, oxazolidinones, and biocides such as silver, triclosan and quaternary 
ammonium compound (QAC).91  The select permeability of the LPS outer membrane 
concomitant with the pumps provides higher levels of resistance to highly pump-encoding 
Gram-negative bacteria P. aeruginosa and E. coli.39 
 
1.2.2.4 Antimicrobial Modification 
An efficient method of resistance is the production of enzymes capable of modifying and 
inactivating antibiotics.94  Two classes of modification have been observed: hydrolysis to disrupt 
critical bonds and transfer of a foreign moiety that lowers the binding affinity of the antibiotic for 
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its target (Figure 1.12).95  The first class is popularly represented by the penicillinases or β-
lactamases96 that inactivate the penicillin and cephalosporin classes of antibiotics.97  The β-
lactamases are broken into two major groups, serine38 and metallo-β-lactamases,98 that use an 
active site of serine or zinc to catalyze breakage of the β-lactam ring.  Moiety transferases serve 
metabolic processes in all cells and probably gave rise to the second class of modifying 
enzymes60 making them the most diverse and numerous group of resistance enzymes.95  
Acetylation of chloramphenicol by chloramphenicol acetyltransferases99 occurs across Gram-
negative and Gram-positive bacteria while the VatA-E enzymes confer resistance to 
streptogramin A100 in several Gram-positive bacteria by negating binding to the ribosome.  
Acetyltransferases use the naturally high, intracellular levels of acetyl-CoA as the acetyl group 
source.  Fosfomycin is an antibiotic exhibiting two different transferases, FosA and FosB, which 
bind glutathione and thiol groups respectively to break the antibiotic’s ring structure.101  
Rifampicin is the RNA polymerase inhibiting antibiotic used extensively in the treatment of M. 
tuberculosis infections.  Rifampin ADP-ribosyltransferase (ARR) covalently attaches an ADP 
ribosyl group to rifampicin, inactivating it.102 
Aminoglycosides are a large group of translation inhibiting antibiotics that bind to the 
16S ribosomal subunit.  Their use by environmental bacteria and heavy use by humans has led 
to a large diversity and large net of dissemination of aminoglycoside-modifying enzymes 
(AMEs).  These are composed of three groups: ATP/GTP-dependent aminoglycoside 
phosphotransferases (APHs), ATP-dependent aminoglycoside nucleotidyltransferases (ANTs), 
and acetyl-CoA-dependent aminoglycoside acetyltransferases (AACs) which are similar to the 
acetyltransferases discussed above.103  APHs are ancestors of kinases,60 transferring 
phosphates from nucleotide triphphosphates like ATP to aminoglycosides.  APH(3’)-IIIa is a 
commonly studied APH in E. faecalis104 conferring resistance to most aminoglycosides by 
phosphorylating the 3’ hydroxyl group.105  Only aminoglycosides lacking a 3’ hydroxyl group, 
such as amikacin, are not substrates.106  Marcolide phosphotransferases (MPHs) are a related 
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class of enzymes that only utilize GTP as a phosphate source to modify macrolide antibiotics.107  
ANTs are the smallest class of aminoglycoside inactivating enzymes but are clinically relevant 
due to their high dissemination throughout pathogenic bacteria.   They are able to inactivate 
both gentamicin and tobramycin, clinically preferred antibiotics,108 by covalently attaching the 
NMP group of an NTP.  Due to intracellular concentrations this tends to be an adenyl group.  
Similar to the ANTs, LinA and LinB are two nucleotidyltransferases that inactivate their target 
through adenylation.  They are responsible for the inactivation of the lincosamide class of 
antibiotics including clindamycin that had recently gained attention as a treatment for MRSA.109 
 
1.2.2.5 Others 
Survival in the presence of antimicrobials has selected for the development and 
transmission of the mechanisms above, but generally resistance begins with intermediary 
susceptibility, a state of slight resistance, which in a low concentration environment can lead to 
the selection of higher resistance.  The innate resistance of species or entire phyla, such as 
Gram-negative bacteria, has been discussed above, but there are alternative methods of 
achieving intermediary levels of resistance.  The deletion of porins, outer membrane proteins 
(OMPs) in Gram-negative cells, prevents the accumulation of antibiotics inside the cell, negating 
their effectiveness.  The deletion of Omp36110 and OmpK36,111 porins from Enterobacter 
aerogenes and K. pneumoniae respectively, have been linked to β-lactam resistance.  Deletion 
of porins in conjunction with the LPS outer membrane and efflux pumps produces high levels of 
resistance to hydrophilic antibiotics in several Gram-negative species.39; 112   
Over-expression of a target decreases the effectiveness of an antibiotic by increasing 
the concentration necessary to inhibit growth.  Point mutations in promoter regions can have 
deleterious or inflating effects on the expression of the succeeding gene.  There are numerous 
instances where mutations in the -35 or -10 region of a gene increases the expression of the 
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antibiotic target or an indigenous gene that nullifies the antibiotic’s effect.  In E. coli, the ampC 
gene is a chromosomally encoded Class C β-lactamase113 under a weak constitutive 
promoter.114  Mutations in the -35 region of the promoter cause over-expression and confer 
resistance to a myriad of β-lactams.115  The mechanism by which efflux pumps confer resistance 
to numerous antibiotics simultaneously was discussed earlier.  Numerous efflux pumps are 
chromosomally encoded and under normal conditions are only minimally expressed.  In A. 
baumannii studies, selection for growth in the presence of chloramphenicol and norfloxacin 
resulted in mutants overexpressing a member of the RND efflux protein family and resistance to 
chloramphenicol, trimethoprim, and fluoroquinolones.116  Similar resistance patterns were 
observed in Serratia marcescens,117 P. aeruginosa,112; 118 and E. coli via over-expression of  
transcriptional activator, MarA, of the RND efflux pump family.119  In another example of target 
over-expression, peptide deformylase is a bacterial enzyme necessary for the deformylation of 
the initial methionine during translation and was thought to be a novel target for antimicrobials 
due to bacterial exclusivity.120  Selection for resistance in Haemophilus influenza gave rise to a 
rearrangement of the region surrounding the peptide deformylase gene, resulting in an increase 
in the number of copies of the gene and subsequently an increase in the expression of the 
target.121 
Some clinically relevant species such as E. coli,122 Salmonella enterica123 and especially 
P. aeruginosa124 have demonstrated an ability to increase the mutation frequency of their 
genomes or hypermutation in response to antimicrobial stresses.125  The phenotype manifests 
as an inactivation of various DNA repair mechanisms126 resulting in mutations that over-express 
resistance related proteins such as class C β-lactamases and efflux pumps.  The onset of 
hypermutation has been linked to exposure to sub-lethal levels of an antibotic, increasing the 
levels of resistance to other unrelated antibiotics.127 
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Finally, recent studies into the formation and synergy of biofilms of various species128 
and their relation to antibiotic resistance have sparked concern.129  Low levels of mass transfer 
due to the stratified growth present in biofilms have two effects on the bacterial community.130  
First, it lowers the amount of nutrients and oxygen available to cells inside the biofilm, slowing 
their growth and metabolic activities making them more resistant to the effects of certain 
antimicrobials such as the β-lactams.  The resulting oxidative stress at the biofilm’s core has 
also been shown to induce hypermutability.131  Second, the outer cells reduce the permeability 
of antibiotics, decreasing exposure to the inner cells.  An added concern is the preponderance 
of persister cells132 that populate the inner core of biofilms and can reseed biofilms after 
antibiotic treatment.133 
 
1.2.3 Origins & Dissemination of Resistance 
The origin of antibiotic resistance is a controversial subject.  What is clear is that the 
occurrence of resistance can be divided into two distinct periods, pre- and post-antibiotic human 
utilization.134  Originally, it was thought that antibiotics evolved amidst chemical warfare between 
microbes competing for resources.135  But more recent studies turn conventional thinking on its 
head implicating antibiotics as signaling molecules136; 137 implicated in the development of larger 
bacterial communities, such as biofilms, in a phenomenon called hormesis.138  If signaling is the 
original intent of antibiotics, it is not hard to imagine some resistance mechanisms have co-
evolved to regulate the signal.139   
The post-antibiotic era is marked by a dramatic increase in the incidence of antibiotic 
resistance due to the stress introduced by human use.140  The rate at which resistance spreads 
can be correlated to horizontal gene transfer of pre-existing resistance mechanisms among 
bacterial cells and even bacterial species.141  Horizontal gene transfer occurs through a myriad 
of mechanisms including transformation of foreign DNA, conjugation, and transduction (Figure 
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1.13),142 but high levels of transfer are achieved once resistance elements are 
compartmentalized in DNA cassettes that are incorporated into plasmids143 and integrons144 for 
more efficient transfer.  In effect, the conversion of mobile genetic elements from parasites to 
facilitators of survival has united the entirety of bacterial genomes against humanity.145  High-
efficiency plasmids, such as those found in the Enterococci146 and implicated in the transfer of 
vancomycin resistance to S. aureus,147 respond to pheromone signals to facilitate gene transfer 
between different genera.  Methicillin resistance in MRSA,78 Qnr-associated quinolone 
resistance in Gram-negative bacteria,85 and cfr-mediated linezolid resistance in 
Staphylococcus148 are recent examples of resistance quickly disseminating and dramatically 
altering the resistance landscape via plasmids. 
 
Figure 1.13:  Methods of horizontal gene transfer in nature including conjugation, the transfer of 
genetic material via plasmids and pili; transformation, the uptake of naked DNA in the 
environment and its incorporation into the host’s chromosome; and transduction, the transfer of 
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foreign DNA and its incorporation into the host’s chromosome facilitated by the replication 
mechanism of a bacteriophage.  Transposons can be transferred into the host by any of these 
processes, increasing the rate of DNA transfer among DNA elements. 
 
The argument has been made that altering the dosing regimen and use of established 
antibiotics149 can alleviate the selection pressure for maintained resistance by increasing fitness 
costs.150  This implies that if enough antimicrobial compounds are developed, a rotation of 
antimicrobial treatments can dissipate resistance mechanisms, increasing the value of old 
antibiotics such as ampicillin.  However, this ignores evidence that compensatory mutations can 
improve a resistant mutant’s fitness,151 that the reservoir of microbial resistance, known as the 
resistome, can maintain resistance mechanisms outside of pathogenic strains or the influence of 
fitness costs are exaggerated.152  Low levels of antibiotics permeating the environment, typically 
from agricultural use, are thought to apply enough selection pressure to maintain resistance in 
non-pathogenic bacteria in nature58; 153 and even the human gut.154  Maintenance in the 
resistome or in pathogenic strains may also be achieved by co-selection of heavy metal 
resistance,155 other antibiotic resistance genes156 on the same genetic element or toxin/antitoxin 
plasmid preservation systems.157; 158 
Logically, the first theory of antibiotic resistance origin was linked to the antibiotic-
producing microbes.159  The genes involved in conferring resistance to the antibiotic-producers 
had been transferred to non-producing organisms.159  Others point out that the guanosine and 
cytosine content of antibiotic-producing streptomycetes is not consistent with that of the 
resistance genes observed in pathogenic strains.160  Phylogeny, however, has demonstrated 
that the metallo-β-lactamases161 and the serine β-lactamases162 evolved over 2 billion years ago 
and have been disseminated on plasmids for millions of years.163  Numerous enzymatic 
resistance mechanisms are homologous with ancient enzymes that likely served a different 
metabolic function in the past.60  Synthetic antibiotics demonstrate the evolution of resistance 
mechanisms.  Initially many theorized that there would never be resistance to the quinolones, 
29 
 
 
 
but first there appeared point mutations in gyrA that reduced binding, then mutated efflux pumps 
capable of reducing intracellular concentrations31 and now finally the QnrA-associated system 
where a protein appears to sequester and shield the target.85  It is the latter system that is now 
arising from environmental bacteria164; 165 and spreading via horizontal gene transfer.  Non-
pathogenic bacteria, members of the resistome, act as more than a bank to preserve resistance 
mechanisms.166  CTX-M type, expanded-spectrum β-lactamases originated in Kluyvera 
ascorbata before transmission to the other pathogenic Enterobacteriaceae,167 VanB-associated 
vancomycin resistance168 may have originated in Clostridium bolteae, a non-pathogenic resident  
of the gastrointestinal tract169 are examples of resistance acquired by pathogenic bacteria from 
their environmental cousins. 
Humans have enjoyed the use of antibiotics for the treatment of bacterial infections for 
over sixty years.  In that period of time we have experienced the golden age of antibiotic 
discovery and the rise of antibiotic-resistant bacteria.   We are now faced with the dilemma of 
how to meet this challenge.  We know that there are a myriad of mechanisms nature has 
developed to counter the antibiotic arsenal we have mobilized against them.  New antibiotics in 
use are based on the scaffolds of previously known classes including the MLS antibiotics,170 
lipoglycopeptides,8 lipopeptides,12 aminoglycosides,17 quinolones,171 tetracyclines,172 
cephalosporins,173 and others.174  This leads to the predictable result of pre-existing resistance 
mechanisms being modified to meet the challenge.117; 175; 176; 177  Other approaches including the 
search for novel targets, such as peptide deformylase178 and aminoacyl-tRNA synthetases179 or 
developing inhibitors of resistance mechanisms, such as ribosome methyltransferases,180 β-
lactamases,181; 182 and efflux pumps183; 184 to improve the efficacy of pre-existing antibiotics have 
had limited success.  Ultimately, we need numerous, de novo antimicrobials that inhibit new 
targets in an attempt to bypass the prevailing problems facing current antibiotics such as the 
ancient origins of resistance mechanisms, the prevalence of horizontal gene transfer, 
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accounting for 18% of E. coli’s genome in the last 100 million years,185 and the ability to modify 
pre-existing resistance mechanisms. 
 
 
1.3  Antimicrobial Peptides (AMPs) 
A field of research that has exploded in the last 15 years is the discovery and 
development of ribosomally-synthesized peptides (or chemically synthesized in vitro)186; 187 with 
antimicrobial properties.  AMPs are generally defined as peptides of less than 100 amino acids 
in length with an overall positive charge complemented by a substantial hydrophobic 
segment.187  To date, the Antimicrobial Peptide Database (APD2)188; 189 lists 1,372 peptides 
exhibiting antibacterial activity that have been synthesized or discovered in nature.   
Categorization of AMPs can become difficult due the lack of information on activity or similarity 
to other members, but the first division is natural versus those synthesized either by screening 
libraries or rational design (synthetic AMPs will be covered in the section on peptide library 
construction and screening).  AMPs in nature are comprised of several groups that are 
surprisingly variable but tend to affect a limited number of targets.190   
 
1.3.1 Bacteriocins 
The first groups of AMPs, bacterocins, are synthesized by bacteria in nutrient deprived 
environments,191 either as a competitive edge or a quorum sensing mechanism.192  It has been 
proposed that 33-100% of bacteria produce at least one bacteriocin,193 and recent studies show 
that many bacteria produce more than one bacteriocin.194 Though first observed in E. coli, the 
most extensively studied bacteriocins are from Gram-positive organisms, especially those 
belonging to the lactic acid bacteria (LAB) including genera Lactococcus, Lactobacillus, 
Leuconostoc, Enterococcus, Pediococcus, Carnobacterium, and Streptococcus195 and have 
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been broken up into three classes based on size and post-translational modifications.  Class I or 
the lantibiotics are small peptides (<5 kDa or 19-28 amino acids) and are composed of rare 
amino acids lanthione, β-methyl lanthione and dehydrated residues.196   Members of this group 
can have either a primarily linear secondary structure such as nisin A, subtilin,197 epidermin and 
Pep5 or a primarily globular structure like mutacin II, cinnamycin,198 mercsacidin and lacticin 
481199 (Figure 1.14).  The antibacterial mechanisms of the lantibiotics are not fully understood, 
but they are believed to either form pores in the membrane or inhibit cell wall synthesis.200  The 
antimicrobial activity of nisin A is due to both mechanisms.201  Recently, more species of 
bacteria outside of the LAB have been found to produce lantibiotics such as Actinomadura 
namibiensis,202 Bacillus subtilis,203 and Bacillus thuringiensis.204   
 
Figure 1.14:  Primary and secondary structures of class I bacteriocins or lantibiotics, 
antimicrobial peptides that are ribosomally-synthesized but heavily modified including modified 
residues (Dha: 2,3-Didehydroalanine, Dhb: (Z)-2,3-Didehydrobutyrine, Abu: 2-aminobutyric 
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acid) and disulfide bridges.  Nisin A and cinnamycin represent the primarily linear and globular 
sub-classes, respectively.  Colors indicate characteristics of the amino acid residues. 
 
Class II bacteriocins are a heterologous group of slightly larger peptides (<10 kDa) that 
are composed of standard amino acids with some post-translational modifications such as 
disulfide bridges or cyclization,205 examples include carnobacteriocin B2, curvacin A, salivaricin 
P, circularin A and lactococcin A.  Class II encompasses the subgroups pediocin-like, non-
pediocin-like, cyclic and two-peptide bacteriocins with all peptides being largely cationic and 20-
70 residues in length.  Similar to the peptides of Class I they disturb membrane permeability.206  
Class III bacteriocins or bacteriolysins are large secreted proteins including helveticin J from 
Lactobacillus helveticus and enterolysin A207 from E. faecalis that induce cell lysis by breaking 
down the cell wall.  
Gram-negative bacteria also produce bacteriocins, albeit not to the extent of their Gram-
positive cousins.  Mainly arising from the family Enterobacteriaceae,208 Gram-negative 
bacteriocins have been split into two groups based on their size: the high molecular weight, 
structured colicins (30-80 kDa) and the low molecular weight peptides or microcins (1-10 
kDa).209  Microcins are further subdivided into the small (<5 kDa) and highly post-translational 
modified class I and larger (5-10 kDa), unmodified class II.210  Class I microcins are similar to 
class I or lantibiotics of Gram-positive origin, but there is evidence that they have intracellular 
targets and are not solely involved in cell membrane perturbance211 while class II occupy the 
traditional role of cell membrane disruptors.210  Members of the colicin class,212 large 
antimicrobial proteins, can kill cells one of three different ways.  First, they can create voltage-
dependent pores in the inner membrane, similarly to the mechanisms previously discussed for 
other AMPs (e.g. Colicin A) (Figure 1.15).213; 214; 215  Second, once in the cytoplasm they can 
degrade DNA, rRNA or tRNA (e.g. Colicin E2-9)216 or finally, they can inhibit peptidoglycan 
formation (e.g.  Colicin M).217  The majority of known microcins and colicins come from E. coli, 
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but there is evidence that other Gram-negative bacteria produce AMPs such as the pyocins 
from P. aeruginosa,218 lumicins from Photorhabus luminescens,219 pesticins from Yersinia 
pestis,220 and klebicins from K. pneumonia.221 
 
Figure 1.15:  Crystal structures of colicins that exhibit various antimicrobial mechanisms 
including A) colicin A’s pore-forming domain (PDB ID: 1COL)213 responsible for membrane 
destabilization, B) colicin E9’s Dnase domain (PDB ID: 2WPT)214 that degrades intracellular 
DNA and RNA, and C) colicin M (PDB ID: 2XMX)215 that inhibits peptidoglycan synthesis. 
 
1.3.2 Immunopeptides 
Higher order eukaryotes produce a series of AMPs as a part of their innate immune 
systems.222  The use of AMPs is ubiquitous including plants,223; 224 mollusks225 and arthropods226 
among others, but here we focus on the clinically relevant examples found in mammals and 
insects.  Defensins and cathelicidins comprise the two major AMP families in mammals.227  Both 
families follow the familiar path of earlier AMPs having basic residues interspersed with 
hydrophobic residues.228  Defensins are non-glycosylated, arginine-rich peptides with molecular 
weights around 3.5-6 kDa.  Six cysteine residues form three disulfide bridges to stabilize its 
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tertiary structure.229  The defensins are broken up into two groups, the α and β defensins, whose 
overall tertiary structure is very similar due to the disulfide bridges but the primary sequences 
show no homology229 (Figure 1.16).230; 231; 232  They have a wide range of activity against 
bacteria and fungi and along with the cathelicidins have been associated with other functions 
within the immune system.233  Cathelicidins are grouped based on their precursor protein which 
contains a cathelin domain prior to the carboxy terminal AMP.  LL-37, the only cathelicidin 
discovered in humans to date, is a 37 amino acid AMP (Figure 1.16)232 cleaved from its 
precursor protein, hCAP18234 and exhibits activity against Gram-positive and Gram-negative 
bacteria.  Related AMPs exist in other mammals but share no homology except for that found in 
the precursor protein.  General characteristics include basic charges (either lysine or arginine) 
and a hydrophobic interface as part of its secondary structure227 (Figure 1.17).232  In the case of 
LL-37, in a hydrophobic environment it forms an α-helix but cathelicidins from other species, 
such as pigs, form β-sheets.235  A smaller immunopeptide group is the histatins.  These are 
small (3-4 kDa) cationic peptides found in saliva and thought to reduce the bacterial load in the 
oral cavity.236  Unlike previous AMPs, the histatins, as their name denotes, have a high 
concentration of histidine residues instead of the more common lysine or arginine in 
aforementioned AMPs. 
The second group of immunopeptides is widely dispersed but is typified by the well-
studied examples in insects.237  Cysteine-rich peptides such as the defensins are prevalent in 
insects as well, but a smaller peptide, thanatin, has a disulfide bridge while only having 21 
amino acid residues (Table 1.2, Figure 1.18).238  Isolated from Podisus maculiventris and 
having sequence homology to amphibian skin peptides, thanatin has been shown to not target 
the membrane even though it exhibits the classic cationic/hydrophobic prerequisites.239   Its 
mechanism, like other peptides to be discussed, has not been fully elucidated.  Linear, proline-
rich peptides, exemplified by drosocin, apidaecin IA and pyrrhocoricin extracted from Drosophila 
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melanogaster, Apis mellifera and Pyrrhocoris apterus respectively, range from 14-39 residues 
(Table 1.2).  Proline residues represent more than 25% of the total amino acid content, often 
appearing in context with basic residues as doubles or triplets.240  The cecropins,241 named from 
their first source of isolation, the moth Hyalophora cecropia , and the cecropin-like peptides, 
such as melittin242 (Figure 1.18)243 isolated from the honeybee A. mellifera, exhibit classical 
amphipathic α-helixes like small AMPs in other species such as magainin 2244 (Figures 1.18-
19)245 from Xenopus laevis. 
 
 
 
 
Figure 1.16:  Crystal structures of the common, human immunopeptides including the 
structurally similar α- (PDB ID: 1ZMM)230 and β-defensins (PDB ID: 1IJU),231 characterized β-
sheets and disulfide bonds, and the cathelicidin, LL-37 (PDB ID: 2K6O),232 which forms an α-
helix. 
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Figure 1.17:  Crystal structure of cathelicidin, LL-37 (PDB ID: 2K6O),232 demonstrating its 
amphipathic α-helix with a polar interface, consisting of mostly basic residues, and a 
hydrophobic interface. 
 
 
 
Table 1.2:  Amino acid sequences, organism of origin and targets of extensively-studied, low 
molecular weight, antimicrobial peptides. 
 
37 
 
 
 
 
Figure 1.18:  Crystal structures of common, small antimicrobial peptides (AMPs) including A) 
magainin 2 (PDB ID: 2MAG),245 an α-helix; B) thanatin (PDB ID: 8TFV),238 consisting of a β-
sheet, β-turn and a disulfide bridge; C) melittin (PDB ID: 3QRX),243 an α-helix; and D) indolicidin 
(PDB ID: 1G89),246 an unstructured peptide. 
 
Anionic AMPs appear out of place given the ubiquity of cationic AMPs, but their 
presence is well documented in eukaryotes, where they most likely play a role in innate 
immunity.247  They range in size from 5-70 amino acids and have a net charge of -1 to -7 and 
include peptides such as enkelytin/peptide B family.248  Not much is known of their antimicrobial 
mechanisms other than post-translational modifications, such as the phosphorylation of serine 
residues, are necessary for their function.  Some peptides require the association of divalent 
cations for interacting with membranes, perhaps in a similar manner to their cationic AMP 
brethren, but other peptides do not require any such association to maintain activity as in the 
case of maximin H5,249 a peptide with activity against S. aureus isolated from the toad Bombina 
maxima. 
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Figure 1.19:  Crystal structure of AMP, magainin 2 (PDB ID: 2MAG),245 demonstrating its 
amphipathic α-helix with both a basic and a hydrophobic interface. 
 
1.3.3 Mechanisms 
1.3.3.1 Membrane Disruption 
Most AMPs exhibit a cationic, amphipathic α-helix conformation when in hydrophobic 
environments250, as seen with LL-37 and magainin 2 (Figures 1.17, 19).  This structure is 
directly related to the peptides’ interactions with the bacterial inner membrane which is 
negatively charged due to the prevalence of phospholipids at the surface.251  For some peptides 
that have intracellular targets, this structure is necessary for translocation across the inner 
membrane but their interaction with the membrane may have a synergistic effect with their 
activity in the cytoplasm.  For the majority of AMPs that remain, however, this structure is 
responsible for their sole antimicrobial mechanism via inner membrane disruption that results in 
cell lysis.252  Three models have been proposed to explain their antimicrobial activity based on 
specific peptides.253  The ‘carpet’ model (Figure 1.20) envisions peptides first binding with the 
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outer interface of the inner membrane via their basic surface, causing the peptides to ‘lie’ on the 
inner membrane.  When a local, critical concentration of peptides is achieved, they disrupt the 
membrane and form micelles.  This mechanism has been observed with cecropin254 and 
melittin.255  The second model, ‘barrel-stave’ (Figure 1.21), involves the insertion of individual 
peptides into the inner membrane.  The amphipathic helixes then associate with other peptides 
to form a pore with their hydrophobic surfaces oriented towards the lipid core.  The result is a 
positively charged pore through which ions can freely pass.256  Surprisingly, this mechanism is 
rarely seen alone and is often observed with data that suggest the ‘carpet’ model as well, as in 
the cases of pardaxin257 and alamethicin.258  The ‘toroidal pore’ or ‘wormhole’ model (Figure 
1.22) is similar to the ‘barrel-stave’ model in that peptides insert into the membrane and form 
channels, but they also reorient the lipids so that their negatively-charged heads face the inside 
of the channel alongside the basic residues this is seen with magainin 2259 and LL-37.260  
The characteristics of membrane disrupting AMPs have been altered in attempts to 
optimize cell lysis or specificity.  Increasing the net positive charge also increases a peptide’s 
antibacterial activity by strengthening the interaction with the anionic bacterial inner membrane 
without increasing hemolytic or anti-eukaryotic activity due to their overall neutral charge.261  A 
certain level of hydrophobicity is required for membrane penetration but increasing the size of 
the hydrophobic face of the peptide decreases specificity for bacterial membranes, causing 
hemolysis262 and potentially leads to peptide dimerization that can lower the peptide’s ability to 
enter the cell.  Methods to optimize a peptide’s lytic activity may depend on the model proposed 
for the original peptide and what bacterial species is being targeted based on their inner 
membrane composition. 
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Figure 1.20:  Schematic of the ‘carpet’ model of antimicrobial peptide bacteriolytic activity.  The 
generally amphipathic α-helical peptides interact with the negatively-charged, periplasmic 
surface of the cytosolic membrane along the helices’ basic interfaces.  Membrane disruption 
leads to the formation of miscelles of lipids surrounded by the peptides producing large holes in 
the membrane, disrupting various ionic gradients leading to cell lysis. 
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Figure 1.21:  Schematic of the ‘barrel-stave’ model of antimicrobial peptide bacteriolytic activity.  
The generally amphipathic α-helical peptides insert themselves into the cytosolic membrane 
forming a pore with their hydrophobic interfaces facing into the membrane and the basic 
interfaces forming a pore.  Disruption of ionic gradients through the pore leads to cell lysis. 
 
 
 
Figure 1.22:  Schematic of the ‘torodial pore’ or ‘wormhole’ model of antimicrobial peptide 
bacteriolytic activity.  Similar to the ‘barrel-stave’ model, the generally amphipathic α-helical 
peptides insert themselves into the cytosolic membrane, but recruit the heads of the lipids in the 
formation of the pore.  This disrupts the ionic gradients maintained by the membrane, leading to 
cell lysis. 
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1.3.3.2 Intracellular Targets 
A minority of known AMPs’ activities do not involve disruption of the membrane but 
instead, inhibit the function of a particular intracellular target.  Some members of the heavily-
modified lantibiotics from Gram-positive bacteria, such as nisin A, are able to form pores in the 
inner membrane and bind to a key component in the synthesis of peptidoglycan, lipid II.263  
Lantibiotics are too small to span the membrane and thus form pores but are still capable of 
causing lysis by binding the pyrophosphate of lipid II inhibiting its function by sequestering it 
from the septum.264 
The three heavily modified microsins produced by E. coli, B17, J25, and C, each have a 
distinct intracellular target.208  Microcin B17 (Figure 1.23) has a molecular weight (MW) of 3.1 
kDa and stops DNA replication by causing the accumulation of gyrase-DNA complexes that 
inhibit the function of DNA polymerase.265  The MW of Microcin J25 (Figure 1.24) is 2.1 kDa 
and it has exceptional stability, being protease-resistant and surviving autoclave conditions 
without losing function due to its threaded structure sterically stabilized by residues Phe19 and 
Tyr20 (Figure 1.25).266   It inhibits transcription by binding to the secondary channel of the β’ 
subunit of RNAP267; 268 which grants access of NTPs to the catalytic core.269  Microcin C7 is a 
uniquely modified peptide with an adenosine monophosphate bound to its C-terminus (Figure 
1.26).211  Once inside the target cell it is processed to create an analogue of aspartyl-adenylate 
which competitively inhibits aspartyl-tRNA synthetase.270 
Among the eukaryotic AMPs, there are a few examples of peptides with intracellular 
targets.271  Buforin II is 21-amino acid peptide from the toad Bufo bufo gargarizans (Table 1.2).  
Like other AMPs, it is formed by processing an initial, longer peptide, that is itself derived from 
histone H2A, to form an α-helical structure.272  Buforin II’s structural similarity to other AMPs 
does not enable it to cause cell lysis, but evidence suggests that its antimicrobial activity arises 
from its affinity for DNA once translocation occurs.273  Another DNA binding AMP is indolicidin 
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(Table 1.2, Figure 1.18),246 a tryptophan and proline-rich, 13-residue peptide derived bovine 
neutrophils.274  Again, its primary structure enables it to cross the membrane to get access to 
the cytoplasm, but does not cause lysis at concentrations quadruple that of the minimum 
inhibitory concentration.275  The three peptides, apidaecin 1A,276 drosocin, and pyrrhocoricin 
(Table 1.2)277 from the innate immune systems of insects share a similar proline-rich structure 
and mechanism.  Using pyrrhocoricin as an example, the peptide translocates into the 
cytoplasm and binds the chaperone protein DnaK278 at its ATPase domain near the C-terminus 
(Figure 1.27).279  Drosocin, while inhibiting DnaK’s ability as a chaperone, does not bind to or 
limit the ATPase domain and its activity. 
 
 
 
 
 
Figure 1.23:  The primary structure of the ribosomally-synthesized, but heavily modified 
microcin B17 that inhibits DNA replication by forming DNA gyrase-DNA complexes.  The 
colored circles indicate the characteristics of the residues. 
  
44 
 
 
 
 
Figure 1.24:  The primary and secondary structure of the ribosomally-synthesized and modified 
microcin J25 that RNA transcription by binding to DNA-dependent RNA polymerase’s (RNAP) β’ 
subunit. 
 
 
Figure 1.25:  Crystal structure of microcin J25 (PDB ID: 1Q71).266  Microcin J25 forms a 
threaded structure following modification by passing the C-terminus through the N-terminal loop.  
This structure is maintained sterically by large residues Phe19 and Tyr20, making it 
exceptionally resistant thermodynamically and to proteolytic degradation. 
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Figure 1.26:  The primary structure of ribosomally-synthesized and modified microcin C7, a 
fusion of a peptide and adenosine monophosphate.  Upon entry into the cell, the peptide is 
processed producing an analogue of aspartyl-adenylate which competitively inhibits aspartyl-
tRNA synthetase, blocking translation. 
 
When looking at AMPs with intracellular targets we notice that they have characteristics 
not typically observed in the membrane disrupting peptides.  First, bacteriocins, such as nisin A 
and microcin J25, are heavily modified post-translation by dedicated enzymes.  Extensive post-
translational modification has made them appear more like the lipoglyco-, glyco-, and 
lipopeptides such as vancomycin (Figure 1.3), bleomycin, polymixin B, and daptomycin (Figure 
1.4) which are non-ribosomally synthesized.  They demonstrate the functionality and diversity 
capable of peptides as well as ways of modifying peptide leads to increase their therapeutic 
potential.  Second, the eukaryotic AMPs discussed are largely differentiated from their 
membrane disrupting cousins due to the lack of activity of their all-D-amino acid analogues.280  
Their stereo-specific target, a protein, DnaK, could not interact with the D-amino acid 
analogues, unlike membrane-disrupting peptides which have activity whether composed of D or 
L-amino acids.  The absence of AMPs with intracellular targets may have more to do with the 
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ease of creating membrane disrupting peptides and an inability to develop resistance to them 
than difficulty in developing peptides with protein or nucleic acid targets. 
 
Figure 1.27:  Crystal structure of the antimicrobial peptide, pyrrhocoricin, binding the ATPase 
domain of heat-shock chaperon protein, DnaK (PDB ID: 3DPP)278.  Pyrrhocoricin remains 
largely unstructured when binding its target.  Similar binding has been suggested for insect 
AMPs drosocin and apidaecin 1A. 
 
1.3.4 Therapeutic Potential 
In the last two decades, pioneers seeing the effectiveness of peptides from natural 
reservoirs (AMPs) and those produced synthetically have tried to use them therapeutically.  
Currently there are over 70 therapeutic peptides treating a variety of ailments on the market.281 
Unfortunately, little success has been seen in the field of antimicrobials.282  While membrane 
disrupting peptides derived from the immune system have several advantages such as broad 
spectrum activity, low levels of induced resistance,283 and anti-inflammatory activity, a synthetic 
peptide developed against a target has none of these advantages but exhibits the same 
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disadvantages of being a macromolecule present in our systems.  Peptides are less likely to be 
toxic than a small molecule drug due to their high specificity,284 and possibly their short half-lives 
and low bioavailability due to clearance from the body and binding to protein present in the 
blood.285  These problems can be addressed through the modification of the peptide’s structure 
through medicinal chemistry286 and peptidomimetics.287 
A large component of a peptide’s bioavailability is its inability to penetrate biological 
membranes.  This is not as great a problem with antimicrobials as with other drugs as infections 
tend to be extracellular, but the brain-blood barrier presents a challenge.288  Substitution of the 
peptide’s amide backbone can reduce hydrophilicity and increase permeability.289  The main 
disadvantage of peptide drugs is their degradation by proteases and peptidases in the blood.  
Chemical modification of the peptide structure such as D-amino acid substitution290 (as long as 
its target is non-chiral), incorporation of non-natural amino acids,291 peptoid292 and β-peptide 
backbones (Figure 1.28) and peptide cyclization293 can obviate degradation.  Another example 
is prodrugs,294 chemically modified peptide molecules that mature at the location of their target 
making them protease resistant prior to maturation.   
Transport vectors direct and increase the concentration of the therapeutic peptide at 
their target’s location.  Chimeric or hybrid peptides are two moieties conferring different 
attributes when covalently attached.  The peptide A3-APO295 is composed of portions from 
AMPs discussed above including a membrane disruption domain that also facilitates 
translocation and increases its specificity for bacterial cells and a segment derived from 
pyrrhocoricin’s DnaK binding domain.  Another approach utilizes the attachment of 
antibodies296/mimotopes297 or species-specific pheromones298 to give a peptide with broad 
spectrum activity a specific bacterial target.  Finally, the use of nanoparticles to deliver 
antibiotics299 can be modified to carry protease-sensitive peptides to their targets and localize 
their activity. 
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Figure 1.28:  Common peptide backbone derivatives used in peptidomimetics to prevent 
proteolytic degradation.  Peptoid backbones move the side group to the amine.  β2 and β3 
peptide backbones move the side group to the β carbon instead of the α carbon, as in a natural 
amino acid.  The proximity of the side group to the amine (β2) or the carboxyl (β3) differentiates 
the two mimetics.  Because glycine does not have a β carbon, it cannot be modified into either β 
format. 
 
Peptides and their mimics are not necessarily the end of antimicrobial development.  It is 
possible to formulate small molecule drugs based on peptides that inhibit microbial growth.  
Strong peptide leads can be used in displacement screens of chemical libraries to identify small 
molecules that bind relevant targets with greater affinity,300 avoiding the pitfalls of using a 
peptide therapeutic. 
 
1.4 Antimicrobial Discovery 
The prevalence of resistance has led to demand for new antimicrobials.301  Several 
methods for finding new antimicrobials have emerged, some preferred for their high rates of 
return, others for the novelty of their products.  Numerous methods already exist and more 
technology is being adapted for this task, each with their own advantages and disadvantages.302  
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However, all of these methods combined since 2003 have only begot six antibiotics approved 
for therapeutic use.303 
 
1.4.1 Biomass Screening 
The original, accidental method of antimicrobial discovery was first demonstrated with 
Fleming’s serendipitous observation of P. notatum inhibiting bacterial growth around it 
correlating with penicillin secretion.304  Streptomyces are a genus of soil bacteria that are known 
secondary metabolite powerhouses.305  Typically lawns of pathogenic bacteria were grown on 
plates, and then soil samples would be applied, seeding Streptomyces species.306  If zones of 
inhibition were observed around a colony of Streptomyces, the cells were harvested and their 
metabolites purified for further analysis.  During the ‘golden age’ of antibiotic discovery most 
new antibiotics came from soil samples collected by graduate students and pharmaceutical 
company employees from around the world.307 This practice continues with some success 
today, much as it was practiced 60 years ago.308; 309; 310; 311; 312; 313; 314  Recently similar methods 
have been used to screen other microbes for antimicrobial secondary metabolites,315 screen 
actinomycetes in more exotic places other than soil such as sediment from the Sea of Japan316 
and setup assays to screen microbes that inhibit necessary microbial activities such as quorum 
sensing.317  However, the discovery of molecules from different chemical classes then those 
previously known and suitable for human use has dramatically slowed with time. 
 
1.4.2 Bioinformatics 
The advent of bioinformatics arrived with cost-effective high-throughput sequencing.  
Entire genomes of microbes can now be scrutinized by computer programs in search of open 
reading frames or non-coding RNA genes.  One approach used for finding new potential 
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antibiotics is the search for novel gene clusters that produce secondary metabolites,318 similar to 
the approach used in biomass screening.  Once a gene cluster or operon is identified the amino 
acid sequence of each gene can be used to predict its function and form a prediction of the 
cluster/operon’s product.319  Using this method novel antibiotics have been discovered such as 
ECO-02301 and ECO-0501 in Streptomyces aizunensis320 and Amycolatopsis orientalis,321 
respectively, and  the orfamides in Pseudomonas fluorescens.319  The ability to sequence an 
entire genome from one bacterial cell322 hurdles problems with culturing exotic microbes to 
screen their cell extracts for antibiotics.  Further advances in bioinformatics and its integration 
with rational design techniques may prove powerful avenues of discovery in the future. 
 
1.4.3 High-throughput Screening (HTS) 
Over the past 15 years high-throughput screening of large chemical libraries has been 
the most utilized weapon in the pharmaceutical industry’s arsenal against a variety of relevant 
targets including antimicrobials.  Two major assays are used depending on the availability of 
target information.  The first, the in vitro method, screens large chemical libraries against a 
target that can be immobilized in individual binding environments or wells.323  Whole-cell 
screens offer an alternative where less information is required to select for hits.  Cells of 
interest, in our case bacteria, are grown in the presence of a small molecule in an assay that is 
capable of efficiently reporting the viability of the cell or a particular process.324; 325  New 
advances in whole-cell screening harness RNA silencing technology to lower the amount of 
target in a cell and make it more sensitive to screened libraries.326  Smaller scale screens have 
been performed in the context of the host organism affected by the pathogenic microbe to better 
reflect the circumstances of infection.327   
The genomic age has given us full access to DNA sequences comprising all target 
information, including the determination of essential genes, that has been used to develop 
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leads,328 but largely the glut of information has been a disappointment in the development of 
new leads.302  Companies have led the charge for increased minimization and automation to 
increase the rate of return in all fields of pharmaceuticals,329 unfortunately they have ignored the 
success rate of their chemical libraries pertaining to antimicrobial development.302  Most 
antibiotics in use violate Lipinski’s ‘rule of five’330 concerning drug solubility that is used in the 
construction of chemical libraries.331  Additionally, current libraries lack diversity among the 
basic scaffold molecules on which the design of new antimicrobials are based.  Attempts have 
been made to rectify this and the concomitant claim that some targets are un-druggable332 by 
instituting new synthetic methods such as click chemistry,333 diversity-oriented synthesis334 or 
returning to the use of natural compounds for screening,335; 336; 337 given the success of 
screening natural extracts in the past.338  Another approach to increasing library diversity uses 
fragments or low molecular weight molecules339 that cannot bind targets strongly.  Weak binding 
fragments can then be used as scaffolds in rational design techniques to improve binding.340 
 
1.4.4 Rational Design 
Rational design uses previous knowledge concerning a target to construct a new 
molecule that is hypothesized to block the target’s function.341  This method is also known as 
structure-based drug discovery (SBDD).342; 343  There are three approaches to this method. 
The first, substrate and known inhibitor-inspired design, utilizes known antimicrobials, 
such as previously successful antibiotics, to make predictions on what molecular manipulations 
of the antimicrobial will increase its effectiveness,344 bio-availability345 or specificity346 et alia.  In 
the current environment of resistance, this method is often used to find molecular changes that 
will not change the binding of the antimicrobial to its target, but preclude the effectiveness or 
binding of a resistance mechanism such as an enzyme.  Target data are typically based on 
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crystal structures or homology models.  Modified structures of the original antimicrobial are then 
tested for fitting at the original binding site.  Recent uses of this method have taken advantage 
of the concomitant increase in computing power to supplant analyses that relied on chemistry in 
a process similar to constrained chemical library construction.347   Thus new, semi-synthetic 
antibiotics that are less susceptible to resistance mechanisms have arisen from older medicinal 
chemistry and newer computational methods including tigecycline (tetracycline),348 ceftaroline 
(β-lactam) and clavulanic acid (β-lactamase inhibitor),181 and azepane-glycosides 
(aminoglycosides)108; 349 giving new life to antibiotic classes exhibiting high levels of resistance.  
It is also possible to derive information based on ligand-target binding to develop new 
antimicrobials such as in the case of the ribosome20; 350; 351 or increase the specificity of new 
leads.352 
In silico or virtual screening is a computer-based chemical library screening utilized 
when less information is known about potential ligands.  Virtual libraries containing the 
structures of small molecules are searched to identify compounds that dock in the desired 
binding site on the target and scored to predict a binding affinity.  Virtual libraries have been 
screened to find molecules proven to have antimicrobial effects on M. tuberculosis353 and other 
organisms.354  Various parameters can be modified to increase the quality of a search including 
constraining the structures to molecular scaffolds with desired chemical characteristics or 
domains associated with particular functions.355 
The third approach, de novo design, requires vast computing power to develop novel 
molecules that bind to targets by utilizing algorithms that account for hydrogen bonds, ionic 
interactions, hydrophobic pockets and van der Waals forces.  De novo design was harnessed 
as the final optimization in a multi-step screen involving an initial virtual screen to discover novel 
DNA gyrase inhibitors targeting the ATP binding domain.356  It has also been used to find 
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inhibitors of D-alanyl-D-alanine ligase, DdlB,357 VanA (a DdlB homologue involved in 
vancomycin resistance),358 and RNA polymerase.359 
 
1.4.5 Peptide Screens 
Peptides are small polymers of amino acids that can contain a vast array of complexity 
due to the 20 naturally occurring side groups.  The use of peptide libraries over their chemical 
counterparts increases the diversity of the library and has vastly reduced costs of acquisition.  
Moreover, peptides have a proclivity for binding to a few, functionally relevant sites on target 
proteins.360  Established methods allow us to manipulate biological systems to create and 
screen peptide libraries of large complexity with relative ease. 
 
1.4.5.1 Split Pool Synthesis 
Split pool synthesis is an entirely in vitro selection, its title referring to how the library is 
constructed.361  Amino acids are added one at a time to beads or other surface elongating a 
chain of pre-existing amino acids or peptides (Figure 1.29).  Since only one residue is added 
each time, the sequence of the peptide on each bead is known.361  Peptides can then be 
excised from the beads and affixed to the individual wells of a microtiter plate for screening.  
SPOT synthesis is a popular example.362  On a porous medium such as cellulose, amino acid 
coupling reactions are carried out on separate areas with known residues.  After each round of 
coupling, acetylation is used to cap any unreacted amines.  This creates a matrix of known 
peptides on the cellulose that can be detached and used in binding assays.  In one assay, a 
strain of P. aeruginosa with a luminescence gene cassette, whose expression corresponds with 
cell viability,363 was used to screen for or optimize antimicrobial peptides from semi-random364 or 
scrambled365 libraries.  Reliance on chemical synthesis leads to low complexity libraries and 
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slow setup times making this a less than optimal system to screen large peptides with the 
optimal size due to reaction constraints being twelve amino acids.  Screening large amounts of 
peptides is labor intensive, and even with the use of robotics, one can expect to screen only 
2,000,000 peptides per year. 
 
Figure 1.29:  Generation of a hypothetical, tripeptide library using the split pool synthesis 
method.  The method ensures that each bead has only one peptide bound.  The peptides can 
then be cleaved off the beads and transferred to wells and screened or be assayed on the 
beads. 
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1.4.5.2 Ribosome Display 
Our knowledge of translation machinery and mechanisms has aided the exploitation of 
the ribosome complex as a platform for displaying peptides.  The use of polymerase chain 
reaction (PCR) for construction of the library (an identical strategy is used in mRNA display) 
exponentially increases the size (up to 1014 members366) and diversity of the library and the 
length of the peptide without a concomitant increase in cost.  DNA encoding the peptide of 
interest and a tether sequence downstream of an initiation codon are used as templates in an in 
vitro transcription-translation coupled or uncoupled reactions (Figure 1.30).  Because the 
original DNA templates contain no stop codons, the ribosomes freeze on the corresponding 
mRNAs.  This complex comprises the translated peptide encoded by the mRNA which are non-
covalently bound to each other via the stalled ribosome.367  The tether sequence spans the 
ribosome tunnel exposing the entire peptide to the environment.  It is crucial that there is 
stoichiometry between ribosomes and mRNAs during translation.  A selected target is 
immobilized and the ribosome-peptide library is added and allowed to interact.  Washes remove 
non-binding and weakly binding peptide complexes.  Peptides with high affinity for the target are 
eluted by destabilizing the ribosome complex with EDTA.  Isolated mRNA is subjected to 
reverse transcription.  The subsequent PCR can be used to introduce mutations to new DNA 
templates for peptide binding optimization in a second round of panning.  By binding the mRNA 
to the peptide the potential binding phenotype is linked to its genotype, identifying the peptide’s 
sequence.   
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Figure 1.30:  A schematic of the ribosome display peptide screening method.  PCR is used to 
produce a DNA library that is transcribed in vitro producing an mRNA with a start codon, the 
randomized region encoding the peptide library and a tether sequence.  The mRNA library can 
be separately or co-translated with transcription in vitro.  Ribosomes translate the mRNAs, but 
due to the lack of a stop codon stall on the mRNA producing a complex displaying the peptide 
and linking it to its encoding mRNA.  The complexes are screened for binding to an immobilized 
target, washed and eluted.  The complex is denatured and the mRNAs of the binding peptides 
are used as template in an RT-PCR to produce a DNA library enriched for target-binding 
peptides.  This process is repeated until strong binders are selected.  The resultant DNA library 
can then be sequenced to identify the peptides’ amino acid sequences. 
 
Ribosome display utilization has been minimal in the search for antimicrobial peptide 
hits.366  One instance targeted the negatively charged bacterial membrane, the known target of 
numerous AMPs, using a model membrane immobilized on magnetic beads.368  Peptides that 
bound the membrane components were then verified in subsequent assays focusing on 
membrane disruption.  Instability of the ribosome complex, necessitating the use of high Mg2+ 
concentrations that may interfere in the binding of screened peptides, and systemic sensitivity to 
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RNase degradation are shortfalls of a system that has been used with success to isolate 
peptides binding their targets in the nano and picomolar range.366 
 
1.4.5.3 mRNA Display 
A second cell-free, biological system capable of attaining high member libraries is mRNA 
display.  Similar to ribosome display, the informative molecule is mRNA produced via 
transcription of a double stranded DNA template library that can be produced by PCR.  
Following transcription, a small, synthetic linker nucleic acid is bound to the antibiotic puromycin 
on its 3’ end (Figure 1.31).  During in vitro translation of the hybrid nucleic acid, a peptide bond 
is formed between the encoded peptide and the C-terminal puromycin which occupies the A site 
of ribosomes,369 attaching the encoding mRNA to the acting peptide.  Panning the library and 
recovery of hits is similar to ribosome display.  Reverse transcription produces an mRNA/cDNA 
duplex, a low pH elution removes the cDNA strand that can be purified and then used for 
sequencing or mutagenic PCR in a second round of panning.  The ability to display large 
peptides of up to 100 amino acids370 in high complexity libraries makes mRNA display a 
powerful tool for finding peptides with low nanomolar affinity.371  Being free of cellular systems 
also enables the easy incorporation of non-natural amino acids into the peptide library that can 
increase the affinity of hits.372  Using the covalent attachment of the peptide via puromycin 
obviates one of the faults of ribosome display, the non-covalent ribosome-peptide-mRNA 
complex, making it an attractive system for screening peptide libraries in vitro. 
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Figure 1.31:  A schematic of the mRNA display peptide screening method.  PCR is used to 
produce a DNA library that is transcribed in vitro.  Molecules consisting of a linker and the 
antibiotic puromycin are then ligated to the mRNAs.  The ligated mRNAs are then translated in 
vitro.  When the ribosomes are translating the ligated complex, they transfer the peptide bond to 
the puromycin producing a mRNA-puromycin-peptide hybrid linking the informative mRNA with 
the active peptide sequence.  The library is screened against an immobilized target, washed 
and eluted.  RT-PCR using the screened hybrids as templates produces a DNA library enriched 
for target-binding peptides.  The process is repeated until strong binders are selected.  The 
resultant DNA library can then be sequenced to identify the peptides’ amino acid sequences. 
 
1.4.5.4 Phage Display 
The most common method of screening peptide libraries is phage display.  The most 
common vector is the filamentous bacteriophage M13 (Figure 1.32) that infects E. coli.  The 
M13 phage, like other viruses, is composed of a nucleic acid core encoding necessary proteins 
and a protein coat that enables infection of host cells.  Filamentous phage replicate within the 
host without causing lysis.  The nucleic acid elements pass through the bacterial membrane, 
collecting coat proteins that have been produced and placed in the membrane.373  Peptide 
libraries can be constructed by placing random DNA sequence at the termini of coat protein 
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genes in the viral genome.  Each genome infects one bacterial cell and produces numerous 
daughter viruses that have the identical peptide exposed.  In M13, several coat proteins can be 
used to manipulate the valence or amount of peptide present on the phage, this directly 
correlates to the binding affinity of a peptide for its target  (higher valence increases the chances 
of getting weak binding peptides).  Capsid pVIII is a major coat protein, present at 2,700 copies 
in the M13 coat while pIII, the most commonly used, has only 5 copies.  The phage genome is a 
circular DNA element that can be transformed into E. coli initially to produce intact virions that 
display the encoded peptides of the library.   
 
Figure 1.32:  A schematic of filamentous coliphage M13.  Peptide libraries can be displayed at 
the N-terminus of the phage’s coat proteins, generally pIII, through genetic manipulation of its 
chromosome.   
 
The intact virions are purified from their host cells and screened in vitro against a bound 
target (Figure 1.33).  Similar to other high-throughput peptide screens, pre-screening of the 
library can remove potential false positives374 and washing steps can remove weakly binding 
peptides.  The bound peptides are then eluted either competitively or with a low pH solution.  
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Resultant phage are used to re-infect E. coli to produce a library enriched for binders of the 
target. 
The in vivo replication steps present in phage display impose limitations on the system.  
As a filamentous phage, passing through the inner membrane comes with entropic costs.  Some 
peptides, particularly those composed of basic residues, such as lysine and arginine, cannot 
pass through the membrane and therefore the coat protein cannot accumulate in the membrane 
and ultimately, the phage cannot reproduce.  The use of lytic phage can circumvent this 
problem.  Unfortunately, this benefit is offset with another problem.  Lytic phage such as T7 and 
lambda also infect E. coli and have coat proteins on which peptide libraries can be displayed,375 
but lysis of the host cell, while freeing the virion without having to translocate also releases host 
proteases and nucleases that can degrade the immobilized target.  Another consequence of the 
in vivo step is its effect on the representative peptides after replication.  The sequence of some 
peptides may cause strain on the cells while others do not.  Strong binding peptides that reduce 
their own fitness during the replication step will not be represented in the final pool of peptides 
creating false negatives.  This is more important in respect to the particular scenario where one 
is attempting to isolate antimicrobial peptides.  Peptides that bind a target identified as a 
potential antimicrobial target are also likely to bind the same target or its homologue in the E. 
coli host slowing the growth of or killing its only means of persistence. 
This has not stopped the isolation of antibacterial peptide candidates.  Phage display 
has garnered hits against MurF, an essential enzyme involved in cell wall synthesis;376 FtsA, 
another essential protein involved in cell division,377 both from the closely related species P. 
aeruginosa, and even prolyl-tRNA synthetase from E. coli that was verified as a therapeutic 
agent in an animal system.378  Some groups have  avoided this problem by targeting non-
essential bacterial proteins that are clinically relevant, such as β-lactamase.379 
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Figure 1.33:  A schematic of the M13 phage display peptide screening method, similar to 
methods using other phage that infect E. coli, such as T7 and λ.  Produced or purchased phage 
libraries are screened against an immobilized target, washed and eluted to select for peptides 
that bind.  The eluted phage are used to infect E. coli cells and then amplified.  The resultant 
phage library is enriched for target binding peptides and rescreened against the target.  After 3-
4 rounds of selection, the phage chromosomal DNA is collected, sequenced and analyzed for 
peptide motifs that bind the target. 
 
Cell surface display using bacterial, yeast or mammalian cells utilize the expression of 
peptide libraries from plasmid DNA.  The peptides are fused to outer membrane proteins such 
as OmpX which are translocated and exposed on the outside of the cell.380  The orders of 
magnitude increase in size between a bacterial or eukaryotic cell in comparison to a virus 
correlates to an increase in the amount of displayed peptides or their valence.  High valence 
increases the probability of obtaining weaker binding peptides that can be used as leads to 
construct stronger binders.  However, the increase in valence is offset by the increased 
complexity of the system versus phage display.381 
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1.4.5.5 Peptide Aptamers & the Yeast Two-Hybrid System 
Yeast two-hybrid systems are generally used to identify protein-protein interactions in 
libraries based on an organism’s genome,382 however, there have been recent modifications to 
amend the system to screen for peptides or peptide aptamers that bind targets.383  Unlike 
previous screening methods, yeast two-hybrid takes place entirely in vivo, providing a more 
accurate binding environment (salt concentrations and presence of potential unintentional 
peptide binder such as DNA, RNA other proteins). Traditional yeast two-hybrid systems involve 
two plasmids within the host yeast cell (Figure 1.34).  The first plasmid expresses the target or 
bait protein, or in some cases RNA.384  The second plasmid expresses a library of proteins 
based on the cDNA of the organism of interest called the prey.  Both bait and prey are 
constructed as fusions.  The bait is attached to a DNA-binding domain capable of binding to an 
upstream activating sequence 5’ to a reporter gene.  The prey is attached to an activation 
domain that facilitates the reporter gene’s transcription by stabilizing RNA polymerase’s binding 
to the promoter.  If the bait and prey interact the binding and activation domains’ synergy 
causes expression of the reporter gene, typically lacZ. 
In modified systems, the cDNA library used as the prey is replaced by a library of 
peptide aptamers typically constrained by being inserted into the active loop of E. coli 
thioredoxin385 or other scaffold proteins386 due to the belief that peptides with conformation 
constraints are better target binders, ignoring the potential effects of ‘induced fit’.387  The fusion 
partner doubles as a means of protecting the small peptides from proteolytic degradation.388  
Expression of the reporter gene would signal an interaction between the peptide and the protein 
bait.  Traditional problems of yeast two-hybrid continue to haunt this method.  False positives, 
via autoactivation and endogenous third-party yeast proteins facilitating bait-prey interactions, 
lead to signals when the interaction is not biologically relevant.389  It also suffers from a slow 
screening process that requires the plating of each interaction separately resembling the speed 
of split pool synthesis. 
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Figure 1.34:  A schematic of a modified yeast two-hybrid system for the isolation of peptide 
aptamers that bind a target.  Yeast cells are co-transformed with two plasmids, one encoding a 
fusion of the target or bait protein and a DNA binding domain and a plasmid encoding a fusion 
of peptide library within a scaffold protein and an activation domain.  When expressed the 
fusions are localized to the nucleus where the target-DNA binding domain binds to the upstream 
activating sequence (UAS) of a reporter gene, generally encoding β-galactosidase (LacZ).  If the 
co-transformed, displayed peptide fusion is able to bind the target, its fused activation domain is 
localized to the reporter gene and recruits RNA polymerase for expression of the reporter.  If 
there is no interaction, then no signal, such as β-galactosidase activity, is observed.  Peptides 
that bind can be identified by extracting the plasmid and sequencing the encoding DNA. 
 
1.5 Conclusion 
Peptide screens provide a relatively inexpensive and efficient means of screening large 
numbers or highly varied molecules in the search for antimicrobials.  The merits of peptides as 
drugs have been discussed previously, but we can also note that peptide screens such as 
phage display390 and yeast two-hybrid300 have been used, upon constraining the peptide’s 
conformation, to develop small molecule drugs via peptidomimetics.  The reverse, producing 
peptides that mimic the binding of small molecules, has also been achieved.391  However, 
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peptide screens have their short comings that invariably lead a researcher astray with false 
positive and negative results.  One foible of peptide screens is that they rely entirely on the pre-
existing knowledge of suitable targets which is based on imprecise information.  This leaves 
unidentified molecules, such as tomorrow’s functional, noncoding RNAs,392 untargeted.  This 
includes the lack of understanding what is essential outside of a laboratory.  Bacteria do not 
compete in rich growth media. They exist in a variety of environments where they may be 
starved of particular nutrients, exposed to anaerobic, high salt, heat and other stressful 
conditions where gene knockouts have not been performed to understand their responses.  
Except for the yeast two-hybrid screen, which occurs in the nucleus of a eukaryotic cell, peptide 
screening occurs in vitro.  This requires that the target protein is synthesized or purified most 
likely from an E. coli based over-expression system.  Normally this is not a problem, especially 
when dealing with bacterial targets, however, recent discoveries have shown there is a role for 
post-translational modification  in bacteria393 including medically relevant species such as M. 
tuberculosis,394 which makes purifying the target at unnatural levels from the host or from 
another species a risky endeavor if one wants the biologically relevant specimen.  This logic 
also applies to transient, intermediate macro or small molecules that could be targeted in the 
cell including transient conformations that offer unique binding opportunities.  Membrane and 
transmembrane proteins are notoriously difficult to purify and maintain in their natural 
conformation395 causing them to be under-utilized as targets.  All of these examples make in 
vitro structures of purified or synthesized targets dubious, we can only be certain their in vivo 
structures are biologically pertinent. 
There have been attempts to construct in vivo, bacterial systems for screening 
peptides396 with various names such as ‘aptamer-based bacterial inhibition system’ (ABBIS)397 
and ‘suicide expression system’ (SES).398  These systems do not exhibit the faults observed 
with those above simply because they occur within the target organism, E. coli.  First, there are 
no problems with permeability of the peptides, a concern when doing whole cell screening in 
65 
 
 
 
split pool synthesis or confirming peptides from other screens.  The peptide is produced in the 
cytoplasm by the cell’s own machinery and therefore no cell barriers need to be breached.  This 
advantage, however, makes it difficult to introduce any non-natural amino acids into the library.  
The main advantage of the selections is ‘hit relevance.’  Because they are within the cell, all 
peptides in the library able to inhibit growth are by definition hits.  With in vitro screens, there is 
always the concern if the consensus peptide is binding a relevant site on the target or if 
individual peptides are binding elements besides the target such as the beads on which the 
target is immobilized.  The limiting factor of in vivo systems is the inability to convert them to a 
high-throughput format.  
A system capable of coupling the high-throughput nature of in vitro systems with the 
intrinsic advantages of an in vivo selection’s lack of a need for a defined target would be a 
powerful tool in finding quality peptide leads.  This high-throughput system would enable us to 
sift through hundreds of millions of peptides and screen them based on their antibacterial 
activity within the cell, in its natural state.  To address this unison of strengths we have 
developed in vivo display (IVD).  Using a random DNA oligomer of twelve random codons as a 
primer in a PCR we produced an immense library of random DNA sequences that we fused to 
an end of a reporter gene.  Placing this behind an inducible promoter on a low copy number 
plasmid, we controlled the expression of the reporter protein-random peptide fusion.  A library of 
peptides encoding plasmids was transformed into E. coli.  A selection for peptides that affect E. 
coli’s growth was performed in liquid medium permitting the screening of hundreds of millions of 
peptides simultaneously.  Plasmids encoding growth-affecting peptides were then separated 
from non-affecting peptides based on their growth phenotypes; bacteriolytic, bacteriostatic or 
bactericidal.  The recovered plasmid DNA was sequenced to elucidate the peptide sequence 
that was further used to optimize binding via mutagenesis or determine minimum inhibitory 
concentrations using synthetic versions of the peptides. 
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E. coli, a Gram-negative cell has two compartments with markedly different functions 
and characteristics; the cytoplasm and the periplasm.  We developed two systems that select 
for peptides in either compartment to identify as many leads as possible against all available 
targets.  The C-terminal cytoplasmic in vivo display (cIVD) system (Chapter 2) has thus far 
yielded 39 peptides that are lethal upon expression within the cell while the modified, N-terminal 
cytoplasmic in vivo display (nIVD) system (Chapter 3) has isolated 5 peptides.  The periplasmic 
in vivo display (pIVD) system (Chapter 4) utilizes inherent cellular mechanisms to screen the 
peptide library solely in the periplasmic space.  Using this system we have garnered 192 unique 
peptide sequences.  Each of the three growth phenotypes, bacteriolytic, bacteriostatic and 
bactericidal have been observed plus a fourth phenotype characterized by a significant slowing 
of the generation time.  Except for a group of 76 bacteriolytic peptides from the periplasmic 
selection that share a basic and hydrophobic amphipathic helical structure, the peptides have a 
variety of chemical characteristics indicating they bind to a variety of targets.  A screen of a 
constrained peptide library for antimicrobial activity based on the sequence elements of the 76 
aforementioned bacteriolytic peptides (Chapter 5) isolated an additional 81 peptides of various 
growth-inhibiting phenotypes.  Additionally, we successfully designed 5 peptides based on the 
same sequence elements (Chapter 6).   Three peptides isolated from these systems; PL098 
(Chapter 4), 84 Pro- (Chapter 5), and EO1 (Chapter 6), demonstrated exogenous antimicrobial 
activity against a variety of bacteria and lacked hemolytic activity.  Thus, IVD and its derivatives 
have proven to be viable strategies for the isolation of antimicrobial peptides for the 
development of clinical antimicrobials. 
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CHAPTER 2 
C-TERMINAL, CYTOPLASMIC IN VIVO DISPLAY SELECTION FOR THE ISOLATION OF 
ANTIMICROBIAL PEPTIDES IN ESCHERICHIA COLI 
 
2.1 Abstract 
 Studies have shown that the usefulness of antibiotic stalwarts and their semi-synthetic 
derivatives is decreasing due to the rise of drug-resistant and multi-drug-resistant strains of 
bacteria ranging from deadly pathogens such as Mycobacterium tuberculosis to opportunistic 
pathogens, like Pseudomonas aeruginosa.  We have developed a novel, in vivo drug-discovery 
technology that focuses on disrupting critical interactions within the cell.  A library of 12-amino 
acid random peptide sequences was added to the C-terminus of the display protein, Emerald 
Green Fluorescent Protein (EmGFP) that also contained an affinity tag. The display protein 
serves as a conformation stabilizer, anti-proteolysis effector, purification adjunct, and activity 
benchmark. Because the peptide’s sequence is directly linked to the DNA sequence of the 
plasmid being expressed, an immense library can be screened and the antimicrobial peptide 
sequences identified rapidly.  
To identify novel peptides that inhibit bacterial growth, E. coli cells expressing the 
random peptide library were screened to isolate peptides with bacteriolytic, bacteriostatic and 
bactericidal phenotypes.  A total of 39 inhibitory transformants were isolated exhibiting various 
phenotpyes; one weakly bacteriolytic, 18 bacteriostatic/bactericidal and 20 growth rate reducing 
or weakly inhibitory.  Variation of expression levels and amino acid sequences among the 
clones indicate distinct mechanisms.  Ten of the twenty peptides assayed for activity as free 
peptides, in the absence of the display protein, maintained their activity demonstrating the 
viability of the system in isolating lead antimicrobial peptides. 
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2.2 Introduction 
 The increase in the incidence of antimicrobial resistance in the recent past has 
increased the need for new antimicrobials in the treatment of bacterial infections.  This is most 
evident in hospital acquired infections (HAIs) now being the 6th leading cause of death in the 
United States with 1.7 million infections culminating in 99,000 deaths.41  In Europe, 
approximately two-thirds of deaths resulting from HAIs are caused by Gram-negative 
pathogens.399  Hospitals have become a breeding ground and bacterial marketplace for 
antimicrobial resistance. 
 To counter this trend we need novel antimicrobials and therefore novel methods for their 
isolation and development to circumvent resistance mechanisms (Figure 2.1).  We have 
developed a system exploiting the pliable and variable nature of amino acid sequences or 
peptides.  A plasmid encoding a display protein under the control of an inducible promoter has a 
random peptide library placed on either its C or N-terminus.  Expression of this fusion within the 
cell produces the display protein with the attached peptide in the cytoplasm where it can interact 
with cellular components.  Peptides such as microcin B17,265 buforin II,400 indolicidin,274 
pyrrhocoricin401 among others are known to have targets and/or activity in the cytoplasm.  
Previous peptide screening methodologies, including phage,376 mRNA370 and ribosome366 
display, would require the identification and production of a target prior to screening and 
assume both that in vitro binding conditions accurately mimic those in vivo and isolate peptides 
that bind to pertinent sites on the target, disrupting its function.  Our system, in vivo display 
(IVD), isolates peptides that inhibit bacterial growth without prior knowledge of pertinent targets 
or binding sites in the relevant cellular environment.  IVD aims to discover peptides along the 
same lines as intracellular targeting peptides such as buforin II, indolicidin, and pyrrhocoricin not 
yet developed in nature.   
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Figure 2.1:  Methods of antimicrobial development discussed within this dissertation.  Chapter 2 
focuses on in vivo display of a random peptide library at the C-terminus of a display protein in E. 
coli’s cytoplasm.  
 
2.2.1 In vivo Display (IVD) 
The system’s advantages include deferment of membrane permeability concerns402 and 
delivery of the antimicrobial until after hit discovery (Figure 2.2, 2.3).  With advancements in cell 
specific delivery mechanisms that can overcome the shortfalls of the molecular constraints of a 
drug, such as vector conjugation,403; 404 delivery of a non-permeable peptide is of diminishing 
importance to finding a peptide that is antimicrobial.  Screens for antimicrobials have been 
utilized with success in the past including the use of peptide libraries.376; 377; 378  However, these 
screens are carried out entirely or partially in vitro with the crucial bait-target interaction step 
occurring in vitro in a simulated environment.  This requires the identification and synthesis or 
purification of an appropriate target beforehand and the assumption that said target is folding in 
to the correct bioactive form.  It should also be noted that targets such as enzymes and possibly 
others, have numerous conformations in vivo that are influenced by what is in their environment.  
70 
 
 
 
Transition states are ephemeral conformations where the enzyme is briefly interacting with its 
substrate and are difficult to mimic in vitro, but present a viable target, as trapping the 
target/substrate complex in a single conformation prevents its cellular activity.405  Multi-protein or 
biomolecule complexes are also difficult to maintain in vitro or to define due to their weak 
interactions.  Weak and transitory, unknown interactions or unidentified targets are not a 
concern with IVD.  The selection of antimicrobial peptides in vivo obviates prior knowledge of 
the target as we are operating within a functional bacterial cell where all relevant processes are 
being carried out.   
There is, however, the difficulty of producing a growth environment that mimics the one 
the bacteria encounters either in its reservoir or in an active infection.  We argue that the basic 
processes of the bacterium such as translation, transcription, DNA replication, cell 
wall/membrane production and synthesis of biomolecules among others, which encompass the 
majority of processes occurring in the bacterium and are generally the targets of traditional 
antibiotics, proceed likewise in typical rich growth medium utilized in a laboratory setting.   
 
Figure 2.2:  In vivo display.  Display protein-peptide fusions expressed within the cell from the 
resident plasmid can bind to cellular components.  If the components are essential for cellular 
growth or reproduction, we can isolate the originating plasmid and obtain the growth affecting 
peptide. 
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Figure 2.3:  In vivo display utilizes the expression of a display protein-peptide fusion from a 
plasmid within a host cell.  The host cells affected by the fusion protein can then be selected for 
and the plasmid recovered and sequenced to attain the growth effecting peptide sequence.  An 
affinity tag aids in purification of the display protein-peptide fusion with or without its target 
bound. 
 
2.2.2 Vector Construction 
For expression, a plasmid containing the PBAD promoter was used.  This promoter 
enables multiple levels of transcriptional control.  AraC, the regulatory protein of the PBAD 
promoter expressed from the plasmid can have its conformation and hence it’s binding sites 
affected by three regulatory molecules.  Glucose acts as a catabolite repressor,406 in its 
presence expression is shutdown.  Arabinose, when glucose is not present, induces 
transcription from the promoter via interactions with AraC.407; 408; 409  Fucose, a competitive 
inhibitor for arabinose’s allosteric binding site on AraC,410; 411 represses induction in the 
presence of arabinose.   
The complete gene expression system was placed in a plasmid derivative of pCC1BAC 
from Epicentre Biotechnologies (a division of Illumina, Inc., Madison, WI) (Figure 2.4), 
pBacEmGH (Figure 2.5).  This plasmid was constructed with two replication origins to control its 
copy number in the cell.412  We selected this plasmid to mitigate the effects of leaky expression 
from the PBAD promoter, which could pre-screen our library during its construction if low levels of 
a particularly lethal peptide slowed the growth or killed its host cell it would not be present in the 
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final library for selection.  The default F plasmid origin maintains the pBacEmGH at ~1 copy per 
cell.413  When using the E. coli strain EPI300 or EPI301, an amber suppressor derivative of 
EPI300, a genomic copy of the trfA gene under the control of the PBAD promoter permits the 
activation of the R2K replication origin also present on pBacEmGH.  The addition of arabinose, 
as an inducer of trfA expression, increases the copy number of pBacEmGH to ~20 per cell.414  
Therefore, the addition of arabinose to a culture of E. coli EPI301 cells containing pBacEmGH 
induces expression of the EmGFP-peptide fusion and concomitantly increases the amount of 
plasmid in the cell 5-10 fold resulting in a flood of fusion proteins. 
 
 
 
Figure 2.4:  pCC1BAC, obtained from Epicentre Biotechnologies, has two replication origins.  
The F plasmid origin (sopA, B, C) maintains the plasmid at 1-2 copies per cell.  In the strain E. 
coli EPI300 copy number can be increased by the addition of L-arabinose inducing a genomic 
copy of R2K replication protein, trfA, that in conjunction with oriV increases copy number to 10-
20 copies per cell. 
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Figure 2.5:  pBacEmGH is derived from the commercial plasmid pCC1BAC which includes two 
replication origins for inducible copy number and cat for chloramphenicol resistance.  The PBAD 
promoter and araC controlling the expression of emgfp were cloned in prior to the inclusion of 
the peptide library. 
 
 
 
Figure 2.6:  In vivo display utilizes the expression of a display protein-peptide fusion from a 
plasmid within a host cell.  The host cells affected by the fusion protein can then be selected for 
and the plasmid recovered and sequenced to attain the growth effecting peptide sequence.  An 
affinity tag aids in purification of the display protein-peptide fusion with or without its target 
bound. 
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A peptide library, fused to EmGFP, was placed under the control of the PBAD promoter 
(Figure 2.6).  The library was comprised of twelve, random amino acids.  The length was 
selected to increase the chances of a functional motif of three or four amino acids occurring 
within the span but also to hamper the formation of secondary structures (α-helixes, β-sheets) 
that may obstruct binding.415; 416  The library was encoded by twelve NNK codons whereas N 
represents any base (A, C, G or T) and K represents either G or T to preclude occurrence of two 
stop codons.  The amber suppressor E. coli strain, EPI301, was constructed to avoid the third 
stop codon.417  This DNA sequence was then placed at the C-terminus of Emerald Green 
Fluorescent Protein (EmGFP),418 a GFP derivative engineered for efficient expression in E. 
coli,419 which served as a display protein.  A display protein serves numerous functions in the 
selection.  It provides conformation stability by presenting the peptide as a linear, unstructured 
chain of amino acids, similar to coat protein pIII in M13 phage display libraries.420  The low 
energy β-barrel conformation of EmGFP421 helps prevent the peptide from folding, an effect that 
may cause the peptide to lose activity later when it is expressed in the absence of the display 
protein.  It increases solubility,422; 423 decreasing agglutination of hydrophobic peptides in the 
library permitting resolution of these conflicts later in the development process and decreases 
the rate of proteolytic degradation commonly seen with small peptides.424  A histidine affinity tag 
(His6)425 on the opposing N-terminus of the random peptide library is used for purification of the 
EmGFP-peptide fusion for studies in vitro or to identify targets bound to the peptide.  Finally, 
monitoring EmGFP’s innate fluorescence, correlated to its expression levels, aids in the 
determining successful transcription/translation of the peptide-EmGFP fusion, lethal 
concentration, and purification.  A short linker encoding the amino acids Gly-Gly-Gly-Glu was 
used to attach EmGFP at its C-terminus to the random peptide library.  This linker was utilized 
by Tao, et al. to confirm the in vivo activity of an antimicrobial peptide fused to a display 
protein.378  The intention is to provide rotational freedom of movement to the peptide increasing 
its chances to bind to a target. 
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2.2.3 Selection 
A random pool of peptides twelve amino acids in length composed of any of the twenty 
natural residues has a diversity of 2012 members.  To isolate rare, antimicrobial peptides from a 
background of non-inhibitory peptides we necessarily need a high-throughput selection.  To 
achieve this, a random peptide library within the pBacEmGH plasmid was transformed into E. 
coli EPI301 cells.  This produces ~109 cells containing plasmids that encode for unique 
peptides.  The cells are grown to mid-log phase when the slowing of growth or death of cells by 
encoded antimicrobial peptides would produce the largest contrast with neighboring, unaffected 
cells expressing non-inhibitory peptides.  During this period of growth, the cellular processes 
essential for growth such as translation, transcription, DNA replication and cell wall/membrane 
synthesis which are targets of traditional antibiotics, are most critical due to increased cellular 
growth and replication.  
At this point the selection diverges theoretically depending on the desired growth 
inhibiting phenotype of the peptides to be isolated.  The phenotypes produced by the peptides 
being expressed within the host cells fall into five categories that are the basis of their 
separation 1) non-inhibitory, 2) bacteriolytic, 3) bacteriostatic, 4) bactericidal, and 5) growth rate 
reducing.  Non-inhibitory peptides comprise the vast majority of the pool.  The objective of the 
selection is to specifically enrich the isolated pool of peptides for those that affect cellular 
growth.  The enrichment for bacteriolytic peptides is the simplest approach (Figure 2.7).  In a 
culture containing ~109 cells, plasmids encode for peptides of various growth phenotypes.  
Arabinose is added to induce expression of EmGFP-peptide fusions in each cell of the culture.  
Host cells expressing non-inhibitory peptides are unaffected by the accumulation of peptide 
fusions in their cytoplasm and continue to grow and replicate. Cells containing bacteriolytic 
peptide-encoding plasmids, however, produce peptide fusions to a minimum inhibitory 
concentration leading to cell lysis.  Upon lysis, the cellular components of the cell are released 
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into the medium.  Among the extricated items is the plasmid encoding the bacteriolytic EmGFP-
peptide fusion.  This leaves the bacteriolytic peptide-encoding plasmids in the medium while 
non-inhibitory peptide-encoding plasmids remain within their host cells.  By centrifugation, whole 
cells can be separated from the media, leaving the remains of the lysed cells in the supernatant.  
Plasmid DNA is then recovered by alcohol precipitation.  
 
 
Figure 2.7:  Selection for the isolation of bacteriolytic peptide-encoding plasmids. 
 
The isolation of bacteriostatic and bactericidal peptide-encoding plasmids requires an 
extra step of negative selection.426  Bacteriostatic agents reversibly inhibit a cell’s ability to 
replicate.37  Therefore if the agent was removed, the cell would resume growth and 
reproduction.  Bacteriostatic agents include viable antibiotics such as the tetracyclines,427 
marcolides,428 lincosamides,429 and the sulfonamides.430  Bacteriostatic antibiotics are viable 
treatments for an infection to inhibit its further growth, allowing the immune system to remove it 
entirely.  Bactericidal agents cause irreversible cell death.  This distinguishes them from 
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bacteriostatic agents by the reversibility of their effect and bacteriolytic agents by the 
preservation of the cell’s integrity.  A mixed culture of non-inhibitory, bactericidal- and 
bacteriostatic-encoding plasmid containing cells are grown to mid-log phase and induced with 
the addition of arabinose (Figure 2.8).  Cells containing non-inhibitory peptide-encoding 
plasmids continue to growth at a slightly reduced rate.  Cells containing bacteriostatic peptide-
encoding plasmids will produce the bacteriostatic peptide until the minimum inhibitory 
concentration is achieved that reversibly prevents the reproduction of the cell or causes them to 
become dormant.  Bactericidal peptide-encoding plasmids kill their host cells irreversibly but the 
cells remain whole and intact.  After the cells accumulate a potentially lethal amount of peptide, 
ampicillin is added to the culture at a high concentration.  Ampicillin is a β-lactam antibiotic that 
inhibits peptidoglycan synthesis causing dividing cells to lyse.431  This negative selection lyses 
the cells harboring plasmids encoding non-inhibitory peptides as they continue to replicate.432  
Cells expressing bacteriostatic and bactericidal peptides are unable to divide and are not 
susceptible to the ampicillin treatment.  In a reversal of what was carried out extracting the 
bacteriolytic peptide-encoding plasmids above, the culture is centrifuged to pull down the whole, 
intact cells and the supernatant containing the cell contents of the non-inhibitory peptide-
encoding plasmid host cells is disposed.  The pellet is then treated with a typical alkaline lysis 
procedure to extricate the bacteriostatic and bactericidal peptide-encoding plasmids.433  
Alternatively, for the bacteriostatic-encoding plasmids, further enrichment is achieved by 
resuspending a portion of the pellet in fresh medium with glucose to repress expression and 
grown overnight to recover cells that contain bacteriostatic peptide-encoding plasmids.  The 
same procedure may be repeated multiple times to enrich for the plasmids. 
A confirmation step is necessary due to the mechanical lysis of cells during the selection 
that releases non-inhibitory peptide-encoding plasmids in the bacteriolytic procedure or simply 
not having all non-inhibitory host cells lyse in the bactericidal/bacteriostatic procedure.  Plasmid 
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preparations from the selections are retransformed into fresh E. coli EPI301 cells and plated on 
repression medium containing glucose. The resultant colonies are then replica plated onto 
induction medium containing arabinose to induce expression of the fusion.  Colonies that form 
on the repression medium but fail to grow on the induction medium are selected for further 
analysis. 
 
 
Figure 2.8:  Selection for the isolation of bacteriostatic- and bactericidal-peptide encoding 
plasmids. 
 
2.3 Objective of the Project 
 The objective of this project is to develop a system and utilize it for the isolation of 
antimicrobial peptides active in the cytoplasm that may be leads in the development of new 
antimicrobials. 
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2.4 Results 
2.4.1 Vector Construction 
 The system plasmid pBacEmGH (Figure 2.5) was constructed by modifying the 
inducible copy number plasmid pCC1BAC412 (Figure 2.4) from Epicentre Biotechnologies (a 
division of Illumina, Inc., Madison, WI).  The EmGFP418 gene under the control of the PBAD 
promoter and araC407 were spliced from pKan-EmGH, a derivative of pKan5-T1T2, and placed 
into pCC1BAC, producing pBacEmGH.  The presence of the CAT (chloramaphenicol 
acetyltransferase) gene enables the selection of transformants.  EmGFP was placed under the 
transcriptional regulation of the PBAD promoter so expression can be modulated by the addition 
of L-arabinose,409 D-glucose406 or D-fucose.410   
 
2.4.2 System Confirmation 
 To confirm the system, a known, ribosomally-synthesized, antimicrobial peptide, 
pyrrhocoricin, was placed at the C-terminus of EmGFP.  Pyrrhocoricin is a 20 amino acid 
bactericidal peptide that binds to and inhibits the heat-shock protein DnaK in E. coli.279  The 
entire pyrrhocoricin DNA sequence was placed at the 3’ end of EmGFP gene with a DNA 
sequence encoding a linker peptide joining the two.  The linker was composed of a repeat of the 
final five amino acids of EmGFP, Asp-Glu-Leu-Tyr-Lys.  The modified pBacEmGH plasmid with 
pyrrhocoricin, pBacEmGH-Pyr (Figure 2.9), was transformed into E. coli EPI301 cells.  Cultures 
of pBacEmGH-Pyr were grown in tandem with pBacEmGH, an EmGFP-only control, to early log 
phase.  L-arabinose was added to the cultures at a concentration of 0.2% to induced expression 
of EmGFP or EmGFP-pyrrhocoricin fusions.  The growth of the cultures was followed at λ = 600 
nm. The induced culture expressing only EmGFP grew more slowly compared to the uninduced 
culture of pBacEmGH.  This is likely an effect of EmGFP over-expression (Figure 2.10).  The 
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induced culture of EmGFP-pyrrhocoricin decreased in growth rate greater than that observed 
with the induced culture of EmGFP alone.  Expression levels of EmGFP or EmGFP-
pyrrhocoricin were approximated by the amount of fluorescence of the cultures divided by their 
turbidity or cell density (Figure 2.11).  Rates of EmGFP production were consistent throughout 
the growth of the cultures.  The rate of EmGFP-pyrrhocoricin was reduced compared to the 
EmGFP-only control. 
 
 
Figure 2.9:  pBacEmGH-Pyr contains EmGFP under the control of the PBAD promoter with a C-
terminally attached 20mer pyrrhocoricin peptide.  Pyrrhocoricin is attached to EmGFP via a 5 
amino acid linker comprised of a repeat of the final 5 amino acids of EmGFP to provide 
sufficient space for the peptide to bind its target, DnaK. 
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Figure 2.10:  Induced growth curve of cultures expressing EmGFP only or EmGFP fused to 
antimicrobial peptide, pyrrhocoricin at the C-terminus. 
 
 
Figure 2.11:  Levels of EmGFP or EmGFP-pyrrhocoricin production in cells exposed to inducer, 
L-arabinose. 
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2.4.3 Library Construction & Selection 
 Primer extension reactions were used to generate the random peptide inserts (Figure 
2.12) that were then cloned into pBacEmGH at the C-terminus of EmGFP (Figure 2.3).  A 
library of ~1.4 x 108 clones was created by transforming the above ligated clones into highly 
electro-competent, E. coli NEB 10-β cells.  Once the library was purified as DNA, it was 
transformed into E. coli EPI301 cells, moved to LB + 25 µg/mL Cm and incubated until mid-log 
phase.  L-arabinose was added to a concentration of 0.2% to induce the expression of EmGFP-
peptide fusions.  Incubation continued allowing EmGFP-peptide fusions to accumulate within 
the host cells’ cytoplasm.   
 
 
 
Figure 2.12:  Primer extension reactions were used to generate the random peptide encoding 
DNA library for insertion into pBacEmGH. 
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Bacteriolytic peptide selection  A sample of the culture was then centrifuged and the 
bacteriolytic peptide-encoding plasmids in the supernantant harvested by alcohol precipitation.   
Bacteriostatic and bactericidal peptide selection  To the remaining culture, ampicillin was 
added to lyse cells that were still able to reproduce.  When the turbidity of the culture had 
reached a minimum, as observed at λ = 600 nm, indicating the completion of cell lysis, the 
culture was centrifuged and the pellet was saved and treated to extract the 
bacteriostatic/bactericidal peptide-encoding plasmids.   
The selection procedure was repeated four times on the same ~1.4 x 108 member 
library.  In total, across the four selections, ~2 x 108 transformants were screened.  After replica 
plating to ensure activity, 39 clones were identified as having an antimicrobial effect on E. coli.  
Each of these clones had their growth effecting peptide sequence derived from DNA 
sequencing the plasmid that encoded them (Table 2.1). 
 
2.4.4 Characterization of Peptides 
2.4.4.1  Phenotypes of Peptides 
 Isolated clones, in order to classify their growth phenotype, were subjected to growth 
curves by monitoring their optical densities with or without the expression of the EmGFP-peptide 
fusion.  E. coli EPI301 cells containing the clones extracted from the screens were grown in LB 
+ 25 µg/mL Cm to early log phase accompanied by a culture  
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Table 2.1:  Amino acid sequences of all peptides from C-terminal, cytoplasmic selection 
confirmed as having an active effect on E. coli growth as determined replica plating.  Peptide 
CC130 has a two amino acid truncation making it 10 amino acids in length. 
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Figures 2.13.A-B:  Induced growth curves of isolated bacteriostatic/bactericidal peptides. 
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Figures 2.13.C-D:  Induced growth curves of isolated bacteriostatic/bactericidal peptides. 
87 
 
 
 
containing a plasmid encoding EmGFP with no C-terminally attached peptide.  L-arabinose was 
added to induce EmGFP-peptide expression and at time intervals following induction, optical 
density measurements were made to approximate the number of cells in the culture.  When 
measuring optical density, peptides can be classified based on the behavior of the culture.  A 
decrease in optical density correlates with fewer whole cells due to lysis.  If the optical density of 
the culture does not change over time after a period following induction then the amount of cells 
is not changing and the culture is no longer growing.  This could mean the cells are either dead 
(bactericidal) or in dormancy (bacteriostatic) (Figures 2.13.A-D).   
A final phenotype that we had not initially expected also occurred.  A population of the 
peptides isolated did not fall into any of the categories described above.  The optical densities of 
the cultures do not decrease or stop but increase at a lower rate than the uninduced cultures.  
This suggests that the peptides cannot attain a lethal concentration in the cytoplasm possibly 
because the peptide binds weakly to its target or limits its own expression by inhibiting upstream 
processes.  These weakly inhibitory or growth rate reducing peptides are still viable candidates 
for antimicrobial leads (Figures 2.14.A-D).   
In total, 18 bacteriostatic/bactericidal peptides, 19 growth rate reducing peptides and one 
bacteriolytic peptide were recovered.  Peptide CC001 was the lone bacteriolytic peptide isolated 
(Figure 2.13.A); demonstrating only slight, but consistent lysis of its host culture. 
 
2.4.4.2  Expression Analysis 
Simultaneously with the growth curves, the amount of fluorescence of each culture was 
measured approximating the amount of EmGFP-peptide fusion produced.  These levels varied 
among the clones (Figures 2.15.A-F).  CL015, CC021, CC042, CC053, CC080, CC098, 
CC100, CC114, and CC122 had levels of fluorescence/cell indicating there was production of 
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the fusion, in comparison the remainder of the clones that failed to produce appreciable levels.  
No clone was able to produce as much EmGFP-peptide fusion as the EmGFP-only control that 
had no peptide fused to its C-terminus. 
 Clones failing to produce observable levels of EmGFP-peptide fusion are categorized 
into two groups; those that are bacteriolytic or bacteriostatic/bactericidal, such as CC001, 
CC015, CC026, CC046, CC057, CC066, CC078, CC098, CC102 and CC127 and those that are 
growth rate reducing or weakly inhibitory, such as CL011, CC006, CC009, CC013, CC023, 
CC028, CC055, CC058, CC069, CC077, CC084, CC086, CC090, CC106, CC112, and CC117.  
The bacteriostatic/bactericidal peptides may be inhibitory at low concentrations requiring only a 
small amount of EmGFP-peptide fusion to be produced prior to the shutdown of all cellular 
processes.  Other bacteriostatic/bactericidal clones demonstrating larger amounts of 
fluorescence/OD600 might be inhibiting processes downstream of translation thus halting cell 
growth but permitting the continued expression of the EmGFP-peptide fusion.  Growth rate 
reducing peptides demonstrating low amounts of EmGFP-peptide production may reflect the 
activity of the peptide.  If the peptides’ are ribosome inhibitors, they may bind to the ribosome 
during their own translation and inhibit the completion of the process.434; 435; 436  This seems 
unlikely as the peptides would be the final portion of the fusion to be  
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Figures 2.14.A-B:  Induced growth curves of isolated growth rate reducing or weakly inhibitory 
peptides. 
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Figures 2.14.C-D:  Induced growth curves of isolated growth rate reducing or weakly inhibitory 
peptides. 
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translated, but could result in the accumulation of stalled ribosomes that fail to kill the cell, but 
slow its growth due to ribosome sequestration.  If these peptides were introduced as 
exogenous, synthetic peptides it may be possible to attain a lethal, intracellular concentration 
not achievable due to the stalling of host ribosomes. 
 
2.4.4.3  Target Identification 
 A histidine affinity tag (His6) was attached to the EmGFP-peptide fusion on the N-
terminus for the purification of possible EmGFP-peptide and target complexes.  Each clone was 
grown to mid-log phase; L-arabinose was then added to induce EmGFP-peptide fusion 
expression.  The culture was then given time to accumulate fusion proteins and allow them to 
bind to their targets.  The cells were lysed and incubated with Ni conjugated magnetic beads for 
purification via the His6 tag.  Various modifications to increase the amount of fusion protein 
purified included strengthening the target-peptide interaction via cross-linking and substituting 
the His6 tag with a Strep (II) tag.437   
Given the amount of protein in the cell and the number of viable binding sites on proteins 
in general, we assumed that the targets would tend to be proteins versus RNA, DNA, lipids or 
small molecules.  Samples of His6 pulldown experiments were analyzed by SDS PAGE and 
compared to an EmGFP-only control (MW: 31.5 kDa) to identify any binding partners of the 
peptides.  Results varied from peptide to peptide (Figures 2.16.A-D).  One obstacle was the 
amount of EmGFP-peptide produced before cell death which limited the amount capable of 
being purified.  Some clones produced no   
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Figures 2.15.A-B:  Levels of EmGFP-peptide expression by different C-terminal, cytoplasmic 
clones.  Fluorescence of cultures of clones and EmGFP only (no peptide) control was measured 
at different time intervals following induction with L-arabinose and divided by the optical density 
(A600) of the culture. 
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Figures 2.15.C-D:  Levels of EmGFP-peptide expression by different C-terminal, cytoplasmic 
clones.  Fluorescence of cultures of clones and EmGFP only (no peptide) control was measured 
at different time intervals following induction with L-arabinose and divided by the optical density 
(A600) of the culture. 
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Figures 2.15.E-F:  Levels of EmGFP-peptide expression by different C-terminal, cytoplasmic 
clones.  Fluorescence of cultures of clones and EmGFP only (no peptide) control was measured 
at different time intervals following induction with L-arabinose and divided by the optical density 
(A600) of the culture. 
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visible bands outside of those observed in all lanes or the EmGFP-only lane, which had no C-
terminal peptide, reducing its MW.  Other clones, CL015, CC042, CC053, CC077, CC098 and 
CC114, show unique bands that may constitute protein binding partners.  Numerous clones had 
doublets near the MW of the EmGFP-peptide band.  These may be binding partners, 
degradation products of the fusion protein or isoforms of the EmGFP-peptide fusion.   
 
 
Figure 2.16.A:  His6 affinity tag pulldowns run of SDS PAGE of various C-terminal, cytoplasmic, 
growth-affecting peptides.  Arrows indicate protein bands not consistently observed in other 
clones’ lanes or the EmGFP-only lane.  Adjacent lanes are from same gel but have been spliced 
together to remove lanes of non-inhibitory peptides. 
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Figures 2.16.B-C:  His6 affinity tag pulldowns run of SDS PAGE of various C-terminal, 
cytoplasmic, growth-affecting peptides.  Arrows indicate protein bands not consistently observed 
in other clones’ lanes or the EmGFP-only lane.  Adjacent lanes are from same gel but have 
been spliced together to remove lanes of non-inhibitory peptides. 
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Figure 2.16.D:  His6 affinity tag pulldowns run of SDS PAGE of various C-terminal, cytoplasmic, 
growth-affecting peptides.  Arrows indicate protein bands not consistently observed in other 
clones’ lanes or the EmGFP-only lane.  Adjacent lanes are from same gel but have been spliced 
together to remove lanes of non-inhibitory peptides. 
 
 
 
Figure 2.17:  His6 affinity tag pulldown of CC066 using a 0.09% formaldehyde cross-linking step 
to help identify protein targets.  Arrows indicate two bands forming a duplex that run at a lower 
MW than EmGFP-CC066 fusion. 
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In a second set of pulldown experiments, we added a reversible cross-linking step during 
the purification process using 0.09% formaldehyde.438  For clone CC066 (MW: 33.4 kDa) this 
revealed two strong bands of interest (Figure 2.17).  Both bands were analyzed using mass 
spectrometry (Table 2.2).  Enzyme inositol 1-monophosphatase (SuhB)439 was proposed as 
being the high MW band.  To confirm SuhB is the target of CC066, we performed a rescue 
assay.  The gene, suhB, was cloned into plasmid pKan-EmGHB2 (Figure 2.18) containing the 
neo gene encoding kanamycin resistance, the p15A replication origin (compatible with 
pBacEmGH) and the PLac promoter.  This plasmid was co-transformed with pBacEmGH 
containing CC066.  As a control pKan-EmGHB2 (containing only EmGFP behind the PLac 
promoter) was also co-transformed with CC066.  The two clones were grown in tandem and 
given various inducers (IPTG for PLac expression, L-arabinose for PBAD expression) for the 
expression of the EmGFP-CC066 fusion only, SuhB/EmGFP only (on pKan plasmid), neither, or 
EmGFP-CC066 fusion and SuhB/EmGFP.  The optical density of each culture was measured at 
time intervals following induction to follow the growth of the culture (Figure 2.19.A-B).  If SuhB 
 
 
Table 2.2:  Mass spectrometry results of both bands extracted from CC066 cross-linking, His6 
affinity tag pulldown.  Comparison of MW’s of potential targets led us to select SuhB for further 
analysis. 
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Figure 2.18:  pKan-SuhBB2 contains the gene for inositol 1-monophosphatase (suhB) under 
the control of the PLac promoter.  It was co-transformed with pBacEmGH CC066 for a rescue 
assay to confirm whether or not SuhB is the target of peptide CC066. 
 
 
Figure 2.19.A:  Rescue assay of CC066 peptide’s lethal phenotype.  A) EmGFP-CC066 
complemented with EmGFP only and B) EmGFP-CC066 complemented with SuhB over-
expression.  SuhB expression shows no negation of CC066’s effect compared to EmGFP only 
over-expression. 
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Figure 2.19.B:  Rescue assay of CC066 peptide’s lethal phenotype.  A) EmGFP-CC066 
complemented with EmGFP only and B) EmGFP-CC066 complemented with SuhB over-
expression.  SuhB expression shows no negation of CC066’s effect compared to EmGFP only 
over-expression. 
 
was the target, its over-expression in the same cell expressing EmGFP-CC066 should relieve or 
negate the effect of the bacteriostatic/bactericidal peptide CC066.  No effect, however, was 
observed indicating SuhB is most likely not the target of CC066. 
 
2.4.4.4  Expression of Free Peptides 
 The display protein serves numerous purposes outlined earlier such as a structure 
stabilizer, proteolysis determent and visible means of quantification.  However, to further 
characterize the peptides as potential leads it is necessary to determine their activity outside the 
context of the fusion protein.  There are two scenarios where the EmGFP-peptide fusion is 
lethal and not the peptide as a stand-alone molecule 1) some of the final residues of EmGFP or 
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the linker peptide may contribute to the lethality of the peptide by participating in the binding 
interaction with its target and 2) the peptide’s binding to a target is not lethal, but steric 
hindrance on the part of the globular EmGFP protein may block key sites on the target, 
preventing its function.   
 To circumvent this we created a construct, pAmp-SoloTev (Figure 2.20).  The plasmid is 
a derivative of pKan5-TIT2.  The bla gene replaced neo to provide ampicillin resistance, the 
p15A replication origin was replaced with the pMB1 replication origin and finally the PBAD 
promoter was replaced with PLac.  The preceding changes were necessitated by plasmid 
compatibility for the in vivo expression of TEV protease.440  The DNA sequence encoding 
EmGFP was removed and replaced with DNA encoding a hybrid peptide comprised of the initial 
23 codons of the emgfp, demonstrated to have efficient transcription and translation, followed by 
the TEV protease recognition sequence and finally the lethal peptide sequence (Figure 2.21).  
Co-transformation with plasmids pRK603440 and pZS4int-tetR permit the in vivo expression of 
TEV protease by the addition of anhydrotetracycline (ATC) (Figure 2.22).  Following expression 
of the hybrid peptide containing a lethal peptide through the addition of isopropyl-β-D-1-
thiogalactopyranoside (IPTG), TEV protease is able to bind to its recognition sequence in the 
hybrid peptide and cleave off the lethal peptide (demonstrated in the setup of the nIVD system 
in Chapter 3), freeing it of any contextual binding concerns (Figure 2.23).  When the constructs 
were produced, DNA sequences encoding the peptides were optimized for expression within E. 
coli.  This produced mRNAs of varying sequence from the originally isolated clones (Table 2.3).  
Clones that preserved antimicrobial activity demonstrate that the peptide sequence is the active 
molecule and not the mRNA encoding them. 
 Twenty of the 39 peptides recovered from the selection were moved into the free peptide 
expression system.  Peptides were selected based on the onset of their activity (either 
bacteriolytic or bacteriostatic/bactericidal) and their EmGFP-peptide expression profile.  
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Fourteen of the 20 peptides cloned into the free peptide expression system maintained some 
level of lethality, while 6 of the peptides (CL015, CC001, CC012, CC096, CC098, and CC114) 
were non-inhibitory, in contrast EmGFP-peptide fusions (Figures 2.24.A-D). 
 
 
 
 
Figure 2.20:  pAmp-SoloTEV was constructed for the solo expression of peptides in the 
cytoplasm.  It is a derivative of pKan5-T1T2 with changes to the replication origin (pMB1), 
selection marker (bla) and promoter (PLac) to insure plasmid compatibility with pRK603 and 
pZS4int-tetR. 
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Figure 2.21:  Constructs for EmGFP-peptide fusion versus free peptide expression. 
 
 
Figure 2.22:  In vivo TEV protease processing of hybrid peptide expressed from pAmp-
SoloTEV results in non-fused, free peptide in the cytoplasm. 
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Figure 2.23:  Co-transformed plasmids with pAmp-SoloTEV for the expression of free peptide in 
the cytoplasm.  pZS4int-tetR expresses Tet repressor protein (TetR) that turns off expression 
from the PTet promoter controlling TEV protease expression.  In the presence of 
anhydrotetracycline (ATC), tetR binds ATC, changes conformation and can no longer repress 
expression from PTet, allowing expression of TEV protease. 
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Table 2.3:  Comparison of encoded mRNA sequences of the isolated, EmGFP-fused peptides 
versus the encoded mRNA sequences of the free peptide expression clones.  Base changes 
are highlighted in red.  Base changes for free peptide expression clones were based on 
optimization of peptides for expression in E. coli. 
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Figures 2.24.A-B:  Growth curves of C-terminal, cytoplasmic peptides expressed as free 
peptides in the absence of display protein, EmGFP.  Optical density was measured at different 
time intervals following the addition of ATC (TEV protease induction) and L-arabinose (peptide 
induction).  A culture of CC114 without the addition of L-arabinose was the uninduced control. 
107 
 
 
 
 
 
Figures 2.24.C-D:  Growth curves of C-terminal, cytoplasmic peptides expressed as free 
peptides in the absence of display protein, EmGFP.  Optical density was measured at different 
time intervals following the addition of ATC (TEV protease induction) and L-arabinose (peptide 
induction).  A culture of CC114 without the addition of L-arabinose was the uninduced control. 
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2.4.5 Antimicrobial Activity of Synthetic Peptides 
 Select peptides lethal in the absence of EmGFP were synthesized for the determination 
of antimicrobial activity when introduced to cells exogenously.  As a preliminary experiment to 
determine which peptides maintained activity high-throughput we had the peptides synthesized 
at a low purity (Desalted ~70% purity).  CL011, CC013, CC046, CC057, CC078, CC098, CC102 
and CC122 were synthesized along with a peptide that showed no antimicrobial activity in the 
cytoplasm within the system, CC028, to be used as a control against the potentially lethal 
impurities of the peptide synthesis process. 
 Minimum inhibitory concentrations (MICs) were calculated using the broth dilution 
method.441  Bacterial cells were diluted to a concentration of ~104 cells/mL in Luria-Bertani broth 
(LB)442; 443 and subjected to an array of serially diluted peptides.  These cultures were incubated 
overnight and their optical densities at 600 nm were measured to determine the amount of 
growth in the presence of the various concentrations of peptide.  The lack of activity of any of 
the peptides versus E. coli SM101, an lpxA mutant with increased membrane permeability,444 E. 
coli W3110, a ‘wild-type’ strain, and Staphylococcus aureus, a Gram-positive cocci, at 
concentrations ≤ 250 µM after having been active in the cytoplasm as free peptides indicates 
either massive levels of proteolysis or permeability concerns. 
 In an attempt to increase cell penetration, modifications were made to peptides CL011 
and CC102.  Two approaches were used: 1) increase solubility of the peptides by the addition of 
polar residues at one termini and 2) inclusion of an amino acid sequence that increases cell 
penetration.  The first derivation incorporated two lysine residues at the N-terminus of the 
peptide to both increase solubility, given the hydrophobic residue content,445; 446 and increase 
permeability.46; 447  In the second set of peptide derivatives, CL011 or CC102 were fused at their 
N-termini to a leader peptide (Cys-Phe-Phe-Lys-Asp-Glu-Leu) that Rajarao, et al. demonstrated 
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increased uptake of GFP into bacterial cells448  when present in the medium and possibly 
increase solubility due to the inclusion of charged residues.  Again, however, the peptides 
demonstrated MICs ≤ 250 µM in E. coli SM101 and S. aureus.   
 
2.5  Discussion 
 The prevalence of antibiotic resistance has necessitated a new approach for the 
identification of the next generation of antimicrobials.  High-throughput peptide screens 
including phage, mRNA, and ribosome display offer inexpensive alternatives for isolating lead 
compounds.  These methods, however, require pre-determined targets, in vitro binding which 
cannot guarantee in vivo binding conditions or conformations, and do not necessarily isolate 
peptides that inhibit the function of the target.  To circumvent these problems we developed in 
vivo display (IVD) for screening peptide libraries within E. coli cells.  Selecting peptides in vivo 
guarantees potential targets are in their active conformation and bypass cell wall penetration 
concerns that are problematic with whole cell, high-throughput screens and the high-throughput, 
phenotypic selection enriches for peptides that bind sites on viable targets that inhibit their 
function and disrupt growth. 
 To select for antimicrobial peptides in the cytoplasm (cytoplasmic IVD or cIVD) of Gram-
negative bacterium, E. coli, the vector pBacEmGH (Figure 2.5) was constructed for expression 
of our peptide library.  One concern when attempting to isolate inhibitory peptides in vivo is that 
they will destroy or inhibit the replication of the host cell and be eliminated from the final pool 
during construction of the peptide library.  To avoid elimination of highly inhibitory peptides from 
the library, we designed a vector in which both the copy number of the plasmid and the 
transcription of the fusion protein are tightly regulated by inducible promoters.  The EmGFP-
peptide fusion was placed under transcriptional regulation of the PBAD promoter,407; 408; 409 and 
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replication of the plasmid vector, a derivative of pCC1BAC, is controlled by both the F and R2K 
replication origins.412  The F-plasmid replication origin maintains the plasmid’s copy number at 
~1 per cell.413  Upon induction with arabinose, however, the R2K origin414 becomes active and 
the plasmid copy number increases to ~20 plasmids per cell.  Furthermore, PBAD promoters are 
subject to catabolite repression and are strongly inhibited by the addition of glucose to the 
growth medium.406  Thus, the system incorporates three levels of repression to prevent 
unwanted expression of the library. 
 To confirm pBacEmGH’s ability to perform its role the antimicrobial peptide, 
pyrrhocoricin was incorporated at the C-terminus of EmGFP, the location of the peptide library.  
Pyrrhocoricin inhibits the function of DnaK,279 a heat-shock protein essential for E. coli growth449 
and has an IC50 of 0.3 µM.  Expression of EmGFP-pyrrhocoricin fusions in vivo slowed the 
growth of the host cells but only slightly more than what was observed with over-expression of 
EmGFP alone.  EmGFP may interfere with pyrrhocoricin’s function decreasing its activity.  
There are instances of antimicrobial peptide (AMP) fusions nullifying the lethality of the AMP 
during recombinant expression.450; 451  Therefore, peptides whose antimicrobial activity is 
inhibited in the presence of the display protein are not captured during the selection and 
screening process in IVD. 
 We identified 39 peptides capable of affecting the growth of E. coli when expressed in 
vivo using cIVD (Table 2.1).  The peptides were isolated from a relatively small library of ~1.37 x 
106 clones from a theoretical sequence space of 2012 clones. This indicates that the cIVD 
system has the potential to produce many more antimicrobial peptides than were isolated in this 
selection and that modifications in the design, selection, and screening strategies will permit the 
isolation of peptides with a variety of characteristics. 
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The 39 inhibitory peptides were isolated using two peptide selection methods based on 
the peptide’s growth phenotype, the bacteriolytic (Figure 2.7) and bacteriostatic/bactericidal 
(Figure 2.8) peptide selections.  As expected, the bacteriolytic peptide selection did not produce 
any lytic peptides.  Mechanisms of inhibition causing cell lysis typically involve the stability 
and/or synthesis of the plasma membrane or cell wall.  The cell wall is largely inaccessible to 
most of the peptides produced by our cIVD system.  While the plasma membrane is clearly a 
potential target for the cIVD system, the potential for hydrophobic peptides to form inclusions 
and the number of potential targets in the cytoplasm may lower the chances of isolating 
peptides with activity against the membrane.  We obtained data consistent with this hypothesis 
when studying peptides isolated from the periplasmic IVD (pIVD) system (see peptides 84 Pro- 
and EO1, Chapters 5 and 6). 
 Some of the peptides we isolated with the cIVD system reduced the growth rate of their 
host cells (Figures 2.14.A-D).  Because they are clearly negatively affecting some aspect of cell 
metabolism, these peptides, while not lethal, offer possibilities for the development of 
derivatives with enhanced antimicrobial activity.  The slow growth phenotype may arise from a 
weak binding to a specific target or from binding a target that is not essential for cell growth.  
Alternatively, the peptides may inhibit some aspect of their own production such as transcription 
or translation, limiting the amount of inhibitory peptide produced to a level below that required to 
completely block cell replication.  This can be resolved by measuring the inhibitory effects of 
synthetic peptide derivatives on growing cells by determining their minimum inhibitory 
concentrations (MICs), provided that the peptides are able to gain entry into the cells.  The 
activity of the weakly inhibitory peptides can be optimized by creating derivatives using random 
mutagenesis via either mutagenic strains or a mutagenic PCR and then assaying the produced 
peptide library for greater antimicrobial activity. 
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The cIVD system isolated several clones that appeared lethal following replica plating, 
but also grew slowly in the absence of induction.  Slow growth, even in the absence of the 
inducer, arabinose, may be due to a mutation in the chromosome that affects cellular 
metabolism.  Another possibility is that the plasmids have acquired a mutation in the PBAD 
promoter controlling the transcription of an inhibitory peptide fusion, rendering it constitutive.452  
A constitutive promoter mutation would not affect plasmid copy number regulation, which is 
consistent with our observation that replication onto arabinose containing medium was lethal, 
since the plasmid copy number and therefore the amount of inhibitory peptide fusion would 
increase 20-fold. 
 The amounts of EmGFP-peptide fusion produced by the host cells were monitored by 
measuring the fluorescence of the host culture.  Interestingly, a majority of the inhibitory clones 
produced small amounts of EmGFP-peptide fusion.  This includes both 
bacteriostatic/bactericidal and weakly inhibitory peptides (Figures 2.15.A-F).  The lack of 
fluorescence among the bacteriostatic/bactericidal peptides may reflect the lower concentrations 
of EmGFP-peptide necessary to inhibit processes upstream of the peptide’s own translation 
thus inhibiting the continuation of EmGFP-peptide production.  Weakly inhibitory peptides with 
low levels of fluorescence, as previously outlined, may be inhibiting their own translation and 
stalling their host ribosome434; 435; 436 (Figure 2.25), reducing the amount of viable ribosomes 
available for normal translation requirements, thus slowing growth or may be reducing some 
other metabolic process that affects transcription or translation. 
 IVD was designed with the intention of isolating lead peptides for antimicrobial 
development and the identification of novel targets or novel binding sites on established targets.  
The His6 affinity tag was added to the N-terminus of the EmGFP-peptide fusion to facilitate 
isolation and identification of peptide targets.453  Our efforts to identify the targets of several of 
our inhibitory peptides using immobilized metal affinity chromatography (IMAC) and 
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formaldehyde cross-linking454 were not successful.  This may be because the targets for these 
peptides are not proteins, or because we were unable to obtain a sufficient amount of target 
bound to the peptides.  The use of other cross-linking strategies,455; 456; 457 radioisotope 
incorporation paired with macromolecule purification to identify what the nature of the target 
is,458; 459; 460 and 2D gels to look at the effects of inhibition on the protein profile of the host cell461; 
462 are future possibilities in determining the identity of the target.  More complex methods such 
as resistance selection, with or without the use of mutagens, for the construction of a genomic 
library to be used to identify genes or mutations involved in resistance463; 464 could be used for 
more difficult peptides.   
 
 
Figure 2.25:  Schematic of potential interaction between a C-terminally fused peptide and its 
translating ribosome.  Binding of a peptide to the peptidyltransferase center or the peptide exit 
channel could inhibit further translation and stall the ribosome, sequestering ribosomes 
translating the fusions in the cell and leading to the inhibition of growth.  The inability of EmGFP 
to fold properly due to incomplete translation would explain the lack of fluorescence. 
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 All of the peptides isolated in our initial selection and screen were bound to the C-
terminus of the display protein, EmGFP418 (Figure 2.3).  It has been shown that the presence of 
the display protein can affect binding of the peptide to its target.450; 451  To analyze a peptide’s 
activity outside of EmGFP’s context, we constructed a system for the expression of free 
peptides in the cytoplasm (Figures 2.20-21).  This system, outlined and confirmed in Chapter 3, 
incorporates the in vivo expression of TEV protease440 (Figure 2.22).  Of the 39 peptides 
isolated from the C-terminal, cytoplasmic selection, 20 were cloned into the system based on 
the onset of their activity following induction.  It is possible that the weakly inhibitory peptides, 
which were not expressed as free peptides, may be further characterized as either non-
inhibitory or having an altered phenotype when expressed as free peptides.   Of the peptides 
cloned into the system, 14 retained some level of antimicrobial activity (Figures 2.24.A-D).  
During the cloning procedure DNA sequences of each peptide were optimized for E. coli 
translation, producing mRNAs of variable sequence compared to the isolated clones (Table 
2.3).  The 14 peptides that retained their antimicrobial activity as free peptides do not require the 
adjacent EmGFP amino acids for their activity and are sufficiently stable in the absence of the 
display protein to attain inhibitory concentrations following induction.  Thus, these peptides are 
viable candidates for further analysis as lead compounds.  For the six peptides that did not 
retain activity as free peptides, the loss of antimicrobial activity may be due to proteolytic 
degradation of the peptides,465 the loss of their original folding context in the absence of the 
linker or neighboring amino acids of EmGFP, or the mRNA sequences of the isolated clones 
were the causation of antimicrobial activity.466 
 Next, the most active 8 of the 14 peptides that retained activity as free peptides were 
synthesized and tested for their ability to inhibit the replication of growing cultures in MIC 
assays.441  None of the peptides tested, however, had any activity against E. coli strains or S. 
aureus.  To determine if solubility was responsible for the loss of activity in the synthetic 
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peptides, two of the peptides were mutated to increase solubility, but were also non-inhibitory.  It 
is possible that these peptides were unable to enter the cells.  One of the strengths of the IVD 
system is that during the initial selection and screen, the peptides are produced within the cell 
and potentially useful leads are not eliminated based on their inability to penetrate the cell wall 
and enter the cytoplasm.  We know these peptides are lethal when expressed within the 
cytoplasm of E. coli absent a fusion with EmGFP, necessitating further study using vectors to 
facilitate cell penetration403; 404 to further prove in vivo display fills a gap in the search for new 
antimicrobials. 
 
Table 2.4:  Amino acid sequences of isolated bacteriostatic/bactericidal peptides that exhibited 
bacteriostatic/bactericidal activity as free peptides. 
 
 The six peptides demonstrating a bacteriostatic/bactericidal effect in the free peptide 
expression assays (Table 2.4) are the strongest candidates for possible development.  Four of 
the six peptides (CL011, CC046, CC057, and CC102) share similar amino acid composition 
mostly comprised of hydrophobic residues with clusters or individual hydrophilic residue 
interspersed.  CL011 has large side group, hydrophobic residues at either termini (W, Y, and F) 
with a stretch of three leucines at positions 4-6 followed by a cluster of small hydrophilic 
residues.  CC046, similar to CC057 and CC102, has greater spacing between hydrophilic 
residues.  Most of the side groups of the residues are small except for three phenylalanines 
distributed throughout the peptide at positions 2, 5 and 9 and a W and N at the C-terminus.  
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CC057, while demonstrating a similar distribution of hydrophobicity, does not contain large side 
groups except for one F at the second position and Q at the position 7.  Peptide CC102 is 
bookended by glutamines with two central, evenly distributed serine residues at positions 4 and 
8.  The small hydrophobic residues V and L comprise the majority of the remaining positions 
with two large residues at positions 5 and 9, F and W, respectively.  Alternatively, CC066 is 
comprised of 11 hydrophobic residues with a single, terminating alanine.  Eight of the 11 
positions contain large amino acids, F, W or Y.  The complete lack of charged residues, dearth 
of hydrophilic residues and occurrence of large hydrophobic residues among the five peptides 
decreases their solubility and possibly prevents their penetration of the outer membrane of the 
cell wall.402  Peptide CC078, however, greatly differs from the previous five peptides.  It is mostly 
composed of the small residue glycine,467 indicating that it has no stable structure.  Two, basic 
arginine residues are present at positions 4 and 11, the only charged residues among the six 
peptides.  Finally, two, adjacent proline residues are located in the middle of the peptide at 
positions 6 and 7, producing a significant kink in the random coil structure.   
While five of the six peptides share similar residue content, they have a level of 
dissimilarity indicating different targets.  Their lack of basic residues would disfavor interactions 
with DNA or RNA468 and it would be difficult to imagine a hydrophobic interaction with a typically 
hydrophilic active site on an enzyme.  The free peptide assays exclude the possibility that the 
peptides are forming deleterious inclusion bodies in the cell even with their high hydrophobicity.  
None of the peptides demonstrated high levels of EmGFP-peptide production, as observed with 
the EmGFP fluorescent assays (Figures 2.15.A, C-E), and quick onsets of their 
bacteriostatic/bactericidal phenotypes upon induction (Figures 2.13.A-C) indicate low 
concentrations of the peptides are sufficient to stop or severely limit E. coli’s growth.  This would 
disfavor general interactions with the hydrophobic core of the plasma membrane or their host 
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ribosome.  While their targets remain elusive, these peptides have demonstrated sufficient 
activity to warrant further investigations for their development as leads. 
The strength of IVD is the in vivo binding interactions between peptide and target 
selecting for realistically functional antimicrobial peptides.  Unfortunately, this method also 
decreases the number of peptides that can be screened in comparison to traditional peptides 
screens such as phage, ribosome and mRNA display.  We produced a library of ~1.37 x 106 
clones to verify the system’s viability.  Production of larger libraries of a billion or more clones is 
feasible with little cost with a sufficient input of time and labor.  Library construction constitutes 
the limiting factor in the isolation of antimicrobial peptides, the screening of billions peptides can 
be achieved in one day with verification of isolated clones taking a couple of days. 
 
2.6 Materials & Methods 
2.6.1 Bacterial Strains & Media 
 All experiments, unless otherwise indicated, were carried out in E. coli EPI301 a 
derivative of strain EPI300 (F-, mcrA, Δ(mrr-hsdRMS-mcrBC), Φ80dlacZΔM15, ΔlacX74, recAI, 
endAI, araD139, Δ(ara, leu)7697, galU, galK, λ-, rpsL, nupG, trfA, dhfr) obtained from Epicentre 
Biotechnologies (a division of Illumina, Inc., Madison, WI).  The amber suppressor gene, 
supE44 (glnV44), was introduced via P1 transduction from DH5α (fhuA2, Δ(argF-lacZ)U169, 
phoA, supE44 (glnV44), Φ80, Δ(lacZ)M15, gyrA96, recA1, relA1, endA1, thi-1, hsdR17) into 
EPI300 to make EPI301.  Clones were grown and maintained in Luria-Bertani (LB) medium 
containing 25 µg/mL chloramphenicol (LB-Cm25) or as with the free peptide constructs, LB 
medium containing 25 µg/mL chloramphenicol, 30 µg/mL kanamycin and 50 µg/mL 
spectinomycin (LB-Cm25Kan30Spec50).  To induce EmGFP-peptide fusions from the PBAD 
promoter L-arabinose was added to the culture at a final concentration of 0.2%.  In instances of 
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induction of expression from plasmids employing the PLac promoter isopropyl-β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM.  Induction times are 
indicated in the individual methods outlined later.  Clones encoding suspected lethal EmGFP-
peptide fusions were propagated in LB medium with the appropriate antibiotic for plasmid 
selection and 0.2% D-glucose to repress expression from either the PBAD or PLac promoters.  
Transformations were carried out via electroporation at 2.44 kV with electro-competent cells 
prepared beforehand and stored at -80 oC.  Transformed cells were recovered in SOC medium 
for 1 hour without antibiotics prior to either plating on solid media or selection. 
 
2.6.2 Enzymes & Reagents 
 Restriction enzymes, T4 DNA ligase and calf intestinal phosphatase (CIP) were 
purchased from New England Biolabs, Inc. (Ipswich, MA).  Restriction enzymes were also 
ordered from Fermentas (a division of Thermo Fisher Scientific, Inc., Glen Burnie, MD).  
Oligonucleotides, for use as primers in polymerase chain reactions (PCRs) or in the formation of 
DNA duplexes, were purchased from Integrated DNA Technologies Inc. (Coralville, IA).  Choice-
Taq™ DNA polymerase and PCR reagents were obtained from Denville Scientific, Inc 
(Metuchen, NJ).  Pfu polymerase, derived from Pyrococcus furiosus and having 3’ to 5’ 
exonuclease proofreading activity, was obtained from the Chow Laboratory in the Wayne State 
University Chemistry Department.  DNA polymerase, dideoxynucleotide mixtures and 
sequencing buffers (SequiTherm Excel™ II DNA sequencing kit) were obtained from Epicentre 
Biotechnologies (a division of Illumina, Inc., Madison, WI).  Sequencing primers for use with the 
LI-COR Biosciences Sequencer 4000L, oligonucleotides bound at the 5’ end to either 700 or 
800 IRDye®, were ordered from either LI-COR (Lincoln, NE) or Integrated DNA Technologies 
Inc. (Coralville, IA). 
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2.6.3 pBacEmGH Construction 
 CopyControl™ pCC1BAC™ was obtained from Epicentre Biotechnologies (a division of 
Illumina, Inc., Madison, WI).  It encodes chloramphenicol acetyltransferase (CAT or CmR) for 
chloramphenicol selection, β-galactosidase (LacZ) and two replication origins, those of the R2K 
and F plasmids.  When transformed into strain EPI300 (or its derivative EPI301), which contains 
a genomic copy of trfA under the control of the PBAD promoter, induction of the culture with 0.2% 
L-arabinose increases the copy number of the plasmid from 1-2 copies using the F plasmid 
replication origin to 10-20 copies using the R2K replication origin in the presence of replication 
protein TrfA.  pCC1BAC was pre-digested with HindIII and treated with CIP.  Laboratory plasmid 
pWK122 was digested with HindIII and the smaller, 568 base pair fragment was ligated with 
pCC1BAC to form a covalently closed, circular plasmid.  The resultant plasmid was transformed 
and amplified in E. coli EPI300 (Figure 2.26).   
 Placement of the random peptide library on the C-terminus of EmGFP requires the use 
of restriction enzymes BsrGI and HindIII.  pCC1BAC contains a second BsrGI recognition 
sequence in the RepE gene making library construction infeasible.  The resultant pCC1BAC 
from above was digested with BglII along with laboratory plasmid pWK122.  The products of the 
digestion were run on an agarose gel to isolate the DNA fragment containing repE and 
pWK122’s backbone.  They were cleaned and ligated to form plasmid pWKBAC.  This plasmid 
was used as a template in a PCR with oligonucleotides pwkBacBsrGI and pwkBacR (Table 
2.5).  The first primer silently removed the unwanted BsrGI recognition sequence.  The PCR 
product was fully digested with restriction enzymes PstI and NaeI, while the vector pWKBAC 
was partially digested with PstI and fully digested with NaeI.  The DNA fragments were isolated 
via gel electrophoresis, cleaned and ligated to produce pWKBACB-, identical to pWKBAC only 
with a single base mutation to remove the BsrGI recognition site.  The clone was verified by 
DNA sequencing.  pWKBACB- and pCC1BAC were both digested with BglII and the products 
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were run on agarose gels to isolate the desired DNA fragments.  The fragments were cleaned 
and ligated to form pCC1BAC without its original BsrGI recognition sequence. 
 
Figure 2.26:  Closing of pre-digested pCC1BAC from Epicentre for further cloning. 
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This plasmid was digested with restriction enzyme NotI, removing lacZ and the pWK122 
insert (Figure 2.27).  Two oligonucleotides, pBacCasUp and pBacCasDn (Table 2.5), were 
annealed forming a DNA double strand with NotI sticky ends but not NotI recognition 
sequences, negating the NotI sites upon ligation.  The resulting DNA cassette was ligated into 
the NotI digest of pCC1BAC to make pCC1Bac-NotI. 
In a separate cloning procedure, pKan-EmGH was generated from pKan5-T1T2, a 
laboratory plasmid.  pKan5-T1T2 was digested with restriction enzymes NotI and HindIII, 3’ to 
the PBAD promoter and 5’ to the transcription terminators T1 and T2 (Figure 2.28).  pRSET-
EmGFP was obtained from Invitrogen (a division of Life Technologies Corp. Grand Island, NY) 
encoding emerald green fluorescent protein (EmGFP), a GFP derivative optimized for 
expression within E. coli.  The EmGFP gene plus the elements 5’ to the gene including a His6 
affinity tag, enterokinase recognition sequence, T7 gene 10 leader, and Xpress epitope were 
amplified using oligonucleotides EmGF and EmGR (Table 2.5) in a polymerase chain reaction 
(PCR) that incorporated NotI and HindIII recognition sequences in the 3’ and 5’ ends, 
respectively.  This PCR product was digested with NotI and HindIII and ligated into the vector 
preparation of pKan5-T1T2 to make pKan-EmGH. 
 After transformation into E. coli cells for plasmid amplification, both pKan-EmGH and 
pCC1BAC-NotI were purified.  Plasmid pCC1BAC-NotI was digested with restriction enzymes 
EcoRI and KpnI via restriction sites introduced with the NotI cassette (Figure 2.29).  pKan-
EmGH was fully digested with KpnI and partially digested with EcoRI (an second EcoRI site is 
present between the PBAD promoter and emgfp).  The piece of DNA containing emgfp and the 
arabinose operon, including the promoter and regulatory protein AraC, was ligated into 
pCC1BAC-NotI to produce pBacEmGH. 
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Figure 2.27:  Construction of plasmid pCC1BAC-NotI.  Insertion of the NotI cassette included 
restriction enzyme cut sites EcoRI and KpnI need for the insertion of the arabinose promoter 
system and the EmGFP gene. 
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Figure 2.28:  Construction of plasmid pKan-EmGH.  The EmGFP gene was cloned behind the 
PBAD promoter into the backbone of pKan5-T1T2. 
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Figure 2.29:  Construction of vector pBacEmGH.  The EmGFP gene and arabinose promoter 
system from pKan-EmGH was inserted into pCC1BAC-NotI to produce the final clone for 
screening the peptide library.  
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2.6.4 pBacEmGH-Pyr Construction 
 Oligonucleotides Kragol20merPC and pKan5EmGRev (Table 2.5) were used to 
incorporate DNA encoding pyrrhocoricin at the C-terminus of EmGFP in a PCR using pKan-
EmGH as a template.  The PCR product and the vector pKan-EmGH were digested with 
restriction enzymes BsrGI and HindIII and ligated to generate plasmid pKan-EmGHPyr.  This 
plasmid and pBacEmGH were digested with NotI and HindIII.  The DNA fragment containing 
EmGFP-Pyrrhocoricin was ligated into pBacEmGH to make pBacEmGH-Pyr. 
 
2.6.5 Induced Growth Curves 
 Cultures of each clone, started with an individual colony, were incubated overnight at 37 
oC in 3 mL LB-Cm25 + 0.2% D-glucose.  The overnight cultures were diluted 1/1000 by moving 
17 µL into 17 mL LB-Cm25 and incubated until early log phase (~240 minutes).  L-arabinose 
was added to the culture to a final concentration of 0.2%.  The optical density of a 700 µL 
sample of the cultures at 600 nm was measured periodically at the point of induction and at 30 
or 60 minute intervals following induction using Spectronic® Genesys™ 20 spectrophotometer 
from Thermo Fisher Scientific, Inc. (Waltham, MA).  In the final analysis, the optical density of 
uninoculated LB broth was subtracted from the values of each clone’s culture at every time 
point. 
 
2.6.6 Random Peptide Library Construction in pBacEmGH 
 Complementary oligonucleotides EmGHCT12F and EmGHCT12R (Table 2.5), the 
former containing twelve NNK random codons, were mixed to equal molarities and subjected to 
a primer extension reaction with dNTPs, Pfu polymerase and the appropriate buffer.  The 
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product then run on a gel, the appropriate MW band was extracted and cleaned using 
QIAquick® Gel Extraction Kits from Qiagen Inc. (Valencia, CA).  The cleaned DNA was digested 
with HindIII and BsrGI.  An identical digestion was performed on the vector pBacEmGH.  The 
digestion products were run on agarose gels, the appropriate MW bands were extracted and 
cleaned using GENECLEAN® Turbo kits from MP Biomedicals, LLC (Solon, OH).  The two 
cleaned DNAs were ligated in a 2:1 insert to vector ratio using T4 DNA ligase with an overnight 
incubation at room temperature.  The ligation reactions were cleaned of protein and salts using 
GENECLEAN® Turbo kits.  Cleaned, ligated plasmid DNA was transformed into NEB 10-β 
electro-competent E. coli cells (araD139, Δ(ara, leu)7697, fhu, lacX74, galK16, galE15, mcrA, 
f80d(lacZΔM15)recA1, relA1, endA1, nupG, rpsL, rph, spoT1Δ(mrr-hsdRMS-mcrBC)) from New 
England Biolabs Inc. (Ipswich, MA).  Four hundred ng of cleaned plasmid DNA was added to 
100 µL of the electro-competent cells.  In 25 µL batches, the cell/plasmid mixture was 
electroporated at 2.44 kV.  The cells were recovered for 1 hr at 37 oC in 1 mL of SOC medium.  
Transformation was performed on 6 tubes of 100 µL of NEB 10-β electro-competent cells.  
Recovered cells were then added to 500 mL LB-Cm25 + 0.2% D-glucose and incubated 
overnight at 37 oC for clone outgrowth.  Amplified plasmid DNA was then recovered by using 
Qiagen® Maxi Plamid kits from Qiagen Inc. (Valencia, CA).  This procedure was repeated four 
times for a total of ~137 million transformants.  Portions of the plasmid preparations were mixed 
together to get roughly equal molar amounts of transformants. 
 
2.6.7 Peptide Selection Procedure 
 One hundred ng of pBacEmGH plasmid DNA encoding the random peptide library was 
mixed with 30 µL of electro-competent EPI301 E. coli cells.  The cell/DNA mixtures were 
electroporated at 2.44 kV and recovered in 1 mL of SOC medium for 1 hr at 37 oC.  This was 
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repeated for 24 transformations.  Recovered cells were centrifuged at 7,000 rpm for 5 minutes 
to pellet the cells.  The supernatant was removed and the cells were washed in 50 mL of pre-
warmed LB twice to remove any untransformed plasmid in the recovery medium.  The cells 
were then resuspended in 550 mL LB-Cm25 + 0.2% D-glucose and incubated at 37 oC and 350 
rpm.  When the cells achieved early to mid-log phase growth, the culture was centrifuged at 
7,000 rpm to pellet the cells.  The supernatant was removed and the cells washed in 50 mL of 
pre-warmed LB twice to remove any free plasmid from the sheering of cells during incubation or 
untransformed plasmids and to remove D-glucose.  The cells were then resuspended in 550 mL 
pre-warmed LB-Cm25 and incubated at 37 oC and 350 rpm.  After 30 minutes L-arabinose was 
added to a final concentration of 0.2% to induce EmGFP-peptide fusion expression and plasmid 
copy number increase.  Incubation at 37 oC continued for 90 minutes.  To isolate plasmids 
encoding bacteriolytic peptides, 21 mL of culture were removed and centrifuged at 13,000 rpm 
for 30 minutes to pellet whole cells.  The supernatant was moved to a new tube and the 
centrifugation repeated.  The supernatant was moved to a new tube with 16 mL of isopropanol, 
2.1 mL 3 M Na acetate pH 5.0 and 52.5 µL of 10 µg/mL salmon testes DNA.  The DNA serves 
as a carrier molecule during the alcohol precipitation.  The solution was inverted several times 
to mix and then centrifuged at 11,000 rpm for 45 minutes.  The supernatant was carefully 
removed and the pellet washed with 5 mL of 70% ethanol.  This was centrifuged at 11,000 rpm 
for 10 minutes and the supernatant removed.  The DNA pellet was dried and then resuspended 
in 500 µL dH2O. 
 Simultaneously with the 21 mL culture removal, ampicillin was added to the remaining 
culture to a final concentration of 500 µg/mL to lyse any actively dividing cells.  The culture 
continued to incubate at 37 oC until its optical density reached a minimum indicating all cells had 
been lysed.  The entire culture was centrifuged at 7,000 rpm for 10 minutes to pellet any whole 
cells.  The supernatant was removed and the pellet was washed in 50 mL of 4-(2-hydroxyethyl)-
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1-piperazineethanesulfonic acid (HEPES)-NaCl (HN) buffer pH 7.0 three times.  The pellet was 
then stored at 4 oC overnight (this step is unnecessary and one may proceed to the next 
incubation).  The pellet was resuspended in 30 mL of DNase I buffer (10 mM Tris HCl pH 7.5, 
2.5 mM MgCl2, 0.5 mM CaCl2) to which 25 µL of 2 units/µL of DNase I was added.  The solution 
was inverted gently to mix and incubated at 37 oC, without shaking, for 3 hours.  This step 
removes any extracellular DNA that may include plasmids from cells lysed by the ampicillin 
shock step.  The mixture was then centrifuged to pellet whole, intact cells at 7,000 rpm for 5 
minutes.  The pellet was washed with Qiagen® Midi Plasmid kit resuspension buffer (50 mM Tris 
HCl pH 8.0, 10 mM EDTA) twice to remove DNase I.  Plasmids encoding 
bacteriostatic/bactericidal peptides still contained within the whole, intact cells were extracted 
using a Qiagen® Midi Plamid kit from Qiagen Inc. (Valencia, CA). 
 Preparations of plasmids including bacteriolytic or bacteriostatic/bactericidal peptides 
were transformed into fresh E. coli EPI301 electro-competent cells and plated on LB-Cm25 + 
0.2% D-glucose so that the colonies are sufficiently separate from each other.  To confirm the 
efficacy of the selected clones, the colonies were replica plated on to plates of LB-Cm25 + 0.2% 
L-arabinose and then LB-Cm25 + 0.2% D-glucose.  The plates were incubated overnight at 37 
oC.  Colonies that failed to grow on the plate containing L-arabinose versus that containing D-
glucose were selected for further analysis. 
 
2.6.8 DNA Sequencing 
 Isolated clones were sequenced using a two-step process.   Overnight cultures were 
grown in LB-Cm25 + 0.2% D-glucose.  One µL of culture was used as template in an initial PCR 
including primers CTseqF2 and CTseqR2 (Table 2.5).  The primers are complimentary to 
sequences on either side of the randomized region.  CTseqF2 has a 5’ tail not complimentary to 
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any region in pBacEmGH, but has been selected for complementarity with a third 
oligonucleotide, JSLF (Table 2.5).  The product of the first reaction incorporates the JSLF-
complimentary tail using Taq polymerase.  The 25 µL product is then diluted in 170 µL dH2O 
and used as a template in a sequencing reaction employing dideoxynucleotide mixes and a 5’ 
IRDye®-labeled primer, JSLF.  The labeled primer binds the tail sequence permitting high-
throughput sequencing. 
 
2.6.9 EmGFP-Peptide Expression Assays 
 Assays were carried out in 96-well plates.  Cultures were started using isolated colonies 
from a streak plate in 200 µL of LB-Cm25 + 0.2% D-glucose and incubated overnight at 37 oC 
and 500 rpm in a GeneMachines HiGro® 96-well plate incubator from Digilab, Inc. (Holliston, 
MA).  Overnight cultures were diluted 1/100 by moving 2 µL into 200 µL LB-Cm25 and 
incubated at 37 oC and 500 rpm in the HiGro.  When the cultures achieved early log phase 
(~150 minutes) the optical densities of the cultures in the plate at 600 nm were measured using 
a SpectraMax 190 from Molecular Devices, Inc. (Sunnyvale, CA) and the fluorescence of the 
cultures (excitation at 395 nm, emission at 509 nm) were measured using a SpectraMax Gemini 
XPS from Molecular Devices, Inc. (Sunnyvale, CA).  L-arabinose was added to each culture to a 
final concentration of 0.2%.  Incubation was continued and at 60 minute intervals the optical 
density and fluorescence were measured as before.  During final analysis, the fluorescence at 
the point before induction was subtracted from all subsequent time values for that clone.  The 
optical density of 200 µL of LB-Cm25 was subtracted from all optical density values.  The 
fluorescence values were then divided by the optical density for each clone to normalize the 
amount of fluorescence to the number of cells in the culture. 
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2.6.10 Target Co-Purification 
 Cultures of each clone were incubated in 3 mL LB-Cm25 + 0.2% D-glucose overnight at 
37 oC.  The overnight cultures were diluted 1/1000 by adding 17 µL into 17 mL of fresh LB-
Cm25.  These cultures were incubated at 37 oC for 5 hours to mid-log phase growth to 
accumulate a large number of cells.  L-arabinose was added to induce EmGFP-peptide 
expression at a final concentration of 0.2%.  After another hour of incubation to accumulate 
EmGFP-peptide fusions within the host cells and allow them to bind their target, the culture was 
centrifuged at 7,000 rpm for 10 minutes.  To lyse the cells the pellet was resuspended in 1/17 
the original volume with BugBuster™ protein extraction reagent from EMD Millipore (a division 
of Merck KGaA, Darmstadt, Germany).  The cell solution was incubated at room temperature for 
15 minutes with occasional shaking.  In one well for each clone cultured of a 96-well plate, 15 
µL of HisMag agarose bead slurry from EMD Millipore (a division of Merck KGaA, Darmstadt, 
Germany) were aliquoted.  The plate was placed on a 96-well plate magnet and the supernatant 
of the slurry was removed.  The beads were washed in 60 µL of binding buffer (20 mM Tris HCl 
pH 8.0, 500 mM NaCl, 5 mM imidazole) three times to equilibrate the beads.  The beads were 
then resuspended in 15 µL of binding buffer before adding 170 µL of the cell lysate.  The plate 
was incubated at room temperature for 5 minutes with shaking.  It was then placed on the 96-
well plate magnet and the supernatant was removed.  Another 150 µL of cell lysate was added 
and the above procedure repeated.  The beads were then washed once with 60 µL of wash 
buffer (20 mM Tris HCl pH 8.0, 500 mM NaCl, 60 mM imidazole).  One hundred seventy µL of 
E. coli DH5 cell lysate, prepared in the same manner as the clones above, was added to the 
beads and incubated at room temperature with shaking for 5 minutes.  The plate was placed on 
the magnet and the supernatant removed.  The beads were then washed twice with 60 µL of 
wash buffer.  The His6-tagged EmGFP-peptide fusions were then eluted by resuspending the 
beads in 40 µL of elution buffer (20 mM Tris HCl pH 8.0, 500 mM NaCl, 500 mM imidazole) and 
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incubated for 10 minutes with shaking.  The plate was placed on the magnet and the 
supernatant collected.  The SDS PAGE loading buffer was added to each supernatant to make 
a final concentration for the following: 50 mM Tris HCl pH 6.8, 2% SDS, 10% glycerol, 1% β-
mercaptoethanol and 0.02% bromophenol blue.  The mixture was then denatured by incubating 
in boiling water for 5 minutes and run on SDS PAGE. 
 The procedure for cross-linking the peptide to its target involving clone CC066 had a 
modified step.  In the above procedure, when 170 µL of E. coli DH5 cell lysate was added to the 
beads, formaldehyde was added to a final concentration of 0.2%.  The succeeding steps 
remained identical to those outlined above. 
 
2.6.11 pAmp-SoloTEV Construction 
 pAmp-SoloTEV was generated as a derivative of pAmp-EmGHB2, itself a derivative of 
lab plasmid pKan-EmGH.  pAmp-EmGHB2 has numerous modifications carried out through 
simple cloning procedures.  The arabinose operon, including PBAD promoter and regulatory 
protein AraC’s gene, were replaced by the lac operon including LacUV5 promoter (PLac) and 
regulatory protein LaqIq’s gene.  Laboratory plasmid pASS2-GFP was digested with restriction 
enzymes BamHI and NotI to extricate the lac operon.  Vector pKan-EmGH, also digested with 
BamHI and NotI and ligated to the lac operon insert from pASS2-GFP removing the PBAD 
promoter but not the AraC gene to produce plasmid pKan5-EmGHB1x.  This intermediate 
plasmid was then digested with restriction enzymes SalI and BamHI, the latter only partially 
digesting the plasmid.  This was ligated to the small 275 bp fragment generated by digesting 
laboratory plasmid pKK3535 with SalI and BamHI to remove the AraC gene and its promoter.  
The resultant plasmid, pKan-EmGHB1, contains the p15A replication origin that is incompatible 
with plasmids pRK603 and pZS4int-tetR.  To rectify this, the p15A replication origin was 
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replaced with that of pMB1.  pKan-EmGHB1 was digested with restriction enzymes BglI and 
DraIII.  Oligonucleotides pBRoriFor and pBRoriRev (Table 2.5) were used with template 
pRNA228, a laboratory plasmid, to amplify the pMB1 replication origin incorporating restriction 
sites for BglI and DraIII on either end.  The PCR product was digested with BglI and DraIII and 
ligated into vector pKan-EmGHB1 to make plasmid pKan-EmGHB2.  The original neo conferring 
kanamycin resistance was replaced with bla granting ampicillin resistance.  Oligonucleotides 
pKanampF and pKanampR (Table 2.5) were used in a PCR with laboratory plasmid pUC19 to 
amplify the bla gene with added enzyme restriction sites DraIII and SalI.  The product and 
plasmid pKan-EmGHB2 were then digested with DraIII and SalI and ligated to generate pAmp-
EmGHB2. 
 Oligonucleotides encoding individual peptides (CXXXXsoloTEV e.g.  CL011soloTEV) to 
be freely expressed were paired with UniTevG-F (Table 2.5) in a primer extension reaction.  
The resulting DNA duplex encoded the TEV protease recognition sequence followed by the 
desired peptide sequence and a stop codon.  Two restriction enzyme recognition sequences, 
NheI and XbaI, were included at either end of the product.  The various DNA duplexes and 
pAmp-EmGHB2 were then digested with NheI and XbaI.  The digestion products of each primer 
extension reaction were ligated to the digested pAmp-EmGHB2 vector.  The final construct, 
pAmp-SoloTEV, replaces the EmGFP gene with a DNA sequence encoding a hybrid peptide 
with a TEV protease recognition sequence and one peptide of interest.  The oligonucleotides 
used in the construction of these plasmids changed the RNA sequence of the expressed 
peptide compared to that of the isolated clones without changing the peptide sequence as a 
consequence of optimizing the codons for over-expression in E. coli. 
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2.6.12 Free Peptide Induced Growth Curves 
 Constructs encoding each peptide of interest were transformed into E. coli EPI301 
electro-competent cells containing plasmids pRK603 and pZS4int-tetR (obtained from 
www.AddGene.org, Addgene plasmid 8831) by electroporation.  The cells were recovered in 1 
mL of SOC medium and plated on LB-Amp100Kan30Spec50 + 0.2% D-glucose medium.  The 
clones were sequenced to confirm the constructs.  Individual colonies from streak plates were 
used to inoculate 3 mL of LB-Amp100Kan30Spec50 + 0.2% D-glucose broth and incubated 
overnight at 37 oC.  The overnight cultures were diluted 1/1000 by adding 17 µL to 17 mL of LB-
Amp100Kan30Spec50 and incubated at 37 oC.  After 210 minutes of incubation, 
anhydrotetracycline (ATC) was added to a final concentration of 250 ng/mL to induce TEV 
protease expression.   Incubation continued until early-log phase was achieved after 270 
minutes.  The optical density of the culture at 600 nm was measured using Spectronic® 
Genesys™ 20 spectrophotometer from Thermo Fisher Scientific, Inc. (Waltham, MA).  
Isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added to each culture to a final concentration 
of 1 mM.  Incubation continued with the optical density being measured periodically until the 
cultures began to enter stationary phase growth.  In the final analysis, the optical density of 
uninoculated LB broth was subtracted from the values of each clone’s culture at every time 
point. 
 
2.6.13 Determination of Minimum Inhibitory Concentrations 
 Peptides were purchased from Selleck Chemicals (Houston, TX) as desalted (~70% 
purity).  Due to the hydrophobic composition of the peptides, dimethylformamide (DMF) or 
dimethyl sulfoxide (DMSO) were used to dissolve the peptides.  Stocks of each peptide at 10 
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mM were stored a -20 oC in aliquots for use in the calculation of their minimum inhibitory 
concentrations (MICs). 
E. coli strains W3110 (F-, λ-, rph-1, INV(rrnD, rrnE))  and SM101 (F-, thr-1, araC14, 
lpxA2(ts), tsx-78, Δ(galK-attLAM)99, hisG4, rfbC1, rpsL136, xylA5, mtl-1, thi-1) and S. aureus 
were streaked on solid LB medium to get individual colonies.  Cultures were started in 3 mL LB 
broth using one colony and incubated overnight at 37 oC.  Overnight cultures were estimated to 
be 109 cells/mL and accordingly serially diluted in LB broth to 104 cells/mL.  Two hundred µL of 
the final dilution were aliquoted into wells of a 96-well plate.  Peptides were diluted serially so 
that adding 5 µL of the dilution to 200 µL of culture would produce a range of final 
concentrations from 1-250 µM.  Plates containing gradients of each peptide alongside identical 
dilutions of the peptide solvents in cultures of the different species were then incubated in a 
GeneMachines HiGro® 96-well plate incubator from Digilab, Inc. (Holliston, MA) at 37 oC and 
500 rpm for 16 hours.  After incubation the plates were removed from the incubator and their 
optical densities were measure at 600 nm using a SpectraMax 190 from Molecular Devices, Inc. 
(Sunnyvale, CA).  The minimum inhibitory concentration was selected as the smallest 
concentration of peptide required to completely inhibit growth of the culture. 
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CHAPTER 3 
N-TERMINAL, CYTOPLASMIC IN VIVO DISPLAY SELECTION FOR THE ISOLATION OF 
ANTIMICROBIAL PEPTIDES IN ESCHERICHIA COLI 
 
3.1 Abstract 
 The rise of antibiotic resistance among pathogenic bacteria has necessitated a 
reexamination of our approaches to finding new antimicrobials.  Previously, we developed a 
system, cIVD, for constructing and screening peptide libraries at the C-terminus of a display 
protein within the cytoplasm of E. coli.  Positioning of peptides at either the N- or C-terminus has 
been shown to influence the ability of displayed peptides to interact with their targets.  
Therefore, we developed a second, N-terminal, cytoplasmic in vivo display system (nIVD).  A 
library of 12-amino acid random peptide sequences was added to the N-terminus of the display 
protein, Emerald Green Fluorescent Protein (EmGFP), which includes an affinity tag on its C-
terminus.   
 To prevent the randomized N-terminal sequences from affecting the translational 
efficiency of the transcripts, an efficiently translated leader was spliced to the N-terminus of the 
randomized sequence, separated by an engineered Tobacco Etch Virus (TEV) protease 
recognition sequence.  In vivo expression of TEV protease was performed from either a fusion 
vector or a separate, compatible plasmid.  During translation of the fusion construct, the leader 
peptide is cleaved from the random peptide sequence by co-expression of the TEV protease, 
leaving the random peptide at the N-terminus of EmGFP. 
 To identify novel peptides that inhibit bacterial growth, E. coli EPI301 cells expressing 
the random peptide library at the N-terminus of EmGFP were screened to select for peptides 
with bacteriolytic, bacteriostatic and bactericidal phenotypes.  A total of five inhibitory 
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transformants have been isolated in the initial selection and characterized.  Two of the isolated 
peptides had bacteriostatic/bactericidal activity and three reduced the growth rate of their host 
cells significantly.  Analysis of expression levels indicates the peptides may prevent their own 
translation by stalling their own ribosome which may ultimately lead to the death of the cell. 
 
3.2 Introduction 
3.2.1 A site Peptide 
 In its original manifestation, IVD was designed to display peptides solely at the C-
terminus of the display protein EmGFP (cIVD) (Figure 3.1).  During the design phase of the C-
terminal, cytoplasmic selection, the system of using EmGFP as a display protein was adapted 
for the study of a peptide discovered by the Chow laboratory in the Chemistry department.  The 
peptide was isolated by screening a M13 phage display library against a synthetic 
oligonucleotide mimicking the A site of the E. coli 16S ribosomal subunit.469  M13 phage display 
is a peptide screening method that has been used with success to find lead antimicrobial 
peptides.376; 377  As opposed to cIVD, the peptide is displayed at the N-terminus of a coat protein 
of the filamentous phage, M13 (Figure 3.2) instead of the C-terminus.420  Via this method the 
Chow laboratory isolated the peptide His-Pro-Val-His-His-Tyr-Gln (HPVHHYQ).   
To verify activity in vivo, the peptide was cloned into plasmid pKan-EmGHA3 (Figure 3.3), a 
forerunner of the pBacEmGH, described in Chapter 2 (Figure 3.4).  The sequence was placed 
at either terminus (N or C) of EmGFP in both the original M13 phage orientation and reverse 
orientation (HPVHHYQ versus QYHHVPH) (Figure 3.5).  These constructs were then subjected 
to induced growth curves with the addition of L-arabinose to express the A site peptide-EmGFP 
fusion.  The optical densities of the cultures were monitored at time intervals following induction.  
At the same time the level of EmGFP-peptide production was approximated by measuring the 
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fluorescence of the culture divided by the optical density.  While induced growth curves did not 
show any abnormal growth phenotypes, other than that expected from the stress of 
overexpressing the fusion protein (Figure 3.6), the EmGFP-peptide production levels showed a 
key difference (Figure 3.7).  Only the peptide whose placement and orientation perfectly 
mimicked that from the isolated M13 phage clone had no fluorescence while the other peptides 
produced copious amounts.   It was suspected that the N-terminal, M13 orientation A site 
peptide was binding to the A site of its own translating ribosome and inhibiting the completion of 
the fusion’s translation.  This and previous study of termini placement470 indicate that the 
placement of a peptide and its orientation has an influence on its activity.  Our selection, as 
described in Chapter 2, can compensate for orientation effects as long as a large enough 
portion of the potential library is screened.  Placement, however, is limited in the original design 
of cIVD to the C-terminus.  Therefore, cIVD was ignoring half of the potential antimicrobial 
peptide pool. 
 
Figure 3.1:  Methods of antimicrobial development discussed within this dissertation.  Chapter 3 
focuses on in vivo display of a random peptide library at the N-terminus of a display protein in E. 
coli’s cytoplasm. 
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Figure 3.2:  Diagram of filamentous M13 phage virion.  The genome encodes a peptide library 
fused to the N-terminus of the coat protein pIII.  The encoded peptide is displayed on all 5 
copies of pIII in the coat, enabling screening against targets in vitro. 
 
 
Figure 3.3:  pKan-EmGHA3 is a derivative of the laboratory plasmid pKan5-T1T2.  It includes a 
pUC19 replication origin, the neo gene for kanamycin selection and the arabinose operator 
including PBAD and regulatory protein AraC. Expression of EmGFP is inducible with the addition 
of L-arabinose to the growth medium. 
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Figure 3.4:  pBacEmGH is derived from the commercial plasmid pCC1BAC which includes two 
replication origins for inducible copy number and cat for chloramphenicol resistance.  The PBAD 
promoter and araC enable inducible expression of EmGFP. 
 
 
Figure 3.5:  The A site peptide was cloned into constructs fused to EmGFP at either the N- or 
C-terminus.  The orientation of the A site peptide’s amino acid sequence as it was isolated from 
the M13 phage library (HPVHHYQ) was reversed (QYHHVPH) and placed at either terminus in 
separate constructs. 
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Figure 3.6:  Growth curves of A site peptide constructs with the peptide fused to either the N- or 
C-terminus and in the original, M13 phage library orientation (HPVHHYQ) or the reverse 
orientation (QYHHVPH). 
 
 
Figure 3.7:  Levels of peptide-EmGFP expression as measured by the amount of fluorescence 
of the culture per optical density (A600) in cultures expressing N-terminally fused A site peptide in 
the original, M13 phage library or reverse orientation. 
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3.2.2 Translation Efficiency Concerns of N-terminal Display 
Comparisons of the nucleotide sequences surrounding the start codon of E. coli and S. 
typhimurium471 and other bacterial genes472 demonstrate non-randomness.  This preference 
implicates a selection based on the necessity for efficient translation.  Degenerate mutations in 
mRNA sequences, encoding the same peptide sequence, showed large variations in translation 
efficiency.473  A bias for adenine bases 3’ of the start codon indicates either specific interactions 
with the ribosome or a preference for an unstructured mRNA.474 
The latter scenario is consistent with the lack of expression of the A site peptide-EmGFP 
fusion.  The secondary structure formed by its mRNA nucleotide sequence may be obscuring its 
anti-Shine-Dalgarno sequence and disrupting interaction with the Shine-Dalgarno sequence of 
the ribosome.475  To test this, a second construct in pKan-EmGHA3 was produced encoding the 
A site peptide at the N-terminus using a DNA sequence that minimized the guanosine and 
cytosine content of the A site peptide’s mRNA.476; 477  These mutations reduced the 
thermodynamic stability of the mRNA by removing the potential stronger base pairing 
nucleotides.  The resultant mRNA’s theoretical secondary structure had a ΔG of -14.7 kcal/mol 
compared to -21.8 kcal/mol for the original construct as determined by the RNA folding program, 
MFOLD478 (Figure 3.8).  Expression of the modified A site peptide-EmGFP fusion produced 
amounts of fluorescence comparable to the reverse orientation A site peptide (Figure 3.9).  This 
indicates that the mRNA sequence located at the N-terminus was having a dramatic effect on its 
translation efficiency. 
To confirm this study a second set of constructs were generated (in collaboration with 
Dr. Tek Lamichhane of the Cunningham laboratory) with random sequences of DNA encoding 
7mer peptides at the N-terminus of EmGFP.  Ten different sequences (Table 3.1) were 
incorporated into pKan-EmGHA3 and underwent similar peptide-EmGFP production level 
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analysis by monitoring fluorescence per optical density levels following induction.  Levels of 
peptide-EmGFP vary greatly between each mRNA sequence (Figure 3.10) confirming the 
strong effect of mRNA sequence on translation efficiency documented in earlier studies.   
 
 
Figure 3.8:  Secondary structure of mRNAs encoding the A site peptide or its derivative to 
minimize the stability of the secondary structure as determined by the program MFOLD. 
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Figure 3.9:  Levels of peptide-EmGFP expression as measured by the amount of fluorescence 
of the culture per optical density (A600) in cultures expressing the original A site peptide, reverse 
orientation, or ΔG minimized constructs. 
 
 
Table 3.1:  Amino acid and mRNA sequences of random peptides fused to the N-terminus of 
EmGFP to assay their effect on translation efficiency. 
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Figure 3.10:  Endpoint expression levels of constructs expressing random peptides fused to the 
N-terminus of EmGFP compared to levels observed with the original or reverse orientation A 
site peptide. 
 
3.2.3 Vector Construction 
We have outlined the need to be able to screen a peptide library on the N-terminus of 
EmGFP in order to not omit half of the potential peptides to screen for antimicrobial behavior, 
but also that it is infeasible to simply place a random library at the N-terminus of EmGFP as it 
would vary the translation levels of each peptide in the pool.  Theoretically, a lethal peptide from 
the pool may be encoded by an mRNA that forms a stable secondary structure.  When induced 
by the addition of L-arabinose within the IVD system, only a small amount, if any, peptide-
EmGFP fusion would be produced, failing to achieve the minimum inhibitory concentration 
(MIC) of the peptide.  Therefore, the translation efficiency of the peptides’ mRNA sequences 
serve to prescreen the library indiscriminately, potentially precluding viable antimicrobial 
peptides from isolation. 
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To prevent prescreening of the library, a new vector was constructed based on 
pBacEmGH from the C-terminal, cytoplasmic selection of Chapter 2.  This vector maintained the 
leader peptide, an amino acid sequence prior to EmGFP containing a His6 affinity tag.  An N-
terminal enterokinase recognition sequence was replaced with one encoding the recognition 
sequence of TEV protease.479  TEV protease can be expressed in vivo within E. coli cells 
without affecting their growth.480  It has also been demonstrated that in vivo expression is able to 
cleave two proteins or protein subunits attached by a linear amino acid sequence containing the 
TEV recognition sequence.440  Because this leader peptide containing the His6 affinity tag and 
enterokinase recognition site is largely unstructured and demonstrated to be translated 
efficiently (Chapter 2, Figure 2.11), we placed a random DNA sequence of (NNK)12 3’ of the 
TEV protease recognition sequence.  When this construct is co-transformed with two plasmids, 
pRK603440 and pZS4int-tetR, (Figure 3.11) controlling the expression of TEV protease, 
expression of all members of the peptide library with the same translation efficiency is achieved 
followed by the removal of the leader peptide.  This exposes the peptide library to the cytoplasm 
at the N-terminus of the peptide-EmGFP fusion (Figure 3.12).  The TEV protease recognition 
sequence (Glu-Asn-Leu-Tyr-Phe-Gln-(Gly/Ser)), whereas cleavage occurs N-terminal to the 
final (Gly/Ser) residue, can be modified to exclude the final (Gly/Ser) residue.  Cleavage assays 
of TEV protease have demonstrated that any amino acid other than proline is efficiently 
cleaved.481  Therefore a random DNA sequence was designed to preclude the chance of a 
proline residue at position 1 on the peptide by using DNK (where D is A, G or T) instead of NNK.  
The inclusion of the TEV protease in vivo, enzymatic cleavage prevents the translation effect of 
randomizing the 5’ mRNA sequence but it does introduced the potential variability of TEV 
protease cleavage efficiency. 
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Figure 3.11:  Co-transformed plasmids for the in vivo expression of TEV protease.  pZS4int-
tetR expresses Tet repressor protein (TetR) that turns off expression from the PTet promoter 
controlling TEV protease expression.  In the presence of anhydrotetracycline (ATC), tetR binds 
ATC, changes conformation and can no longer repress PTet, allowing expression of TEV 
protease. 
 
 
Figure 3.12:  In vivo maturation of the expressed leader peptide-EmGFP fusion upon the 
expression of TEV protease.  The protease binds to its recognition sequence C-terminal to the 
leader peptide and generates two portions following cleavage, the N-terminal leader peptide 
including the TEV protease recognition sequence and the C-terminal fusion of the peptide of 
interest and EmGFP.  A His6 affinity tag is located at the N-terminus of the leader peptide to 
analyze the efficiency of the system. 
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3.3 Objective of the Project 
To demonstrate that in vivo display of peptides at the N-terminus of a protein is a viable 
strategy for the isolation of antimicrobial peptides potentially omitted using the C-terminal 
display system, cIVD. 
 
3.4 Results 
3.4.1 System Construction & Confirmation 
 pBacEmGHt (Figure 3.13) was constructed as a derivation of pBacEmGH, the plasmid 
used in the cIVD selection described in Chapter 2.  The backbone of the plasmid was left intact, 
maintaining the inducible copy number from ~1 up to ~20 copies per cell412 using both the 
replication origins of the F plasmid413 and the R2K plasmid414 in conjunction with the bacterial 
strain E. coli EPI301 which contains a genomic copy of TrfA gene, the replication protein of the 
R2K plasmid, under the control of the PBAD promoter.  Chloramphenicol resistance from the 
chloramphenicol adenyltransferase gene (cat) was also preserved along with the PBAD 
promoter406; 407; 408 governing the expression of the peptide-EmGFP fusion.  The fusion gene 
was altered at both termini.  At the N-terminus, the leader peptide was left unchanged except for 
the replacement of the enterokinase recognition sequence with the TEV protease recognition 
sequence immediately 5’ to the DNA encoding the random peptide library.  A linker peptide 
sequence, comprised of Glu-Gly-Gly-Gly-Ala, was fused the peptide library to EmGFP giving the 
peptide library freedom of movement.378  At the C-terminus, a second His6 affinity tag was 
placed for the purification of the peptide-EmGFP fusion or the fusion bound to its target.   
 Two systems were produced for in vivo expression of TEV protease.  The first system 
was a synthetic operon producing a polycistronic mRNA encoding the peptide- EmGFP fusion 
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Figure 3.13:  pBacEmGHt is derived from the plasmid pBacEmGH with the addition of the TEV 
protease recognition sequence N-terminal to the fusion of the peptide of interest, the A site 
peptide, and EmGFP.  Co-transformation with plasmids pZS4int-tetR and pRK603 enable 
maturation of the fusion to expose the peptide of interest at the N-terminus through cleavage by 
inducible expression of TEV protease. 
 
followed by TEV protease upon the addition of L-arabinose, each with its own start and stop 
codons.  This system theoretically produces one TEV protease per peptide-EmGFP fusion.  It 
also simplifies the system to one plasmid (pBacEmGHtv) (Figure 3.14) lowering the stress on 
the host cell during selection.  The second system utilizes three plasmids.  The first, 
pBacEmGHt is as described in the above paragraph, but without a synthetic operon involving 
TEV protease.  Two plasmids, pRK603440 and pZS4int-tetR are responsible for the expression 
of TEV protease and are co-transformed with pBacEmGHt.  Plasmid pZS4int-tetR expresses 
TetR, the PTet promoter repressor protein, while pRK603 encodes TEV protease under the 
control of the PTet promoter.  Upon the addition of anhydrotetracycline (ATC), TetR changes 
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conformation releasing from PTet, permitting TEV protease expression.  While more complicated 
than the synthetic operon system, the three plasmid system permits non-synchronous 
expression of TEV protease and peptide-EmGH fusion.  If TEV protease is accumulated in the 
host cell prior to induction of the fusion, the peptide library can be displayed immediately 
following or even prior to the completion of translation of the peptide-EmGFP fusion.  
 
 
Figure 3.14:  pBacEmGHtv is derived from the plasmid pBacEmGHt with the addition of the 
TEV protease gene 3’ to the gene encoding the leader peptide-EmGFP fusion.  Induction with 
the addition of L-arabinose to the growth medium produces a polycistronic mRNA with two start 
codons for the translation of the leader peptide-EmGFP fusion and TEV protease.  Co-
expression results in the maturation of the fusion by TEV protease cleavage exposing the 
peptide of interest at the N-terminus of EmGFP. 
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Figure 3.15:  pKan-EmGHA3tASP a derivative of the plasmid pKan-EmGHA3 with the addition 
of the TEV protease recognition sequence 5’ to DNA encoding the A site peptide fused to 
EmGFP.  The plasmid was used to analyze the effectiveness of the leader peptide in negating 
the translation deficiency produced by the 5’ placement of the A site peptide in previous 
constructs. 
 
3.4.1.1  Nullification of 5’ mRNA Translation Efficiency Effect 
 In pKan-EmGHA3, a derivative of pKan-EmGH with the pUC19 replication origin, the 
amounts of A site peptide-EmGFP produced were compared with or without the addition of the 
leader peptide (Figure 3.15).  Constructs were made placing the leader peptide, containing the 
His6 affinity tag and TEV protease recognition sequence, at the N-terminus of both the M13 and 
its reverse orientation derivative (Figure 3.16).  Cultures of the four clones were grown in 
medium containing L-arabinose to induce the expression of A site peptide-EmGFP.  Incubation 
continued overnight for end-point analysis of the levels of expression.  When calculating the 
152 
 
 
 
amount of EmGFP fluorescence per optical density as a percentage of the reverse orientation 
construct in each pair, A site peptide-EmGFP production was increased from 3.5% to 106% of 
the reverse orientation construct (Figure 3.17).  By introducing the leader peptide, 
demonstrated to be translated efficiently (Chapter 2, Figure 2.11), we have nullified the effects 
of mRNA secondary structure. 
 
 
 
Figure 3.16:  Constructs for analyzing the effectiveness of the leader peptide to negate the 
translation deficiency produced by 5’ placement of the A site peptide.  Constructs encoding the 
leader peptide, 5’ to either the A site peptide (HPVHHYQ) or its reverse orientation derivative 
(QYHHVPH) were compared to constructs not encoding the leader peptide. 
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Figure 3.17:  Endpoint expression levels of constructs expressing the A site peptide, in the 
original or reverse orientations, compared to similar constructs incorporating the leader peptide. 
 
 
3.4.1.2  In vivo TEV Protease Cleavage Efficiency 
 Constructs for both the synthetic operon and three plasmid systems were generated 
without a C-terminal His6 affinity tag.  This left only the N-terminal His6 affinity tag as part of the 
leader peptide.  In either TEV protease expression system, when the fusion and TEV protease 
are expressed, the leader peptide should be separated from EmGFP.  When running lysates 
over a His6 purification column and observing the protein fragments purified on an SDS PAGE, 
the lysates from the TEV-induced cultures should no longer contain EmGFP as it will no longer 
be purified via the cleaved His6 affinity tag.  A culture containing pBacEmGHtv with the synthetic 
operon was grown along with a culture of pBacEmGH (contains no TEV recognition sequence 
or TEV protease gene).  After the cultures reached early log phase growth, L-arabinose was 
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added to induce expression of the leader-EmGFP and TEV protease from pBacEmGHtv or 
EmGFP only from pBacEmGH.  The cultures were incubated for another three hours to 
accumulate EmGFP and permit cleavage by TEV protease.  The protein fragments were 
purified using the His6 affinity tags and observed using SDS PAGE.   
The cell lysate of induced pBacEmGHtv shows a decrease in the MW of EmGFP 
compared to the cell lysate of pBacEmGH (Figure 3.18), this coincides with the removal of the 
29 amino acid leader peptide containing the His6 affinity tag.  The elution fractions demonstrate 
the same conclusion.  EmGFP from pBacEmGHtv was purified and run at nearly 33 kDa as 
expected.  EmGFP from pBacEmGH was absent from the lane in the SDS PAGE, which with its 
reduction in MW from the cell lysate gel we can attribute to the loss of the His6 tag.  The three 
plasmid system showed similar results.  The cell lysate of pBacEmGHt shows a reduction in the 
MW of EmGFP and the His6 tag purification eluent has no EmGFP band (Figure 3.19).  A third 
culture where the three plasmid system was induced with L-arabinose, but not ATC presents an 
EmGFP band upon purification at a similar intensity to the pBacEmGH lane. 
 It was originally thought that the three plasmid system may not generate enough TEV 
protease to cleave all leader peptide-EmGFP fusions efficiently, but the gels demonstrate that 
the three plasmid system is just as efficient as the synthetic operon system.  Therefore, further 
studies and the N-terminal, cytoplasmic in vivo display (nIVD) selection itself were carried out in 
the three plasmid system. 
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Figure 3.18:  His6 affinity tag pulldowns of cultures of E. coli containing synthetic operon vector 
pBacEmGHtv for assaying the activity of in vivo TEV protease. 
 
 
Figure 3.19:  His6 affinity tag pulldowns of cultures of E. coli containing three plasmids, 
pBacEmGHt, pZS4int-tetR, and pRK603, for assaying the activity of in vivo TEV protease. 
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3.4.1.3  N-terminal Display of Antimicrobial Peptide Pro-3 
 To confirm if an antimicrobial peptide known to be lethal at the N-terminus of a protein is 
viable in our system and if its lethality is contingent on TEV protease induction, we cloned the 
15 amino acid Pro-3 peptide (SREWHFWRDYNPTSR)378 at the location the peptide library 
would occupy, N-terminal to EmGFP (Figure 3.20).  Pro-3 is a peptide isolated from an M13 
phage display screen using E. coli prolyl-tRNA synthetase as the target.378   
pBacEmGHt-Pro3 was derived from pBacEmGHt and transformed into E. coli EPI301 
containing plasmids pRK603 and pZS4int-tetR.  Six cultures, four containing pBacEmGHt-Pro3 
and two with pBacEmGH-Pro3, which lacks the leader peptide and TEV protease recognition 
sequence, were grown in tandem.  Once the cultures had reached early log phase growth, L- 
arabinose was added to one culture of pBacEmGH-Pro3 (the other was left uninduced) and 
three cultures of pBacEmGHt-Pro3 to induce expression of the Pro-3 peptide-EmGFP fusions.  
Simultaneously, to one induced culture of pBacEmGHt-Pro3, ATC was added to induce 
expression of TEV protease.  The cultures were allowed to grow for 90 mins while measuring 
both optical density at 600 nm and fluorescence.  ATC was then added to a second culture of 
pBacEmGHt-Pro3 for a late induction of TEV protease expression.  Measurements were 
continued until the onset of stationary phase growth. 
The induced pBacEmGH-Pro3, without the leader peptide, showed the most dramatic 
reduction in growth compared to its uninduced control (Figure 3.21).  The pBacEmGHt-Pro3 
culture, where only the Pro-3 peptide-EmGFP fusion was expressed, slightly decreased in 
growth rate, likely due to gene over-expression.  When ATC was added to the fusion-induced 
cultures of pBacEmGHt-Pro3, either simultaneously or at a later point, the growth rate reduction 
resembled that of the clone expressing Pro-3 in the absence of the leader peptide.  This implies 
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that the leader peptide effectively prevented Pro-3 from inhibiting its target, prolyl-tRNA 
synthetase, until it was cleaved off in the presence of TEV protease.   
 
 
 
 
Figure 3.20:  pBacEmGH-tPro3 is a derivative of plasmid pBacEmGHt encoding the 
antimicrobial peptide Pro-3 between the TEV protease recognition sequence and the gene 
encoding EmGFP.  Pro-3 was isolated from a M13 phage display library against prolyl-tRNA 
synthetase and demonstrated to be lethal by Tao et al when expressed as an N-terminal fusion 
to Glutathione S-transferase. 
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Figure 3.21:  Growth curves of E. coli cultures expressing Pro-3 peptide-EmGFP fusions from 
vectors pBacEmGH-Pro3, that does not encode a leader peptide or TEV protease, and 
pBacEmGH-tPro3, that includes the leader peptide that is proteolytically cleaved by TEV 
protease expressed from plasmid pRK603. 
 
The amount of Pro-3 peptide-EmGFP fusion produced per cell was approximated by 
dividing the level of fluorescence by the optical density of the culture at 600 nm.  The 
pBacEmGHt-Pro3 culture where only the fusion was induced produced a large amount of 
fluorescence correlating with a high level of fusion expression in the cells (Figure 3.22).  The 
culture simultaneously induced for fusion and TEV protease shadowed the pBacEmGH-Pro3 
induced culture with a significantly lower rate of production.  The late TEV protease induced 
culture showed an intriguing effect.  After the fusion protein was induced, production followed 
the same rate as the fusion-only induced culture, but once ATC was added to induce TEV 
protease, fluorescence per cell flat-lined for 30 minutes.  Afterwards it proceeded at the lower 
rate observed in the simultaneously induced culture.   
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The lethal peptide Pro-3, which was confirmed in vivo with the induced growth curve of 
pBacEmGH-Pro3, preserved its lethality in the N-terminal/TEV protease expression system.  
The addition of TEV protease was necessary for Pro-3 peptide-EmGFP from the pBacEmGHt-
Pro3 construct to have its growth limiting effect. 
 
 
Figure 3.22:  Levels of expression of Pro-3 peptide-EmGFP fusions as measured by the 
amount of fluorescence of the culture per optical density (A600) in induced cultures containing 
vectors pBacEmGH-Pro3 or pBacEmGH-tPro3. 
 
3.4.2 Library Construction & Selection 
 Primer extension reactions were used to generate DNA encoding 12mer random peptide 
inserts that were cloned into pBacEmGHt at the N-terminus of EmGFP, C-terminal to the TEV 
protease recognition site (Figure 3.23).  The sequence DNK (NNK)11 was used to preclude the 
appearance of proline at position 1, increasing the likelihood TEV protease will be able to cleave 
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all clones.481  A library of ~2 x 108 clones was produced by transforming the ligated clones into 
electro-competent E. coli DH5α cells.  The library was then purified as plasmid DNA and 
transformed into E. coli EPI301 cells containing plasmids pRK603 and pZS4int-tetR, necessary 
for the expression of TEV protease.440  The cells were recovered and then moved into Luria-
Bertani (LB) medium442; 443 with the necessary antibiotics to select for all three plasmids.  Once 
the cells entered early log phase growth, ATC was added to induce TEV protease expression 
and allow it to accumulate in the cytoplasm.  After an additional hour of incubation, L-arabinose 
was added to induce peptide-EmGFP fusion expression within each cell.  Incubation continued 
for the accumulation of enough mature (cleaved) peptide-EmGFP in the cytoplasm.  A portion of 
the culture was then centrifuged to recover medium without whole cells for the isolation of 
bacteriolytic peptide-encoding plasmids by alcohol precipitation.  To isolate 
bactericidal/bacteriostatic peptide-encoding plasmids a negative selection426; 432 using β-lactam 
antibiotic, ampicillin,431 was performed on the remaining culture to lyse cells that were still able 
to reproduce.  After a period of time to allow for complete lysis, the culture was centrifuged and 
the pellet was saved.  Bacteriostatic/bactericidal peptide-encoding plasmids were extracted from 
the pellet.  The selection was repeated three times varying the time at which TEV protease was 
induced from simultaneously with the fusion to 30 minutes prior and 100 minutes prior.  From a 
library of ~2 x 108 clones, five clones demonstrating growth effecting phenotypes were isolated 
and sequenced (Table 3.2). 
 
 
 
 
 
161 
 
 
 
 
 
Figure 3.23:  pBacEmGHt including the 12mer random peptide library cloned 3’ to the TEV 
protease recognition sequence and 5’ to the linker peptide and EmGFP.  The library was then 
co-transformed with plasmids pZS4int-tetR and pRK603 in E. coli EPI301 cells and screened to 
isolate peptides with detrimental growth phenotypes. 
 
 
 
Table 3.2:  Amino acid sequences of all peptides from N-terminal, cytoplasmic selection 
confirmed as having an active effect on E. coli growth as determined replica plating.   
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3.4.3 Phenotypes of Peptides & Expression Analysis 
 To determine the phenotypes of the isolated clones, each was subjected to induced 
growth curves to monitor the optical density and fluorescence during expression of the peptide-
EmGFP fusion.  E. coli EPI301 cells containing the isolated clones from the selection and 
plasmids pRK603 and pZS4int-tetR were grown in LB to a point just prior to early log phase of 
growth.  ATC was added to induce expression of TEV protease.  After 30 minutes of additional 
incubation at early log phase, L-arabinose was added to induce expression of the peptide-
EmGFP fusion.  Optical density and fluorescence of the cultures were measured at time 
intervals following induction until the onset of early stationary phase.   
 
 
Figure 3.24:  Growth curves of isolated, growth inhibiting peptides from the N-terminally 
displayed library. 
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Peptides NC052 and NC055 exhibited early onset of bacteriostatic/bactericidal 
phenotypes following induction (Figure 3.24).  The growth rates of cells expressing peptides 
NL018, NC010 and NC221, while reduced considerably compared to the uninduced control, 
classify them as growth rate reducing peptides.  Peptide-EmGFP levels per cell were 
approximated by dividing the culture’s fluorescence by the optical density at 600 nm.  The only 
clone producing any measurable fluorescence was NC010 (Figure 3.25).  The other clones 
failed to produce fluorescence greater than their uninduced controls. 
 
 
Figure 3.25:  Levels of peptide-EmGFP expression by different N-terminal, cytoplasmic clones.  
Fluorescence of cultures of clones and EmGFP only (no peptide) control was measured at 
different time intervals following induction with L-arabinose and divided by the optical density 
(A600) of the culture. 
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3.5 Discussion 
 Peptide placement has an effect on a peptide’s ability to bind its target.470  With the 
success of the C-terminal cIVD peptide selection (Chapter 2) we developed a system for 
displaying and selecting peptides with antimicrobial activity on the N-terminus of EmGFP, nIVD.  
From a library of ~2.0 x 106 we isolated five clones expressing peptides with either 
bacteriostatic/bactericidal activity (NC052 and NC055) or that are weakly inhibitory (NL018, 
NC010, and NC221). 
 The vector, pBacEmGHt, was derived from pBacEmGH, the plasmid used for selecting 
peptides at the C-terminus in Chapter 2.  The placement of a random mRNA sequence at the 5’ 
end on the EmGFP gene has an impact on its translational efficiency as observed in previous 
studies473; 482; 483 and with the 10 randomly generated peptide sequences (Figure 3.10).  In the 
case of the A site peptide, the generation of a clone with a degenerate mRNA sequence 
encoding the same amino acid sequence was translated efficiently (Figure 3.9).  Likely causes 
of this effect include disruption of conserved mRNA-ribosome interactions necessary for the 
initiation of translation and RNA sequences generating stable mRNA secondary structures 
(Figure 3.8) occluding the anti-Shine-Dalgarno sequence.  To mitigate the effect, we placed the 
5’ region downstream of PBAD in the pBacEmGH construct, including a His6 affinity tag, 
enterokinase protease recognition and cleavage site, and other DNA elements, together known 
as the leader peptide, 5’ to the 36 random nucleotides encoding the random peptide library to 
be displayed.  The DNA encoding the enterokinase recognition sequence was replaced with the 
recognition sequence for TEV protease484 (Figure 3.13).  Induction of pBacEmGHt produced a 
fusion protein composed of the 5’ region, TEV protease cleavage site, peptide library, peptide 
linker, EmGFP and a C-terminal His6 affinity tag.  When the original A site peptide DNA 
sequence was placed within this context, expression levels increased to match the NTRO 
sequence, a DNA sequence encoding the A site peptide in reverse order (Figures 3.16-17). 
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Experiments indicating that in vivo TEV protease expression440 resulted in the cleavage 
of the leader peptide, exposing the potential peptide library in both constructs we generated 
(Figures 3.18-19), confirmed the system’s effective display of peptides at the N-terminus of 
EmGFP, allaying concerns of diminished translation efficiency.  The incorporation of the Pro-3 
peptide,378 isolated from an M13 phage library using prolyl-tRNA synthetase as a target, was 
successfully used to demonstrate the display of an antimicrobial peptide.  The initial study by 
Tao, et al fused the 12mer peptide to the N-terminus of glutathione S-transferase (GST) through 
a short peptide linker encoded on a plasmid under the lambda promoter, PL, in conjunction with 
a Tet operator.  Expression of the fusion protein within E. coli DH5αPRO cells resulted in a 
dramatic reduction in the rate of growth.  A subsequent study examined the effects of Pro3-GST 
expression on the survival of mice infected with pathogenic strain of E. coli, JM109.  Despite 
Pro-3 expression not being bacteriostatic/bactericidal in the E. coli growth curves, expression 
was able to rescue the mice from lethal infection, indicating weakly inhibitory peptides, acting in 
parallel with the subject’s immune system is enough to clear an infection.   
 Induction of the Pro3-EmGFP fusion at the N-terminus of EmGFP without the context of 
the leader peptide had a similar growth phenotype as seen in the Tao, et al study (Figure 3.21) 
demonstrating that the peptide’s display on EmGFP does not affect the peptide’s activity.  When 
cloned into vector pBacEmGHt, behind the leader peptide, induction with the addition of 
arabinose produced no noticeable growth effect.  The presence of the leader peptide effectively 
inhibited Pro-3’s activity, likely by the prevention of binding its target prolyl-tRNA synthetase.  
However, in cultures where both the fusion and TEV protease were induced, the growth rate 
reduction phenotype was observed, therefore, Pro-3 activity is contingent on removal of the 
leader peptide.  Unfortunately, delayed induction of TEV protease did not magnify the initial 
growth phenotype, as theorized due to a large concentration manifesting in vivo near the speed 
on the enzymatic velocity of TEV protease, instead the rate of growth reduction did not change.   
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 With the successful demonstration of the nIVD system, we inserted a 12mer peptide 
encoded by the DNA sequence DNK (NNK)11 between the TEV protease recognition sequence 
and the peptide linker.  The use of DNK as the initial codon precluded the appearance of proline 
residues at position 1 of the peptide which are known to inhibit TEV protease cleavage.481  The 
library consisting of ~2 x 108 clones was constructed in pBacEmGHt and screened in E. coli 
EPI301 cells containing plasmids pRK603440 and pZS4int-tetR for the independent expression of 
TEV protease.  Unfortunately, the extra stresses on the cell of maintaining three plasmids and 
two expression mechanisms significantly slowed growth during screening.  The overall slow 
growth of the culture theoretically makes it more difficult to segregate bacteriostatic/bactericidal 
and weakly inhibitory peptide encoding clones from those that are not inhibitory, compromising 
the system.  Future nIVD selections would benefit from using the simplified, synthetic operon 
system of the vector pBacEmGHtv. 
Similar to its C-terminal counterpart (Chapter 2), the nIVD selection isolated several 
clones that appeared lethal following replica plating.  However, after completing induced growth 
curves on these clones it was observed that whether they were induced with the addition of L-
arabinose or repressed with the addition of D-glucose the clones grew slowly.  The isolation of 
these clones may arise from a selection of chromosome mutations that slow the growth of the 
host cell independent of peptide-EmGFP expression.  However, similar results were not 
observed in the periplasmic selections (Chapters 4 and 5).  This result stresses the importance 
of affirming the activity of the clones in efficacy steps following the selection via induced growth 
curves and replica plating. 
Five peptides were isolated that demonstrated reduced growth phenotypes only upon 
induction of the peptide-EmGFP fusion.  Three of the peptides; NL018, NC010, and NC221, 
were weakly inhibitory, decreasing the growth rate of their host cultures significantly, but not 
completely, within 30 minutes of induction (Figure 3.24).  Peptides NC052 and NC055 were 
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bacteriostatic/bactericidal stopping growth of their induced cultures indicating all five peptides 
have a low inhibitory concentration either due to a low binding constant or localization of the 
peptide to its target as would be the case of translation inhibiting peptides435; 485; 486 binding to 
their host ribosome during translation of their fusion protein.  Simultaneous analysis of the 
expression levels peptide-EmGFP fusion support localization of the peptide to their host 
ribosomes.  Four of the five peptides; NL018, NC052, NC055 and NC221, produce no 
appreciable amounts of fluorescence (Figure 3.25) correlated to the amount of peptide-EmGFP 
being translated.  This may reflect that the peptides are binding to their host ribosomes as they 
are being translated, stalling the ribosome before the entire peptide-EmGFP fusion has been 
translated (Figure 3.26) by either binding to a site on the ribosome or associated molecule  
 
Figure 3.26:  Models of translation inhibition by N-terminal peptides.  A) Peptide-EmGFP fusion 
is translated to an extent that the peptide is able to bind to sites externally on the ribosome of an 
associated molecule such as an rprotein or elongation factor.  B) The peptide binds to a site 
internally such as the exit channel or peptidyl transferase center, inhibiting further translation of 
the fusion. 
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externally or by binding internally such as the peptide exit channel or peptidyl transferase 
center.434  This is more plausible due to the positioning of the peptide at the N-terminus rather 
than the same proposition for C-terminal clones that also lacked EmGFP fluorescence. 
The four peptides that exhibited no fluorescence do not have consistent amino acid 
composition, but all five peptides isolated are predominantly hydrophobic (Table 3.2).  Nearly 
half of the amino acids in NL018 are hydrophobic, including two proline residues.  Two centrally 
located serines, at position 7 and 8, a glutamine at position 11 and an arginine at position 4 
create an even distribution of polar residues throughout the peptide.  The presence of only one 
positively charged residue and a lack of amino acids with large side groups are not consistent 
with ribosome binding or blockage of the exit channel of the ribosome.  NC052 is similar to 
NL018 except for its lack of proline residues.  Polar residues are positioned closer to the N-
terminus, including an arginine at position 2.  Of the hydrophobic amino acids, a phenylalanine 
at position 12 is the only residue with significant size.  Therefore, like NL018, the peptide’s 
characteristics are not consistent with translation inhibition.  The peptide NC055 lacks an 
arginine residue, unlike the other three peptides lacking expression and also contains a higher 
concentration of large, hydrophobic residues including tryptophan and two phenylalanines.  Of 
the five peptides isolated, the only one that contains an acidic residue is NC221, with a glutamic 
acid at position 7.  NC221 also contains two arginine residues at positions 2 and 8 and four 
prolines at positions 4, 5, 9, and 11.  Unlike the other peptides, NC010, was expressed 
efficiently, however, its amino acid composition is entirely hydrophobic, including two proline 
residues, similar to the other peptides. This suggests that a high concentration of prolines at the 
N-terminus or hydrophobicity is not responsible for the negation of expression by inhibiting 
translation as may be the case with the other peptides. 
We have developed and demonstrated the utility of a peptide selection method for an N-
terminally-displayed, random peptide library in the cytoplasm, nIVD.  The implementation of in 
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vivo TEV protease expression has enabled us to randomize the 5’ end of the EmGFP mRNA 
without affecting levels of translation.  From a modest ~2 x 108 member library we isolated five 
peptides with antimicrobial phenotypes using the three plasmid system including pBacEmGHt.  
Future libraries and selections should employ the synthetic operon system expressing both the 
peptide-EmGFP fusion and TEV protease from the same promoter and plasmid to relieve stress 
on the host cell of maintaining three plasmids and thus diminishing its growth rate that may 
affect the ability to isolate antimicrobial peptides.  Further analysis of the five isolated peptides is 
necessary to determine their viability as antimicrobial leads including, free peptide expression in 
the absence of any contextual effects of the linker peptide or EmGFP, and the calculation of 
minimum inhibitory concentrations using synthetic derivatives of the peptides. 
 
3.6 Materials & Methods 
3.6.1 Bacterial Strains & Media 
 All experiments, unless otherwise indicated, were carried out in E. coli EPI301 a 
derivative of strain EPI300 (F-, mcrA, Δ(mrr-hsdRMS-mcrBC), Φ80dlacZΔM15, ΔlacX74, recAI, 
endAI, araD139, Δ(ara, leu)7697, galU, galK, λ-, rpsL, nupG, trfA, dhfr) obtained from Epicentre 
Biotechnologies (a division of Illumina, Inc., Madison, WI).  The amber suppressor gene, 
supE44 (glnV44), was introduced via P1 transduction from DH5α (fhuA2, Δ(argF-lacZ)U169, 
phoA, supE44 (glnV44), Φ80, Δ(lacZ)M15, gyrA96, recA1, relA1, endA1, thi-1, hsdR17) into 
EPI300 to make EPI301.  Clones were grown and maintained in Luria-Bertani (LB) medium 
containing 25 µg/mL chloramphenicol, 30 µg/mL kanamycin, and 50 µg/mL spectinomycin (LB-
Cm25Kan30Spec50).  To induce peptide-EmGFP fusions from the PBAD promoter L-arabinose 
was added to the culture at a final concentration of 0.2%.  Induction times are indicated in the 
individual methods outlined later.  Clones encoding suspected lethal peptide-EmGFP fusions 
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were propagated in LB medium with the appropriate antibiotics for plasmid selection and 0.2% 
D-glucose to repress expression from the PBAD promoter.  Transformations were carried out via 
electroporation at 2.44 kV with electro-competent cells prepared beforehand and stored at -80 
oC.  Transformed cells were recovered in SOC medium for 1 hour without antibiotics prior to 
either plating on solid media or selection. 
 
3.6.2 Enzymes & Reagents 
 Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs Inc. 
(Ipswich, MA).  Restriction enzymes were also ordered from Fermentas (a division of Thermo 
Fisher Scientific Inc., Glen Burnie, MD).  Oligonucleotides, for use as primers in polymerase 
chain reactions (PCRs) or in the formation of DNA duplexes, were purchased from Integrated 
DNA Technologies Inc. (Coralville, IA).  Choice-Taq™ DNA polymerase and PCR reagents 
were obtained from Denville Scientific Inc (Metuchen, NJ).  Pfu polymerase, derived from 
Pyrococcus furiosus and having 3’ to 5’ exonuclease proofreading activity, was obtained from 
the Chow Laboratory in the Wayne State University Chemistry Department.  DNA polymerase, 
dideoxynucleotide mixtures and sequencing buffers (SequiTherm Excel™ II DNA sequencing 
kit) were obtained from Epicentre Biotechnologies (a division of Illumina, Inc., Madison, WI).  
Sequencing primers for use with the LI-COR Biosciences Sequencer 4000L, oligonucleotides 
bound at the 5’ end to either 700 or 800 IRDye®, were ordered from either LI-COR (Lincoln, NE) 
or Integrated DNA Technologies Inc. (Coralville, IA). 
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3.6.3 pRK603 & pZS4int-tetR 
 These two plasmids are necessary for in vivo expression of TEV protease.  They were 
obtained from plasmid repository addgene (www.addgene.org).  pRK603 (addgene plasmid 
8831) was developed by the Waugh laboratory (National Cancer Institute).  It contains antibiotic 
selection marker neo for kanamycin resistance and the p15A replication origin.  The TEV 
protease gene is under the control of the PTet promoter.  pZS4int-tetR encodes TetR, the PTet 
repressor protein.  The plasmid also contains aad for spectinomycin resistance and the pSC101 
replication origin.  When co-transformed with pRK603, constitutive expression of TetR from 
pZS4int-tetR represses expression from the PTet promoter by binding to its operator.  When 
anhydrotetracycline (ATC) is added to a culture of the cell containing both plasmids, ATC binds 
to TetR and causes a conformational change in the protein lowering its affinity for the PTet 
operator.  With TetR removed, expression from PTet proceeds. 
 
3.6.4 pKan-EmGHA3 A site Peptide & Random Peptide Constructs 
 Constructs for studying the translational efficiency of the A site peptide (ASP), its 
reduced ΔG analogue (ASPLG), its reverse orientation derivative (NTRO), and ten random 
peptide sequences at the N-terminus of EmGFP were made using oligonucleotide UniForNT 
(Table 3.3) coupled with an oligonucleotide specific for the peptide to be encoded in a primer 
extension reaction.  These included NTevASPR, ASPLG, NTevNTROR (Table 3.3) for the A 
site peptide and its derivatives, respectively and Ran1R, Ran2R, Ran3R, Ran4R, Ran5R, EFW 
Ran1, EYR Ran2, LYE Ran3, VYF Ran4, and QYH Ran5 (Table 3.3) for the random peptides.  
The products of these reactions, along with vector pKan-EmGHA3 were digested with restriction 
enzymes NotI and NcoI.  The desired DNA fragments were isolated via gel electrophoresis, 
cleaned and ligated.  The resultant constructs were confirmed by DNA sequencing. 
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3.6.5 pKan-EmGHA3tASP & tNTRO Construction 
 First, pKan-EmGHA3 was derived from pKan-EmGH (described in Chapter 2) by 
replacing the original p15A replication origin with that of the pUC19 plasmid resulting in a high 
copy number of ~700 per cell.  Oligonucleotides pUC19oriFor and pUC19oriRevII (Table 3.3) 
were used to amplify the pUC replication origin using pUC19 as a template in a PCR.  The 
oligonucleotides incorporated the restriction enzyme recognition sequences of DraIII and BglI at 
either end of the PCR product.  Both product and pKan-EmGH were digested with DraIII and 
BglI.  The desired digestion products were isolated via gel electrophoresis and cleaned.  The 
DNA fragments were ligated to form pKan-EmGHA3. 
One of two oligonucleotides, NTevASPR or NTevNTROR, was paired with a third, 
NTevF (Table 3.3), in a primer extension reaction.  The reaction product preserves the 
upstream DNA sequence of pKan-EmGHA3, replacing the enterokinase recognition sequence 
with that of TEV protease.  NTevASPR and NTevNTROR incorporate either the A site peptide 
(ASP) or its reverse orientation analogue (NTRO) and a KasI recognition site to simplify 
placement of the N-terminal peptide library.  The primer extension product and pKan-EmGHA3 
were digested with NheI and NcoI (pKan-EmGHA3 was partially digested with NcoI).  The 
appropriate DNA fragments were isolated via gel electrophoresis, cleaned and ligated to form 
pKan-EmGHA3tASP and tNTRO.  These constructs were used to demonstrate the 
normalization of translation efficiency compared to the original pKan-EmGHA3ASP plasmid.  
DNA sequencing was used to confirm the constructs. 
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3.6.6 Expression Assays of the A site & Random Peptide Constructs 
 E. coli EPI300 cells containing one of the following plasmids, pKan-EmGHA3ASP, 
NTRO, ASPLG, tASP, tNTRO and each of the random peptides were used to inoculate cultures 
of 3 mL LB-Kan30 + 0.2% D-glucose and incubated at 37 oC with shaking overnight.  The 
overnight cultures were diluted 1/100 by adding 30 µL to 3 mL of fresh LB-Kan30 + 0.2% L-
arabinose to induced peptide-EmGFP production cultures with no L-arabinose were also done 
as controls.  The cultures were incubated at 37 oC with shaking for 24 hours.  Five-hundred µL 
samples of each culture were removed and centrifuged at 11,000 rpm for 1 minute to pellet the 
cells.  The supernatant was removed and the cell pellet was resuspended in 500 µL of HN 
buffer by vortexing.  The suspension was centrifuged at 11,000 rpm for 1 minute to pellet the 
cells and the supernatant was removed.  The cells were washed once more with 500 µL of HN 
buffer and then resuspended in 500 µL of HN buffer.  Two-hundred µL of this suspension was 
transferred to wells of a 96-well, clear-bottom microtiter plate by Costar® (a division of Corning, 
Inc., Corning, NY).   
 The optical density of each clone was measured at 600 nm using a SpectraMax 190 
from Molecular Devices, Inc. (Sunnyvale, CA) and the fluorescence of the cultures (excitation at 
395 nm, emission at 509 nm) were measured using a SpectraMax Gemini XPS.  Fluorescence 
values were divided by the OD600 to approximate the amount of fluorescence per cell.  The 
values of duplicate cultures were averaged.  The A site peptide clones (ASP and tASP) were 
compared to the reverse orientation A site peptides (NTRO and tNTRO) by calculating their 
peptide-EmGFP production as a percentage of that produced by pKan-EmGHA3NTRO or 
tNTRO.  The random peptide clones’ peptide-EmGFP production was calculated as a 
percentage of the amount produced by pKan-EmGHA3NTRO. 
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Figure 3.27:  Construction of plasmid pKan-EmGHA3tvNTRO.  The TEV protease gene was 
cloned via PCR behind the EmGFP gene in pKan-EmGHA3tNTRO to produce a polycistronic 
gene product.  
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3.6.7 pKan-EmGHA3tvNTRO Construction 
 To make the synthetic operon encoding EmGFP and TEV protease two oligonucleotides, 
TevopF and TevopR (Table 3.3), were designed to amplify the TEV protease gene.  Plasmid 
pRK603, obtained from AddGene.org, was used as a template in a PCR that incorporated 
recognition sites for restriction enzymes BsrGI and XbaI (Figure 3.27).  Primer TevopF was also 
used to silently remove a HindIII recognition site in the 5’ end of the TEV protease gene that 
would have interfered with downstream cloning steps.  The PCR product and pKan-
EmGHA3tNTRO were digested with restriction enzymes BsrGI and XbaI.  The desired DNA 
fragments were isolated via gel electrophoresis, cleaned and ligated to form plasmid pKan-
EmGHA3tvNTRO.  The final plasmid places the TEV protease gene 3’ to the stop codon of the 
EmGFP gene with its own start codon and an appropriate spacer sequence for efficient 
translation resulting, upon induction, in a polycistronic mRNA encoding EmGFP and TEV 
protease.  The transcription terminators T1 and T2 were preserved at the 3’ end of the TEV 
protease gene.  The insertion of the TEV protease gene was verified via DNA sequencing. 
 
3.6.8 pBacEmGHt & pBacEmGHtv Construction 
 Plasmids pKan-EmGHA3tNTRO, tvNTRO and pBacEmGH (described in Chapter 2) 
were digested with restriction enzymes NotI and EcoRI (Figure 3.28).  The desired bands were 
isolated via gel electrophoresis, cleaned and ligated to form plasmids pBacEmGHt and 
pBacEmGHtv.  These plasmids were used in the analysis of TEV protease’s in vivo cleavage 
efficiency.  The constructs were verified by DNA sequencing. 
For target purification following the isolation of antimicrobial peptides from the peptide 
selection an affinity tag was attached to the C-terminus of EmGFP.  Through previous cloning 
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Figure 3.28:  Construction of vectors pBacEmGHt and pBacEmGHtv.  Plasmid pBacEmGH was 
digested and spliced with fragments of pKan-EmGHA3tNTRO or pKan-EmGHA3tvNTRO to 
produce vectors pBacEmGHt or pBacEmGHtv, respectively. 
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steps the original His6 affinity tag on the N-terminus of EmGFP in the plasmid pBacEmGH was 
rendered useless by the incorporation of the TEV protease recognition sequence that detaches 
it from the peptide-EmGFP fusion to expose the random peptide library.  The oligonucleotides 
EmGH-CT HisA and EmGH-CT HisB (Table 3.3) were annealed (25 mM Tris HCl, 150 mM 
NaCl, 0.1 mM EDTA pH 8.0)  forming a DNA duplex with exposed sticky ends for BsrGI and 
HindIII on either side.  Plasmids pBacEmGHtv and pBacEmGHtv were digested with BsrGI and 
HindIII and the vector DNA fragments were isolated via gel electrophoresis and cleaned.  The 
DNA cassette was ligated into the digested vectors placing a His6 affinity tag at the C-terminus 
of EmGFP, just 5’ to the stop codon. 
 
3.6.9 TEV Protease In Vivo Cleavage Assay 
 To study the efficiency of proteolytic cleavage of TEV protease in vivo, cultures of 
pBacEmGH, pBacEmGHt, pBacEmGHtv in E. coli EPI301 cells were started in 3 mL LB-Cm25 
+ 0.2% D-glucose and a culture of pBacEmGHtv co-transformed with pRK603 and pZS4int-tetR 
in E. coli EPI301 cells started in 3 mL LB-Cm25Kan30Spec50 + 0.2% D-glucose were 
incubated overnight at 37 oC which shaking.  Each culture was then diluted 1/1000 by adding 15 
µL to 15 mL of the appropriate, fresh medium without D-glucose.  They were incubated at 37 oC 
with shaking for 4 hours to attain mid-log phase growth.  L-arabinose and ATC were added to 
final concentrations of 0.2% and 250 ng/mL, respectively, to induce either peptide-EmGFP or 
TEV protease expression.  Control cultures were left uninduced or with only the peptide-EmGFP 
fusion being induced.  Incubation continued for an additional 3 hours.  Whole cell lysates were 
prepared by centrifuging 1 mL of each culture at 7,000 rpm for 2 minutes.  The supernatants 
were removed and the pellets were resuspended in 25 µL of dH2O and 25 µL of denaturing 
SDS-PAGE loading buffer (final concentrations: 50 mM Tris HCl pH 6.8, 2% SDS, 10% glycerol, 
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1% β-mercaptoethanol and 0.02% bromophenol blue) and stored on ice.  For purified peptide-
EmGFP via the His6 affinity tag, 4.5 mL of each culture was added to 5 mL Talon™ single step 
columns by Clontech Laboratories, Inc. (Mountain View, CA).  Fifthteen µL of 2 Units/µL Dnase I 
was added and the tubes were inverted for 30 minutes.  Column flow-through was removed by 
gravity and 4.5 mL of equilibrium/wash buffer (50 mM sodium phosphate, 300 mM NaCl pH 7.0) 
was added and the tubes were inverted for 30 minutes.  Column flow-through was removed by 
gravity and 4.5 mL of wash-2 buffer (50 mM sodium phosphate, 300 mM NaCl, 7.5 mM 
imidazole pH 7.0) was added and the tubes were inverted for 30 minutes.  Column flow-through 
was removed by gravity and 500 µL of elution buffer (50 mM sodium phosphate, 300 mM NaCl, 
150 mM imidazole pH 7.0) was added.  The columns were inverted for 2 minutes and the flow-
through was collected via gravity flow.  Fifthteen µL of eluent was mixed with 3 µL of SDS-
PAGE loading buffer.  The whole cell lysate and His6 affinity tag purification samples were 
incubated in boiling water for 10 minutes to lyse the cells and denature the proteins.  All 
samples were then loaded on an SDS-PAGE gel and electrophoresed to get band separation.  
The gels were then stained with GelCode® blue stain reagent by Pierce (a division of Thermo 
Fisher Scientific Inc., Rockford, IL) 
 
3.6.10 pBacEmGH-tPro3 Construction 
 Oligonucleotides UniTevG-F and NTevPro3G-R (Table 3.3) were designed to anneal to 
each other for use in a primer extension reaction.  The resulting product and the plasmid 
pBacEmGHt were digested with restriction enzymes NheI and KasI.  The digests were run on 
an agarose gel and the desired DNA fragments were removed and cleaned.  The fragments 
were then ligated to form the plasmid pBacEmGH-tPro3 which was verified via DNA 
sequencing. 
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3.6.11 Induced Growth Curves 
 Cultures of each clone, started with an individual colony, were incubated overnight at 37 
oC in 3 mL LB-Cm25Kan30Spec50 + 0.2% D-glucose.  The overnights were diluted 1/1000 by 
moving 17 µL into 17 mL LB-Cm25Kan30Spec50 and incubated until late lag phase (~210 
minutes).  ATC was added to a final concentration of 250 ng/mL to induce TEV protease 
expression.  In certain control cultures, the addition of ATC was omitted to observe WT growth 
or the effect of the peptide-EmGFP fusion without TEV protease processing.  Incubation was 
continued until early log phase (~240 minutes) then L-arabinose was added to the culture to a 
final concentration of 0.2%.  The optical density of a 700 µL sample of the cultures at 600 nm 
was measured periodically at the point of induction and at 30 or 60 minute intervals following 
induction using Spectronic® Genesys™ 20 spectrophotometer from Thermo Fisher Scientific, 
Inc. (Waltham, MA).  In the final analysis, the optical density of uninoculated LB broth was 
subtracted from the values of each clone’s culture at every time point. 
 
3.6.12 Random Peptide Library Construction in pBacEmGHt 
 Complementary oligonucleotides UniTevG-F and NTev12R (Table 3.3), the former 
containing eleven NNK random codons with the initial codon being DNK to preclude the chance 
of proline residues from inhibiting TEV protease cleavage, were mixed to equal molarities and 
subjected to a primer extension reaction with dNTPs, Pfu polymerase and the appropriate 
buffer.  The product then run on a gel, the appropriate MW band was extracted and cleaned 
using QIAquick® Gel Extraction Kits from Qiagen Inc. (Valencia, CA).  The cleaned DNA was 
digested with NheI and KasI.  An identical digestion was performed on the vector pBacEmGHt.  
The digestion products were run on agarose gels, the appropriate MW bands were extracted 
and cleaned using GENECLEAN® Turbo kits from MP Biomedicals, LLC (Solon, OH).  The two 
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cleaned DNAs were ligated in a 2:1 insert to vector ratio using T4 DNA ligase with an overnight 
incubation at room temperature.  The ligation reactions were cleaned of protein and salts using 
GENECLEAN® Turbo kits.  Cleaned, ligated plasmid DNA was transformed into E. coli DH5α 
cells (fhuA2, Δ(argF-lacZ)U169, phoA, supE44 (glnV44), Φ80, Δ(lacZ)M15, gyrA96, recA1, 
relA1, endA1, thi-1, hsdR17).  Four hundred ng of cleaned plasmid DNA was added to 100 µL 
of the electro-competent cells.  In 25 µL batches, the cell/plasmid mixture was electroporated at 
2.44 kV.  The cells were recovered for 1 hr at 37 oC in 1 mL of SOC medium.  Recovered cells 
were then added to 500 mL LB-Cm25 + 0.2% D-glucose and incubated overnight at 37 oC for 
clone outgrowth.  Amplified plasmid DNA was then recovered by using a Qiagen® Maxi Plamid 
kit from Qiagen Inc. (Valencia, CA).  This procedure was repeated four times for a total of ~2.0 x 
106 transformants.  Portions of the plasmid preparations were mixed together to get roughly 
equal molar amounts of transformants. 
 
3.6.13 Peptide Selection Procedure 
 One hundred ng of pBacEmGHt plasmid DNA encoding the random peptide library was 
mixed with 30 µL of electro-competent EPI301 E. coli cells containing plasmids pRK603 and 
pZS4int-tetR.  The cell/DNA mixtures were electroporated at 2.44 kV and recovered in 1 mL of 
SOC medium for 1 hr at 37 oC.  This was repeated for 24 transformations.  Recovered cells 
were centrifuged at 7,000 rpm for 5 minutes to pellet the cells.  The supernatant was removed 
and the cells were washed in 50 mL of pre-warmed LB twice to remove any untransformed 
plasmid in the recovery medium.  The cells were then resuspended in 550 mL LB-
Cm25Kan30Spec50 + 0.2% D-glucose and incubated at 37 oC and 350 rpm.  When the cells 
achieved early to mid-log phase growth, the culture was centrifuged at 7,000 rpm to pellet the 
cells.  The supernatant was removed and the cells washed in 50 mL of pre-warmed LB twice to 
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remove D-glucose and any free plasmid from the sheering of cells during incubation or 
untransformed plasmids.  The cells were then resuspended in 550 mL pre-warmed LB-
Cm25Kan30Spec50 + 250 ng/mL anhydrotetracycline (ATC) and incubated at 37 oC and 350 
rpm.  After 30 minutes L-arabinose was added to a final concentration of 0.2% to induce 
EmGFP-peptide fusion expression and plasmid copy number increase.  Incubation at 37 oC 
continued for 90 minutes.  To isolate plasmids encoding bacteriolytic peptides, 21 mL of culture 
were removed and centrifuged at 13,000 rpm for 30 minutes to pellet whole cells.  The 
supernatant was moved to a new tube and the centrifugation repeated.  The supernatant was 
moved to a new tube with 16 mL of isopropanol, 2.1 mL 3 M Na acetate pH 5.0 and 52.5 µL of 
10 µg/mL salmon testes DNA.  The DNA serves as a carrier molecule during the alcohol 
precipitation.  The solution was inverted several times to mix and then centrifuged at 11,000 rpm 
for 45 minutes.  The supernatant was carefully removed and the pellet washed with 5 mL of 
70% ethanol.  This was centrifuged at 11,000 rpm for 10 minutes and the supernatant removed.  
The DNA pellet was dried and then resuspended in 500 µL dH2O. 
 Simultaneously with the 21 mL culture removal, ampicillin was added to the remaining 
culture to a final concentration of 500 µg/mL to lyse any actively dividing cells.  The culture 
continued to incubate at 37 oC until its optical density reached a minimum indicating all cells had 
been lysed.  The entire culture was centrifuged at 7,000 rpm for 10 minutes to pellet any whole 
cells.  The supernatant was removed and the pellet was washed in 50 mL of HEPES-NaCl (HN) 
buffer pH 7.0 three times.  The pellet was then stored at 4 oC overnight (this step is unnecessary 
and one may proceed to the next incubation).  The pellet was resuspended in 30 mL of DNase I 
buffer (10 mM Tris HCl pH 7.5, 2.5 mM MgCl2, 0.5 mM CaCl2) to which 25 µL of 2 units/µL of 
DNase I was added.  The solution was inverted gently to mix and incubated at 37 oC, without 
shaking, for 3 hours.  This step removes any extracellular DNA that may include plasmids from 
cells lysed by the ampicillin shock step.  The mixture was then centrifuged to pellet whole, intact 
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cells at 7,000 rpm for 5 minutes.  The pellet was washed with Qiagen® Midi Plasmid kit 
resuspension buffer (50 mM Tris HCl pH 8.0, 10 mM EDTA) twice to remove DNase I.  Plasmids 
encoding bacteriostatic/bactericidal peptides still contained within the whole, intact cells were 
extracted using a Qiagen® Midi Plamid kit from Qiagen Inc. (Valencia, CA). 
 Preparations of plasmids encoding bacteriolytic or bacteriostatic/bactericidal peptides 
were transformed into fresh E. coli EPI301 electro-competent cells containing plasmids pRK603 
and pZS4int-tetR and plated on LB-Cm25Kan30Spec50 + 0.2% D-glucose so that the colonies 
are sufficiently separate from each other.  To confirm the efficacy of the selected clones, the 
colonies were replica plated on to plates of LB-Cm25Kan30Spec50 + 250 ng/mL ATC, + 0.2% 
L-arabinose and then LB-Cm25Kan30Spec50 + 0.2% D-glucose.  The plates were incubated 
overnight at 37 oC.  Colonies that failed to grow on the plate containing L-arabinose versus that 
containing D-glucose were selected for further analysis. 
 
3.6.14 DNA Sequencing 
 Isolated clones were sequenced using a two-step process.   Overnight cultures were 
grown in LB-Cm25Kan30Spec50 + 0.2% D-glucose.  One µL of culture was used as template in 
an initial PCR including primers arapromseqF and EmGHrtRev (Table 3.3).  The primers are 
complimentary to sequences on either side of the randomized region.  arapromseqF has a 5’ tail 
not complimentary to any region in pBacEmGHt, but has been selected for complementarity 
with a third oligonucleotide, JSLF (Table 3.3).  The product of the first reaction incorporates the 
JSLF-complimentary tail using Taq polymerase.  The 25 µL product is then diluted in 170 µL 
dH2O and used as a template in a sequencing reaction employing dideoxynucleotide mixes and 
a 5’ IRDye®-labeled primer, JSLF.  The labeled primer binds the tail sequence permitting high-
throughput sequencing. 
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3.6.15 Peptide-EmGFP Expression Assays 
 Assays were carried out in 96-well plates.  Cultures were started using isolated colonies 
from a streak plate in 200 µL of LB-Cm25Kan30Spec50 + 0.2% D-glucose and incubated 
overnight at 37 oC and 500 rpm in a 96-well plate incubator, the GeneMachines HiGro® from 
Digilab, Inc. (Holliston, MA).  Overnight cultures were diluted 1/100 by moving 2 µL into 200 µL 
LB-Cm25Kan30Spec50 and incubated at 37 oC and 500 rpm in the HiGro.  After 120 minutes of 
incubation, ATC was added to each culture to a final concentration of 250 ng/mL.  Incubation 
was resumed and when the cultures achieved early log phase (~150 minutes) the optical 
densities of the cultures in the plate at 600 nm were measured using a SpectraMax 190 from 
Molecular Devices, Inc. (Sunnyvale, CA) and the fluorescence of the cultures (excitation at 395 
nm, emission at 509 nm) were measured using a SpectraMax Gemini XPS.  L-arabinose was 
added to each culture to a final concentration of 0.2%.  Incubation was continued and at 60 
minute intervals the optical density and fluorescence were measured as before.  During final 
analysis, the fluorescence at the point before induction was subtracted from all subsequent time 
values for that clone.  The optical density of 200 µL of LB-Cm25Kan30Spec50 was subtracted 
from all optical density values.  The fluorescence values were then divided by the optical density 
for each clone to normalize the amount of fluorescence to the number of cells in the culture. 
 
  
185 
 
 
 
CHAPTER 4 
PERIPLASMIC SELECTION FOR THE ISOLATION OF ANTIMICROBIAL PEPTIDES IN 
ESCHERICHIA COLI 
 
4.1 Abstract 
 Therapeutic antibiotics act by a number of mechanisms and on a variety of targets.  
Some of these targets such as the ribosome, RNA polymerase and DNA gyrase are located in 
the cytoplasm and offer viable targets for the peptide selection methods we have previously 
developed for selecting antimicrobial peptides, cIVD and nIVD.  However, the most popular 
antibiotics, penicillins and cephalosporins, and a number of other antibiotics of last resort, 
vancomycin and daptomycin, inhibit the function of molecules exclusive to the periplasm, a cell 
volume located between the inner and outer membranes of Gram-negative bacteria.  In vivo 
display was modified for the isolation of antimicrobial peptides that target components of the 
periplasm.  A library of 12-amino acid random peptide sequences was added to the N-terminus 
of the display protein, alkaline phosphatase (PhoA), between PhoA’s signal peptide, dictating 
translocation to the periplasm, and the initial codon of PhoA.  PhoA serves as a purification 
adjunct, through the inclusion of an affinity tag, and a benchmark of translation and 
translocation. 
 To identify novel peptides that inhibit bacterial growth, a library of ~1 x 109 clones was 
screened in E. coli cells to isolate peptides with bacteriolytic, bacteriostatic and bactericidal 
phenotypes.  A total of 192 inhibitory transformants have been isolated, sequenced, and 
characterized.  Of the total, 53 peptides were bacteriostatic, 44 significantly reduced E. coli’s 
growth rate, and 95 were bacteriolytic.  Sequence analysis of the lytic peptides revealed 
common sequence motifs that may critical for their activity.  Further analysis revealed one 
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peptide, PL098, demonstrated a spectrum of activity against Gram-negative bacteria making it a 
potential lead for antimicrobial development. 
 
Figure 4.1:  Methods of antimicrobial development discussed within this dissertation.  Chapter 4 
focuses on in vivo display of a random peptide library at the N-terminus of a display protein in E. 
coli’s periplasm. 
 
4.2 Introduction 
 Bacterial cells are composed of two distinct compartments separated by membranes.  
The cytoplasm comprises ~90% of the total cell volume487 and is the site of DNA replication, 
transcription and translation.  Other metabolic processes necessary for growth and replication, 
such as macromolecule synthesis and various carbon and energy harvesting pathways, also 
occur in the cytoplasm.  The cIVD and nIVD systems (Chapters 2 & 3) were designed to target 
components of the cytoplasm to identify peptides that disrupt these essential processes.   
The periplasm is located between the inner plasma membrane and the outer membrane 
beyond the cell wall and constitutes ~12% of the total cell volume487 in Gram-negative cells.  
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While present in Gram-positive cells, its size is greatly reduced and importance diminished.  
Like the cytoplasm, the periplasm presents numerous antibacterial targets most of which are not 
present in the cytoplasm.  These include macromolecules such as enzymes involved in cell 
wall,488 inner and outer membrane synthesis,263; 489; 490 the proton motive force491 and nutrient 
transport492; 493 and processing.494; 495  Structures present only in the periplasm, such as the 
periplasmic surface of the inner membrane, the outer membrane and proteins and modified 
lipids integral to these structures, constitute a multitude of potential targets not accessible to the 
cytoplasmic in vivo display systems, cIVD and nIVD (Figure 4.1). 
 
4.2.1 Translocation & Peptide Display 
 To adapt the in vivo display system for the discovery of antimicrobial peptides that target 
periplasmic components, a periplasmic in vivo display system, pIVD, was developed.  EmGFP 
and other green fluorescent protein derivatives are unable to fold properly in the periplasm.496  
This necessitated the identification and utilization of a different display protein that folds 
correctly and functions in the periplasm but, like EmGFP, would serve as a reporter of 
successful translation and translocation.  Alkaline phosphatase (PhoA) is a native E. coli 
enzyme present in the periplasm that catalyzes dephosphorylation of various molecules such as 
nucleotides and proteins.497; 498  Through the use of the colorimetric substrate, 5-bromo-4-
chloro-3-indoxyl-phosphate (X-Phos) which, in the presence of PhoA is converted to a blue dye 
upon reaction with oxygen, PhoA activity can be monitored in the periplasm by the appearance 
of the blue precipitate in colonies producing mature, active PhoA, in a similar fashion as LacZ/X-
gal assays.499; 500  PhoA is unable to fold into an active conformation until it translocates into the 
periplasm.501  Therefore, the presence of PhoA activity indicates that the PhoA protein was 
transcribed, translated, translocated and folded correctly.  Translocation of PhoA occurs through 
the Sec pathway.502  The fusion of the PhoA and its signal peptide, or pre-PhoA, is fully 
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translated in the cytoplasm.  The unfolded, pre-PhoA is then bound by the secretory protein, 
SecB, which facilitates binding to SecA.  Through its ATPase activity, SecA threads the 
unfolded, pre-PhoA through the inner membrane via the SecYEG pore complex.  As the signal 
peptide enters the periplasm, a signal peptidase binds to its recognition sequence and cleaves 
off the peptide before the first amino acid of PhoA.  Once in the oxidizing environment of the 
periplasm, PhoA folds into its active conformation.   We manipulated this natural system by 
introducing a random peptide library between the final residue of the signal peptide and PhoA.  
This serves two purposes, 1) it ensures that peptides attached to PhoA are translocated into the 
periplasm where its presence can be detected using X-Phos and 2) it sequesters the random 
peptide library behind the signal peptide from possible targets in the cytoplasm so its activity is 
not pre-screened for lethality before it reaches the periplasmic space. 
 
4.2.2 Vector Construction 
 The plasmid pKan-EmGH (Figure 4.2) was modified to contain the pIVD system 
primarily due to its low copy number.503  The periplasmic space is smaller than the cytoplasm 
and we did not want to saturate it with peptide-PhoA fusions thus isolating non-inhibitory 
peptides lethal due to aggregation.  The p15A replication origin of pKan-EmGH maintains the 
plasmid at ~10 copies per cell, ~25-50% less than the pBacEmGH plasmid used in the 
cytoplasmic selections.  The EmGFP gene was replaced with the genomic copy of PhoA, 
containing its signal peptide from E. coli W3110.  A modification of the DNA sequence in the 
signal peptide, without a resultant change in the amino acid sequence, permitted the 
incorporation of a restriction enzyme recognition sequence for the incorporation of the random 
DNA sequence encoding the peptide library as a cassette.  As with TEV protease, the signal 
peptidase responsible for cleaving off the signal peptide has a recognition sequence whose final 
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position, which stays attached to the peptide-PhoA fusion can be altered to any residue except 
proline.504  To prevent the incorporation of proline at position 1, we used the random DNA 
sequence DNK (NNK)11 whereas D is A, G or T, K is G or T and N is any base to encode amino 
acids in the peptide cassette.  DNK (NNK)11 also excludes histidine and glutamine from position 
1 as well as two of three stop codons that could truncate some of the peptides in the library.  To 
prevent premature termination by the third, amber stop codon (UAG), selection experiments 
were performed in the amber-suppressor strain E. coli DH5α.  This strain is also phoA ensuring 
that any PhoA activity detected during the selection experiments was due to the presence of the 
plasmid-encoded PhoA gene. 
With the utilization of pIVD, we hoped to isolate bacteriolytic peptides at a higher rate 
than what was observed in the cytoplasmic selections.  Disruption of cell wall synthesis or 
membrane integrity can lead to cell lysis as demonstrated by antimicrobials such as penicillin 
and magainin 2.244  
 
Figure 4.2:  pKan-EmGH is derived from the laboratory plasmid pKan5-T1T2.  It includes a 
p15A (pACYC) replication origin, the neo gene for kanamycin selection and the arabinose 
operator including PBAD and regulatory protein AraC. Expression of EmGFP is inducible with the 
addition of L-arabinose to the growth medium. 
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4.3 Objective of the Project 
 To demonstrate that in vivo display targeting components of the periplasm, pIVD, 
is a viable method for the isolation of antimicrobial peptides. 
 
4.4 Results 
4.4.1 Vector Construction 
 The plasmid, pKan-PhoA1 (Figure 4.3), was constructed as a derivative of pKan-EmGH 
(Figure 4.2).  The neo gene, conferring kanamycin resistance, was preserved for plasmid 
selection.  The p15A replication origin, maintaining a copy number of ~10 plasmids per cell,503 
produces a low level of peptide-PhoA fusion.  PBAD, the arabinose promoter and its regulatory 
protein AraC, was used for controlling the expression, through induction with the addition of L-
arabinose407; 408; 409 or repression with D-glucose,406 of peptide-PhoA fusions.  The PhoA gene 
was cloned from the genome of E. coli W3110 in place of EmGFP, modifying the C-terminus to 
incorporate at His6 affinity tag.  The DNA sequence encoding the signal peptide was altered to 
include a restriction enzyme site for the emplacement of the random peptide library and the 
peptide linker378 attaching it to the N-terminus of PhoA (Figure 4.4). 
 Expression of the construct in E. coli cells produces a fusion of display protein PhoA 
covalently attached at its N-terminus to a theoretically unstructured peptide comprised of three 
sections 1) the signal peptide required for translocation into the periplasm, 2) the peptide library 
to be screened for antimicrobial activity and 3) a linker peptide (Glu-Gly-Gly-Gly-Ala)378 to give 
the peptide freedom of movement (Figure 4.4).  Upon translocation the signal peptide is 
cleaved forming the mature peptide-PhoA fusion with the peptide library exposed at the N- 
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Figure 4.3:  pKan-PhoA1 is derived from plasmid pKan-EmGH.  The gene encoding EmGFP 
was replaced with phoA, encoding periplasmic display protein alkaline phosphatase (PhoA), a 
native enzyme of E. coli.  Expression of PhoA is inducible by the addition of L-arabinose to the 
growth medium. 
 
 
Figure 4.4:  pKan-PhoA1 including the 12mer random peptide library cloned 3’ to the PhoA 
signal peptide sequence and 5’ to the linker peptide and PhoA.  The library into E. coli DH5α 
cells and screened to isolate peptides with detrimental growth phenotypes. 
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Figure 4.5:  The gene product of pKan-PhoA1 contains the PhoA signal peptide, 12mer random 
peptide library, peptide linker, PhoA and a His6 affinity tag.  Following translocation of the signal 
peptide through the inner membrane, a peptidase cleaves off the signal peptide exposing the 
random peptide library at the N-terminus in the periplasm. 
 
 
Figure 4.6:  The induction of pKan-PhoA1 results in the accumulation of mature, peptide-PhoA 
fusion in the periplasm where it can bind to targets and inhibit the growth of the host E. coli cell. 
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terminus (Figure 4.5).  Peptide-PhoA fusion accumulates in the periplasm where it can bind to 
potential targets and affect cellular growth (Figure 4.6).  
 
4.4.2 Library Construction & Selection 
Primer extension reactions were performed and the product was cloned into pKan-
PhoA1 in between the signal peptide and PhoA to create a 12mer random peptide library 
encoded by the DNA sequence DNK (NNK)11.  This represents a potential library diversity of 
~3.5 x 1015 unique peptides.  We produced a library sampling this diversity with ~1 x 109 clones 
by transforming ligated plasmid DNA into highly electro-competent NEB 10-β E. coli cells.  
Plasmid DNA was then purified from the cells.  Approximately 5 x 108 transformants were 
screened for antimicrobial activity in E. coli DH5α cells.  Transformed cells were recovered and 
then moved into fresh Luria-Bertani (LB) medium.442; 443  The culture was grown to mid-log 
phase growth and induced by the addition of 0.2% L-arabinose.  Expression of the peptide-
PhoA fusions was carried out one and a half hours to allow for accumulation of the fusion and 
time to interact with potential targets. 
 
Figure 4.7:  Selection for the isolation of bacteriolytic peptide-encoding plasmids. 
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 Bacteriolytic peptide selection (Figure 4.7)  Samples of the culture were removed for the 
isolation bacteriolytic peptide-encoding (lytic) plasmids.  The samples of culture were 
centrifuged to remove whole cells and prospective lytic plasmids were recovered from the 
supernatant by isopropanol precipitation.   
 Bacteriostatic/bactericidal peptide selection (Figure 4.8)  An ampicillin shock of 500 
µg/mL was added to the culture.  Ampicillin causes cell lysis by disrupting the synthesis of the 
cell wall.  As cells grow, they require larger cell walls to maintain their intracellular pressure. 
Therefore in the presence of ampicillin, actively dividing cells are lysed.426; 432  Cells containing 
prospective bacteriostatic/bactericidal peptide-encoding (non-lytic) plasmids are not affected by 
ampicillin and are not lysed.  Incubation in the presence of ampicillin was continued until the 
optical density of the culture had reached a minimum, indicating the completion of cell lysis.  
Centrifugation of the culture pelleted whole, unlysed cells leaving the debris of cell lysis in the 
supernatant.  After a series of washes to remove any free-plasmid DNA, the pellet was treated 
to extract the non-lytic plasmids. 
Confirmation of peptide efficacy  Isolated lytic and non-lytic plasmid pools were 
retransformed into fresh E. coli DH5α cells.  Transformants were plated on solid, LB media 
containing D-glucose to get isolated colonies and repress fusion expression.  Colonies were 
replica plated onto induction media with 0.2% L-arabinose and repression media with 0.2% D-
glucose.  Colonies that failed to grow on induction media were selected for further analysis.  
One hundred ninety-two total peptides demonstrating antimicrobial activity were isolated from 
both selections. 
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Figure 4.8:  Selection for the isolation of bacteriostatic and bactericidal peptide-encoding 
plasmids. 
 
4.4.3 Characterization of Peptides 
4.4.3.1  Phenotypes of Peptides  
 Cultures of each colony, confirmed to have antimicrobial activity upon induction, were 
grown to grown to early log phase.  The cultures were induced with the addition of 0.2% L-
arabinose to express peptide-PhoA fusions.  The growth of the cultures was monitored by 
measuring the turbidity at λ = 600 nm.    
Peptides isolated via bacteriolytic peptide selection  179 peptides in total were isolated 
using the bacteriolytic peptide selection.  Peptides were categorized based on the observed 
growth phenotypes of their host cultures (Figure 4.9).  Ninety-four of these peptides (Table 
4.1.A-B) exhibited cell lysis or a decrease in the optical density with time following induction of 
the culture (Figures 4.10.A-S).  Peptides can further characterized by their varying degrees of 
onset of lysis, rate of lysis and optical density endpoint.  Peptides demonstrating an early onset 
of lysis, defined as causing lysis within 30 minutes to an hour after induction, are thought to be 
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more active or efficient at cell lysis, requiring less of the peptide-PhoA fusion to be produced 
(e.g. PL062, PL137 and PL208).  Other peptides required 2 hours or more for a reduction in the 
culture’s turbidity to be observed (e.g. PL029, PL030 and PL055). The decrease in optical 
density also varied as a percentage from the onset of lysis among the clones indicating some 
peptides were capable of nearly lysing all cells in the culture (e.g. PL049, PL064 and PL122) 
while others only lysed a small portion of their host cells with the culture’s turbidity approaching 
an asymptote well above that of a cleared culture (e.g. PL097, PL111 and PL145).  The rate of 
lysis also varied.  Some clones, once lysis set in, decreased in optical density rapidly (e.g. 
PL049, PL055 and PL062) while others only subtly decreased (e.g. PL035, PL095 and PL104).  
Alignment of all lytic peptide sequences shows demonstrable similarity at specific amino acid 
positions.   
Surprisingly, 44 peptides demonstrating either bacteriostatic or bactericidal growth 
phenotypes were isolated as well (Table 4.2).  These are distinguished from lytic peptides by 
their lack of a decrease in the culture’s turbidity, but cause a complete cessation of growth 
(Figures 4.11.A-H). It is possible that these clones, while demonstrating a non-lytic phenotype, 
may disrupt the membrane and/or cell wall in a manner that during the isolation procedure they 
were lysed and their freed plasmids recovered.  The onset of growth cessation varied among 
the clones.  Some peptides were able to halt the growth of their host cells within 30 minutes of 
induction (e.g. PL049, PL069 and PL088) while others required more time, perhaps indicative of 
lower binding constants for their targets or their targeting of molecules present in large amounts 
(e.g. PL125, PL126 and PL164). 
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Figure 4.9:  Antimicrobial peptides isolated from the periplasmic bacteriolytic or 
bacteriostatic/bactericidal selections grouped based on their phenotypes. 
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Table 4.1:  Amino acid sequences of bacteriolytic peptides isolated from the bacteriolytic 
peptide selection using the in vivo periplamic display system. 
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Figures 4.10.A-B:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format. 
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Figures 4.10.C-D:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format. 
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Figures 4.10.E-F:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format. 
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Figures 4.10.G-H:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format. 
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Figures 4.10.I-J:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format. 
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Figures 4.10.K-L:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format. 
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Figures 4.10.M-N:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format. 
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Figures 4.10.O-P:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format. 
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Figures 4.10.Q-R:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format. 
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Figure 4.10.S:  Induced growth curves of isolated, bacteriolytic peptides from both the 
bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide.  All growth curves were 
performed in a 96-well plate format.  Peptide PC016 is a lytic peptide isolated from the 
bacteriostatic/bactericidal selection. 
 
Peptides belonging to an unexpected phenotype demonstrated no decrease or cessation 
of bacterial growth were also isolated.  These peptides have been grouped as weakly inhibitory 
or growth rate reducing peptides.  Forty-one such clones (Table 4.3) were isolated from the 
bacteriolytic peptide selection.  While these peptides have less antimicrobial activity compared 
to lytic and non-lytic lethal peptides (Figures 4.12.A-I), their further analysis may present useful 
information in the design of new antimicrobials.  
 Peptides isolated via bacteriostatic/bactericidal peptide selection  A total of 13 peptides 
demonstrating various growth-affecting phenotypes were isolated using the non-lytic peptide 
selection (Figure 4.9, Table 4.4).  One peptide, PC016, exhibited cell lysis (Figure 4.10.S).  
Nine peptides demonstrated non-lytic phenotypes, completely stopping the growth of the culture 
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in either a bacteriostatic or bactericidal fashion (Figures 4.13.A-B).  A final three peptides are 
categorized as weakly inhibitory, slowing the growth of the host culture (Figures 4.12.G, I).   
 
 
Table 4.2:  Amino acid sequences of bacteriostatic/bactericidal peptides isolated from the 
bacteriolytic peptide selection using the in vivo periplasmic display system. 
 
The peptide NI001, featured in all induced growth curves, is a non-inhibitory peptide 
isolated from the periplasmic library and used as a negative control.  Its activity, when 
expression is induced, accounts for the stresses on the cell of over-expression that slightly 
lowers the growth rate of the cell. 
Bacteriostatic and bactericidal peptides remain grouped due to the difficulty of reliably 
determining each peptide’s phenotype.  Viability assays of host cultures would be required to 
determine if a peptide’s effect was reversible or irreversible.  However, the occurrence of 
210 
 
 
 
mutations in the PBAD promoter409 or regulatory protein, AraC,505; 506 among a population in each 
culture gives rise to cells that contain the plasmid, but are unable to express the peptide-PhoA 
fusion in the presence of L-arabinose (the effect of promoter mutants is further discussed in 
Chapter 6).  These mutants would make bactericidal peptide expressing cells indistinguishable 
from bacteriostatic ones. 
 
 
 
Figure 4.11.A:  Induced growth curves of isolated, bacteriostatic/bactericidal peptides from the 
bacteriolytic selection.  Peptide NI001 represents the effects on E. coli growth of expression of a 
non-inhibitory, translocating peptide.  Growth curves were performed in large cultures of 17 mL 
of growth medium. 
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Figures 4.11.B-C:  Induced growth curves of isolated, bacteriostatic/bactericidal peptides from 
the bacteriolytic selection.  Peptide NI001 represents the effects on E. coli growth of expression 
of a non-inhibitory, translocating peptide.  Growth curves were performed in large cultures of 17 
mL of growth medium. 
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Figures 4.11.D-E:  Induced growth curves of isolated, bacteriostatic/bactericidal peptides from 
the bacteriolytic selection.  Peptide NI001 represents the effects on E. coli growth of expression 
of a non-inhibitory, translocating peptide.  Growth curves were performed in a 96-well plate 
format.  
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Figures 4.11.F-G:  Induced growth curves of isolated, bacteriostatic/bactericidal peptides from 
the bacteriolytic selection.  Peptide NI001 represents the effects on E. coli growth of expression 
of a non-inhibitory, translocating peptide.  Growth curves were performed in a 96-well plate 
format. 
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Figure 4.11.H:  Induced growth curves of isolated, bacteriostatic/bactericidal peptides from the 
bacteriolytic selection.  Peptide NI001 represents the effects on E. coli growth of expression of a 
non-inhibitory, translocating peptide.  Growth curves were performed in a 96-well plate format. 
 
 
Table 4.3:  Amino acid sequences of weakly inhibitory or growth rate reducing peptides isolated 
from the bacteriolytic peptide selection using the in vivo periplasmic display system. 
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Figures 4.12.A-B:  Induced growth curves of isolated, weakly inhibitory or growth rate reducing 
peptides from both the bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 
represents the effects on E. coli growth of expression of a non-inhibitory, translocating peptide.  
Growth curves were performed in large cultures of 17 mL of growth medium. 
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Figure 4.12.C:  Induced growth curves of isolated, weakly inhibitory or growth rate reducing 
peptides from both the bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 
represents the effects on E. coli growth of expression of a non-inhibitory, translocating peptide.  
Growth curves were performed in large cultures of 17 mL of growth medium. 
 
 
Figure 4.12.D:  Induced growth curves of isolated, weakly inhibitory or growth rate reducing 
peptides from both the bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 
represents the effects on E. coli growth of expression of a non-inhibitory, translocating peptide.  
Growth curves were performed in a 96-well plate format. 
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Figures 4.12.E-F:  Induced growth curves of isolated, weakly inhibitory or growth rate reducing 
peptides from both the bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 
represents the effects on E. coli growth of expression of a non-inhibitory, translocating peptide.  
Growth curves were performed in a 96-well plate format. 
218 
 
 
 
 
Figure 4.12.G:  Induced growth curves of isolated, weakly inhibitory or growth rate reducing 
peptides from both the bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 
represents the effects on E. coli growth of expression of a non-inhibitory, translocating peptide.  
Growth curves were performed in a 96-well plate format. 
 
 
Figure 4.12.H:  Induced growth curves of isolated, weakly inhibitory or growth rate reducing 
peptides from both the bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 
represents the effects on E. coli growth of expression of a non-inhibitory, translocating peptide.  
Growth curves were performed in large cultures of 17 mL of growth medium. 
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Figure 4.12.I:  Induced growth curves of isolated, weakly inhibitory or growth rate reducing 
peptides from both the bacteriolytic and bacteriostatic/bactericidal selections.  Peptide NI001 
represents the effects on E. coli growth of expression of a non-inhibitory, translocating peptide.  
Growth curves were performed in large cultures of 17 mL of growth medium. 
 
 
 
Table 4.4:  Amino acid sequences of all antimicrobial peptides isolated from the 
bacteriostatic/bactericidal peptide selection using the in vivo periplasmic display system. 
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Figures 4.13.A-B:  Induced growth curves of isolated, bacteriostatic/bactericidal peptides from 
the bacteriostatic/bactericidal selection.  Peptide NI001 represents the effects on E. coli growth 
of expression of a non-inhibitory, translocating peptide.  Growth curves were performed in a 96-
well plate format 
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4.4.3.2  Sequence Analysis of Bacteriolytic Peptide Pool 
 To analyze the similarity of bacteriolytic peptides isolated from the periplasmic library 
using the bacteriolytic peptide selection procedure, sequences were aligned and compared to 
random distributions.  χ2 and binomial distributions were used to determine if there were 
patterns in amino acid sequence relating the peptides to each other.  No such patterns were 
observed among the non-lytic peptides isolated. 
Unselected peptide sequences  Two hundred eight clones from the unselected peptide 
library were sequenced to establish the distribution of residues prior to selection (Tables 4.5A-
E).  A non-random distribution of residues favoring amino acids arginine and glycine was 
observed (Figures 4.14.A-L, Table 4.6).  Glycine biases were present at every position of the 
peptide library (Tables 4.7.A-C, 4.8).  Preferences for arginine were especially apparent at 
positions 4-9 and 11-12.  To compensate, hydrophobic and hydrophilic residues were selected 
against.  The preference for arginine and glycine likely arises from a non-random distribution of 
guanine and cytosine in the DNA encoding the peptides.  This indicates that the bias was 
introduced at the time of library construction perhaps during the ligation or primer extension 
reactions.  This proclivity skewed the representation of all amino acid sequences in the library 
compared to what would theoretically be expected from the DNA sequence DNK (NNK)11.  
Subsequent distribution analysis of the bacteriolytic peptides has used the distribution of the 
unselected peptides as the expected probabilities. 
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Table 4.5.A:  Amino acid sequences of the unselected peptide library. 
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Table 4.5.B:  Amino acid sequences of the unselected peptide library. 
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Table 4.5.C:  Amino acid sequences of the unselected peptide library. 
 
 
Figure 4.14.A:  Amino acid distribution of unselected, periplasmic peptide library (observed) 
versus a theoretically, random distribution of DNK codons at position 1 (expected). 
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Figures 4.14.B-C:  Amino acid distribution of unselected, periplasmic peptide library (observed) 
versus a theoretically, random distribution of NNK codons at positions 2-12 (expected). 
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Figures 4.14.D-E:  Amino acid distribution of unselected, periplasmic peptide library (observed) 
versus a theoretically, random distribution of NNK codons at positions 2-12 (expected). 
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Figures 4.14.F-G:  Amino acid distribution of unselected, periplasmic peptide library (observed) 
versus a theoretically, random distribution of NNK codons at positions 2-12 (expected). 
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Figures 4.14.H-I:  Amino acid distribution of unselected, periplasmic peptide library (observed) 
versus a theoretically, random distribution of NNK codons at positions 2-12 (expected). 
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Figures 4.14.J-K:  Amino acid distribution of unselected, periplasmic peptide library (observed) 
versus a theoretically, random distribution of NNK codons at positions 2-12 (expected). 
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Figure 4.14.L:  Amino acid distribution of unselected, periplasmic peptide library (observed) 
versus a theoretically, random distribution of NNK codons at positions 2-12 (expected). 
 
 
Table 4.6:  χ2 analysis of the unselected peptide sequences compared to the theoretically 
random distribution of DNK (position 1) and NNK (positions 2-12) codons. 
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Table 4.7.A:  Binomial distribution of the individual amino acids of the unselected peptide 
sequences compared to the theoretically random distribution of DNK (position 1) and NNK 
(positions 2-12) codons. 
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Table 4.7.B:  Binomial distribution of the individual amino acids of the unselected peptide 
sequences compared to the theoretically random distribution of DNK (position 1) and NNK 
(positions 2-12) codons. 
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Table 4.7.C:  Binomial distribution of the individual amino acids of the unselected peptide 
sequences compared to the theoretically random distribution of DNK (position 1) and NNK 
(positions 2-12) codons. 
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Table 4.8:  Binomial distribution of the amino acid side chain groups of the unselected peptide 
sequences compared to the theoretically random distribution of DNK (position 1) and NNK 
(positions 2-12) codons. 
  
235 
 
 
 
General peptide biases  Upon aligning the linear sequences of all the bacteriolytic 
peptides isolated, obvious patterns of amino acid (Figures 4.15.A-L, Tables 4.9.A-C, 4.10) and 
side chain group (Figures 4.16.A-L, Tables 4.10, 4.11) distributions emerged.  Overall the 
peptides have a proclivity for basic residue, especially arginine and lysine and hydrophobic 
residue, especially tryptophan and leucine composition.  The different classes of residues (basic 
and hydrophobic) tend to alternate in pairs through the twelve positions (Table 4.12).  Among 
the basic residues, arginine is by far more common than lysine and histidine is rarely observed.  
The occurrence of arginine compared to lysine is likely due to the number of codons arising 
from NNK, three for arginine versus one for lysine.  The absence of histidine cannot be 
explained away thus.  As with lysine, there is one codon, but the observed occurrences do not 
match each other.  Similar analysis applies to the hydrophobic residues.  Three codons code for 
leucine, the most of any hydrophobic residue and along with arginine the most of any residue.  
Therefore we can surmise that the occurrence of leucine and arginine at particular positions 
likely satisfies only a predilection for the amino acid group characteristics (basic or hydrophobic) 
versus the residue itself (arginine or leucine).  Tryptophan offers a dramatically different 
proposition.  Tryptophan is only encoded by one codon (UGG) and yet its occurrence exceeds 
all other residues at positions beyond what would be expected randomly.  Several studies 
suggest tryptophan plays a special role among antimicrobial peptides,507; 508; 509 disrupting 
membrane integrity due to its unique molecular structure.   
Position 1 (Tables 4.9.A, 11, Figures 4.15.A, 4.16.A) The first position in the peptide, 
just C-terminal to the signal peptidase recognition site, shows a preference for hydrophobic 
residues (p = 6 x 10-37) at the expense of hydrophilic, basic, acidic and small (glycine and 
alanine) residues.  Tryptophan is particularly popular in the pool at this position (p = 4.1 x 10-19).  
Position 1 was encoded by the codon DNK biasing the position against proline, histidine, 
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leucine, glutamine and arginine in order to remove the possibility of proline incorporation which 
interferes with signal peptidase cleavage.504   
Position 2  (Tables 4.9.A, 11, Figures 4.15.B, 4.16.B) The position exhibits a dearth of 
hydrophobic residues (p = 3.7 x 10-11) including tryptophan (p = 6.1 x 10-3) to the benefit of basic 
residues (p = 2.4 x 10-4), especially arginine (p = 1.6 x 10-3), and non-basic residues alanine (p = 
4.0 x 10-4) and hydrophilic residues (p = 3.4 x 10-2).   
Position 3  (Tables 4.9.A, 11, Figures 4.15.C, 4.16.C) Tryptophan dominates (p = 2.4 x 
10-17) with leucine heavily overrepresented (p = 2.7 x 10-3) at position 3.  Arginine (p = 4.0 x 10-
2), alanine (p = 3.6 x 10-2) and phenylalanine (p = 0, this anomaly arises from the lack of 
phenylalanine residues at position 3 in the unselected pool) were also represented reflecting 
either the occurrence of a motif where arginine or tryptophan/leucine are interchangeable at the 
position or it may be an instance of sequence staggering.   
Position 4  (Tables 4.9.A, 11, Figures 4.15.D, 4.16.D) This position is heavily biased in 
favor of leucine (p = 3.9 x 10-32) with valine (p = 4.6 x 10-7) and isoleucine (p = 1.2 x 10-8) was 
also being favored.  The three residues share the same side chain size and hydrophobicity with 
leucine being represented in the theoretical pool by three codons while the other two are 
encoded by only 1 and 2 codons, respectively.  This may account for the high amount of leucine 
versus valine and isoleucine.  Basic residues (p = 6.2 x 10-10), especially arginine (p = 1.5 x 10-7) 
and small residue glycine (p = 1.5 x 10-7) are selected against. 
Position 5  (Tables 4.9.B, 11, Figures 4.15.E, 4.16.E) Here, a heavy preference for 
arginine (p = 6.5 x 10-8) and lysine (p = 5.2 x 10-13) is observed with lysine being represented 
over 1100% compared to the unselected library.   
Position 6  (Tables 4.9.B, 11, Figures 4.15.F, 4.16.F) A similar bias as seen with 
position 5 is apparent, albeit with greater inclination for arginine (p = 5.6 x 10-14)  rather than 
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lysine.  This preference comes at the expense of hydrophobic residues (p = 5.8 x 10-8) that are 
underrepresented. 
Position 7  (Tables 4.9.B, 11, Figures 4.15.G, 4.16.G) Following two positions with 
preferences for basic residues, position 7 shows a strong bias for hydrophobic amino acids (p = 
4.8 x 10-17), dominated by residues tryptophan (p = 7.9 x 10-29) and leucine (p= 7.0 x 10-12).  
Oddly, this bias comes at the expense of hydrophilic (p = 2.6 x 10-9) and not basic (p = 8.0 x 10-
2) amino acids.  This again indicates that some peptide sequences may be staggered by one 
position and still satisfy the general alternating sequence over 11 positions. 
Position 8  (Tables 4.9.B, 11, Figures 4.15.H, 4.16.H) Similar to position 7, there is a 
preference for tryptophan (p = 5.0 x 10-32) and leucine (p = 2.1 x 10-6) and to a lesser extent 
phenylalanine (p = 9.4 x 10-3).  This leads to a large bias for hydrophobic residues (p = 1.3 x 10-
21) coming mostly at the expense of basic amino acids (p = 1.1 x 10-7). 
Position 9  (Tables 4.9.C, 11, Figures 4.15.I, 4.16.I) Preferences switch back from 
hydrophobic (p = 4.0 x 10-2) to basic residues (p = 5.0 x 10-10) with arginine (p = 2.8 x 10-8) being 
highly favored.   
Position 10  (Tables 4.9.C, 11, Figures 4.15.J, 4.16.J) Continuing the alternating pairs 
of basic and hydrophobic residues, position 10 demonstrates a strong preference for basic 
amino acids (p = 1.2 x 10-8) including arginine (p = 2.8 x 10-6) and lysine (p = 3.4 x 10-5). 
Position 11  (Tables 4.9.C, 11, Figures 4.15.K, 4.16.K) While position 11 and 12 
demonstrate weaker preferences than prior positions they continue the trend of alternating 
amino acid groups.  Position 11 shows a proclivity for hydrophobic residues (p = 4.9 x 10-5), with 
much of the bias caused by tryptophan (p = 8.6 x 10-10).  Basic residues are not selected 
against.  This is possibly an indication of toleration or staggering of the peptide sequence 
among a smaller population of peptides. 
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Position 12  (Tables 4.9.C, 11, Figures 4.15.L, 4.16.L) Position 12 lies N-terminal to the 
linker peptide that adjoins PhoA.  This may influence the selective forces on its distribution.  The 
peptide linker, composed of amino acids Glu-Gly-Gly-Gly, places an acidic glutamic acid residue 
at the C-terminus of the peptide.  Acidic residues have been selected against throughout the 
peptide and may account for a reversal in the alternating pairs of hydrophobic/basic residues 
with position 12 weakly favoring basic amino acids (p = 1.8 x 10-4), especially lysine (p = 2.4 x 
10-3).  This result may indicate that the final two residues are unimportant for completion of a 
motif or basic structure in the preceding ten residues.   
Proline, acidic residues and secondary structure analysis  The bacteriolytic peptides 
demonstrate a lack of proline and acidic residues, aspartic acid and glutamic acid.  Proline is 
notable for its kinked structure, incorporating the amide bond into the side group of the amino 
acid.  This kinked structure is notorious for disrupting secondary structures, especially α-
helixes.510; 511; 512; 513; 514  The only positions that could compensate the presence of proline were 
8, 10 and 11.  The nearly unbiased distribution of residues at positions 11 and 12 indicated that 
they may not play a large role in the overall function of the peptides.  This may also be true for a 
portion of peptides at position 10 as well.  Of the five peptides containing proline, PL215 
(YRALRAWLWAPR) is very weakly bacteriolytic and PL251’s sequence, the only peptide with a 
proline at position 8, (GDRVAAAPGALL) does not conform to the observed pattern of the 
bacteriolytic peptide pool at several residues implying a different mechanism. 
 The trend in the linear peptide sequence makes structural sense when assuming the 
peptides are forming α-helices.  The α-helix is a standard 2nd structure of proteins involving the 
formation of a coil of amino acids that hydrogen bond via their amide and carboxyl groups with 
residues N- and C-terminal to themselves in the helix.  When the pattern arising from the 
bacteriolytic peptide pool is depicted as an Edmundson wheel projection,515 a simple graphical 
representation of an α-helix observed down the through the core of the helix with the side 
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groups jutting out, an amphipathic structure is observed (Figure 4.17).  By wrapping the 
alternating hydrophobic, basic residue pairs around the helix, a basic side and hydrophobic side 
materialize.  This is similar to other antimicrobial peptides such as magainin 2516 (Figure 4.18) 
only of a much smaller length (12 versus 23 amino acids).  As delineated in previous studies, 
the basic interface selectively interacts with the acidic cytosolic membrane of bacterial cells 
while the hydrophobic interface is thought to aid in the disruption of the membrane through a 
number of proposed mechanisms253 including the, ‘carpet’,254; 255 ‘barrel-stave’257; 517 and 
‘torodial’259; 260 pore models (Chapter 1, Figures 1.20-22).  This proposal is furthered by the 
dearth of proline residues, known helix-breakers, and acidic residues which would disrupt either 
the basic or hydrophobic interface.  If these peptides are forming amphipathic α-helices as a 
major determinant of their antimicrobial activity than the placement of a glutamic acid as the first 
residue of the linker peptide is serendipitous as the negative charge would disrupt the C-
terminal dipole of the α-helix,518 insuring that the linker peptide and initial PhoA residues played 
no role in its antimicrobial activity.  As these peptides are being selected based only on their 
activity against E. coli, it is interesting that the basic interface is preserved.  Studies suggest that 
the basic interface and its size directly influence the selectivity of antimicrobial peptides for 
acidic bacterial membranes contrary to the largely neutral membranes of eukaryotes,519; 520 a 
selective force not present in our bacterial system. 
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Figures 4.15.A-B:  Amino acid distribution of bacteriolytic peptides (observed) versus the 
distribution observed among the unselected peptides (expected). 
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Figures 4.15.C-D:  Amino acid distribution of bacteriolytic peptides (observed) versus the 
distribution observed among the unselected peptides (expected). 
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Figures 4.15.E-F:  Amino acid distribution of bacteriolytic peptides (observed) versus the 
distribution observed among the unselected peptides (expected). 
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Figures 4.15.G-H:  Amino acid distribution of bacteriolytic peptides (observed) versus the 
distribution observed among the unselected peptides (expected). 
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Figures 4.15.I-J:  Amino acid distribution of bacteriolytic peptides (observed) versus the 
distribution observed among the unselected peptides (expected). 
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Figures 4.15.K-L:  Amino acid distribution of bacteriolytic peptides (observed) versus the 
distribution observed among the unselected peptides (expected). 
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Table 4.9.A:  Binomial distribution of the individual amino acids of the bacteriolytic peptides 
isolated from the periplasmic selection compared to the distribution observed among the 
unselected peptides. 
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Table 4.9.B:  Binomial distribution of the individual amino acids of the bacteriolytic peptides 
isolated from the periplasmic selection compared to the distribution observed among the 
unselected peptides. 
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Table 4.9.C:  Binomial distribution of the individual amino acids of the bacteriolytic peptides 
isolated from the periplasmic selection compared to the distribution observed among the 
unselected peptides. 
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Figures 4.16.A-B:  Distribution of amino acids based on characteristics of their side chains 
(observed) versus the distribution observed among the unselected peptides (expected). 
250 
 
 
 
 
 
Figures 4.16.C-D:  Distribution of amino acids based on characteristics of their side chains 
(observed) versus the distribution observed among the unselected peptides (expected). 
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Figures 4.16.E-F:  Distribution of amino acids based on characteristics of their side chains 
(observed) versus the distribution observed among the unselected peptides (expected). 
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Figures 4.16.G-H:  Distribution of amino acids based on characteristics of their side chains 
(observed) versus the distribution observed among the unselected peptides (expected). 
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Figures 4.16.I-J:  Distribution of amino acids based on characteristics of their side chains 
(observed) versus the distribution observed among the unselected peptides (expected). 
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Figures 4.16.K-L:  Distribution of amino acids based on characteristics of their side chains 
(observed) versus the distribution observed among the unselected peptides (expected). 
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Table 4.10:   χ2 analysis of the bacteriolytic peptides isolated from the periplasmic selection 
compared to the distribution observed among the unselected peptides. 
 
 
Table 4.11:  Binomial distribution of the amino acid side chain groups of the bacteriolytic 
peptides isolated from the periplasmic selection compared to the distribution observed among 
the unselected peptides. 
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Table 4.12:  The distribution of basic residues arginine and lysine and hydrophobic residues 
leucine and tryptophan at each position among the bacteriolytic peptides isolated in the 
periplasmic selection.  Positions having ≥ 30% of either the basic or hydrophobic residues are 
highlighted in red.   
 
 
Figure 4.17:  Edmundson wheel projection of amino acid group distribution.  The number within 
each circle indicates the position in the linear peptide sequence.  Colors represent the amino 
acid groups based on side chain characteristics and the size of the circle is proportional to the 
frequency of the group observed. 
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Figure 4.18:  Comparison of natural, amphipathic, α-helical, antimicrobial peptide, magainin 2’s 
amino acid distribution as seen on an Edmundson wheel projection to isolated bacteriolytic 
peptides PL064 and PL177. 
 
 
4.4.3.3  Expression & Translocation Analysis  
 To assay PhoA activity in each clone, they were plated on solid media containing 50 
µg/mL X-phos and 0.2% L-arabinose.  If X-Phos is catalyzed by mature PhoA it localizes in the 
solid media around the colony.500 
 Of the 94 bacteriolytic peptide clones, 80 demonstrated no PhoA activity suggesting the 
peptide-PhoA fusion is not translocating into the periplasm (Tables 4.13.A-D).  One explanation 
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for this observation is that the peptides in these clones are obstructing the translocation process 
as a part of their bacteriolytic activity either by interacting with the lipid bilayer of the inner 
membrane (Figure 4.19) or the proteins of the Sec pathway, blocking translocation of essential, 
periplasmic proteins (Figure 4.20).  The clones exhibiting PhoA activity fell into three groups 
(Table 4.14):  1) strongly lytic with amounts of X-Phos precipitate rivaling or exceeding NI001, a 
non-inhibitory, translocating peptide, 2) those with a small amount of precipitate that are strongly 
lytic and 3) peptides that are weakly lytic with weak PhoA activity.  Interestingly, none of the 
strongly lytic peptides with strong PhoA activity align with the overall trend observed among the 
α-helical model peptides with alternating pairs of hydrophobic and basic residues (Figure 4.21).  
This implies that these peptides operate by a different mechanism other than the α-helical 
peptides.  The weakly PhoA active clones, except for PL066 and PL473 which also do not follow 
the α-helical model (Figure 4.22), coincided with a weakly bacteriolytic phenotype.  If we 
assume that the peptides tend to form an α-helix, then those exhibiting weak PhoA activity may 
be peptides whose interactions, while in the membrane or Sec pathway, are only 
thermodynamically stable enough to preserve a portion of their population in the membrane as 
the others escape via full translocation.  The escaping peptide-PhoA fusions would deplete the 
concentration of peptide in the membrane resulting in a weaker bacteriolytic phenotype.   
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Table 4.13.A:  Isolated bacteriolytic peptides exhibiting no PhoA activity.  Amino acid 
sequences as they would appear in an α-helix demonstrate that most of the peptides have basic 
and hydrophobic interfaces supporting their formation of amphipathic α-helices. 
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Table 4.13.B:  Isolated bacteriolytic peptides exhibiting no PhoA activity.  Amino acid 
sequences as they would appear in an α-helix demonstrate that most of the peptides have basic 
and hydrophobic interfaces supporting their formation of amphipathic α-helices. 
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Table 4.13.C:  Isolated bacteriolytic peptides exhibiting no PhoA activity.  Amino acid 
sequences as they would appear in an α-helix demonstrate that most of the peptides have basic 
and hydrophobic interfaces supporting their formation of amphipathic α-helices. 
 
 
Figure 4.19:  Membrane disruption mechanistic models of the α-helical model peptides.  A) 
Peptides translocate into the periplasm and interact with the periplasmic interface of the inner 
membrane.  Peptides increase the permeability of the membrane in a fashion similar to the 
‘carpet’ model of AMP activity.  B) Peptides accumulate in the inner membrane in high 
concentrations in proximity to the Sec complexes that aid in their translocation.  Peptides 
increase permeability by the formation of pores through the ‘barrel-stave’ or ‘torodial’ models for 
lytic AMP activity. 
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Figure 4.20:  Sec pathway blockage mechanistic model of the α-helical model peptides.  
Peptides bind to or obstruct their own passage through the Sec translocation machinery by 
binding to SecA or SecYEG channels, preventing essential proteins from translocating into the 
periplasm, leading to cell lysis. 
 
 
Figure 4.21:  Edmundson wheel projections of strongly lytic, NI001-comprable PhoA activity 
peptides.  None of the peptides establish basic, hydrophobic opposing interfaces to form an 
amphipathic α-helix. 
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Table 4.14:  Isolated bacteriolytic peptides exhibiting PhoA activity.  Amino acid sequences as 
they would appear in an α-helix demonstrate that most of the peptides do not form amphipathic 
α-helices. 
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Figure 4.22:  Edmundson wheel projections of strongly lytic, weak PhoA activity peptides.  
Neither peptide demonstrates basic, hydrophobic opposing interfaces to form an amphipathic α-
helix. 
 
4.4.3.4  Expression of Free Peptides  
 PhoA, similar to EmGFP in the cytoplasm, serves numerous purposes such as a 
structure stabilizer, proteolysis determent and visible means of determining if translocation is 
occurring.  However, to further characterize the peptides’ potential as antimicrobial leads, it is 
necessary to determine their activity outside the context of the fusion protein.  There are two 
scenarios where the fusion protein is lethal and not the peptide as a stand-alone molecule 1) 
some of the initial residues of PhoA or the linker peptide may contribute to the lethality of the 
peptide by participating in the binding interaction and 2) the peptide’s binding to a target is not 
lethal, but steric hindrance on the part of the globular PhoA protein may block key sites on the 
target preventing its function.   
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Figure 4.23:  pKan-Solo was derived from the plasmid pKan-PhoA1.  The DNA encoding PhoA 
was removed leaving a gene product comprised of the signal peptide and the peptide of 
interest.   
 
To achieve the expression of the peptide in the absence of PhoA, DNA encoding the 
peptides was cloned into pKan-Solo (Figure 4.23).  This plasmid is identical to pKan-PhoA1 
except the DNA encoding PhoA and the linker peptide has been deleted.  This leaves the PhoA 
signal peptide, necessary for translocation of the peptide, N-terminal to the peptide followed by 
a stop codon.  When expression is induced with the addition of L-arabinose, the signal peptide 
bound to a peptide of interest is produced.  As before with the full peptide-PhoA fusion, the 
signal peptide directs the translation product to be translocated into the periplasm.  Upon 
entering the periplasm the signal peptide is cleaved off exposing the free peptide (Figure 4.24).   
Bacteriolytic peptides incorporated into the system were limited to those whose sequences were 
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not predicted to conform to the α-helical model.  Analysis of α-helical model, bacteriolytic 
peptides is discussed in Chapter 5.  Select bacteriostatic/bactericidal peptides were also placed 
into the construct.  When the constructs were produced, DNA sequences encoding the peptides 
were optimized for expression within E. coli.  This produced mRNAs of varying sequence from 
the originally isolated clones (Table 4.15).  Clones that preserved antimicrobial activity 
demonstrate that the peptide sequence is the active molecule and not the mRNA encoding 
them.   
 
 
Figure 4.24:  Induction of pKan-Solo cultures produces a fusion of the PhoA signal peptide and 
the peptide of interest.  Following translocation, a peptidase cleaves off the signal peptide 
permitting the peptide of interest to be free of contextual effects. 
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Cultures were grown to early log phase and induced with L-arabinose.   The optical 
density of the cultures was measured at time intervals following induction (Figures 4.25.A-D).  
As before with the expression of free cytoplasmic peptides (Chapter 2, Figures 2.24.A-D), 
some peptides lost all of their antimicrobial activity without the PhoA and peptide linker context 
including PL014, PL126, PL251, PL274, PL444, PL466, PC006, and PC036 (Table 4.16).  The 
lytic activity of PL098 and PL473 is significantly reduced to weakly inhibitory in the free peptide 
form.  Three of the peptides that are lytic when bound to PhoA, PL066, PL137 and PL459, are 
strongly bacteriostatic/bactericidal as free peptides.  Peptides PL045, PL048, PL069, PC025 
and PC042 are strongly bacteriostatic/bactericidal in both the PhoA-bound and free forms. 
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Table 4.15:  Comparison of encoded mRNA sequences of the isolated, PhoA-fused peptides 
versus the encoded mRNA sequences of the free peptide expression clones.  Base changes 
are highlighted in red.  Base changes for free peptide expression clones were based on 
optimization of peptides for expression in E. coli. 
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Figures 4.25.A-B:  Growth curves of periplasmic peptides expressed as free peptides in the 
absence of display protein, PhoA.  Optical density was measured at different time intervals 
following the addition of L-arabinose. 
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Figures 4.25.C-D:  Growth curves of periplasmic peptides expressed as free peptides in the 
absence of display protein, PhoA.  Optical density was measured at different time intervals 
following the addition of L-arabinose. 
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Table 4.16:  Growth phenotypes of free peptides in comparison to their phenotypes as peptide-
PhoA fusions. 
 
4.4.4 Antimicrobial Activity of Synthetic Peptides 
4.4.4.1  Determination of Minimum Inhibitory Concentrations  
 To determine if peptides with antimicrobial activity in both the PhoA-bound and free 
forms are also active when added to bacterial cultures exogenously, three peptides, PL045, 
PL098 and PL137 were synthesized and the MIC of each was determined.   
 PL098 was dissolved in water and PL045 and PL137 were dissolved in 
dimethylformamide (DMF).  Minimum inhibitory concentrations (MICs) were calculated using the 
broth dilution method.441  Cultures were incubated overnight and their turbidities (A600) were 
measured.   
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Table 4.17:  MICs of PL098 against various organisms.  A value of ‘> 125’ indicates no MIC 
was determined.  MICs were determined in Luria-Bertani growth medium. 
a MICs determined in Todd Hewitt Broth 
 
PL045 and PL137 showed no effect at concentrations ≤ 250 µM against E. coli SM101, 
an lpxA mutant with increased membrane permeability,444 or Staphylococcus aureus a Gram-
positive coccus.  For PL098, the MIC was 62.5 µM for both E. coli SM101 and a ‘WT’ E. coli 
strain, W3110.  To determine its antimicrobial spectrum, the MICs of PL098 for six Gram-
negative and three Gram-positive bacteria were measured.  The MIC of PL098 for Gram-
negatives Pseudomonas aeruginosa, Serratia marcesens, and Klebsiella pneumoniae and 
Gram-positives S. aureus or Bacillus subtilis is > 250 µM.    Surprisingly, it strongly inhibited the 
growth of Micrococcus luteus (Table 4.17), a Gram-positive, opportunistic pathogen.521; 522 
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To further delineate the antimicrobial spectrum of PL098, MICs were determined for 
Proteus mirabilis, Enterobacter aerogenes, Edwardsiella tarda, Shigella sonnei, Salmonella 
typhimurium and Yersinia enterocolitica.  Initial MIC assays in LB showed PL098 was ineffective 
against all species at concentrations ≤ 125 µM.  A subsequent assay preformed using the rich 
medium, Todd Hewitt Broth (THB),523 instead of LB consistently produced PL098 MICs for both 
S. sonnei and S. typhimurium of 55 and 30 µM, respectively.  Both species are common food-
borne pathogens524; 525; 526 that cause potentially serious food infections.  The recipe for THB 
includes peptone, heart infusion, sodium carbonate, dextrose, sodium chloride and disodium 
phosphate compared to tryptone, yeast extract and sodium chloride in LB it is yet unknown what 
the contributing factor for enabling PL098’s lethality. 
 
4.4.4.2  The Effect of PL098 on Microbial Growth 
 To observe the phenotypic effect of the peptide on growing cultures, E. coli SM101 and 
M. luteus were grown to mid-log phase, PL098 was added at varying concentrations, and the 
turbidity at A600 was monitored.  
 Though all of the E. coli SM101 cultures decreased in optical density 30 minutes after 
the addition of the peptide, only the culture containing 250 µM PL098 was unable to recover 
during the course of the experiment (Figures 4.26.A-B). Turbidity in the 125 and 250 µM PL098 
cultures clearly decreased following the addition of peptide indicating that cells were lysing. 
 M. luteus was treated with a smaller range of PL098 concentrations since the previously 
calculated MIC was 2 µM.  Surprisingly, at the lower concentrations of peptide,15.6, 7.8, 3.9, 
and 1.95 µM, the cultures were hardly affected and continued to grow without slowing down 
(Figures 4.27.A-B).  At 31.3 µM, the peptide completely inhibited the growth of the culture for a 
duration of 15 minutes starting 5 minutes after the peptide’s addition.  Afterwards the culture 
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recovered at a greatly decreased rate of growth.  Both the 125 and 62.5 µM cultures stopped 
growing within approximately 10 minutes of PL098’s addition.  The cultures then decreased in 
turbidity slowly for the next 155 minutes.  After an additional 15 hours incubation the 62.5 µM 
culture recovered completely compared to the no peptide control while the 125 µM culture 
increased to only 50% of the no peptide control. 
 The concentration of PL098 required to inhibit the growth of a mid-log phase culture 
differs greatly from the MIC which was performed using ~2 x 103 cells.  This may result from 
numerous peptides being required to kill a cell in an irreversible fashion.  Therefore if the 
amount of cells in the culture is increased exponentially then so must the amount of PL098 to 
achieve lethality.  It may also be the case that actively growing cells can nullify the activity of 
PL098 through expression of proteases in the cytoplasm or secreted into the medium. 
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Figures 4.26.A-B:  Growth curves of E. coli strain, SM101, supplemented with synthetic PL098 
peptide at various concentrations.  Figures A and B show the same cultures, with B including an 
overnight incubation. 
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Figures 4.27.A-B:  Growth curves of Gram-positive bacterium, M. luteus, supplemented with 
synthetic PL098 peptide at various concentrations.  Figures A and B show the same cultures, 
with B including an overnight incubation. 
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4.4.4.3  Hemolytic Activity of Peptide PL098 
 Many natural, lytic, antimicrobial peptides, especially those targeting bacterial 
membranes, conform to the amphipathic α-helix model and lyse red blood cells, limiting their 
applications for treating human disease.527; 528  To determine if PL098 is also hemolytic we 
performed a sheep red blood cell (SRBC) hemolysis assay.529 
 The SRBCs were washed and resuspended in a phosphate buffered saline solution at 
pH 7.4.  PL098 was diluted and added to the erythrocyte suspensions at concentrations similar 
to those used in the MIC experiments.  The erythrocytes/peptide mixtures were incubated at 37 
oC for 18 hrs, a longer duration than is commonly used in analysis of hemolysis, but properly 
reflects the clearance of the peptide if it were to be present in the blood.  After incubation, the 
samples were centrifuged to remove whole, unlysed erythrocytes and the optical densities of 
aliquots of each sample were measured at 570 nm to quantify the amount of hemoglobin 
present in the supernatant that had been released by lysed erythrocytes.  The background was 
approximated by the dH2O-only control which was subtracted from the values of the other 
samples (Table 4.18). 
 Interestingly, unlike many natural lytic peptides, PL098 produced no hemolysis when 
compared with the negative and positive controls.  This makes PL098 a viable lead for 
antimicrobial development.  Thus while PL098 has significant antimicrobial activity against 
select bacterial pathogens, it does not conform to the characteristic of previously identified 
antimicrobial peptides and may constitute a viable lead for the development of novel anti-
infectives. 
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Table 4.18:  Hemolytic activity of PL098 at various concentrations against sheep red blood cells 
calculated as a percentage of the amount of hemolysis observed with 0.1% of detergent Triton 
X-100. 
 
4.5 Discussion 
 We have successfully designed and implemented the pIVD system for the isolation of 
antimicrobial peptides active in the periplasm.  The occurrence of the β-lactams530; 531, other 
peptidoglycan synthesis inhibitors532 and membrane disrupting533 antibiotics, that are only active 
in the periplasm indicated that our initial cIVD and nIVD systems in the cytoplasm omitted a 
number of peptides that would only be lethal if present in the periplasm.  Accordingly, 
adjustments were made to IVD for periplasmic display of a random peptide library.  From a 
library of ~1 x 109 clones, ~5 x 108 transformants were screened to isolate a total of 192 
peptides with antimicrobial activity (Tables 4.1.A-B, 4.2, 4.3, 4.4).  Unlike the cytoplasmic IVD 
systems, approximately 50% of peptides isolated from the periplasmic selection caused some 
degree of lysis in cultures in which they were expressed.  Several cellular structures and 
metabolic activities involved in maintenance of cellular integrity are associated with the 
periplasm, including the inner and outer membranes, cell wall, chemiosmosis, and 
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osmoregulation.  Displayed peptides that disrupt any of these structures of processes are likely 
to also affect the ability of cells to maintain osmotic balance and envelope integrity and will 
therefore predispose the cells to lysis.  
 The vector pKan-PhoA was constructed including the E. coli gene encoding native 
protein alkaline phosphatase (PhoA).534  PhoA enzymatically converts X-Phos into a precipitate 
correlating to the amount of PhoA successfully translated and translocated into the periplasm 
where it can fold properly.501  The inclusion of the PhoA signal peptide535 directs the peptide-
PhoA fusion, following translation, to the Sec pathway for secretion through the inner membrane 
into the periplasm.502; 536  By cloning a random peptide library between the PhoA signal peptide 
and PhoA we are able to display a peptide library on the N-terminus once translocation is 
complete with the cleavage of the signal peptide (Figures 4.5-6).   
Initially, we shied away from the use of the Sec pathway for translocation because of 
known issues during M13 phage display.  The coat proteins of phage display are inserted into 
the membrane using the Sec pathway.  It has been demonstrated that peptides with high 
concentrations arginine are selected against incorporation.537  This is believed to occur by the 
residue’s disruption of translocation through the membrane.  However, the residue distributions 
of the lytic peptides demonstrate that our system does not select against basic residues, 
especially arginine.  This observation possibly elucidates the mechanism of bias against basic 
residues in M13 phage display selections; the peptides are lytic at low concentrations killing 
their host cells prior to the accumulation of mature phages. 
Sequence analysis of the 94 lytic peptides isolated from the bacteriolytic peptide 
selection revealed a non-random distribution of amino acids (Figures 4.15.A-L, 4.16.A-L, 
Tables 4.9.A-C, 4.10, 4.11).  Linear sequences had roughly alternating pairs of basic amino 
acids, especially arginine, and hydrophobic amino acids, notably tryptophan and leucine (Table 
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4.12).  We hypothesized that the majority of the lytic peptides conform to an α-helical model, 
where the peptides, upon entering the inner membrane during translocation, form an α-helix.  
When the linear peptide sequences are presented in an Edmundson wheel projection (Figure 
4.17) the alternating pairs of basic and hydrophobic sequences distribute themselves in a 
manner that produces an amphipathic α-helix where basic residues are generally on one side, 
opposing an interface dominated by hydrophobic residues.   
The significant similarities among the bacteriolytic peptides indicate a common target.  
However, antimicrobial peptides isolated from the cIVD and nIVD selections (Chapters 2 & 3) 
and the bacteriostatic/bactericidal and growth rate reducing peptides of the periplasmic 
selection show no similar trends that would indicate multiple peptides binding one target 
(Tables 4.2-4).  This suggests that the target is large and has a generally uniform structure as 
opposed to the catalytic core of an enzyme or a target that encompasses a large percentage of 
the overall available targets in the cell.  Examples of this include the backbone of DNA or RNA, 
the cell wall or the plasma membrane.  Localization to the periplasm precludes DNA and RNA 
targets which are inaccessible from the periplasm, but translocation necessitates interaction of 
the peptide with the plasma membrane and Sec pathway proteins.502  Therefore, the majority of 
the bacteriolytic peptides giving rise to the pattern observed in the amino acid sequence may 
follow a general rule of binding in the bacterial membrane and destabilizing it (Figure 4.19), or 
an integral protein of the Sec pathway blocking further cellular translocation and causing cell 
lysis (Figure 4.20). 
Antimicrobial, amphipathic α-helices found in nature, such as the magainins538 and the 
cecropins,539 destabilize plasma membranes leading to bacterial cell lysis.517   Different 
mechanisms have been proposed, including the ‘carpet’, ‘barrel-stave’ and ‘torodial pore’ 
models.256  The isolated bacteriolytic peptides can be separated into four groups based on PhoA 
activity 1) peptides that lyse cells but have no PhoA activity (Tables 4.13.A-C), 2) peptides that 
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lyse cells quickly after induction and have strong PhoA activity (Table 4.14), 3) peptides that 
lyse cells quickly after induction and have weak PhoA activity, and 4) peptides that lyse cells 
slowly or have a low lytic efficiency and have weak PhoA activity.  The majority of our lytic 
peptides (80 of 94 peptides) are of the first group, the remaining 14 peptides are split into the 
latter three groups to be discussed later.  The 80 peptides conform closely to an amphipathic, α-
helical model proposed based on the sequence alignments of all 94 peptides.  The lack of PhoA 
activity indicates PhoA is not folding correctly in the cytoplasm prior to translocation501 or 
following entry into the periplasm.  Consistent patterns in the amino acid sequences of the 
peptides and their bacteriolytic activity suggest that misfolding of the fusion, resulting in a lack of 
PhoA activity, is not responsible for their antimicrobial activity.  Therefore, this indicates that the 
lytic peptides, located at the N-terminus and the first segment after the signal peptide to cross 
the membrane, are inhibiting translocation by either an interaction with the lipid bilayer or a 
protein of the Sec pathway.  The membrane destabilization model (Figure 4.19) includes two 
possible scenarios; the peptides enter the membrane, form the amphipathic, α-helix, due to 
environmental forces, and bind the lipids in the membrane, or the peptides are secreted into the 
periplasm where they can fold backwards and interact with the membrane.  The second 
scenario would likely produce some level of PhoA activity as completion of translocation, 
including the functional domain of PhoA, would not be obstructed.  The required utilization of the 
Sec pathway would necessarily create high local concentrations of the peptides in the 
membrane, proximal to Sec complexes.  In Chapter 5, peptide 84 Pro-, a representative of the 
α-helical model peptides, demonstrated lethality when introduced to cells exogenously (Chapter 
5, Table 5.17).  This is inconsistent with membrane disruption activity as the peptide would not 
be localized to Sec complexes because translocation would no longer be necessary for entry 
into the periplasm.  Recovery of growth in E. coli cells during growth curves in hypertonic growth 
media (Chapter 5, Figure 5.35) suggests that disruption of cell wall synthesis and not 
membrane integrity are targeted by 84 Pro-.  Reinforcing these data, the peptides do not appear 
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to conform to any of the previous membrane disruption mechanisms.253  The ‘carpet’ model 
requires peptides to interact with outer or inner surface of the membrane254; 255 (Chapter 1, 
Figure 1.20), neither of which seems to be accessible as indicated by the PhoA activity assays.  
The ‘torodial pore’259; 260 and ‘barrel-stave’257; 517 models (Chapter 1, Figures 1.21-22) require 
the peptide to span the length of the membrane or ~25-35 Å540 to produce a pore, unfortunately, 
the estimated length of a 12mer peptide is only 18 Å.  It is, however, possible that sufficient 
disruption can occur due to non-membrane spanning peptides to induce cell lysis.  The initial 
glutamic acid of the linker peptide likely disrupts the helix dipole518 at the antimicrobial peptide’s 
C-terminus indicating only the 12 positions of the peptide participate in activity. 
A bias against acidic amino acids was another characteristic of the bacteriolytic peptides 
(Table 4.11).  Paired with the preference for basic amino acids, especially arginine, it is difficult 
to understand why the hydrophilic interface of the α-helix is necessarily basic.  The mechanisms 
attributed to most known, lytic antimicrobial peptides postulate that a basic interface is 
necessary for interaction with the surface of the negatively-charged, bacterial membrane.519; 520  
Our peptides, however, do not exhibit PhoA activity, suggesting they do not translocate, making 
membrane surface interactions difficult.  Yet basic residues are still preferred.  Pore formation, 
facilitating the leakage of anions from the periplasm or cytoplasm into the opposing space may 
disrupt the osmotic balance of the cell,541 causing lysis.  However, cation gradients, such as 
those of K+, Ca2+ and H+, would seem to select for α-helical peptides with acidic interfaces that 
form negatively-charged pores.542  The dearth of codons encoding acidic residues across all 12 
positions of the peptide may decrease the probability of isolating an acidic amino acid interface 
containing peptide.  A study of a 12mer peptide with an acidic interface may help elucidate the 
mechanism of these peptides’ activity. 
The bias against the hydrophobic residue proline also supports the α-helical model 
(Tables 4.9.A-C).  Proline’s kinked cyclic structure produces rigidity know to disrupt α-helix 
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formation510; 511; 512; 513; 543 due to its inability to form the necessary H-bond to stabilize the 
structure.544  Further studies analyzing the effect of proline on the activity of an α-helical model 
peptide are discussed in Chapter 5 indicating the necessity for α-helix formation for activity.  The 
peptide EO1, discussed in Chapter 6, also provides insight to the viability of the model as its 
linear sequence is similar to the α-helical model but likely does not produce an amphipathic α-
helix as it translocates efficiently. 
To test the efficacy of the system two peptides previously characterized as bacteriolytic 
were incorporated at the site the peptide library would occupy (Table 4.19).  The peptide LfcinB 
is derived from the protein, bovine lactoferrin.545  Pac-525 is a tryptophan-rich peptide important 
in the innate immune system mechanisms of various higher order eukaryotes and is thought to 
selectively destabilize bacterial plasma membranes.546  The peptides were chosen as 
antimicrobial peptides from nature that had demonstrated pore-forming mechanisms in the lysis 
of bacterial cells.  Neither of the peptides within the pIVD system had any adverse effects on E. 
coli’s growth except the expected decrease in growth rate from over-expression of the fusion 
protein (Figure 4.28).  The constraint of being attached at the C-terminus to PhoA may be 
inhibiting the peptides from assuming their active structure or binding their target450; 451 (although 
their suggested target is the plasma membrane) due to the steric hindrance of PhoA.  Feng et 
al., showed that expressing a larger 25 amino acid portion of LfcinB as a fusion with GST was 
inactive when expressed in the cytoplasm suggesting a fusion of the peptide may disrupt its 
function.547  These results may indicate that the isolated peptides are causing cell lysis by a 
mechanism separate from that of the natural AMPs, such as an interaction with the proteins of 
the Sec pathway; a scenario further discussed in Chapter 5. 
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Table 4.19:  Lytic antimicrobial peptides incorporated into the periplasmic in vivo display 
system. 
 
 
Figure 4.28:  Induced growth curves of constructs encoding lytic AMPs fused to the N-terminus 
of PhoA.  The optical density of each culture was measured at different time intervals following 
the addition of L-arabinose. 
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PhoA, the display protein used in this study provides several advantages during the 
selection.  It acts as a proteolytic inhibitor, a reporter of successful translation and 
translocation501; 548 and a scaffold for displaying the random peptide library in a non-structured 
format.  Contextual effects of PhoA and the linker peptide,378 attaching the peptide library to 
PhoA, can play a role in the activity of isolated peptides either by the incorporation of amino 
acids of the linker peptide or N-terminus of PhoA in the inhibitory motif of the peptide or through 
steric hindrance if the peptide were to interact with a non-essential binding site but the presence 
of the globular PhoA blocked the target’s function or limited its motility.  Therefore, the activity of 
non-α-helical model peptides outside the context of the attached residues was studied by the 
free expression of the peptides in the periplasm (Figure 4.24).  The plasmid pKan-Solo was 
constructed (Figure 4.23), removing the PhoA gene and the linker peptide from plasmid pKan-
PhoA.  The remaining elements in the construct included the PhoA signal peptide, necessary for 
translocation, and the peptide of interest under the control of the PBAD promoter.  During cloning, 
the DNA encoding the peptide sequences were optimized for translation in E. coli which altered 
the mRNA sequences (Table 4.15).  Therefore, if peptides maintained lethality in the free 
expression system, the likely causative agent is the amino acid sequence and not the precursor 
mRNA sequence.  A study of the free expression of a representative of the α-helical model 
peptides is discussed in Chapter 5.   
 A total of 53 bacteriostatic/bactericidal peptides were isolated from both the bacteriolytic 
and bacteriostatic/bactericidal peptide selections (Tables 4.20.A-B), though no statistically 
significant amino acid motifs were identified among them.  Eight of these peptides were assayed 
for activity as free peptides expressed in vivo, their selection was based on their activity as 
fusion constructs (including onset of activity following induction and having a low optical density 
endpoint).  Ten bacteriolytic peptides that are not consistent with the sequence distribution of 
the α-helical model peptides (Table 4.21) were also selected for free peptide expression 
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analysis.  Three of the peptides, PL126, PL444 and PL466 had no PhoA activity (Table 4.14), 
like the α-helical model peptides, while the other 7 had varying levels from strong (PL098, 
PL137, PL251, PL274, and PL459) to weak (PL066 and PL473) activity.   
 
 
 
 
 
Table 4.20.A:  Bacteriostatic/bacteriostatic peptides isolated from both the bacteriolytic and 
bacteriostatic/bactericidal periplasmic selections.  Amino acids are color-coded by their side 
chain group.  Amino acid sequences are presented in a linear and α-helical format to 
demonstrate the lack of basic and hydrophobic interfaces that are present in the lytic, α-helical 
model peptides. 
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Table 4.20.B:  Bacteriostatic/bacteriostatic peptides isolated from both the bacteriolytic and 
bacteriostatic/bactericidal periplasmic selections.  Amino acids are color-coded by their side 
chain group.  Amino acid sequences are presented in a linear and α-helical format to 
demonstrate the lack of basic and hydrophobic interfaces that are present in the lytic, α-helical 
model peptides. 
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Table 4.21:  Isolated bacteriolytic peptides selected for free peptide expression in the 
periplasmic in vivo display system.  The peptides were selected based on the dissimilarity of 
their amino acid sequences in comparison to the α-helical model peptides.  The peptides 
demonstrated various levels of PhoA activity. 
 
Five of the bacteriolytic peptides lost all activity when they were not fused to PhoA 
(Table 4.16, Figures 4.25.A-D); while two others, PL098 and PL473, were reduced to a weakly 
inhibitory phenotype (PL098 maintained a level of lethality worthy of further investigation).  The 
three remaining bacteriolytic peptides, PL066, PL137 and PL459, were strongly 
bacteriostatic/bactericidal. PL066 inhibits growth completely within 30 minutes of induction while 
PL137 and PL459 required 10 minutes.  Peptide PL066 had weak PhoA activity, and peptides 
PL137 and PL459 had greater levels of PhoA suggesting different mechanisms of activity.  The 
chemical characteristics of the three peptides were similar with an overall density of 
hydrophobic residues, however, placement of larger hydrophobic residues such as W, F and Y 
and the location of hydrophilic and charged residues varied.  PL066, of the three peptides, alone 
had one K at position 2.  The acidic amino acid, glutamic acid, present in all three peptides, 
unlike the pool of α-helical model peptides where acidic residues were generally selected 
against, was present at the C-terminus at position 11.  PL066 also has three Ws at positions 1, 
3 and 8.  The weak PhoA activity of PL066 as a fusion correlates with the 20 minute delay in 
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inhibition versus peptides PL137 and PL459.  Peptide PL137 lacked any Ws or basic residues, 
two of the conserved elements of the α-helical model peptides and except for E at position 6, F 
at position 7 and Q at position 12 the amino acid side groups were small, differentiating it from 
both PL066 and PL459.  PL139 was also the sole peptide to demonstrate a consistent and 
gradual decline in optical density following induction, may indicate that cell lysis is directly linked 
to its activity.  The final bacteriolytic peptide, PL459, had two centrally positioned hydrophilic 
residues, S and T, and an N-terminal, acidic E at position 2.  Large hydrophobic residues, 
mainly F and Y are evenly distributed at positions 1, 4, 5, 9 and 11 with a W at position 5.  The 
lack of basic residues and the ability to translocate into the periplasm suggest their activity does 
not directly involve disruption of the inner membrane. 
Three of the bacteriostatic/bactericidal peptides, PL014, PC006 and PC036 lost activity 
when expressed in the absence of PhoA (Table 4.16).  The remaining five peptides, PL045, 
PL048, PL069, PC025, and PC042, maintained activity, inhibiting growth completely within 10 
minutes after induction.  The peptides are differentiated from the lytic peptides discussed above 
by a higher concentration of hydrophobic residues, generally ones with small side groups such 
as L and V.  The peptides, except for PL045, lack any basic residues suggesting that if they are 
interacting with the inner membrane, it is by a dissimilar mechanism than natural AMPs.  PL045 
is composed of 10 hydrophobic residues, 9 of which are small residues A, L, V or I.  One 
histidine residue is located at position 8 with only one other polar residue, C, at position 1.  
Similarly, PL048 is largely composed of small hydrophobic residues V and L.  Two hydrophilic 
residues, S and T, are located penultimate to either terminus.  PL069 has a similar makeup 
except for the inclusion of some of the larger hydrophobic residues, F, W, and Y, notably two F’s 
at position 1 and 2.  A C and a T at positions 3 and 11 are the only polar amino acids in the 
peptide.  A C-terminal proline is also present at position 12.  PC025 has only one hydrophilic 
residue, a serine at position 2.  With the exception of a W at position 3 the residues have small 
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side groups.  The final peptide, PC042, is completely composed of hydrophobic residues with 
two large Ws at positions 4 and 9.  The peptides vary in the position and amount of sparse 
hydrophilic residues and the hydrophobicity of the remaining residues.  Overrepresentation of 
highly hydrophobic residues among the three bacteriostatic/bactericidal peptides may indicate a 
common target in the periplasm or membrane, but if hydrophobicity was the sole indicator of 
activity it would seem likely that more highly-hydrophobic peptides would have been isolated 
during selection.  The lack of basic and hydrophilic residues contrasts the peptides from those 
conforming to the α-helical model.  PhoA activity analysis would clarify if the peptides were likely 
interacting with the lipophilic center of the membrane or if their target was in the periplasm. 
While each of the eight peptides discussed merits further study to elucidate mechanism 
and their viability as antimicrobial leads, their hydrophobicity makes study of their synthetic 
derivatives difficult due to solvency issues.  Methods to increase their solubility or use of 
vectors403; 404 for delivery into the cell would greatly improve our understanding of these 
peptides. 
During peptide synthesis to study the effectiveness of the exogenous free peptides, it 
was initially assumed that the peptides could be synthesized as they appeared in the 
endogenous free peptide expression assays and enter the bacterial cell via typical nutrient 
uptake.  The highly hydrophobic composition of the peptides that produced solubility problems 
may have also decreased their penetration of the outer membrane and cell wall.402  Of the 
peptides selected for analysis as synthetic constructs, only PL098 had activity; its basic residue 
content making it water-soluble. 
PL098 is a highly basic peptide with five arginines and a lysine distributed throughout the 
peptide (Table 4.21).  The remaining 6 residues are hydrophobic, including two Ws at positions 
1 and 4.  In an Edumundson wheel projection515 (Figure 4.21), the basic residues form a large 
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interface separated by two hydrophobic residues, M and A, resulting in a small hydrophobic 
interface not consistent with the α-helical model peptides.  PL098 also translocated strongly 
according to PhoA activity assays, localizing it in the periplasm in contrast to α-helical model 
peptides.  Unlike 84 Pro- and EO1 peptides (discussed in Chapters 5 and 6), PL098 did not 
have activity against the Gram-positive organisms Staphylococcus aureus and Bacillus subtilis 
(Table 4.17), though it strongly inhibited the opportunistic pathogen521; 522 and skin resident 
Micrococcus luteus with an MIC of 2 µM.  Introducing PL098 to a log phase culture of M. luteus 
greatly increased the MIC from 2 µM to 125 µM (Figures 4.27.A-B), indicating a decrease of 
importance or increase in concentration of the target during log phase growth, contrasting with 
the exogenous activity of peptides, 84 Pro- and EO1 (Chapters 5 & 6).  Surprisingly, the peptide 
also had activity against Gram-negative bacterium, E. coli, when introduced externally with an 
MIC of 62.5 µM.  Similarly, the MIC of a mid-log phase culture of E. coli had a greatly increased 
MIC of 250 µM (Figure 4.26.A-B).  Interestingly, PL098 was weakly lytic when added to E. coli 
cultures but not lytic to M. luteus.  Furthermore, PL098’s lethality is contingent on supplemented 
nutrients as seen with the MICs of Gram-negative and close relatives of E. coli, Shigella sonnei 
and Salmonella typhimurium.  In standard rich medium, Luria-Bertani broth, neither organism 
exhibited PL098 sensitivity, however, when MICs were performed in the enriched medium, Todd 
Hewitt Broth, the MICs decreased to 55 and 30 µM, respectively.  Several of the antimicrobial 
peptides isolated during the cIVD and pIVD selections were not effective when added 
exogenously.  The effect of the different broths on PL098 activity may reflect a continuation of 
this problem.  This stresses the importance of devising a reliable peptide delivery mechanism to 
fully understand the exogenous, antimicrobial activities of the peptides.   
PL098’s antimicrobial activity and lack of hemolytic activity (Table 4.18) necessitate 
further study of its mechanism and optimization of its activity for its development as an 
antimicrobial lead compound.  This is only one peptide of the 192 isolated from the pIVD 
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selection, with nearly half not consistent with the α-helical model.  It is important that these 
peptides are further characterized to determine their value as lead compounds.  The potential 
use of the pIVD system for the isolation of antimicrobial lead compounds has been 
demonstrated by the partial screening of a ~1 x 109 member library which is only a small sample 
of the potential library of 2012 peptides.  Clearly, there are many more antimicrobial peptides yet 
to be isolated. 
 
4.6 Materials & Methods 
4.6.1 Bacterial Strains & Media 
 All experiments, unless otherwise indicated, were carried out in E. coli DH5α (fhuA2, 
Δ(argF-lacZ)U169, phoA, glnV44, Φ80, Δ(lacZ)M15, gyrA96, recA1, endA1, thi-1, hsdR17).  
Clones were grown and maintained in Luria-Bertani (LB) medium containing 30 µg/mL 
kanamycin (LB-Kan30).  To induce peptide-PhoA fusions from the PBAD promoter L-arabinose 
was added to the culture at a final concentration of 0.2%.  Induction times are indicated in the 
individual methods outlined later.  Clones encoding suspected lethal peptide-PhoA fusions were 
propagated in LB-Kan30 medium with 0.2% D-glucose to repress expression from the PBAD 
promoter.  Transformations were carried out via electroporation at 2.44 kV with electro-
competent cells prepared beforehand and stored at -80 oC.  Transformed cells were recovered 
in SOC medium for 1 hour without antibiotics prior to either plating on solid media or selection. 
 
4.6.2 Enzymes & Reagents 
 Restriction enzymes and T4 DNA ligase and were purchased from New England Biolabs 
Inc. (Ipswich, MA).  Restriction enzymes were also ordered from Fermentas (a division of 
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Thermo Fisher Scientific Inc., Glen Burnie, MD).  Oligonucleotides, for use as primers in 
polymerase chain reactions (PCRs) or in the formation of DNA duplexes, were purchased from 
Integrated DNA Technologies Inc. (Coralville, IA).  Choice-Taq™ DNA polymerase and PCR 
reagents were obtained from Denville Scientific Inc (Metuchen, NJ).  Pfu polymerase, derived 
from Pyrococcus furiosus and having 3’ to 5’ exonuclease proofreading activity, was obtained 
from the Chow Laboratory in the Wayne State University Chemistry Department.  DNA 
polymerase, dideoxynucleotide mixtures and sequencing buffers (SequiTherm Excel™ II DNA 
sequencing kit) were obtained from Epicentre Biotechnologies (a division of Illumina, Inc., 
Madison, WI).  Sequencing primers for use with the LI-COR Biosciences Sequencer 4000L, 
oligonucleotides bound at the 5’ end to either 700 or 800 IRDye®, were ordered from either LI-
COR (Lincoln, NE) or Integrated DNA Technologies Inc. (Coralville, IA).  5-bromo-4-chloro-3-
indoxyl-phosphate (X-Phos) was obtained from Denville Scientific for assaying alkaline 
phosphatase (PhoA) activity. 
 
4.6.3 pKan-PhoA1 Construction 
 The plasmid pKan-PhoA1 is a derivative of pKan-EmGH and preserves the original 
plasmid backbone.  The EmGFP gene was replaced by the gene of PhoA in a series of cloning 
steps that modified either terminus of PhoA for use as a display protein.  The oligonucleotides 
PhoAgF and PhoAgR (Table 4.22) were used as primers with prepared genomic DNA from E. 
coli DH5 as template in a PCR to amplify the PhoA gene.  PhoAgF is complimentary to the 5’ 
end of the PhoA signal peptide encoding DNA, while PhoAgR binds the 3’ end of the PhoA 
gene, including the stop codon.  The product of the PCR was isolated using gel electrophoresis 
and cleaned.  It was used as a template in a second PCR reaction using oligonucleotides 
PhoAF and PhoAR (Table 4.22).  The PhoAF primer incorporates the DNA sequence 
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preceeding the EmGFP gene in pKan-EmGH including an NdeI restriction enzyme cut site 5’ to 
the PhoA signal peptide and a 5’ NotI recognition sequence.  Primer PhoAR incorporates an 
XbaI restriction enzyme recognition sequence 5’ to the stop codon of the PhoA gene.  The 
resulting product was isolated and cleaned using gel electrophoresis.  The DNA, along with 
prepared DNA of plasmid pKan-EmGHA3 (discussed in Chapter 2) were digested with 
restriction enzymes NotI and XbaI.  The appropriate DNA fragments were isolated and cleaned 
using gel electrophoresis.  The fragments were ligated to form plasmid pKan-PhoA3 where the 
EmGFP gene has been replaced with PhoA and its signal peptide with modifications.  The clone 
was verified by DNA sequencing. 
 Oligonucleotides PhoABK and PhoHisR (Table 4.22) were paired with pKan-PhoA3 as a 
template for a PCR that modified the 3’ and 5’ DNA sequences of the PhoA gene.  Primer 
PhoABK is largely complimentary to the 5’ end of the PhoA gene, binding the DNA encoding the 
PhoA signal peptide and upstream, untranslated regions.  It introduces a silent mutation to 
produce a BsrGI restriction enzyme recognition site within the DNA encoding the PhoA signal 
peptide to facilitate the incorporation of the random peptide library.  DNA encoding a linker 
peptide (EGGGA) was introduced in between the signal peptide and PhoA, giving the peptide 
library freedom to move versus the display protein PhoA.  A KasI restriction enzyme recognition 
sequence was included within the DNA encoding the linker for random peptide library 
incorporation.  Primer PhoHisR places DNA encoding a His6 affinity tag at 3’ end of PhoA prior 
to the stop codon.  The PCR product was run on an agarose gel to purify the DNA.  This DNA 
and plasmid pKan-PhoA3 were digested with restriction enzymes XbaI and NotI, isolated and 
cleaned via gel electrophoresis and ligated to form modified plasmid pKan-PhoAH3.  The 
various modifications were confirmed by DNA sequencing. 
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To reduce the chances of pre-screening the random peptide library of particularly lethal 
peptides due to leaky expression from the PBAD promoter and to limit the amount of peptide-
PhoA fusion produced because of the smaller volume of the periplasm, the plasmid copy 
number needed to be decreased.  To do this the pUC replication origin of pKan-PhoAH3 was 
replaced with that of p15A.   Both pKan-PhoAH3 and pKan-EmGH were digested with restriction 
enzymes DraIII and BglI.  The desired DNA fragments were isolated and cleaned by gel 
electrophoresis and ligated to form the plasmid pKan-PhoA1. 
 
4.6.4 Random Peptide Library Construction in pKan-PhoA1 
 Complementary oligonucleotides Per12F and Per12R (Table 4.22), the former 
containing eleven NNK random codons preceded by one DNK codon to preclude the 
occurrence of a proline residue that would disrupt peptidase cleavage, were mixed to equal 
molarities and subjected to a primer extension reaction with dNTPs, Pfu polymerase and the 
appropriate buffer.  The product was then run on a gel; the appropriate MW band was extracted 
and cleaned using QIAquick® Gel Extraction Kits from Qiagen Inc. (Valencia, CA).  The cleaned 
DNA was digested with BsrGI and KasI.  An identical digestion was performed on the vector 
pKan-PhoA1.  The digestion products were run on agarose gels, the appropriate MW bands 
were extracted and cleaned using GENECLEAN® Turbo kits from MP Biomedicals, LLC (Solon, 
OH).  The two cleaned DNAs were ligated in a 2:1 insert to vector ratio using T4 DNA ligase 
with an overnight incubation at room temperature.  The ligation reactions were cleaned of 
protein and salts using GENECLEAN® Turbo kits.  Cleaned, ligated plasmid DNA was 
transformed into NEB 10-β electro-competent E. coli cells (araD139, Δ(ara, leu)7697, fhu, 
lacX74, galK16, galE15, mcrA, f80d(lacZΔM15)recA1, relA1, endA1, nupG, rpsL, rph, 
spoT1Δ(mrr-hsdRMS-mcrBC)) from New England Biolabs Inc. (Ipswich, MA).  Four hundred ng 
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of cleaned plasmid DNA was added to 100 µL of the electro-competents cells.  In 25 µL 
batches, the cell/plasmid mixture was electroporated at 2.44 kV.  The cells were recovered for 1 
hr at 37 oC in 1 mL of SOC medium.  Transformation was performed on 6 tubes of 100 µL of 
NEB 10-β electro-competent cells.  Recovered cells were then added to 500 mL LB-Kan30 + 
0.2% D-glucose and incubated overnight at 37 oC for clone outgrowth.  Amplified plasmid DNA 
was then recovered by using a Qiagen® Maxi Plamid kit from Qiagen Inc. (Valencia, CA).  This 
procedure was repeated four times for a total of ~1 billion transformants.  Portions of the 
plasmid preparations were mixed together to get roughly equal molar amounts of transformants. 
 
4.6.5 Peptide Selection Procedure 
 One hundred ng of pKan-PhoA1 plasmid DNA encoding the random peptide library was 
mixed with 30 µL of electro-competent E. coli DH5α cells.  The cell/DNA mixtures were 
electroporated at 2.44 kV and recovered in 1 mL of SOC medium for 1 hr at 37 oC.  This was 
repeated for 24 transformations.  Recovered cells were centrifuged at 7,000 rpm for 5 minutes 
to pellet the cells.  The supernatant was removed and the cells were washed in 50 mL of pre-
warmed LB twice to remove any untransformed plasmid in the recovery medium.  The cells 
were then resuspended in 550 mL LB-Kan30 + 0.2% D-glucose and incubated at 37 oC and 350 
rpm.  When the cells achieved early to mid-log phase growth, the culture was centrifuged at 
7,000 rpm to pellet the cells.  The supernatant was removed and the cells washed in 50 mL of 
pre-warmed LB twice to remove any free plasmid from sheering of cells during incubation or 
untransformed plasmids and D-glucose.  The cells were then resuspended in 550 mL pre-
warmed LB-Kan30 and incubated at 37 oC and 350 rpm.  After 30 minutes L-arabinose was 
added to a final concentration of 0.2% to induce peptide-PhoA fusion expression.  Incubation at 
37 oC continued for 90 minutes.  To isolate plasmids encoding bacteriolytic peptides, 21 mL of 
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culture were removed and centrifuged at 13,000 rpm for 30 minutes to pellet whole cells.  The 
supernatant was moved to a new tube and the centrifugation repeated.  The supernatant was 
moved to a new tube with 16 mL of isopropanol, 2.1 mL 3 M Na acetate pH 5.0 and 52.5 µL of 
10 µg/mL salmon testes DNA.  The DNA serves as a carrier molecule during the alcohol 
precipitation.  The solution was inverted several times to mix and then centrifuged at 11,000 rpm 
for 45 minutes.  The supernatant was carefully removed and the pellet washed with 5 mL of 
70% ethanol.  This was centrifuged at 11,000 rpm for 10 minutes and the supernatant removed.  
The DNA pellet was dried and then resuspended in 500 µL dH2O. 
 Simultaneously with the 21 mL culture removal, ampicillin was added to the remaining 
culture to a final concentration of 500 µg/mL to lyse any actively dividing cells.  The culture 
continued to incubate at 37 oC until its optical density at 600 nm reached a minimum indicating 
all cells had been lysed.  The entire culture was centrifuged at 7,000 rpm for 10 minutes to pellet 
any whole cells.  The supernatant was removed and the pellet was washed in 50 mL of HEPES-
NaCl (HN) buffer pH 7.0 three times.  The pellet was then stored at 4 oC overnight (this step is 
unnecessary and one may proceed to the next incubation).  The pellet was resuspended in 30 
mL of DNase I buffer (10 mM Tris HCl pH 7.5, 2.5 mM MgCl2, 0.5 mM CaCl2) to which 25 µL of 
2 units/µL of DNase I was added.  The solution was inverted gently to mix and incubated at 37 
oC, without shaking, for 3 hours.  This step removes any extracellular DNA that may include 
plasmids from cells lysed by the ampicillin shock step.  The mixture was then centrifuged to 
pellet whole, intact cells at 7,000 rpm for 5 minutes.  The pellet was washed with Qiagen® Midi 
Plasmid kit resuspension buffer (50 mM Tris HCl pH 8.0, 10 mM EDTA) twice to remove DNase 
I.  Plasmids encoding bacteriostatic/bactericidal peptides still contained within the whole, intact 
cells were extracted using a Qiagen® Maxi Plamid kit from Qiagen Inc. (Valencia, CA). 
 Preparations of plasmids including bacteriolytic or bacteriostatic/bactericidal peptides 
were transformed into fresh E. coli DH5α electro-competent cells and plated on LB-Kan30 + 
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0.2% D-glucose so that the colonies are sufficiently separate from each other.  To confirm the 
efficacy of the selected clones, the colonies were replica plated on to plates of LB-Kan30 + 
0.2% L-arabinose and then LB-Kan30 + 0.2% D-glucose.  The plates were incubated overnight 
at 37 oC.  Colonies that failed to grow on the plate containing L-arabinose versus that containing 
D-glucose were selected for further analysis. 
 
4.6.6 DNA Sequencing 
 Isolated clones were sequenced using a two-step process.   Overnight cultures were 
grown in LB-Kan30 + 0.2% D-glucose.  One µL of culture was used as template in an initial 
PCR including primers arapromseqF and Per12R (Table 4.22).  The primers are complimentary 
to sequences on either side of the randomized region.  ArapromseqF has a 5’ tail not 
complimentary to any region in pKan-PhoA1, but has been selected for complementarity with a 
third oligonucleotide, JSLF (Table 4.22).  The product of the first reaction incorporates the 
JSLF-complimentary tail using Taq polymerase.  The 25 µL product was then diluted in 170 µL 
dH2O and used as a template in a sequencing reaction employing dideoxynucleotide mixes and 
a 5’ IRDye®-labeled primer, JSLF.  The labeled primer binds the tail sequence permitting high-
throughput sequencing. 
 
4.6.7 Induced Growth Curves 
 Two methods were employed for observing the effect of an induced peptide-PhoA fusion 
on its host cell.  The first used large cultures in flasks of 17 mL, the second used small cultures 
of 200 µL in 96-well plates.  Both methods are described.  For the large culture induced growth 
curves, a culture of each clone, started with an individual colony, was incubated overnight at 37 
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oC in 3 mL LB-Kan30 + 0.2% D-glucose.  The overnights were diluted 1/1000 by moving 17 µL 
into 17 mL LB-Kan30 and incubated until early log phase (~210 minutes).  L-arabinose was 
added to the culture to a final concentration of 0.2%.  The optical density of a 700 µL sample of 
the cultures at 600 nm was measured periodically at the point of induction and at 30 or 60 
minute intervals following induction using Spectronic® Genesys™ 20 spectrophotometer from 
Thermo Fisher Scientific, Inc. (Waltham, MA).  In the final analysis, the optical density of 
uninoculated LB broth was subtracted from the values of each clone’s culture at every time 
point.  Clones were compared to the induced growth curve of clone NI001, a peptide recovered 
during selection that showed no inhibition when grown in the presence of 0.2% L-arabinose. 
 Induced growth curves in 96-well plates started with the inoculation of 200 µL of LB-
Kan30 + 0.2% D-glucose with a single, isolated colony of each clone.  The plate was incubated 
at 37 oC and 500 rpm in a GeneMachines HiGro® 96-well plate incubator from Digilab, Inc. 
(Holliston, MA) overnight.  The overnight cultures were diluted 1/100 by adding 2 µL to 200 µL 
of fresh LB-Kan30 and incubated in the HiGro at 37 oC and 500 rpm.  When the cultures 
achieved early log phase (~150 minutes) the optical densities of the cultures in the plate at 600 
nm were measured using a SpectraMax 190 from Molecular Devices, Inc. (Sunnyvale, CA).  L-
arabinose was added to each well at a final concentration of 0.2%.  Incubation of the plates 
continued with the optical densities being measured every 60 minutes following induction until 
the onset of stationary phase growth.  The optical density of uninoculated LB broth was 
subtracted from the values of each clone’s culture at every time point.  Clones were compared 
to the induced growth curve of clone NI001, a peptide recovered during selection that showed 
no inhibition when grown in the presence of 0.2% L-arabinose. 
 
4.6.8 Peptide-PhoA Expression Assays 
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 Individual colonies of each clone were placed on solid LB-Kan30 + 0.2% D-glucose 
medium atop a 0.45 µm nylon transfer membrane and incubated at 37 oC for 20 hours.  The 
membranes allow for the diffusion of nutrients and inducers through the pores but also permit 
the transfer of colonies to fresh medium.  The presence of the membranes slows growth such 
that after 20 hours of incubation the colonies are still small and in exponential phase growth.  
The colonies were transferred to solid LB-Kan30 + 50 µg/mL X-Phos + 0.2% L-arabinose 
medium and incubated at 37 oC for 2 hours.  The use of solid medium with X-Phos localizes the 
generation of the precipitant making visualization easier, especially if the peptide is bacteriolytic 
and kills its host cell soon after its induction.  The color of the colonies, determined by the 
amount of PhoA activity, was recorded in comparison to the non-inhibitory clone NI001 that 
demonstrates high PhoA activity. 
 
4.6.9 pKan-Solo Construction 
 pKan-Solo was generated as a derivative of pKan-PhoA1.  This was achieved in two 
different ways.  The first was used in the generation of PL126 and PL444 free peptide 
constructs.  Oligonucleotide arapromseqF was paired with either PL126solo2 or PL444solo2 
(Table 4.22) in a PCR using the isolated clones of PL126 or PL444 in pKan-PhoA1 as 
templates.  The PCR products were run on agarose gels and the desired DNA fragment was 
excised and cleaned.  The PCR products and pKan-PhoA were then digested with restriction 
enzymes NotI and XbaI.  This digestion removed the PhoA gene from pKan-PhoA1.  Once the 
products of the digest were cleaned they were ligated and generated constructs pKan-
PL126Solo and pKan-PL444Solo.  In both plasmids the 5’ section of the originally isolated 
clones was preserved including the PhoA signal peptide.  The 3’ end was modified to remove 
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the linker sequence and PhoA, deleting them and placing a stop codon at the 3’ end of the 
peptide. 
 For latter constructs encoding peptides without PhoA, a simpler procedure was 
developed.  The oligonucleotide PerisoloF was paired with an oligonucleotide encoding the 
desired peptide (PXXXXSolo e.g. PL014Solo), (Table 4.22).  PerisoloF was complimentary to 
the paired primer and formed a duplex DNA upon primer extension.  The products were cleaned 
and digested with restriction enzymes BsrGI and XbaI.  Plasmid pKan-PhoA1 was similarly 
digested.  The digestion products were cleaned via gel electrophoresis and ligated to form free 
peptide expressing derivatives of the originally isolated clones.  Identical to the previous 
method, the linker sequence and PhoA gene had been removed and a stop codon placed at the 
immediate 3’ end of the peptide without disturbing the 5’ signal peptide.  Unlike the previous 
method, the mRNA sequences of the peptides differed from those of the isolated clones due to 
the use of a primer extension reaction instead of a template based PCR.  Therefore these 
clones demonstrate both the peptide’s lethality in the absence of PhoA as well as determining if 
the peptide sequence versus the mRNA sequence is the causative factor. 
 
4.6.10 Determination of Minimum Inhibitory Concentrations 
 Peptides were purchased from Selleck Chemicals (Houston, TX) as desalted (~70% 
purity).  Due to the hydrophobic composition of PL045 and PL137, dimethylformamide (DMF) 
was used to dissolve the peptides.  In the case of PL098, the presence of charged residues 
facilitated the dissolving of the peptide in dH2O.  Stocks of each peptide at 10 mM were stored a 
-20 oC in aliquots for use in the calculation of their minimum inhibitory concentrations (MICs). 
E. coli strains W3110 (F-, λ-, rph-1, INV(rrnD, rrnE))  and SM101 (F-, thr-1, araC14, 
lpxA2(ts), tsx-78, Δ(galK-attLAM)99, hisG4, rfbC1, rpsL136, xylA5, mtl-1, thi-1) and various 
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other organisms including Gram-negative bacteria Proteus mirabilis, Enterobacter aerogenes, 
Edwardsiella tarda, Pseudomonas aeruginosa, Serratia marcesens, Klebsiella pneumonia and 
Gram-positive bacteria Staphylococcus aureus, Bacillus subtilis and Micrococcus luteus were 
streaked on solid LB medium to get individual colonies.  Further MIC studies of Gram-negative 
bacteria Shigella sonnei, Salmonella typhimurium, and Yersinia enterocolitica substituted Todd 
Hewitt Broth (THB), a rich medium for fastidious organisms for LB.  Cultures were started in 3 
mL LB broth using one colony and incubated overnight at 37 oC.  Overnight cultures were 
estimated to be 109 cells/mL and accordingly serially diluted in LB broth to 104 cells/ mL.  Two 
hundred µL of the final dilution were aliquoted into wells of a 96-well plate.  Peptides were 
diluted serially so that adding 5 µL of the dilution to 200 µL of culture would produce a range of 
final concentrations from 250-1 µM.  Plates containing gradients of each peptide alongside 
identical dilutions of the peptide solvents in cultures of the different species were then incubated 
in a GeneMachines HiGro® 96-well plate incubator from Digilab, Inc. (Holliston, MA) at 37 oC 
and 500 rpm for 16 hours.  After incubation the plates were removed from the incubator and 
their optical densities were measured at 600 nm using a SpectraMax 190 from Molecular 
Devices, Inc. (Sunnyvale, CA).  The minimum inhibitory concentration was selected as the 
smallest concentration of peptide required to completely inhibit growth of the culture. 
 
4.6.11 PL098 Synthetic Peptide Growth Curves 
 Cultures of both E. coli SM101 and M. luteus were incubated overnight in 3 mL of LB 
medium.  The cultures were diluted from 109 to 105 cells/mL in LB.  Two hundred µL of the 
dilutions were placed in wells of a 96-well plate and incubated at 37 oC and 500 rpm in a 
GeneMachines HiGro® 96-well plate incubator from Digilab, Inc. (Holliston, MA).  The optical 
densities of the cultures were monitored at 600 nm using a SpectraMax 190 from Molecular 
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Devices, Inc. (Sunnyvale, CA).  When the cultures had reached mid-log growth phase, dilutions 
of PL098 peptide were added to make a gradient of final concentrations ranging from 250 to 0 
µM.  Incubation of the cultures was continued and the optical density was measured periodically 
following the addition of PL098.  In the final analysis, the optical density of uninoculated LB at 
600 nm was subtracted from the measured values of each culture. 
 
4.6.12 PL098 Hemolytic Assays 
 Defibrinated sheep’s blood (38% PCV) obtained from HemoStat Laboratories (Dixon, 
CA) was washed twice and resuspended to a final concentration of 10% PCV in phosphate 
buffered saline (PBS) pH 7.4.  Two hundred µL aliquots of the defibrinated sheep’s blood 
suspension were distributed to microcentifuge tubes.  Serial dilutions of PL098 were prepared 
using PBS pH 7.4.  The dilutions of PL098 were added to the aliquots to a final concentration of 
PL098 ranging from 250 to 1 µM.  Control aliquots of defbrinated sheep’s blood containing 
either dH2O, PL098’s solvent, or 0.1% Triton X-100 were used as 0%  and 100% hemolysis 
benchmarks respectively.  The aliquots were incubated, with shaking at 37 oC for 18 hrs.  The 
aliquots were then centrifuged to pellet whole erythrocytes or cell debris from lysis.  The optical 
density at 570 nm of 50 µL of each samples’ supernatant was measured using a SpectraMax 
190 from Molecular Devices, Inc. (Sunnyvale, CA) to calculate the amount of hemoglobin 
released by lysed erythrocytes.  The level of hemolysis of the dH2O-only aliquot was subtracted 
from the PL098 samples.  Percent hemolysis was calculated by dividing the PL098 sample 
values by the 0.1% Triton X-100 complete hemolysis sample and multiplied by 100. 
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4.6.13  pKan-PhoALfcinB & Pac525 Construction 
 The oligonucleotide PerF was paired with either LfcinBR or Pac525R (Table 4.22) in a 
primer extension reaction.  The products of these reactions were cleaned and digested with 
restriction enzymes BsrGI and KasI.  Plasmid pKan-PhoA1 was digested similarly.  The 
reactions were run on agarose gels and the desired DNA fragments were excised and cleaned.   
The purified PCR fragments were individually ligated to pKan-PhoA1 to form the respective 
plasmids pKan-PhoALfcinB and pKan-PhoAPac525.  Both plasmids were verified by DNA 
sequencing. 
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CHAPTER 5 
2ND GENERATION PEPTIDE SCREEN BASED ON THE BACTERIOLYTIC PEPTIDE POOL 
OF THE PERIPLASMIC SELECTION 
 
5.1 Abstract 
 Bacteriolytic peptides isolated from the pIVD antimicrobial peptide selection share a 
common distribution of amino acids suggesting formation of amphipathic α-helices.  For the 
isolation of more lytic peptides and optimization of their activity we generated a constrained 
peptide library.  Of the 146 clones assayed, 68 were bacteriolytic, 9 were 
bacteriostatic/bactericidal, and 4 were weakly inhibitory improving the yield of antimicrobial 
peptides versus that of the randomized pool.  Analysis of the amino acid distributions of the 
peptides isolated reveled preferences not observed in the original pool of lytic peptides used in 
the constrained peptide library’s design.   
 Circular dichroism and the effect of proline substitution of peptide 84 and its derivative 
84 Pro- strongly suggest an α-helical conformation is critical for function of the lytic peptides 
sharing similar amino acid distributions.  As a representative of these peptides, 84 Pro- 
exhibited a spectrum of activity against Escherichia coli, and numerous Gram-positive bacteria 
such as Staphylococcus aureus, Enterococcus faecalis, Streptococcus salivarius, Bacillus 
subtilis and Mycobacteria smegmatis possibly inhibiting cell wall synthesis by blocking 
translocation through the Sec pathway.  These results, coupled with its lack of hemolytic activity, 
make it and its related peptides viable leads for antimicrobial development. 
 
 
307 
 
 
 
5.2 Introduction 
 Ninety-four peptides exhibiting bacteriolytic phenotypes were isolated using the 
periplasmic selection described in Chapter 4 (Table 4.1, Figure 5.1).  The majority of these 
peptides share a common amino acid pattern of alternating hydrophobic and basic residue 
pairs.  When these peptides are placed in Edmundson wheel projections,515 they display 
amphipathic, α-helices (Figure 4.17).  A number of naturally occurring antimicrobial peptides, 
such as magainin 2,516 also form these structures517; 539 (Figure 4.18).  These lytic peptides 
destabilize bacterial and eukaryotic membranes though the precise mechanism by which they 
act is unknown.253; 272  Previous studies suggest that pore-forming antimicrobial peptides require 
a minimum degree of hydrophobicity.529  Increasing the hydrophobicity of the peptides, however, 
through the substitution or addition of hydrophobic residues increases hemolysis.262  High 
hydrophobicity is also thought to stabilize dimerization of peptides which dramatically lowers 
their permeability in Gram-negative cells, but not eukaryotes, thus decreasing the therapeutic 
index of the peptides.262  The basic interface is thought to interact with the negatively-charged 
bacterial membrane, enhancing specificity for bacterial membranes, since eukaryotic 
membranes are less negatively charged.520  Increasing the positive charge of a peptide, 
therefore, provides more specificity, minimizing hemolysis.  The sequences recovered in 
Chapter 4 suggest that basic residues provide more than specificity.  Because peptides are 
expressed within E. coli cells in the periplasmic in vivo display system (pIVD), membrane 
permeability is not a factor when selecting for antimicrobial peptides.  This approach, therefore, 
facilitates the optimization of peptides based solely on their interactions with the bacterium and 
not phylogenetic domain specificity. 
 To optimize the design and isolation of new lytic peptides, the 94 lytic peptides were 
further analyzed for common motifs and categorized by their phenotypes.  A subset of the lytic 
peptides isolated was composed of peptides that lyse their host cells rapidly after induction 
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(Figure 5.2).  These data were used to isolate additional peptides with enhanced lytic activity.  
Two approaches were used.  Characteristics of the peptides were implemented in the rational 
design of peptides with optimized lytic activity (Chapter 6) or to constrain or limit the amino acids 
at each position of a library of peptides and select for increased function.  This latter method is 
discussed in the following chapter. 
 
 
 
 
Figure 5.1:  Methods of antimicrobial development discussed within this dissertation.  Chapter 5 
focuses on in vivo display of a constrained peptide library based on the amino acid distribution 
observed in the bacteriolytic peptides isolated in Chapter 4. 
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Figure 5.2:  Phenotypic groupings of antimicrobial peptides isolated from the periplasmic in vivo 
display selection in Chapter 4.  Twelve lytic peptides exhibiting an early onset of lysis after 
induction were sub-grouped as EO. 
 
5.3 Objective of the Project  
To isolated new antimicrobial peptides based on the amino acid sequence patterns 
observed in the early onset of lysis, bacteriolytic peptide pool isolated via the pIVD system.  
Optimize bacteriolytic activity by screening a library of constrained amino acid sequences and 
further characterize the structure and function of peptides whose sequences are in congruence 
with an amphipathic, α-helical structure. 
 
5.4 Results 
Phenotypic analyses of the lytic peptides isolated in Chapter 4 revealed that 12 peptides 
(Table 5.1) lysed their host cells very rapidly following induction (Figures 5.3.A-C).  This group, 
termed early onset (EO) of lysis peptides, was further characterized to determine if particular 
310 
 
 
 
sequence characteristics correlated with the EO phenotype.  We assumed that the early onset 
is related to the amount of peptide necessary for lysis to occur, therefore, these peptides are the 
most strongly lytic of the pool. 
 
 
 
Table 5.1:  Amino acid sequences of early onset of lysis peptides (EO) isolated from the 
periplasmic selection that cause cell lysis at or within an hour of induction. 
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Figures 5.3.A-B:  Growth curves of EO peptides expressed in E. coli DH5α cells.  Lysis of cells 
begins at or within one hour of induction.  Optical density was measured at different time 
intervals following the addition of L-arabinose.   
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Figure 5.3.C:  Growth curves of EO peptides expressed in E. coli DH5α cells.  Lysis of cells 
begins at or within one hour of induction.  Optical density was measured at different time 
intervals following the addition of L-arabinose.   
 
5.4.1 Sequence Analysis of Early Onset of Lysis Peptides 
 The residue distributions of the 12 EO peptides were compared to a baseline of 
expected frequencies established using the sequences of 208 unselected peptides from the 
periplasmic peptide library (Figures 4.14.A-L, Tables 4.6, 4.7.A-C, 4.8).  Statistical analysis 
indicated that there were non-random distributions of amino acids at each position of the EO 
peptides (Table 5.2).  Binomial distributions of individual amino acids (Tables 5.3.A-C) and 
amino acid side chain groups (Table 5.4) at each position were used to determine amino acid 
preferences compared to the unselected library. 
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Table 5.2:  χ2 analysis of the early onset of lysis peptides (EO) isolated from the periplasmic 
selection compared to the distribution observed among the unselected peptides. 
 
 Position 1 (Figure 5.4.A) The first position is represented by the restricted DNA codon 
DNK, to eliminate the incorporation of proline that inhibits the function of the signal peptidase.504  
A bias for several hydrophobic (p = 2.6 x 10-4) residues was observed with individual amino 
acids methionine (p = 2.0 x 10-2) and phenylalanine (p = 1.8 x 10-6) being preferred. 
Position 2 (Figure 5.4.B) Except for a large incidence of alanine residues (p = 2.5 x 10-
3), the position shows no preferences for either individual residues or functional groups of amino 
acids.  There is, however, an underrepresentation of hydrophobic residues (p = 7.3 x 10-2). 
Position 3 (Figure 5.4.C) A slight preference for basic residues (p = 1.2 x 10-1), especially 
arginine (p = 1.5 x 10-1), and hydrophobic residues (p = 6.9 x 10-2), including leucine (p = 1.1 x 
10-1) and tryptophan (p = 1.2 x 10-2), were preferred at the third position. 
 Position 4 (Figure 5.4.D) A bias for hydrophobic residues (p = 3.0 x 10-5) was observed.  
Residue leucine (p = 4.5 x 10-7) was particularly preferred with a smaller bias for valine 
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Table 5.3.A:  Binomial distribution of the individual amino acids of the early onset of lysis 
peptides (EO) isolated from the periplasmic selection compared to the distribution observed 
among the unselected peptides. 
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Table 5.3.B:  Binomial distribution of the individual amino acids of the early onset of lysis 
peptides (EO) isolated from the periplasmic selection compared to the distribution observed 
among the unselected peptides. 
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Table 5.3.C:  Binomial distribution of the individual amino acids of the early onset of lysis 
peptides (EO) isolated from the periplasmic selection compared to the distribution observed 
among the unselected peptides. 
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Table 5.4:  Binomial distribution of the amino acid side chain groups of the early onset of lysis 
peptides (EO) isolated from the periplasmic selection compared to the distribution observed 
among the unselected peptides. 
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Figures 5.4.A-B:  Amino acid distribution of EO bacteriolytic peptides (observed) versus the 
distribution observed among unselected peptides of the library (expected). 
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Figures 5.4.C-D:  Amino acid distribution of EO bacteriolytic peptides (observed) versus the 
distribution observed among unselected peptides of the library (expected). 
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Figures 5.4.E-F:  Amino acid distribution of EO bacteriolytic peptides (observed) versus the 
distribution observed among unselected peptides of the library (expected). 
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Figures 5.4.G-H:  Amino acid distribution of EO bacteriolytic peptides (observed) versus the 
distribution observed among unselected peptides of the library (expected). 
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Figures 5.4.I-J:  Amino acid distribution of EO bacteriolytic peptides (observed) versus the 
distribution observed among unselected peptides of the library (expected). 
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Figures 5.4.K-L:  Amino acid distribution of EO bacteriolytic peptides (observed) versus the 
distribution observed among unselected peptides of the library (expected). 
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(p = 7.9 x 10-2) and phenylalanine (p = 1.0 x 10-1).  These biases were compensated for by a 
dearth of hydrophilic (p = 7.7 x 10-2) and basic (p = 6.7 x 10-2) amino acids.  
Position 5 (Figure 5.4.E) Position 5 lacks strong preferences.  Hydrophobic residues (p 
= 7.8 x 10-2), represented by tryptophan (p = 1.1 x 10-1), and small residue alanine (p = 6.3 x 10-
2), however, were slightly preferred. 
 Position 6 (Figure 5.4.F) A bias against hydrophobic residues (p = 2.3 x 10-2) was 
evident at position 6.  Residues arginine (p = 1.6 x 10-1) and serine (p = 7.9 x 10-4) were 
preferred. 
 Position 7 (Figure 5.4.G) A strong bias in favor of tryptophan (p = 6.9 x 10-10) was 
observed.  A non-random, lack of hydrophilic amino acids (p = 3.7 x 10-2) was also observed. 
 Position 8 (Figure 5.4.H) Hydrophobic amino acids (p = 1.6 x 10-3) were preferred with 
eight residues being overrepresented in the pool.  There was a strong selection for tryptophan 
(p = 3.9 x 10-6) in particular. 
 Position 9 (Figure 5.4.I) The position is dominated by a preference for the basic amino 
acid arginine (p = 1.1 x 10-2).  No other biases were observed in the peptides that remained. 
 Position 10 (Figure 5.4.J) A bias for the small amino acids (p = 2.1 x 10-1) glycine and 
alanine were observed, with alanine (p = 2.5 x 10-2) being preferred.  Hydrophobic residues 
were selected against (p = 1.6 x 10-1) while serine (p = 2.3 x 10-1) and arginine (p = 2.8 x10-1) 
had slight biases in their favor. 
 Position 11 (Figure 5.4.K) The position had a bias in favor of hydrophobic residues (p = 
2.7 x 10-2) and against small amino acids (p = 4.7 x 10-2).  There are, however, slight 
preferences for basic residue arginine (p = 1.7 x 10-1) and hydrophobic residue tryptophan (p = 
3.0 x 10-2). 
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 Position 12 (Figure 5.4.L) Basic residues (p = 1.8 x 10-1), dominated by lysine (8.8 x 10-
3), were preferred at the final peptide position.  Amino acids from other side chain groups, 
however, demonstrated a fairly distributed array. 
 
5.4.2 Constrained Library Construction & Screen 
 The number of peptides recovered by screening ~5 x 108 transformants representing a 
library of 1220 unique sequences indicates there are more peptides of similar sequence that 
exhibit a bacteriolytic phenotype.  It is also likely that the most efficient cell-lysing peptide has 
yet to be isolated.  To increase the probability of isolating bacteriolytic peptides and optimizing 
their activity, we constrained or limited the amino acid residues represented by the encoding 
DNA at the 5’ end of the PhoA gene.  The constrained DNA sequence (Figure 5.5) was 
designed by observing the patterns of residue distribution of the aligned, linear amino acid 
sequences of the EO subset of lytic peptides.   
Based on the analysis outlined above, Positions 1 and 3 were constrained to 4 and 3 
residues each, mostly composed of hydrophobic residues, except for an incidence of arginine at 
position 3.  Positions 6, 7, and 10 were limited to two residues either R or S, R or W, and R or G 
respectively.  Positions 4, 8 and 9 were fixed at one residue each; L, W, and R respectively.  
Finally, positions 2, 5, 11 and 12 were randomized using the NNK codon due to a small bias at 
each position in the bacteriolytic peptide pool.  Given the small amount of peptides in the EO 
pool, twelve, assumptions on the importance of residues at positions were made to identify a 
constrained peptide sequence that would increase the frequency of lytic peptide isolation. 
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Figure 5.5:  Edmundson wheel projection of amino acid sequence of the constrained peptide 
library.  Colors correspond with amino acid side chain groups.  NNK represents a position that 
was randomized.  Numbers represent a residue’s position in the linear peptide sequence. 
 
Oligonucleotides were designed, in the same manner as those for the random peptide 
library, and utilized in primer extension reactions.  The total unique number of peptides 
represented by the degenerate DNA sequence is 1.5 x 107.  A small library sampling the total 
number was placed within pKan-PhoA1 between the PhoA signal peptide and PhoA.  It was 
then transformed into electro-competent DH5α cells and plated on repression medium 
containing D-glucose.406  Individual colonies were then sequenced and subjected to induced 
growth curves without concern as to their phenotype as we assumed that the majority would be 
bacteriolytic.  A total of 146 unique sequences were assayed and subjected to further analyses. 
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5.4.3 Characterization of Peptides 
5.4.3.1  Phenotypes of Peptides  
 Individual clones were subjected to induced growth curves in a 96-well plate and 
compared to non-inhibitory peptide NI001 to determine their phenotypes.  While the incidence of 
isolating bacteriolytic peptides was greatly increased, 68 of 146 peptides having lytic activity 
(Tables 5.5.A-B, Figures 5.6.A-N), versus the screening of the DNK (NNK)11 randomized pool, 
surprisingly, roughly half of the analyzed clones were not bacteriolytic.  Thirteen of the 149 
clones exhibited either bacteriostatic/bactericidal or weakly inhibitory phenotypes (Table 5.6, 
Figures 5.7.A-B, 5.8); while a large population of 65 peptides had no inhibitory activity (Tables 
5.7.A-B).  The incidence of non-inhibitory clones helps identify what factors are important for 
bacteriolytic activity.  First, the occurrence of proline residues at the randomized positions of 2, 
5, 11, and 12 is increased in the non-inhibitory pool versus the bacteriolytic pool.  Proline 
residues, due to their kinked structure, are known helix disrupters.512; 544  Their placement may 
be inhibiting the critical formation of α-helices among the peptides509; 513 (Chapter 4, Section 
4.4.3.2).  However, a number of bacteriolytic peptides (4, 6, 13, 40, 46, 77, and 82) also contain 
proline residues either occupying the 11th or 12th position which may not affect that ability of the 
peptide to form the helix.  Secondly, the basic core of the sequences, as they would appear in 
an α-helix, are generally disrupted by the inclusion of hydrophobic residues whereas this is 
generally not observed among the bacteriolytic sequences.  Interestingly most peptides 
demonstrate a weaker bacteriolytic phenotype than the 12 early onset of lysis peptides used in 
the construction of the constrained library.  Peptides 30, 33 and 48 were comparable to the 
strongest bacteriolytic peptides from the original periplasmic selection, with peptide 48 having 
an earlier onset of lysis than any peptides previously isolated in Chapter 4 (Figure 5.9).  
Peptides from the constrained peptide screen that exhibited an onset of cell lysis within 1 hour 
of induction were grouped as early onset of lysis peptides (EO2) (Table 5.8). 
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Table 5.5.A:  Amino acid sequences of the general pool of bacteriolytic peptides (GP) isolated 
from the constrained library screen.  Amino acid sequences as they would appear in an α-helix 
are included determining the potential for formation of an amphipathic α-helix. 
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Table 5.5.B:  Amino acid sequences of the general pool of bacteriolytic peptides (GP) isolated 
from the constrained library screen.  Amino acid sequences as they would appear in an α-helix 
are included determining the potential for formation of an amphipathic α-helix. 
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Figures 5.6.A-B:  Induced growth curves of all isolated, bacteriolytic peptides from the 
constrained peptide library screen.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide.  All growth curves were performed in a 96-
well plate format. 
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Figures 5.6.C-D:  Induced growth curves of all isolated, bacteriolytic peptides from the 
constrained peptide library screen.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide.  All growth curves were performed in a 96-
well plate format. 
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Figures 5.6.E-F:  Induced growth curves of all isolated, bacteriolytic peptides from the 
constrained peptide library screen.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide.  All growth curves were performed in a 96-
well plate format. 
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Figures 5.6.G-H:  Induced growth curves of all isolated, bacteriolytic peptides from the 
constrained peptide library screen.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide.  All growth curves were performed in a 96-
well plate format. 
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Figures 5.6.I-J:  Induced growth curves of all isolated, bacteriolytic peptides from the 
constrained peptide library screen.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide.  All growth curves were performed in a 96-
well plate format. 
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Figures 5.6.K-L:  Induced growth curves of all isolated, bacteriolytic peptides from the 
constrained peptide library screen.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide.  All growth curves were performed in a 96-
well plate format. 
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Figures 5.6.M-N:  Induced growth curves of all isolated, bacteriolytic peptides from the 
constrained peptide library screen.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide.  All growth curves were performed in a 96-
well plate format. 
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Table 5.6:  Amino acid sequences of bacteriostatic/bactericidal and weakly inhibitory peptides 
isolated from the constrained library screen.  Amino acid sequences as they would appear in an 
α-helix are included determining the potential for formation of an amphipathic α-helix. 
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Figures 5.7.A-B:  Induced growth curves of all isolated, bacteriostatic/bactericidal peptides from 
the constrained peptide library screen.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide.  All growth curves were performed in a 96-
well plate format. 
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Figure 5.8:  Induced growth curves of all isolated, weakly inhibitory peptides from the 
constrained peptide library screen.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide.  All growth curves were performed in a 96-
well plate format. 
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Table 5.7.A:  Amino acid sequences of non-inhibitory peptides (NI) isolated from the 
constrained library screen.  Amino acid sequences as they would appear in an α-helix are 
included determining the potential for formation of an amphipathic α-helix. 
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Table 5.7.B:  Amino acid sequences of non-inhibitory peptides (NI) isolated from the 
constrained library screen.  Amino acid sequences as they would appear in an α-helix are 
included determining the potential for formation of an amphipathic α-helix. 
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Figure 5.9:  Bacteriolyic peptides from the constrained peptide screen with increased activity 
compared to previously isolated bacteriolytic peptides from the random peptide, periplasmic 
selection. 
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Table 5.8:  Amino acid sequences of the early onset of lysis peptides (EO2), a subgroup of the 
general pool of bacteriolytic peptides (GP) isolated from the constrained peptide library screen. 
 
5.4.3.2  Sequence Analysis of Peptides 
  The lytic activities of the peptides isolated from the constrained library vary.  Although 
the constrained peptide sequence was based on the patterns observed among the bacteriolytic 
peptides demonstrating an early onset of lysis from the periplasmic selection, there were 
several peptides recovered that demonstrate only weak cell lysis.  The amino acid distribution at 
each position was analyzed for three groups of peptides isolated from the constrained library  
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Figure 5.10:  Phenotypic groupings of antimicrobial peptides isolated from the constrained 
peptide screen.  Sequence analysis was focuses on three groups: the general pool of 
bacteriolytic peptides (GP), the early onset of lysis peptides (EO2), and the non-inhibitory 
peptides (NI). 
 
screen:  the general pool of all lytic peptides (GP), the early onset of lysis peptides (EO2), a 
subset of the general pool, and the non-inhibitory peptides (NI) (Figure 5.10).   
Position 1  In the general pool, position 1 showed a slight preference for I (p = 3.9 x 10-2) 
and against F (p = 8.3 x 10-2) and M (p = 1.0 x 10-1) among the hydrophobic residues available 
(Figure 5.11.A, Table 5.9).  The bias was less pronounced in the EO2 subset of peptides which 
had weaker preferences for residues I (p = 1.7 x 10-1) and against F (p = 1.8 x 10-1) (Figure 
5.12.A, Table 5.10). Among the non-inhibitory (NI) peptides, a bias for against F (p = 6.8 x 10-2) 
in favor of M (p = 4.9 x 10-2) was observed in contrast to the lytic peptide groups (Figure 5.13.A, 
Table 5.11).   
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Position 2  To determine if specific functional groups were preferred at the fully 
randomized positions 2, 5, 11 and 12, amino acids were grouped according to their chemical 
side chains and used to analyze the peptide pools.  Position 2 demonstrated a bias for basic 
residues in the GP peptides (p = 7.5 x 10-4) that was compensated for by a decrease in the 
incidence of hydrophobic residues (p = 2.8 x 10-3) (Figure 5.14.A, Table 5.12).  All basic 
residues, R (p = 1.4 x 10-2), K (p = 1.0 x 10-1) and H (p = 4.2 x 10-2), contributed (Figure 5.11.B, 
Table 5.9).  Non-basic residues I (p = 4.2 x 10-2) and N (p = 1.4 x 10-2) were overrepresented as 
well.  Proline was completely absent (p = 1.2 x 10-2).  Among the EO2 peptides there was a 
general bias against hydrophobic residues (p = 3.1 x 10-2) in favor of basic (p = 1.4 x 10-1) and 
hydrophilic residues (p = 3.8 x 10-2) (Figure 5.15.A, Table 5.13).  The NI pool greatly differed, 
having a proclivity for hydrophobic residues (p = 6.6 x 10-4) (Figure 5.16.A, Table 5.14), 
including L (p = 7.2 x 10-2), M (p = 9.3 x 10-2) and especially proline (p = 1.6 x 10-3) (Figure 
5.13.B, Table 5.11).   
Position 3  This position was restricted to R or the hydrophobic residues L or W.  In the 
GP there was a bias towards W (p = 5.5 x 10-3) at the expense of R (p = 1.4 x 10-3) (Figure 
5.11.C, Table 5.9).  The EO2 pool bias against R (p = 4.6 x 10-2) in favor of W (p = 5.6 x 10-4) 
was similar to that of the GP peptides (Figure 5.12.C, Table 5.10).  Among the NI peptides, L 
was the predominant amino acid (p = 1.8 x 10-5) at position 3 (Figure 5.13.C, Table 5.11). 
Position 5  The second fully randomized position showed considerable difference among 
the groups.  Basic residues were highly favored (p = 3.0 x 10-4) (Figure 5.14.B, Table 12) with 
both R (p = 2.5 x 10-38) and K (p = 1.4 x 10-2) contributing among the GP peptides (Figure 
5.11.E, Table 5.9).  The hydrophobic residue L was overrepresented (p = 5.0 x 10-2), and there 
were no incidences of proline (p = 1.2 x 10-2).  The EO2 group differed with a lack of basic 
amino acids (p = 9.7 x 10-2) (Figure 15.5.B, Table 5.14).  Instead, there was increase in 
preference for hydrophobic residues (p = 8.1 x 10-3), including L (p = 3.6 x 10-2) and M (p = 2.6 x 
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10-2) (Figure 5.12.D, Table 5.10).  A bias in favor of hydrophobic amino acids (p = 1.6 x 10-2) 
(Figure 5.16.B, Table 5.15), contributed mainly by proline (p = 4.7 x 10-3) (Figure 5.13.D, Table 
5.11) and against hydrophilic residues (p = 7.2 x 10-3) at position 5 was observed among the NI 
peptides. 
Position 6  Among all groups of peptides, the GP (p = 4.7 x 10-2) (Figure 5.11.F, Table 
5.9) and EO2 (p = 1.5 x 10-1) (Figure 5.12.E, Table 5.10) peptides favored R while the NI 
peptides preferred S (p = 2.7 x 10-2) (Figure 5.13.E, Table 5.11).   
Position 7 Here a significant difference between the GP and NI groups was observed.  
The GP peptides had a preference for W (p = 4.3 x 10-5) instead of R (Figure 5.11.G, Table 
5.9).  A similar bias was present among the EO2 subgroup, but less pronounced (p = 7.6 x 10-2) 
(Figure 5.12.F, Table 5.10).  In contrast, the NI peptides had a strong bias for R (p = 1.7 x 10-6) 
(Figure 5.13.F, Table 5.11). 
Position 10 Each of the groups of peptides, GP (p = 9.0 x 10-3) (Figure 5.11.J, Table 
5.9), EO2 (p = 1.2 x 10-1) (Figure 5.12.G, Table 5.10), and NI (p = 1.8 x 10-2) (Figure 5.13.G, 
Table 5.11) had a preference for R instead of G. 
Position 11  Positions 11 and 12 were also fully randomized due to only weak 
preferences observed in the original EO peptide pool.  This may be due to their relatively small 
influence on helix formation elicited by the preceding 10 residues and the hydrophobic 
environment of the plasma membrane.549  For the GP there was a preference for hydrophilic 
residues S (p = 8.3 x 10-2) and T (p = 3.6 x 10-2) (Figure 5.11.K, Table 5.9), hydrophobic 
residues W (p = 4.2 x 10-2) and basic residue H (p = 4.2 x 10-2).  Surprisingly, five GP peptides 
tolerated the presence of proline (p = 1.7 x 10-1).  The lack of preference for P at previous 
positions indicates a possible tolerance of the residues at the end of the helix.  EO2 peptides, 
however, show no tolerance for P (p = 2.42 x 10-1) (Figure 5.12.H, Table 5.10), but have a 
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preference for basic residues (p = 3.0 x 10-2) (Figure 5.15.C, Table 13), hydrophobic residues V 
(p = 1.1 x 10-1) and Y (p = 1.2 x 10-1) and hydrophilic amino acid T (p = 1.1 x 10-1).  Small amino 
acids (p = 5.3 x 10-2) glycine and alanine were biased against among the EO2 peptides.  The 
amino acid distribution was nearly random at position 11 among the NI peptides (Figure 5.13.H, 
Table 5.11).  Six NI peptides contained proline at position 11. 
Position 12  In the GP group, hydrophilic residues were overrepresented (p = 1.2 x 10-2) 
(Figure 5.14.D, Table 5.12), especially S (p = 5.1 x 10-2) and T (p = 1.6 x 10-2) (Figure 5.11.L, 
Table 5.9).  There was a general bias against hydrophobic residues (p = 5.4 x 10-2) but, leucine 
was favored (p = 1.4 x 10-2) although related amino acid, valine, was not conserved (p = 5.6 x 
10-2).  Two peptides of the GP group also contained proline at position 12, again suggesting all 
12 residues are not important for helix formation.  Like the GP group, the EO2 subgroup favored 
hydrophilic amino acids (p = 3.8 x 10-2) (Figure 5.15.D, Table 5.13), especially T (p = 1.6 x 10-3) 
(Figure 5.12.I, Table 5.10).  The hydrophobic residue L was also preferred (p = 9.6 x 10-2).  The 
distribution of amino acids among the NI peptides was nearly random with the exception of an 
overrepresentation of proline (p = 1.3 x 10-2) (Figure 5.13.I, Table 5.11). 
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Figures 5.11.A-B:  Individual amino acid distribution of the general pool of bacteriolytic peptides 
(GP) at each position.  Positions 4, 8 and 9 were constrained to one residue each; L, W, and R, 
respectively. 
349 
 
 
 
 
 
Figures 5.11.C-D:  Individual amino acid distribution of the general pool of bacteriolytic peptides 
(GP) at each position.  Positions 4, 8 and 9 were constrained to one residue each; L, W, and R, 
respectively. 
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Figures 5.11.E-F:  Individual amino acid distribution of the general pool of bacteriolytic peptides 
(GP) at each position.  Positions 4, 8 and 9 were constrained to one residue each; L, W, and R, 
respectively. 
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Figures 5.11.G-H:  Individual amino acid distribution of the general pool of bacteriolytic 
peptides (GP) at each position.  Positions 4, 8 and 9 were constrained to one residue each; L, 
W, and R, respectively. 
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Figures 5.11.I-J:  Individual amino acid distribution of the general pool of bacteriolytic peptides 
(GP) at each position.  Positions 4, 8 and 9 were constrained to one residue each; L, W, and R, 
respectively. 
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Figures 5.11.K-L:  Individual amino acid distribution of the general pool of bacteriolytic peptides 
(GP) at each position.  Positions 4, 8 and 9 were constrained to one residue each; L, W, and R, 
respectively. 
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Table 5.9:  Binomial distribution of the individual amino acids of the general pool of lytic 
peptides (GP) isolated from the constrained peptide library screen compared to the theoretical 
distribution arising from the constraints of each position’s codon. 
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Figures 5.12.A-B:  Individual amino acid distribution of the early onset of lysis peptides (EO2) 
at each position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one 
residue each; L, W, and R, respectively. 
356 
 
 
 
 
 
Figures 5.12.C-D:  Individual amino acid distribution of the early onset of lysis peptides (EO2) 
at each position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one 
residue each; L, W, and R, respectively. 
357 
 
 
 
 
 
Figures 5.12.E-F:  Individual amino acid distribution of the early onset of lysis peptides (EO2) at 
each position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one 
residue each; L, W, and R, respectively. 
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Figures 5.12.G-H:  Individual amino acid distribution of the early onset of lysis peptides (EO2) 
at each position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one 
residue each; L, W, and R, respectively. 
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Figure 5.12.I:  Individual amino acid distribution of the early onset of lysis peptides (EO2) at 
each position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one 
residue each; L, W, and R, respectively. 
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Table 5.10:  Binomial distribution of the individual amino acids of the early onset of lysis 
peptides (EO2) isolated from the constrained peptide library screen compared to the theoretical 
distribution arising from the constraints of each position’s codon. 
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Figures 5.13.A-B:  Individual amino acid distribution of the non-inhibitory peptides (NI) at each 
position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one residue 
each; L, W, and R, respectively. 
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Figures 5.13.C-D:  Individual amino acid distribution of the non-inhibitory peptides (NI) at each 
position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one residue 
each; L, W, and R, respectively. 
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Figures 5.13.E-F:  Individual amino acid distribution of the non-inhibitory peptides (NI) at each 
position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one residue 
each; L, W, and R, respectively. 
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Figures 5.13.G-H:  Individual amino acid distribution of the non-inhibitory peptides (NI) at each 
position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one residue 
each; L, W, and R, respectively. 
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Figure 5.13.I:  Individual amino acid distribution of the non-inhibitory peptides (NI) at each 
position.  Figures for positions 4, 8 and 9 were excluded due to their constraint to one residue 
each; L, W, and R, respectively. 
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Table 5.11:  Binomial distribution of the individual amino acids of the non-inhibitory peptides 
(NI) isolated from the constrained peptide library screen compared to the theoretical distribution 
arising from the constraints of each position’s codon. 
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Figures 5.14.A-B:  Amino acid side chain group distribution of the general pool of bacteriolytic 
peptides (GP) at randomized positions 2, 5, 11, and 12. 
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Figures 5.14.C-D:  Amino acid side chain group distribution of the general pool of bacteriolytic 
peptides (GP) at randomized positions 2, 5, 11, and 12. 
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Table 5.12:  Binomial distribution of the amino acid side chain groups of the general pool of lytic 
peptides (GP) isolated from the constrained peptide library screen compared to the theoretical 
distribution arising from the re-randomized NNK codons at position 2, 5, 11, and 12. 
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Figures 5.15.A-B:  Amino acid side chain group distribution of early onset of lysis peptides 
(EO2) at randomized positions 2, 5, 11, and 12. 
371 
 
 
 
 
 
Figures 5.15.C-D:  Amino acid side chain group distribution of early onset of lysis peptides 
(EO2) at randomized positions 2, 5, 11, and 12. 
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Table 5.13:  Binomial distribution of the amino acid side chain groups of the early onset of lysis 
peptides (EO2) isolated from the constrained peptide library screen compared to the theoretical 
distribution arising from the re-randomized NNK codons at position 2, 5, 11, and 12. 
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Figures 5.16.A-B:  Amino acid side chain group distribution of the non-inhibitory peptides (NI) 
at randomized positions 2, 5, 11, and 12. 
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Figures 5.16.C-D:  Amino acid side chain group distribution of the non-inhibitory peptides (NI) 
at randomized positions 2, 5, 11, and 12. 
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Table 5.14:  Binomial distribution of the amino acid side chain groups of the non-inhibitory 
peptides (NI) isolated from the constrained peptide library screen compared to the theoretical 
distribution arising from the re-randomized NNK codons at position 2, 5, 11, and 12. 
 
5.4.3.3  Expression & Translocation Analysis 
 To determine if any of the peptides isolated in these experiments affect their own 
expression and translocation across the membrane, we used PhoA’s unique ability to hydrolyze 
5-bromo-4-chloro-3-indoxyl-phosphate (X-Phos)499; 500 (Chapter 4, Section 4.4.3.3).  All isolated 
clones, including those encoding non-inhibitory peptides, were assayed for PhoA activity and 
compared to the activity of non-inhibitory, translocating peptide, NI001. 
376 
 
 
 
All of the clones demonstrating NI001-comparable PhoA activity were non-inhibitory 
including 100, 101, 111, 46b, 47b and 49b with the exception of clone 30, which was classified 
as having an early onset of lysis but did not follow the α-helix model (Table 5.15).  A number of 
non-inhibitory clones also showed weak PhoA activity manifested by a lower amount of X-Phos 
precipitate as compared to NI001.  These included clones 3, 31, 90, 102, 104, 131, and 26b.  
These data suggest that 53 of the non-inhibitory peptides were unable to pass through the 
membrane, preventing PhoA from folding into its active conformation.  Alternatively, these 
clones may not be expressed due to transcription or translation problems, but it may indicate 
that what distinguishes a lytic peptide from a non-lytic peptide with a similar amino acid 
composition is not simply the ability to insert into the membrane.  Clones 122 and 56b had both 
weak PhoA activity and bacteriostatic/bactericidal phenotypes.  Similarly, the weakly inhibitory 
clone 93 also had weak PhoA activity.  Bacteriolytic peptides, with the exception of clone 30, 
had only weak PhoA activities.  Clones 17 and 27 exhibited weaker levels of cell lysis, while 56, 
89 and 7b were strongly lytic and are considered early onset of lysis peptides.  Of all the 
peptides with PhoA activity, the only one whose amino acid sequence fits the α-helix model is 
56 (Chapter 4, Section 4.4.3.2).  Peptide 56 has a clear definition of both a basic and 
hydrophobic interface without any acidic residues buried in the basic interface or proline 
residues throughout the helix. 
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Table 5.15:  All peptides isolated from the constrained peptide library that exhibit PhoA activity.  
Amino acid sequences as they would appear in an α-helical structure indicate that most of the 
peptides do not form amphipathic α-helices. 
*Weakly inhibitory ^Bacteriostatic/bactericidal 
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5.4.3.4  Proline Disruption of Bacteriolytic Activity 
 We propose that a majority of the lytic peptides isolated in the periplasmic selection and 
the constrained library form α-helices as a determinant of their activity.  When projected as an 
α-helix, the residue distribution of the linear peptide sequences forms an amphipathic structure 
(Figure 5.5).  Basic amino acids, such as arginine and lysine, are presented on one side of the 
helix while the opposing face generally displays hydrophobic residues.  This is similar to the 
structure and sequence of several natural antimicrobial peptides (AMPs) that have been 
studied.550; 551  The AMPs are thought to be membrane disrupters that cause cell lysis through 
their interactions with the bacterial membrane.253  The pIVD system we have developed places 
these peptides on the N-terminus of PhoA.  The signal peptide dictates that the peptide be 
translocated into the periplasm following translation.  To achieve this, the peptides must pass 
through the cytosolic, inner membrane.  PhoA activity analysis indicates translocation is not 
occurring.  We hypothesize that the peptides form amphipathic α-helices, possibly stabilized 
once they are introduced to the hydrophobic environment within the inner membrane.  They 
then disrupt the membrane by either interacting with membrane components, such as 
transmembrane proteins or specialized lipids, or form local concentrations of peptide that 
permeabilize the membrane.  Alternatively, they may interact with the integral Sec pathway 
proteins such as SecA or the protein complex SecYEG, preventing the translocation of essential 
periplasmic or cell wall proteins.  All of these scenarios ultimately result in bacterial cell lysis.  
Residue distribution analysis of the bacteriolytic peptide pool from the original periplasmic 
selection and the bacteriolytic and non-inhibitory peptide pools of the constrained peptide 
screen indicate the exclusion of proline at particular positions, generally the N-terminus and 
middle of the peptide sequences, plays a key role in the activity of the peptides.  Proline is a 
known helix disrupter due to its kinked molecular structure.510; 511; 512; 514  
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Table 5.16:  Amino acid sequences of unmodified peptides 37 and 84 and proline-modified 
peptides 37 Pro+ and 84 Pro- and their activities. 
*Weakly Inhibitory 
 
We tested our hypothesis for the necessity of an α-helix for lytic activity by introducing or 
removing proline residues from peptides previously isolated (Table 5.16).  Two peptides from 
the constrained library screen were selected for proline modification.  Clone 37 is a highly 
bacteriolytic peptide classified as having an early onset of lysis that does not contain a proline 
residue.  It follows the α-helix model with a defined basic and hydrophobic interface.  The clone 
was modified to test the α-helix hypothesis by substituting a proline for the alanine at position 5.  
Likewise the clone 84 was also modified.  Clone 84 is not inhibitory and contains a proline at 
position 5.  Except for the presence of proline, clone 84 follows our hypothesis, having 
delineation of both a hydrophobic and basic interface.  We hypothesize that substituting a 
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leucine residue for the proline at position 5 will change the antimicrobial phenotype from non-
inhibitory to lytic. 
The proline-modified clones were placed in the same vectors as the peptide-PhoA 
library, pKan-PhoA1.  They were then subjected to induced growth curves as before.  Within 
one hour of induction a decrease in optical density coinciding with cell lysis occurs in the culture 
hosting the modified clone of peptide 84, 84 Pro- (Figure 5.17).  Its original unmodified peptide 
was not lethal (Figure 5.18), but the substitution of the proline residue at position 5 makes the 
peptide have an early onset of lysis.  The inclusion of proline into clone 37, 37 Pro+, drastically 
lowered activity from an early onset of lysis to a late onset of growth rate reduction, making the 
peptide weakly inhibitory.   
The presence of proline within representatives of the bacteriolytic peptides of the 
constrained peptide screen, thought to abide by the α-helix model, is critical for a lethal 
phenotype.  Inclusion of proline into the early onset of lysis peptide, 37, negated lysis.  
Removing proline form the non-inhibitory peptide 84 enabled the peptide to cause cell lysis at a 
low intracellular concentration.  This supports our hypothesis of proline modifications critically 
affect the lytic phenotype of peptides we have isolated.  Further, it supports the α-helical model, 
indicating secondary structure is important for our isolated lytic peptides’ function. 
 
 
 
381 
 
 
 
 
Figure 5.17:  Induced growth curves of E. coli DH5α cells expressing proline-modified peptides 
37 Pro+ and 84 Pro-.  Optical density (A600) was measured at different time intervals following 
the addition of L-arabinose. 
 
 
Figure 5.18:  Induced growth curves of E. coli DH5α cells expressing isolated, unmodified 
peptides 37 and 84.  Optical density (A600) was measured at different time intervals following the 
addition of L-arabinose. 
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5.4.3.5  Expression of Free 84 Pro- Peptide 
 Periplasmic expression  PhoA, similar to EmGFP in the cytoplasm, serves numerous 
purposes such as a structure stabilizer, proteolysis determent and visible means of determining 
if translocation is occurring.  However, to further characterize the peptides as potential leads it is 
necessary to determine their strength and activity outside the context of the fusion protein.  
There are two scenarios where the fusion protein is lethal and not the peptide as a stand-alone 
molecule 1) some of the initial residues of PhoA or the linker peptide may contribute to the 
lethality of the peptide by participating in the binding interaction and 2) the peptide’s binding to a 
target is not lethal, but steric hindrance on the part of the globular PhoA protein may block key 
sites on the target preventing its function.  Here, a peptide representative of those belonging to 
the α-helix model, 84 Pro-, was cloned into the same construct used in Chapter 4 to study free 
peptide expression, pKan-Solo (Figure 5.19).  pKan-Solo is an identical vector to pKan-PhoA1, 
the vector used in both the periplasmic and constrained peptide screens, except that PhoA gene 
and linker sequence at the 3’ end of the peptide sequence has been removed.  Within a host 
cell, the vector, when induced, expresses a hybrid peptide composed of the PhoA signal peptide 
and the peptide of interest.  As before, the signal peptide enables translocation of the peptide 
into the periplasm (Figure 5.20). 
 The construct was transformed into E. coli DH5α cells and grown to early log phase.  L-
arabinose was added to induce expression of the peptide and the optical density at 600 nm was 
measured to monitor the growth of the culture.  An uninduced culture was monitored in parallel 
and then the growth curves were compared. The peptide 84 Pro- maintained its bacteriolytic 
phenotype in the absence of PhoA (Figure 5.21).  The optical density of the induced culture 
began to decrease within 30 minutes of induction.  This was 30 minutes faster than the original 
peptide-PhoA construct and likely due to lack of the need for PhoA maturation. 
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Figure 5.19:  pKan-Solo was derived from the plasmid pKan-PhoA1.  The DNA encoding PhoA 
was removed leaving a gene product comprised of the signal peptide and the peptide of 
interest. 
 
 
Figure 5.20:  Induction of pKan-Solo cultures produces a fusion of the PhoA signal peptide and 
the peptide of interest.  Following translocation, a peptidase cleaves off the signal peptide 
permitting the peptide of interest to be free of contextual effects. 
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Figure 5.21:  Free peptide expression of proline-modified peptide 84 Pro- in the periplasm.  
Optical density (A600) was measured at different time intervals following the addition of L-
arabinose. 
 
Cytoplasmic expression  To determine the effect of location on 84 Pro-‘s activity, the peptide 
was moved into the construct pAmp-SoloTEV (Figure 5.22), a derivative of pKan-EmGH.  
pAmp-SoloTEV has been modified in several ways to accommodate co-transformation with 
plasmids pZS4int-TetR and pRK603440 for the in vivo expression of TEV protease.  The original 
p15A replication origin was replaced with pMB1 while the PLac promoter was substituted for the 
original PBAD promoter.  The selection marker bla was inserted in place of neo to enable 
selection of all three plasmids (pRK603 has neo).  The DNA sequence encoding peptide 84 Pro- 
was placed 3’ to the TEV protease recognition sequence and 5’ to a stop codon.  Upon the 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG), a hybrid peptide is expressed under 
the power of the PLac promoter.  This hybrid peptide is composed of three parts: 1) the N-
terminal sequence of EmGFP or the leader peptide (Figure 5.23) which is efficiently transcribed 
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and translated (Chapter 2, Figure 2.11), 2) the TEV recognition and cleavage sequence,440 and 
3) the 84 Pro- peptide.  When induced in a host cell containing plasmids pZS4int-tetR and 
pRK603 (Figure 5.24) with the addition of anhydrotetracycline (ATC), TEV protease binds to its 
recognition sequence and cleaves the hybrid peptide releasing peptide 84 Pro- (Figure 5.25).  
The system was constructed for free peptide expression in the cytoplasm only.  With the PhoA 
signal peptide absent, peptide 84 Pro- should be unable to translocate into the periplasm.  A 
minor change to previous constructs in pAmp-SoloTEV was the inclusion of the final glycine 
residue in the TEV protease recognition sequence.  This residue remains on the N-terminus of 
the peptide after cleavage and in the past had been removed allowing only the lethal peptide to 
be expressed instead of a glycine-peptide hybrid.   
 
 
Figure 5.22:  pAmp-SoloTEV was constructed for the solo expression of peptides in the 
cytoplasm.  It is a derivative of pKan5-T1T2 with changes to the replication origin (pMB1), 
selection marker (bla) and promoter (PLac) to insure plasmid compatibility with pRK603 and 
pZS4int-tetR. 
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Figure 5.23:  Hybrid peptide generated by inducing pAmp-SoloTEV with the addition of L-
arabinose to the growth medium comprised of the leader peptide, TEV protease recognition 
sequence and proline-modified peptide 84 Pro-. 
 
 
Figure 5.24:  Co-transformed plasmids with pAmp-SoloTEV for the expression of free peptide in 
the cytoplasm.  pZS4int-tetR expresses Tet repressor protein (TetR) that turns off expression 
from the PTet promoter controlling TEV protease expression.  In the presence of 
anhydrotetracycline (ATC), tetR binds ATC, changes conformation and can no longer repress 
PTet, allowing expression of TEV protease. 
 
The construct was co-transformed with pZS4int-tetR and pRK603 into E. coli EPI301 
cells.  The culture was incubated until late lag phase when ATC was added to induce TEV 
protease expression.  Incubation continued until early log phase when IPTG was added to 
induce the expression of the hybrid 84 Pro- peptide.  The optical density of the culture at 600 
nm was measured to monitor the growth rate.  The culture that was left uninduced for the 
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peptide and TEV protease grew slowly due to the stresses of maintaining three plasmids in the 
cell (Figure 5.26).  The induction of TEV protease was unnecessary for the inhibition of growth.  
The 84 Pro- peptide was lethal within the context of the uncleaved hybrid peptide, an 
unexpected result.  Given that the curves both demonstrated a weakly inhibitory or growth rate 
reducing phenotype and not the original bacteriolytic phenotype observed in other formats, there 
may have been a problem with expression.  However, since it is possible that the α-helical 
model peptides target the plasma membrane, they would still have access to their target when 
present in the cytoplasm.  The lowered level of lethality may arise from the lack of a forced 
interaction with the membrane via the PhoA signal peptide versus random interaction with the 
membrane while floating in the cytoplasm. 
 
 
Figure 5.25:  In vivo TEV protease processing of hybrid peptide expressed from pAmp-
SoloTEV results in non-fused, free 84 Pro- peptide in the cytoplasm. 
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Figure 5.26:  Growth curve of proline-modified peptide 84 Pro- expressed as a free peptide in 
the cytoplasm only.  Optical density was measured at different time intervals following the 
addition of ATC (TEV protease induction) and L-arabinose (peptide induction). 
 
5.4.3.6  Morphological Effects of Free Peptide Expression 
 The bacteriolytic peptides isolated thus far in the periplasm likely disrupt the plasma 
membrane or the cell wall directly or by interrupting its synthesis.  This should have adverse 
effects on the cell morphology of the host.  E. coli DH5α cells containing the pKan-Solo 
construct encoding peptide 84 Pro- were grown to mid-log phase.  As a control, one culture had 
D-glucose added to suppress expression during growth.  L-arabinose was added to the other 
culture to induce peptide 84 Pro-’s expression.  At time intervals following induction, samples of 
each culture were viewed using differential interference contrast (DIC) microscopy.  This 
procedure obviates the need for staining the cells to make them visible and potentially altering 
the cell morphology.  Ethidium bromide (EtBr) was added to the samples at a low concentration 
(~5.7 ng/mL).  EtBr helps in the assessment of cell viability without changing cell morphology.  
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Dead cells or cells whose membrane has increased membrane permeability due to disruption 
have increased uptake of EtBr.552; 553  When viewing the cells under a TRITC filter on a 
fluorescent microscope the amount of EtBr uptake by each cell is observable, using the DIC 
field as a comparison we can differentiate viable and dead cells. 
 The control culture, with repressed peptide 84 Pro- expression, shows healthy rod-
shaped cells of varying length at the point of induction (Figure 5.27).  After 120 minutes of 
further incubation the control culture cells maintain the same morphology (Figure 5.28).  The 
addition of EtBr to the sample showed that only a small minority of the population of the cells 
are capable of EtBr uptake, consistent with healthy cells.  In the culture to be induced, prior to 
the addition of L-arabinose, the cells have a similar morphology and there is only a small 
amount of EtBr uptake or a small population that has taken up a significant amount of EtBr 
(Figure 5.29).  This observation may be due to leaky expression of peptide 84 Pro- from the 
PBAD promoter in the absence of D-glucose.  Approximately 30 minutes after induction, the cells 
have taken up considerably more of EtBr (Figure 5.30).  Elongated cells begin to appear more 
frequently and develop small, black circles or lesions on their surfaces.  When viewed under the 
TRITC filter the cells with the lesions appeared to have compartments that lack uptake of EtBr, 
likely due to lysis.  The appearance of elongated cells with lesions continued throughout the 
experiment (Figures 5.31-34).  Cells that lack uptake of EtBr begin to appear at 120 and 150 
minutes after induction.  This may be linked to clones in the culture that lack arabinose-
responsive PBAD promoters409 or AraC regulatory proteins505; 506 or have mutations in the PBAD 
promoter that lower expression levels.409  Varying expression levels and lack of expression 
among cells utilizing the PBAD promoter has been demonstrated previously.554  In Chapter 6 this 
phenomenon is demonstrated with the expression of the bacteriolytic peptide EO1 and resolved 
by co-transformation of plasmids in the same cell using the PBAD and PLac promoters. 
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Figure 5.27:  DIC photomicrographs of E. coli DH5α cells with plasmid pKan-Solo84Pro- in LB 
growth medium supplemented with 0.2% glucose to repress 84 Pro- expression.  Photos were 
taken when the cultures were entering mid-log phase growth, simultaneous with the addition of 
L-arabinose to induce test cultures.  
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Figure 5.28:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-Solo84Pro- in LB growth medium supplemented with 0.2% glucose to repress 84 Pro- 
expression.  Photos were taken 120 minutes following the addition of L-arabinose to induce test 
cultures.  DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the 
right column (D, E, F) observing EtBr uptake using a TRITC filter.  
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Figure 5.29:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-Solo84Pro- in LB growth medium supplemented with 0.3% arabinose to induce 84 Pro- 
expression.  Photos were taken at the point of induction with the addition of L-arabinose.  DIC 
photos in the left column (A, B, C) correspond with the fluorescent photos in the right column (D, 
E, F) observing EtBr uptake using a TRITC filter. 
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Figure 5.30:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-Solo84Pro- in LB growth medium supplemented with 0.3% arabinose to induce 84 Pro- 
expression.  Photos were taken 30 minutes following induction with the addition of L-arabinose.  
DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the right 
column (D, E, F) observing EtBr uptake using a TRITC filter. 
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Figure 5.31:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-Solo84Pro- in LB growth medium supplemented with 0.3% arabinose to induce 84 Pro- 
expression.  Photos were taken 45 minutes following induction with the addition of L-arabinose.  
DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the right 
column (D, E, F) observing EtBr uptake using a TRITC filter. 
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Figure 5.32:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-Solo84Pro- in LB growth medium supplemented with 0.3% arabinose to induce 84 Pro- 
expression.  Photos were taken 90 minutes following induction with the addition of L-arabinose.  
DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the right 
column (D, E, F) observing EtBr uptake using a TRITC filter. 
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Figure 5.33:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-Solo84Pro- in LB growth medium supplemented with 0.3% arabinose to induce 84 Pro- 
expression.  Photos were taken 120 minutes following induction with the addition of L-
arabinose.  DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the 
right column (D, E, F) observing EtBr uptake using a TRITC filter. 
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Figure 5.34:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-Solo84Pro- in LB growth medium supplemented with 0.3% arabinose to induce 84 Pro- 
expression.  Photos were taken 150 minutes following induction with the addition of L-
arabinose.  DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the 
right column (D, E, F) observing EtBr uptake using a TRITC filter. 
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5.4.3.7  84 Pro-‘s Effect on Cell Osmolarity 
 Cell lysis arises from a number of mechanisms typically involving disruption of the inner 
membrane, increasing the membrane’s permeability and causing leakage of ions required for 
osmolarity or inhibition of cell wall synthesis that maintains intracellular pressure.  Antimicrobial 
peptides such as the cecropins have been characterized as pore-forming agents, disrupting the 
inner membrane.241  In the presence or absence of the cell wall these peptides elicit cell lysis 
through destabilization of the inner membrane.541; 555  Alternatively, β-lactam antibiotics inhibit 
the synthesis of the cell wall, which in hypertonic solutions that stabilize intracellular pressure, 
form viable spheroplasts within E. coli cultures.556; 557   
 To examine the mechanism of peptide 84 Pro-, as a representative of the α-helical 
model peptides, we expressed its PhoA fusion in E. coli DH5α cells containing the plasmid 
pKan-PhoA84Pro- in Luria-Bertani (LB) growth media442; 443 supplemented with various 
concentrations of sucrose and MgSO4 to produce hypertonic solutions.  Cultures were incubated 
until early log phase growth, then 84 Pro- peptide-PhoA fusion expression was induced and the 
growth of the culture was monitored to detect if 84 Pro- maintained its lytic activity.  Samples of 
the cultures were removed at time intervals following induction to observe changes in cell 
morphology using differential interference contrast (DIC) microscopy. 
 Expression of the 84 Pro- peptide-PhoA fusion in the absence of solutes caused rapid 
cell lysis within 100 minutes after induction.  Sucrose decreased the growth of the 
supplemented cultures with increasing concentration.  The addition of 0.3 or 0.5 M sucrose 
slowed the inception of cell lysis, while the additional supplementation of 16.6 mM MgSO4 
negated cell lysis (Figure 5.35).  Identical experiments were carried out without inducing 
peptide 84 Pro-, but instead adding 250 ng/mL ampicillin at the same point during growth.  The 
addition of 0.3 and 0.5 M sucrose did not inhibit the activity of ampicillin, but LB supplemented 
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with 0.5 M sucrose and 16.6 mM MgSO4 inhibited cell lysis (Figure 5.36).  Growth was stopped 
in the culture corresponding to the production of spheroplasts in culture observed in the 
photomicrographs (Figure 5.37).  Therefore, the hypertonic solution did not prevent cell wall 
inhibition but preserved the stability of the inner membranes of the spheroplasts.  
Photomicrographs of the peptide 84 Pro- induced cultures, however, did not form spheroplasts 
(Figure 5.38).  The cell morphology of the cells did change compared to that observed in 
section 5.4.3.5 as the development of small, black circles on the surfaces of elongated cells did 
not occur.  Instead the cells appeared to have a rough surface in contrast to the smooth surface 
of uninduced cells.  The negation of cell lysis suggests that 84 Pro-‘s activity is not related to 
inner membrane disruption, but the lack of spheroplast formation indicates a separate 
mechanism than ampicillin, possibly unrelated to the synthesis of the cell wall. 
 
Figure 5.35:  Induced growth curves of E. coli DH5α cells expressing 84 Pro- peptide-PhoA 
fusions in various hypertonic growth media supplemented with L-arabinose. 
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Figure 5.36:  Growth curves of E. coli DH5α containing plasmid pKan-PhoA1 encoding 84 Pro- 
peptide-PhoA fusions in various hypertonic growth media supplemented with the bacteriolytic 
antibiotic ampicillin. 
 
 
Figure 5.37:  DIC photomicrographs of E. coli DH5α cells containing plasmid pKan-PhoA1 
encoding 84 Pro- peptide-PhoA fusions in LB medium supplemented with 0.5 M sucrose and 
16.6 mM MgSO4.  Photos were taken after the addition of 250 ng/mL ampicillin: A) 160 mins 
after, B) 200 mins after.  Arrows indicate spheroplast formation. 
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Figure 5.38:  DIC photomicrographs of E. coli DH5α cells containing plasmid pKan-PhoA1 
encoding 84 Pro- peptide-PhoA fusions in LB medium supplemented with various additives to 
produce an hypertonic solution.  Photos were taken 160 mins after induction with the addition of 
0.2% arabinose.  A) 0.5 M sucrose, 16.6 mM MgSO4, uninduced; B) 0.5 M sucrose, 0.2% 
arabinose; C) 0.5 M sucrose, 16.6 mM MgSO4, 0.2% arabinose.  Arrows indicate cells exhibiting 
rough surface phenotype. 
 
5.4.4 Antimicrobial Activity of Synthetic Peptides 84 and 84 Pro- 
5.4.4.1  Determination of Minimum Inhibitory Concentrations 
 Peptides 84 and 84 Pro- were synthesized at ~95% purity for in vitro testing.  Both 
peptides were dissolved in either dimethyl formamide (DMF) or dimethyl sulfoxide (DMSO) and 
used to calculate the minimum inhibitory concentration (MIC) using the broth dilution method.441  
Peptide 84 was used as an innocuous control in the following experiments.   
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Table 5.17:  MICs of peptides 84 and 84 Pro- against various organisms.  A value of ‘> 250’ 
indicates no MIC was determined. 
 
E. coli ‘WT’ strain, W3110, and permeable lpxA mutant strain, SM101,444 both had MICs 
of 15.6 µM (Table 5.17).  A number of organisms were analyzed to find the spectrum of 84 Pro-
‘s activity.  Gram-negative species Pseudomonas aeruginosa, Klebsiella pneumoniae and 
Enterobacter aerogenes were all resistant to concentrations ≥ 250 µM.  However, 84 Pro- 
demonstrated greater activity versus Gram-positive organisms, including Staphylococcus 
aureus, Enterococcus faecalis, Streptococcus salivarius, Bacillus subtilis and Mycobacterium 
smegmatis.  Growth conditions had to be changed to accommodate several of the fastidious 
Gram-positive organisms.  Growth media for E. faecalis, S. salivarius was Todd Hewitt Broth 
(THB), for M. smegmatis it was Middlebrook 7H9 broth558 while S. aureus and B. subtilis 
demonstrated the same growth and MIC in both LB and THB.  S. aureus’s calculated MIC of 9 
µM was the lowest compared to 15.6 µM for both S. salivarius and B. subtilis, 31.3 µM for E. 
faecalis and 30 µM for M. smegmatis.   
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 The MIC of eukaryote Saccharomyces cerevisiae was also determined.  It is not unusual 
that antimicrobial peptides found or derived from nature have activity against bacteria, yeasts559 
and even viruses.560  Theoretically, the basic charge of peptide 84 Pro- should decrease its 
activity against eukaryotes such as S. cerevisiae or mammalian cells due to their neutrally 
charged membranes.520  The same procedure was used as above, substituting YPD medium561 
for the growth of S. cerevisiae BY4742.  Peptide 84 Pro- did show activity at a greatly reduced 
MIC of 125 µM compared to the bacterial species assayed indicating the peptide would have 
less toxicity against higher eukaryotes.562  Specificity for bacterial membranes could be 
optimized by manipulating the amino acid sequence of 84 Pro-, increasing its therapeutic value. 
 The exclusion of proline at position 5 has a definitive effect on the activity of peptide 84.  
When a leucine was substituted in its place the peptide had strong activity against E. coli and a 
number of Gram-positive bacteria.  Proline’s influence on the overall structure of the peptide 
must affect its ability to interact with its target. 
 
5.4.4.2  The Effect of 84 Pro- on Microbial Growth 
 To observe the phenotypic effect of the peptide exogenously, growth curves using E. coli 
SM101 and S. aureus were done with varying concentrations of peptides 84 and 84 Pro-.  
Peptides 84 or 84 Pro- were added to growing cultures of either E. coli SM101 or S. aureus at 
concentrations varying from 125 to 0 µM.  The optical density of the cultures was then 
monitored at short time intervals following the peptide’s addition. 
 Of the two bacteria assayed, S. aureus demonstrated the greatest sensitivity.  Peptide 
84 Pro- demonstrated bacteriolytic activity, reducing the optical densities of the cultures (Figure 
5.39), while peptide 84 demonstrated no antimicrobial activity (Figure 5.40).  Concentrations of 
84 Pro- from 62.5 to 15.6 µM showed a reduction in optical density within 15 minutes of the 
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peptide’s addition.  The 125 µM culture acted oddly, continuing to grow, slowing in growth and 
then lysing 165 minutes after the peptide’s addition.  The other lethal concentrations continued 
to lyse for at least 45 minutes and then the lower concentration cultures began to recover and 
grow exponentially.  The 62.5 µM culture never recovered, continuing to lyse for 285 minutes.  
The 15.6 and 31.3 µM showed the most recovery after large decreases in the optical density of 
the cultures.  This may have been caused by the selection of a resistance mechanism or a lack 
of enough peptide to lyse all cells.  The former case seems unlikely given the recovery should 
not correlate to the concentration of peptide; the 15.6 µM culture recovered first, 45 minutes 
after the peptide was added, while the 31.3 µM culture recovered 105 minutes after.  Also, 
peptide 84 Pro- resistance should have occurred in the 125 µM culture, which it did not.  If we 
assume that the resistance mechanism is only partially resistant accounting for the correlation to 
peptide concentration, then the recovery growth rates should be slower than wild-type rates, 
which they are not.  A similar resistance appeared in synthetic peptide growth curves of EO1 in 
S. aureus (Chapter 6, Section 6.4.4.2).  An MIC assay carried out on an isolated clone from the 
recovered culture had an MIC similar to that prior to the recovery, therefore there was no 
resistance. 
 E. coli SM101 growth curves did not show the dramatic results observed with S. aureus 
(Figures 5.41.A-B).  All concentrations slowed in growth upon the addition of 84 Pro-.  Only 125 
µM, however, demonstrated any reduction in optical density correlating to cell lysis.  The MIC of 
84 Pro- in E. coli (15.6 µM) was nearly double that of S. aureus (9 µM) this disparity does not 
account for the difference between the lethal concentrations at mid-log phase growth of the 
same species.  It is possible that the same mechanism that makes other Gram-negative 
bacteria, such as P. aeruginosa, resistant aids E. coli during exponential growth or that E. coli is 
capable of greater peptide degradation than S. aureus.  It would appear that E. coli’s growth 
curve data is more consistent with its MIC than those of S. aureus.  S. aureus has an MIC of 9  
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Figure 5.39:  Growth curves of S. aureus, supplemented with synthetic 84 Pro- peptide at 
various concentrations. 
 
Figure 5.40:  Growth curves of S. aureus, supplemented with synthetic 84 peptide at various 
concentrations. 
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Figures 5.41.A-B:  Growth curves of E. coli strain, SM101, supplemented with synthetic 84 Pro- 
peptide at various concentrations.  Figures A and B show the same cultures, with B including an 
overnight incubation. 
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µM when there are ~104 cells/mL, but at mid-log phase we can approximate that there are 108 
cells/mL, a 10,000-fold difference, whereas the MIC is 62.5 µM, only a 7-fold difference.  This 
indicates that each peptide can be ‘recycled’ or used to kill multiple cells.  If that is the case, why 
is there a lower limit to the MIC in any of the S. aureus growth curves or E. coli as well?  A 
balance between peptide recycling and degradation may account for the difference. 
 
5.4.4.3  Replication Dependence of 84 Pro- Activity 
 Antimicrobial peptides in nature demonstrate activity against persister563 and stationary 
phase cells.564  This has been presented as particularly advantageous in dealing with biofilms 
and slow-growing intracellular parasites such as M. tuberculosis since both lack growth and the 
associated metabolic processes targeted by most conventional antibiotics.  For instance, 
penicillin, a cell wall synthesis inhibitor, requires cell division to have its bacteriolytic effect. 
 Mid-log growth phase, Gram-positive S. aureus cells were washed and resuspended in 
HEPES-NaCl (HN) buffer.  Peptides 84 Pro- and 84 (60 µM) and ampicillin (1480 µM) were 
added to aliquots of the suspension.  These were incubated at 37 oC with shaking for 45 
minutes while the optical density at 600 nm of each was measured to follow the lysis of cells.  
Concetrated, 10x THB was added to the suspensions to resume growth and samples were 
plated on LB to determine viable cell counts. 
 The addition of peptide 84 had no effect on the optical density or viable cell count on the 
cells in either the HN buffer or the THB supplemented buffer (Figure 5.42).  The cells resumed 
growth shortly after the addition of growth medium to the cell suspensions.  The optical density 
and viable cell count of the ampicillin culture did not change in the HN buffer (Figure 5.43).  
Once the 10x THB was added, the optical density did not increase while the viable cell count 
decreased toward zero.  The viable cell count of the aliquot containing peptide 84 Pro- 
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decreased by about 56.4% in the HN buffer, however, a subsequent, more dramatic decrease of 
99.99% was observed once THB was added and the cells were able to resume growth (Figure 
5.44.A).  The log-scale chart better reflects this decrease after THB was added (Figure 5.44.B).  
The optical density remained largely unchanged. 
 Peptide 84 Pro- has activity against non-replicating cells.  This activity is diminished 
compared to that against actively replicating cells as was the case once THB was added to the 
cell suspension.  The uptake of the peptide may be increased with the uptake of nutrients once 
growth medium was added.  Experiments comparing these bacteriolytic activities to naturally 
occurring pore-forming peptides would be more conclusive. 
 
 
Figure 5.42:  Replication dependence assay monitoring the effects of synthetic peptide 84 on 
the viable count and optical density (A600) of non-replicating and replicating S. aureus cells in 
HN buffer or HN buffer supplemented with Todd Hewitt Broth. 
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Figure 5.43:  Replication dependence assay monitoring the effects of bacteriolytic antibiotic 
ampicillin on the viable count and optical density (A600) of non-replicating and replicating S. 
aureus cells in HN buffer or HN buffer supplemented with Todd Hewitt Broth. 
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Figure 5.44.A-B:  Replication dependence assay monitoring the effects of synthetic peptide 84 
Pro- on the viable count and optical density (A600) of non-replicating and replicating S. aureus 
cells in HN buffer or HN buffer supplemented with Todd Hewitt Broth.  A) Standard scale, B) 
logarithmic scale for viable count y-axis. 
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5.4.4.4  Hemolytic Activity of Peptide 84 Pro- 
 Antimicrobial peptides, especially those targeting the bacterial membrane and conform 
to the amphipathic α-helix model outlined previously, have a tendency to also lyse red blood 
cells.527; 528  To determine if peptide 84 Pro- is also hemolytic we performed a sheep red blood 
cell (SRBC) hemolysis assay.529 
 The SRBCs were washed and resuspended in a phosphate buffered saline solution at 
pH 7.4.  Either peptide 84 or 84 Pro- was then serially diluted into the erythrocyte suspensions 
at a range of concentrations from 1 to 250 µM.  The erythrocytes/peptide mixtures were 
incubated at 37 oC for 18 hrs for a stringent examination of 84 Pro-’s hemolytic capabilities.  The 
longer incubation properly reflects the clearance of the peptide if it were to be present in the 
blood.529  After incubation, each mixture was centrifuged to remove whole, unlysed erythrocytes.  
The optical density of aliquots of each sample was measured at 570 nm to quantify the amount 
of hemoglobin present in the supernatant that had been released by lysed erythrocytes.  The 
background was approximated by the PBS only control which was subtracted from the values of 
the other samples. 
 Unlike many natural lytic peptides and similar to PL098 (Chapter 4, Section 4.4.4.3), 
none of the samples demonstrated appreciable levels of hemolysis compared to the positive 
and negative controls (Table 5.18).  Non-inhibitory 84 peptide had a high hemolytic value of 
0.88% at a concentration of 3.9 µM while the highest value for the bacteriolytic 84 Pro- peptide 
was 1.34% also at 3.9 µM.  Peptide 84 Pro- shares several structural characteristics with natural 
antimicrobial peptides, but does not conform to the general hemolytic nature of AMPs.  Given 84 
Pro-‘s activity against Gram-positive bacteria and lack of hemolytic activity, it may constitute a 
viable lead for anti-infective development. 
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Table 5.18:  Hemolytic activity of peptides 84 and 84 Pro- at various concentrations against 
sheep red blood cells calculated as a percentage of the amount of hemolysis observed with 
0.1% of detergent Triton X-100. 
 
5.4.4.5  Secondary Structure Determination of 84 and 84 Pro- Peptides 
 Circular dichroism is a property, particularly of peptides, formed by the absorption of 
polarized light by chemical bonds.  The angles of bonds prevalent in secondary structures of 
peptides and proteins, such as α-helices, β-sheets (both parallel and anti-parallel), and β-turns, 
have characteristic effects on the ellipticity of the light they absorb.  By measuring ellipticity with 
a circular dichroism spectrometer with given wavelengths of polarized light we can determine 
the dominant structure of the population.565; 566; 567  Peptides 84 and 84 Pro- were resuspended 
in a number of buffers including PBS buffer pH 7.0, a 25% 2,2,2-trifluoroethanol (TFE)/75% PBS 
solution, and a 50% TFE/PBS solution to a concentration of 400 µM.  TFE is a hydrophobic, 
peptide solvent used to mimic the hydrophobic environment on the inside of a plasma 
membrane.568; 569  Varying concentrations were used to determine if peptide 84 Pro- has an 
induced α-helical structure caused by its insertion into the membrane and how stable this 
structure is with or without hydrophobic effects. 
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 The ellipticity of each sample was measured at wavelengths 190 to 260 nm and plotted.  
The characteristic curve of an α-helix has two minima; one at 208 and the other at 222 nm.570  
Peptide 84 Pro- had minima at 206 and 221 nm (Figure 5.45), approximating those observed 
for α-helices.  Peptide 84 demonstrated a spectrum lacking minima and maxima characteristic 
of α-helices, β-sheets or random coils571 (Figure 5.46).  These data are consistent with our 
hypothesis that peptide 84 Pro-, a representative of similar bacteriolytic peptides isolated from 
the periplasmic selection and constrained library screen, forms an α-helix.  Our proline mutation 
data also indicates that formation of the amphipathic α-helix is necessary for the bacteriolytic 
activity of the peptides. 
 
Figure 5.45:  Circular dichroism of synthetic peptide 84 Pro- in solutions of various TFE 
concentrations.  In the presence of TFE, minima are observed at 206 and 221 nm. 
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Figure 5.46:  Circular dichroism of synthetic peptide 84 in solutions of various TFE 
concentrations.  Regardless of TFE concentration, minima are observed at 203 and 224 nm. 
 
5.5 Discussion 
 The pIVD selection isolated a total of 192 antimicrobial peptides of which 95 are 
bacteriolytic (Chapter 4, Tables 4.1, 4.4).  A subset of the lytic peptides shared similar 
characteristics including amino acid distribution and PhoA activity suggesting that they may 
share a common mechanism of inhibition or target.  We further hypothesized that these 
peptides form amphipathic, α-helices as can be seen when their sequences are projected on an 
Edmundson wheel515 (Chapter 4, Figure 4.17).  Amphipathic, α-helical, antimicrobial peptides 
(AMPs) such as magainin 2244 (Chapter 4, Figure 4.18) and cecropins,539 have been studied 
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and well-characterized as part of the innate immune responses of several organisms.  Studies 
have sought to determine what characteristics are important for their use as therapeutics529; 572 
identifying three 1) the number and location of basic residues at the polar interface, 2) the 
number, location and hydrophobicity of the residues at the hydrophobic interface, and 3) 
specificity determinants, whereas the peptide has activity against only bacterial and not 
eukaryotic cells.  There has been success in the rational design of new AMPs or activity 
optimization of natural peptides based on these premises.529; 573; 574; 575; 576  Given our selection 
results, we sought to focus the pIVD system for the isolation of amphipathic, α-helical peptides, 
in contrast to the rational design methods used previously, to further characterize and optimize 
their lytic activity and isolate more potent lytic peptides. 
 We designed and implemented a library representing the biases observed among the 
bacteriolytic peptides isolated from the periplasmic selection, similar to antimicrobial peptide 
optimization screening methods.363; 398; 577; 578  Potential residues represented at each position of 
the library were constrained (Figure 5.5).  Positions 1, 3, 6, and 7 were limited to 2 to 4 residues 
each and positions 4, 8, 9, and 10 were fixed at a particular residue that was uniquely favored at 
the position in the pool of lytic peptides.  Positions 2, 5, 11, and 12, however were kept random, 
through the incorporation of the NNK codon, due to their lack of or weak biases in the lytic pool.  
A total of 146 clones produced from the constrained library were then assayed for activity and 
sequenced.  Of the 146 unselected isolates 68 or 46.6% were lytic (Tables 5.5.A-C).  Curiously, 
a number of clones with unexpected growth phenotypes were also isolated, including 9 
bacteriostatic/bactericidal, 4 weakly inhibitory (Table 5.6) and 65 non-inhibitory peptides 
(Tables 5.7.A-C).  The amount of inhibitory, non-lytic peptides isolated and their similarity in 
sequence to the isolated lytic peptides suggests that their mechanisms may be similar and their 
activity correlated to their degree of interaction with a hypothetical target, such as the inner 
membrane or Sec pathway.  Further characterization of amino acid sequences eliciting cell lysis 
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may be gained through a comparison of non-inhibitory and inhibitory peptides from the 
constrained library. 
 Sequence analysis revealed several differences among the lytic (GP) (Tables 5.5.A-C, 
5.9, 5.12, Figures 5.11.A-L, 5.14.A-D) and non-inhibitory (NI) (Tables 5.7.A-C, 5.11, 5.14, 
Figures 5.13.A-I, 5.16.A-D) peptides and a subset of the lytic peptides, having an early onset of 
lysis (EO2) (Tables 5.8, 5.10, 5.13, Figures 5.12.A-I, 5.15.A-D).  Basic amino acids were 
favored at position 2, which was fully randomized, among the lytic peptide groups, GP (Table 
5.12, Figure 5.14.A) and EO2 (Table 5.13, Figure 5.15.A).  In contrast, hydrophobic residues 
were overrepresented among NI peptides (Table 5.14, Figure 5.16.A), especially proline.  At 
position 3, the lytic peptide groups preferred W (Tables 5.9, 5.10, Figures 5.11.C, 5.12.C), 
while NI peptides favored leucine (Table 5.11, Figure 5.13.C), where L, R, and W were the only 
available amino acids.  The second randomized position, 5, varied among the lytic groups, the 
GP preferring basic residues and L (Tables 5.9, 5.12, Figures 5.11.E, 5.14.B) with the EO2 
lacking basic residues and favoring hydrophobic amino acids L and M (Tables 5.10, 5.13, 
Figures 5.12.D, 5.15.B).  The NI peptides also favored hydrophobic residues (Table 5.14, 
Figure 5.16.B) with a proclivity for proline (Table 5.11, Figure 5.13.D) which was absent in the 
lytic groups.  Position 6 was limited to R or S, the lytic groups preferring R (Tables 5.9, 5.10, 
Figures 5.11.F, 5.12.E) and the NI peptides S (Table 5.11, Figure 5.13.E).  Likewise, position 7 
permitted the two amino acids W and R, the lytic groups favoring W (Tables 5.9.B, 5.10.B, 
Figures 5.11.F, 5.12.E) while the NI peptides preferred R (Table 5.11, Figure 5.13.E).  The 
final two positions, 11 and 12, were both randomized.  At position 11 the GP peptides favored 
small, hydrophilic residues S and T (Table 5.9, Figure 5.11.K) and surprisingly W, a large, 
hydrophobic amino acid.  Also, proline, absent at the randomized positions 2 and 5 in the GP 
peptides, was present in five peptides indicating a tolerance of proline’s unique kinking of the 
peptide backbone.512; 544  No such tolerance was observed among the EO2 peptides (Table 
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5.10, Figure 5.12.H) which preferred basic residues (Table 5.13, Figure 5.15.C), hydrophobic 
residues V and Y, and the hydrophilic T.  Position 12 had similar preferences.  The GP peptides 
again preferring small hydrophilic amino acids S and T (Table 5.9.B, Figure 5.11.L), but instead 
of W, as with position 11, they favored the smaller L.  Two GP peptides contain proline, 
demonstrating again a toleration of the peptide not seen at previous positions.  EO2 peptides 
did not tolerate proline (Table 5.10, Figure 5.12.I), similar to position 11 and favored hydrophilic 
amino acids (Table 5.13, Figure 5.15.D) especially T, and hydrophobic L.  The NI peptides at 
positions 11 and 12 had a near random distribution of amino acids with the exception of proline 
which was slightly favored at both positions (Table 5.11, Figures 5.13.H-I).   
In general, the trend of preserving the basic/hydrophilic and hydrophobic interfaces 
predominated.  EO2 peptides, as evidenced by preferences at position 5 (Tables 5.10, 5.13, 
Figures 5.12.D, 5.15.B), tend to produce a smaller basic/hydrophilic interface than the GP 
peptides.  These preferences are reversed in the NI peptides, notably at positions 2, 6, and 11.  
The salient distribution of proline residues at the randomized positions contrasts the lytic and NI 
peptides, indicating proline’s unique structure plays a determinative role in the peptides’ 
activity.509; 513  However, positions 11 and 12, among the GP peptides, tolerate the presence of 
proline residues.  This indicates that these positions are unnecessary for the formation of the 
hypothetically critical α-helix. This could be compensated by a reduced entropic cost of 
amphipathic α-helix formation within the hydrophobic environment of the inner membrane.549  In 
contrast, the EO2 peptides did not tolerate proline residues at either position.  This could 
possibly be due to the small sample size or a distinguishing characteristic of EO2 activity that 
utilizes all positions.  Therefore, the presence of proline residues in the NI peptides and their 
absence or dearth in the lytic peptide groups suggests that proline disrupts the elements of 
structure required for lytic activity. 
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PhoA activity was used to determine if the peptide-PhoA fusions were being translated 
and crossing the inner membrane into the periplasm.501  All peptides isolated in the constrained 
peptide library screen, including the non-inhibitory peptides, were assayed for PhoA activity 
(Table 5.15).  Remarkably, only 22 of the 146 peptides exhibited PhoA activity, 7 of which had 
comparable activity to NI001, a non-inhibitory, translocating peptide.  Thirteen of the PhoA-
active peptides were non-inhibitory, including 6 of the 7 with NI001-comparable activity.  Five of 
the six lytic, PhoA-active peptides did not conform to the amphipathic α-helix model (Figure 
5.47), peptide 56 being the sole exception, lacking defined basic or hydrophobic interfaces.  
Similar lytic, PhoA-active peptides were isolated in the general periplasmic selection (Chapter 4, 
Table 4.14). 
To further study the effects of proline on the activity of α-helical model peptides, proline 
substitutions were introduced into two peptides (Table 5.16).  Peptide 37, lacking a proline in its 
amino acid sequence, has an early onset of lysis (Figure 5.18).  Peptide 84, on the other hand, 
contains a proline at position 5 and is non-inhibitory upon induction.  Neither peptide 37 or 84 
exhibited PhoA activity, indicating possible localization to the membrane.  This suggests that 
proline is the determinative factor for lytic activity and not PhoA activity.  Two clones were 
generated, 37 Pro+ and 84 Pro-, substituting a proline or leucine, respectively, for the original 
amino acid at position 5 in the original 37 and 84 peptides (Table 5.16).  Bacteriolytic activity 
was recovered upon the substitution of leucine for proline at position 5 of peptide 84 (Figure 
5.17), characterizing 84 Pro- as having an early onset of lysis.  The substitution of proline for 
alanine into peptide 37 at position 5 reduced its bacteriolytic phenotype to weakly inhibitory.  
Circular dichroism of synthetic peptide derivatives of 84 and 84 Pro- demonstrated differences 
in their secondary structures.  Peptide 84 Pro- formed an α-helix in contrast to a likely random 
coil for peptide 84 (Figures 5.45-46).  The substitution of proline disrupts the α-helical structure 
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Figure 5.47:  Edmundson wheel projections of lytic, PhoA-active peptides isolated from the 
constrained peptide library screen.  The peptides, with the exception of peptide 56, do not form 
defined basic interfaces and peptide 7b does not form a hydrophobic interface either.  The lack 
of interfaces is inconsistent with the amphipathic, α-helical model peptides and may explain why 
they exhibit PhoA activity. 
 
of 84 Pro- with the original, proline containing peptide, 84, no longer active as a bacteriolytic 
peptide.  This suggests the α-helix secondary structure producing amphipathic interfaces is the 
causative agent of cell lysis. 
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The peptide 84 Pro-, a representative of the α-helical model peptides, had varying levels 
of activity depending on localization of the peptide within the bacterial cell.  To study 84 Pro-‘s 
activity in the absence of PhoA context, we expressed the free peptide in vivo, localizing it both 
to the periplasm and the cytoplasm, independently.  Periplasmic expression of the PhoA signal 
peptide and peptide 84 Pro- forces an interaction of the peptide with the inner membrane and 
Sec pathway, two of its potential targets, during translocation (Figure 5.20).  The free 84 Pro- 
peptide maintained its lethality in the absence of PhoA (Figure 5.21), unsurprising, once circular 
dichroism established the small 12mer peptide is capable of forming an α-helix (Figure 5.45).  A 
similar scheme expressing free 84 Pro- peptide in the cytoplasm (Figures 5.23, 5.25), and 
therefore eliminating the forced interaction between the peptide and the inner membrane, had 
reduced activity (Figure 5.26).  Peptide 84 Pro-‘s weakly inhibitory phenotype in the cytoplasm 
may be correlated to the reduced probability of interacting with the inner membrane or Sec 
pathway compared to the periplasmic system that forces an interaction between the peptide and 
its potential targets.  Interestingly, if this is true, lowering the concentration of a lytic peptide in 
the inner membrane or Sec pathway causes a decrease in the growth rate, a possible 
explanation for isolated peptides of similar sequence to the α-helical model peptides exhibiting 
weakly inhibitory or bacteriostatic/bactericidal phenotypes.  These include peptides from the 
constrained peptide screen and the periplasmic selection in Chapter 4 that had observable, but 
reduced levels of PhoA activity compared to the NI001 peptide (Table 5.15, and Chapter 4, 
Table 4.14).  The peptides may not have adequate presentation of amphipathic interfaces for a 
stable interaction with their target, allowing a population of the peptide to fully translocate and 
therefore lowering the local concentration of the peptide in the membrane or Sec pathway, 
capable of causing cell lysis. 
Lytic activity is also tied to the replication of the cell.  When introduced to non-
metabolically active S. aureus cells, the reduction in optical density was small (Figures 5.44.A-
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B).  The observed decrease was likely due to the lysis of a small population of metabolically 
active cells arising from our inability to completely remove all nutrients from the cell solution.  
Subsequent addition of rich growth medium to reinstate full growth of the cells caused a larger, 
nearly complete reduction in the number of viable cells.  E. coli cells expressing free 84 Pro- 
peptide are longer than control cells with repressed peptide expression (Figures 5.28, 5.33).  
This phenotype has been associated with E. coli cells exposed to replication-dependent β-
lactam antibiotics.579; 580  The increased membrane permeability of the cells, indicated by the 
increased uptake of ethidium bromide EtBr552; 553 (Figures 5.27-34), preceded the appearance 
of black circles or lesions on the surfaces of elongated cells (Figures 5.30-34).  Therefore, the 
EtBr-stained, black circle, elongated cell phenotype suggests that the cells were killed during 
replication by compromising cell wall integrity before cell division could occur.  The reduction in 
optical density observed in the growth curves of 84 Pro- expressing E. coli cells (Figure 5.17) 
indicates that this is the point at which lysis occurs.  However, following longer incubation times, 
theoretically correlated with a greater accumulation of peptide in the cells arising from continued 
expression, cells not actively replicating, observed as a small cell phenotype, also developed 
the black circle or lesion phenotype (Figures 5.33-34).  This indicates that while replicating cells 
may be more sensitive to the lytic activity of peptide 84 Pro-, that metabolically-active cells are 
also sensitive at potentially higher concentrations of peptide.  Oddly, amphipathic AMPs have 
activity against persister563 and non-replicating cells564 making them potential antimicrobials for 
use against cells located at the core of biofilms or slow-growing bacteria such as M. 
tuberculosis.  In contrast, the replication dependence of peptide 84 Pro-‘s activity and 
phenotypic cell morphology indicate 84 Pro- is more active against replicating cells with a 
possibly weaker activity against non-replicating, metabolically active cells.   
General membrane perturbing peptides’ activities would not be dependent on replication 
and would reliably lyse cells during any stage of growth.  This introduces the possibility of the α-
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helical model peptides having a target besides the membrane.  We have assumed that the 
onset of lysis shortly after induction correlates with a low intracellular MIC.  If the amphipathic α-
helical peptides are binding to the Sec pathway proteins, such as SecA or the transmembrane 
complex SecYEG (Figure 5.48),502; 581 they could prevent the secretion of periplasmic proteins 
necessary for the synthesis of peptidoglycan at relatively low concentrations; the number of Sec 
pathways present in the membrane comprising a small percentage of the membrane itself.  The 
inhibition of peptidoglycan synthesis would manifest as a phenotype similar to that of ampicillin, 
 
 
Figure 5.48:  The proteins of the Sec pathway facilitate the translocation of proteins with the 
appropriate signal peptide into the periplasm. 
 
where osmotic balance cannot be maintained as the cell elongates during replication due to loss 
of integrity of the cell wall resulting in the lysis of the cell.579; 580  This would explain the lack of 
target purifications during His6 tag affinity purifications of α-helical model peptide-PhoA fusions 
due to the presence of the Sec pathway in the membrane,582 a portion of the cell typically lost 
during purification.  Affinity tag purifications focusing on the membrane fraction could identify the 
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peptides’ target.  The mechanism of peptidoglycan inhibition versus inner membrane disruption 
can be resolved by the viability of cells expressing the 84 Pro- peptide in an hypertonic growth 
medium.  If the peptide disrupts the membrane, cell death should still occur,541; 555 but if 
peptidoglycan synthesis is targeted the cells should remain viable in the hypertonic growth 
medium and be able to grow through the formation of spheroplasts.556; 557  Growth and induction 
of 84 Pro- peptide PhoA fusions in hypertonic LB supplemented with 0.5 M sucrose and 16.6 
mM MgSO4 mitigated 84 Pro-‘s lethality (Figure 5.35).  Cell lysis was prevented and the E. coli 
cells continued to grow until stationary phase was achieved.  In contrast, cell lysis was 
prevented in ampicillin-treated cultures (Figure 5.36) but further growth was inhibited.  
Photomicrographs of the cultures showed that the ampicillin-treated cells produced stable 
spheroplasts in the hypertonic medium (Figure 5.37), with no reduction in the optical density 
correlating with cell lysis.  The 84 Pro- expressing cells did not form spheroplasts but showed 
irregularities on their surfaces suggesting that peptide 84 Pro- still affected cell wall integrity, but 
non-lethally (Figure 5.38).  However, resistance to cell lysis in these cells was not accompanied 
by the formation of spheroplasts.  Therefore, 84 Pro-, and the other α-helical model peptides, 
are likely not causing inner membrane disruption or inhibiting peptidoglycan synthesis.  The 
mitigation of 84 Pro-‘s activity through stabilization of cell osmolarity, however, does suggest 
that an aspect of the cell wall is affected.   
Preference for arginine among the amphipathic α-helical peptides possibly correlates 
with similar biases observed in unscreened M13 phage display libraries.537  The bias against 
arginine-rich peptides displayed at the N-terminus of M13 coat protein pIII is likely due to stable 
interaction with the translocation machinery of the Sec pathway.  Prescreening M13 phage 
libraries can be resolved by the use of prlA (secY) suppressor E. coli strains537 through the 
production of SecYEG complexes of weaker association.583  SecY is accessible at the 
periplasmic interface of the inner membrane (Figure 5.48),502 consistent with 84 Pro-‘s 
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extracellular antimicrobial activity (Table 5.17).  Verification of SecY as the purported target of 
84 Pro- and the other amphipathic α-helical peptides could be resolved by the in vivo 
expression or exogenous addition of peptide 84 Pro- to the prlA suppressor strain.  However, 
without further data, it is still possible that peptide 84 Pro- inhibits the Sec pathway preventing 
translocation of important proteins in an isotonic environment. 
Exogenous supplementation of either peptide 84 or 84 Pro- to various microorganisms 
indicated 84 Pro- may be a promising antimicrobial lead for continued development.  Besides an 
MIC of 15.6 µM against the Gram-negative bacterium E. coli (Table 5.17), it had consistent 
activity against all Gram-positive organisms assayed.  Gram-positive bacteria sensitive to the 
peptide 84 Pro- included Streptococcus salivarius (15.6 µM), a contributor of dental caries584 
and potential opportunistic pathogen,585 Enterococcus faecalis (31.3 µM), which can cause 
meningitis,586 endocarditis,587 and bacteremia588 and is a notable hospital acquired infection,589 
and Staphylococcus aureus (9 µM), which causes extensive ailments including pneumonia,590 
meningitis,591 bacteremia,592 toxic shock syndrome593 and a number of skin conditions.594  E. 
faecalis and S. aureus represent strains exhibiting antibiotic resistance, especially vancomycin-
resistant Enterococcus (VRE)595 and methicillin-resistant S. aureus (MRSA).596  The sensitivity 
of Mycobacterium smegmatis (30 µM) indicates that peptide 84 Pro- might also have activity 
against the Mycobacterium tuberculosis597 the typical causative agent of tuberculosis and 
increasingly antibiotic resistant.598; 599  The lack of activity versus Gram-negative bacteria other 
than E. coli, such as Pseudomonas aeruginosa, Klebsiella pneumoniae and Enterobacter 
aerogenes, may be due to 84 Pro-‘s inability to penetrate the outer membrane of their more 
complex cell walls402 (Figures 5.49.A-B) compared to Gram-positive bacteria or the presence of 
efflux pumps283; 600; 601 although a study by Rieg, et al., disputes that antimicrobial peptide 
resistance arises from the employment of efflux pumps.602 
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In S. aureus growth curves supplemented with various concentrations of peptide, 84 
Pro- demonstrated resilient activity against mid-log phase cells (Figure 5.39) with an MIC of 
62.5 µM, a 7-fold increase compared to orders of magnitude increase in the amount of cells.  
This indicates that 84 Pro- has a low therapeutic concentration.  Natural, lytic antimicrobial 
peptides (AMPs) form amphipathic, α-helices with basic interfaces and have activity against a 
variety of microorganisms.  Unfortunately, several of the peptides, including melittin527 and 
magainin 2,528 also exhibit hemolytic activity, diminishing their value as therapeutic agents.  To 
thoroughly examine the hemolytic activity of peptide 84 Pro-, which shares a common structure 
and sequence elements with the lytic AMPs, we incubated sheep red blood cells with the 
peptide in a non-isotonic solution for 18 hours at 37 oC to properly reflect therapeutic 
conditions.529  All concentrations of peptide 84 Pro- up to 250 µM, ~28-times the MIC of S. 
aureus, demonstrated negligible hemolysis (Table 5.18).  Peptide 84 Pro-’s lack of hemolytic 
activity and its low MICs against medically pertinent pathogens, such as S. aureus and E. coli, 
make it an attractive candidate for antimicrobial use and development.  
 The amino acid patterns observed in the bacteriolytic peptide pool from the pIVD 
selection and those of the constrained library, regardless of the mechanism they act by, have 
enough variation that they could be optimized to find the most active peptide related utilizing the 
pattern.  Three characteristics of membrane-disrupting AMPs have been identified previously529; 
572 and used for the optimization of rationally designed derivatives including 1) the number and 
location of basic residues at the polar interface, 2) the number, location and residues at the 
hydrophobic interface, and 3) specificity determinants, that limit the peptide’s activity to 
negatively-charged bacterial membranes, not neutral eukaryotic membranes.  The pIVD system 
can be modified, with the exception of the specificity determinant with the system operating 
within E. coli, to optimize peptide characteristics.  We identified a similar group of characteristics 
to investigate 1) the size of the hydrophobic interface, 2) the hydrophobic composition of the 
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same interface, 3) the overall charge of the peptide, 4) the length of the peptide, and 5) helix 
stabilization via dipole maintenance and helix caps.  Through the production of several libraries 
examining the effects of varying each of the characteristics it should be possible to construct a 
more potent bacteriolytic peptide.  The production of more accurately constrained libraries for 
the continued isolation of lytic peptides, fine tuning amino acid placement and peptide size can 
be simultaneously pursued.  The constrained peptide library was produced based solely on the 
linear amino acid sequence of 94 lytic peptides; with our current hypothesis proposing the 
necessity of α-helix formation and knowledge of potential mechanisms we could enhance future 
peptide libraries through the use of rational design. 
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Figures 5.49.A-B:  Figures A (Gram-negative) and B (Gram-positive) present a physical 
comparison of the two major cell walls developed by bacteria.  The cell wall of Gram-negative 
bacteria, including E. coli, is more complex than that of Gram-positive bacteria such as S. 
aureus including a hydrophobic outer membrane. 
 
A 
B 
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5.6 Materials & Methods 
5.6.1 Bacterial Strains & Media 
 All experiments, unless otherwise indicated, were carried out in E. coli DH5α (fhuA2, 
Δ(argF-lacZ)U169, phoA, glnV44, Φ80, Δ(lacZ)M15, gyrA96, recA1, endA1, thi-1, hsdR17).  
Clones were grown and maintained in Luria-Bertani (LB) medium containing 30 µg/mL 
kanamycin (LB-Kan30).  To induce peptide-PhoA fusions from the PBAD promoter L-arabinose 
was added to the culture at a final concentration of 0.2%.  Induction times are indicated in the 
individual methods outlined later.  Clones encoding suspected lethal peptide-PhoA fusions were 
propagated in LB-Kan30 medium with 0.2% D-glucose to repress expression from the PBAD 
promoter.  Transformations were carried out via electroporation at 2.44 kV with electro-
competent cells prepared beforehand and stored at -80 oC.  Transformed cells were recovered 
in SOC medium for 1 hour without antibiotics prior to either plating on solid media or screening. 
 
5.6.2 Enzymes & Reagents 
 Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs Inc. 
(Ipswich, MA).  Restriction enzymes were also ordered from Fermentas (a division of Thermo 
Fisher Scientific Inc., Glen Burnie, MD).  Oligonucleotides, for use as primers in polymerase 
chain reactions (PCRs) or in the formation of DNA duplexes, were purchased from Integrated 
DNA Technologies Inc. (Coralville, IA).  Choice-Taq™ DNA polymerase and PCR reagents 
were obtained from Denville Scientific Inc (Metuchen, NJ).  Pfu polymerase, derived from 
Pyrococcus furiosus and having 3’ to 5’ exonuclease proofreading activity, was obtained from 
the Chow Laboratory in the Wayne State University Chemistry Department.  DNA polymerase, 
dideoxynucleotide mixtures and sequencing buffers (SequiTherm Excel™ II DNA sequencing 
kit) were obtained from Epicentre Biotechnologies (a division of Illumina, Inc., Madison, WI).  
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Sequencing primers for use with the LI-COR Biosciences Sequencer 4000L, oligonucleotides 
bound at the 5’ end to either 700 or 800 IRDye®, were ordered from either LI-COR (Lincoln, NE) 
or Integrated DNA Technologies Inc. (Coralville, IA).  5-bromo-4-chloro-3-indoxyl-phosphate (X-
Phos) was obtained from Denville Scientific for assaying alkaline phosphatase (PhoA) activity. 
 
5.6.3 Constrained Peptide Library Construction in pKan-PhoA1 
 Oligonucleotides EODegb and PerF (Table 5.19) were mixed in equal molar amounts in 
a primer extension reaction.  PerF encodes the region upstream of the peptide within the PhoA 
signal peptide.  It maintains the BsrGI restriction enzyme recognition sequence necessary for 
cloning.  EODegb’s 3’ end is complimentary to PerF, permitting primer extension using Pfu 
polymerase.  It maintains the 5’ end of the PhoA gene, the linker peptide and the KasI site 
necessary for cloning.  It also encodes for a constrained peptide library of the amino acid 
sequence: (F/I/L/M), X, (L/R/W), L, X, (R/S), (R/W), W, R, (G/R), X, X whereas X is any amino 
acid.  The constrained library’s sequence was based on the linear sequence of the bacteriolytic 
peptide pool isolated in Chapter 4. 
 The primer extension reaction product was isolated and cleaned via gel electrophoresis.  
The resultant product and plasmid pKan-PhoA1 were digested with restriction enzymes BsrGI 
and KasI.  The desired DNA fragments were isolated and cleaned using gel electrophoresis and 
ligated to produce a library of pKan-PhoA1 plasmids encoding the constrained library of 
peptides at the N-terminus of PhoA. 
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5.6.4 Constrained Peptide Library Screen 
 One hundred ng of pKan-PhoA1 plasmid DNA encoding the constrained random peptide 
library was mixed with 30 µL of electro-competent E. coli DH5α cells.  The cell/DNA mixtures 
were electroporated at 2.44 kV and recovered in 1 mL of SOC medium for 1 hr at 37 oC.  
Recovered cells were plated on LB-Kan30 + 0.2% glucose solid medium so that individual 
colonies could be isolated.   
 Individual colonies were used to inoculate 200 µL of LB-Kan30 + 0.2% glucose in wells 
of a 96-well plate.  The plate was incubated at 37 oC and 500 rpm in a GeneMachines HiGro® 
96-well plate incubator from Digilab, Inc. (Holliston, MA) overnight.  The overnight cultures were 
diluted 1/100 by adding 2 µL to 200 µL of fresh LB-Kan30 and incubated in the HiGro at 37 oC 
and 500 rpm.  When the cultures achieved early log phase (~150 minutes) the optical densities 
of the cultures in the plate at 600 nm were measured using a SpectraMax 190 from Molecular 
Devices, Inc. (Sunnyvale, CA).  L-arabinose was added to each well at a final concentration of 
0.2%.  Incubation of the plates continued with the optical densities being measured every 60 
minutes following induction until the onset of stationary phase growth.  The optical density of 
uninoculated LB broth was subtracted from the values of each clone’s culture at every time 
point.  Clones were compared to the induced growth curve of clone NI001, a peptide recovered 
during screening that showed no inhibition when grown in the presence of 0.2% L-arabinose.  
Peptides were categorized based on their growth phenotypes, including: bacteriolytic, 
bacteriostatic/bactericidal, growth rate reducing and non-inhibitory. 
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5.6.5 DNA Sequencing 
 Isolated clones were sequenced using a two-step process.   Overnight cultures were 
grown in LB-Kan30 + 0.2% D-glucose.  One µL of culture was used as template in an initial 
PCR including primers arapromseqF and Per12R (Table 5.19).  The primers are complimentary 
to sequences on either side of the randomized region.  ArapromseqF has a 5’ tail not 
complimentary to any region in pKan-PhoA1, but has been selected for complementarity with a 
third oligonucleotide, JSLF (Table 5.19).  The product of the first reaction incorporates the 
JSLF-complimentary tail using Taq polymerase.  The 24 µL product is then diluted in 170 µL 
dH2O and used as a template in a sequencing reaction employing dideoxynucleotide mixes and 
a 5’ IRDye®-labeled primer, JSLF.  The labeled primer binds the tail sequence permitting high-
throughput sequencing. 
 
5.6.6 Peptide-PhoA Expression Assays 
 Individual colonies of each clone were placed on solid LB-Kan30 + 0.2% D-glucose 
medium atop a 0.45 µm nylon transfer membrane and incubated at 37 oC for 20 hours.  The 
membranes allow for the diffusion of nutrients and inducers through the pores but also permit 
the transfer of colonies to fresh media.  The presence of the membranes slows growth such that 
after 20 hours of incubation the colonies are still small and in exponential phase growth.  The 
colonies were transferred to solid LB-Kan30 + 50 µg/mL X-Phos + 0.2% L-arabinose medium 
and incubated at 37 oC for 2 hours.  The use of solid medium with X-Phos localizes the 
generation of the precipitant making visualization easier, especially if the peptide is bacteriolytic 
and kills its host cell soon after its induction.  The color of the colonies, determined by the 
amount of PhoA activity, was recorded in comparison to the non-inhibitory clone NI001 that 
demonstrates high PhoA activity. 
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5.6.7 pKan-PhoA37Pro+ & 84Pro- Construction 
 Bacteriolytic peptide 37 and non-inhibitory peptide 84 isolated using the constrained 
peptide screen were selected for proline modification to elucidate the residue’s effect of the 
peptides’ growth phenotypes.  The oligonucleotide PerF was paired with either oligonucleotide 
EOD84Mod-Pro or EOD37Mod+Pro (Table 5.19) in a primer extension reaction.  The 3’ end of 
both primers is complimentary to PerF allowing Pfu polymerase to produce of complete DNA 
duplex.  The primer extension products were cleaned to remove the buffer and enzymes by gel 
electrophoresis.  The cleaned products and pKan-PhoA1 were then digested with restriction 
enzymes BsrGI and KasI.  The digestion products were cleaned and ligated to form plasmids 
pKan-PhoA84Pro- and pKan-PhoA37Pro+.  The first clone substitutes a leucine residue at 
position 5 or the peptide for the original proline.  In 37 Pro+ the alanine residue at position 5 of 
the original 37 peptide was replaced with a proline residue. 
 
5.6.8 Large Volume Induced Growth Curves 
 A culture of each clone, started with an individual colony, was incubated overnight at 37 
oC in 3 mL LB-Kan30 + 0.2% D-glucose.  The overnights were diluted 1/1000 by moving 17 µL 
into 17 mL LB-Kan30 and incubated until early log phase (~210 minutes).  L-arabinose was 
added to the culture to a final concentration of 0.2%.  The optical density of a 700 µL sample of 
the cultures at 600 nm was measured periodically at the point of induction and at 30 or 60 
minute intervals following induction using Spectronic® Genesys™ 20 spectrophotometer from 
Thermo Fisher Scientific, Inc. (Waltham, MA).  In the final analysis, the optical density of 
uninoculated LB broth was subtracted from the values of each clone’s culture at every time 
point.   
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5.6.9 Free 84 Pro- Peptide Expression Constructs  
5.6.9.1  pKan-Solo84Pro- Construction 
 pKan-Solo was generated as a derivative of pKan-PhoA1 for free peptide expression in 
the periplasm.  The oligonucleotide PerisoloF was paired with an oligonucleotide encoding the 
84 Pro- peptide, EOD84P-solo (Table 5.19).  PerisoloF has complimentary to the paired primer 
and formed a duplex DNA upon primer extension.  The products were cleaned and digested 
with restriction enzymes BsrGI and XbaI.  Plasmid pKan-PhoA1 was similarly digested.  The 
digestion products were cleaned via gel electrophoresis and ligated to form a free peptide 
expressing derivative of the original pKan-PhoA84Pro-  The linker sequence and PhoA gene 
were removed and a stop codon placed at the immediate 3’ end of the peptide without 
disturbing the 5’ signal peptide.   
 
5.6.9.2  pAmp-SoloTEV84Pro- Construction 
 pAmp-SoloTEV was generated as a derivative of pAmp-EmGHB2, itself a derivative of 
lab plasmid pKan-EmGH, for free peptide expression in the cytoplasm.  The construction of this 
plasmid is outlined in the Material & Methods section of chapter 2.  Oligonucleotide 
EOD084modsolotev, encoding 84 Pro- to be expressed in the absence of display protein, PhoA, 
in the cytoplasm, was paired with UniTevG-F (Table 5.19) in a primer extension reaction.  The 
resulting DNA duplex encoded the TEV protease recognition sequence followed by the desired 
peptide sequence and a stop codon.  Two restriction enzyme recognition sequences, NheI and 
XbaI, were included at either end of the product.  The DNA duplex and pAmp-EmGHB2 were 
then digested with NheI and XbaI.  The digestion product of the duplex was ligated to the 
digested pAmp-EmGHB2 vector.  The final construct, pAmp-SoloTEV84Pro-, replaces the 
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EmGFP gene with a DNA sequence encoding a hybrid peptide with a TEV protease recognition 
sequence and 84 Pro-. 
 
5.6.10  Free 84 Pro- Peptide Induced Growth Curves 
 For 84 Pro- free peptide expression in the periplasm, the induced growth curve 
procedure was identical to that outlined in section 5.6.8.  To study the effect of 84 Pro- free 
peptide expression in the cytoplasm, E. coli EPI301 cells containing plasmids pAmp-
SoloTev84Pro-, pRK603 (addgene plasmid 8831) and pZS4int-tetR were cultured from an 
individual colony in 3 mL LB-Amp100Kan30Spec50 + 0.2% D-glucose and incubated overnight 
at 37 oC with shaking.  The overnight culture was diluted 1/1000 by adding 17 µL to 3 flasks of 
17 mL of LB-Amp100Kan30Spec50.  All flasks were incubated at 37 oC with shaking until late 
lag phase growth was achieved (~210 minutes).  To measure the optical density at 600 nm 700 
µL samples of each culture were analyzed using Spectronic® Genesys™ 20 spectrophotometer 
from Thermo Fisher Scientific, Inc. (Waltham, MA).   Anhydrotetracycline (ATC) was added to 
one flask to a final concentration of 250 ng/µL to induce TEV protease expression.  Incubation 
was continued until early log phase growth (~270 minutes).  IPTG was added to a final 
concentration of 1 mM to two of the flasks, including the one previously induced for TEV 
protease, to induce 84 Pro- hybrid peptide expression.  Incubation was resumed and the optical 
density monitored until the cultures entered stationary phase growth. 
 
5.6.11  Microscopy of E. coli Cells Expressing Free 84 Pro- Peptide 
 E. coli DH5α cells containing plasmid pKan-Solo84Pro- were grown in 3 mL LB-Kan30 + 
0.2% D-glucose overnight at 37 oC with shaking.  The overnight culture was diluted 1/1000 by 
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adding 17 µL into 2 flasks of 17 mL of fresh LB-Kan30 medium, one flask contained 0.2% 
glucose to repress expression of the free 84 Pro- peptide.  The cultures were incubated at 37 oC 
with shaking until mid-log phase growth was achieved (~5 hours).  Two hundred µL samples of 
both cultures were removed from both cultures and mixed gently in a microcentrifuge tube with 
12 µL of 100 ng/mL ethidium bromide (EtBr) to stain dead or permeable cells.  The tubes were 
incubated for 1 min at room temperature.  One to 5 µL, depending on the concentration of cells 
in the culture, was placed on a microscope slide.  A coverslip was added atop which a drop of 
immersion oil was added for increased resolution.  The samples were viewed under a 
differential interference contrast (DIC) to observe cell morphology and a tetramethylrhodamine 
isothiocyanate (TRITC) filter to observe EtBr staining on an Olympus BX51 fluorescent 
microscope using an Olympus DP30BW camera from Olympus Imaging America Inc. (Center 
Valley, PA).  L-arabinose was added to the second culture, which was left unrepressed, to a 
final concentration of 0.3%.  Incubation of the cultures was continued and samples were 
removed periodically to observe cell morphology and EtBr staining. 
 
5.6.12  Cell Osmolarity Assays  
 E. coli DH5α cells containing plasmid pKan-PhoA84Pro- were grown in 3 mL LB-Kan30 
+ 0.2% D-glucose + 0.3 M sucrose overnight at 37 oC with shaking.  The overnight culture was 
diluted 1/1000 by adding 17 µL into three flasks of 17 mL of fresh LB-Kan30 + 0.3 M sucrose 
medium, three flasks of fresh LB-Kan30 + 0.5 M sucrose + 16.6 mM MgSO4 medium, two flasks 
of fresh LB-Kan30 + 0.5 M sucrose and one flask of fresh LB-Kan30.  The cultures were 
incubated at 37 oC with shaking until an optical density of A600 of ~0.3 was achieved.  Ampicillin 
was added to a final concentration of 250 ng/mL to one of each of the following growth media: 
0.5 M sucrose, 0.5 M sucrose + 16.6 mM MgSO4, 0.3 M sucrose and plain LB-Kan30.  
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Arabinose was added to a final concentration of 0.2% to one of each of the growth media: 0.5 M 
sucrose, 0.5 M sucrose + 16.6 mM MgSO4, 0.3 M sucrose, and plain LB-Kan30.  Incubation of 
cultures continued.  Periodically 700 µL samples were removed for the measurement of optical 
density at A600.  After 400 minutes of incubation, 200 µL samples were removed from the 
cultures each hour.  Two µL of each sample were placed on a microscope slide, a coverslip was 
added atop which a drop of immersion oil was added for increased resolution.  The samples 
were viewed under a differential interference contrast (DIC) to observe cell morphology on an 
Olympus BX51 fluorescent microscope using an Olympus DP30BW camera from Olympus 
Imaging America Inc. (Center Valley, PA). 
 
5.6.13  Determination of Minimum Inhibitory Concentrations 
 Peptides 84 and 84 Pro- were purchased from Selleck Chemicals (Houston, TX) at 95% 
purity.  Dimethylformamide (DMF) was used to dissolve the peptides to 10 mM stock 
concentrations and stored at -20 oC in aliquots for use in the calculation of their minimum 
inhibitory concentrations (MICs). 
E. coli strains W3110 (F-, λ-, rph-1, INV(rrnD, rrnE))  and SM101 (F-, thr-1, araC14, 
lpxA2(ts), tsx-78, Δ(galK-attLAM)99, hisG4, rfbC1, rpsL136, xylA5, mtl-1, thi-1) and various 
other organisms including Gram-negative bacteria Enterobacter aerogenes, Pseudomonas 
aeruginosa, Klebsiella pneumonia and Gram-positive bacteria Staphylococcus aureus, Bacillus 
subtilis and were streaked on solid LB medium to get individual colonies.  Further MIC studies of 
Gram-positive bacteria Enterococcus faecalis and Streptococcus salivarius substituted Todd 
Hewitt Broth (THB), a rich medium for fastidious organisms for LB.  Mycobacterium smegmatis 
required 7H9 medium for growth.  Cultures were started in 3 mL LB, THB or 7H9 broth using 
one colony and incubated overnight at 37 oC, or three days for M. smegmatis.  Overnight 
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cultures were estimated to be 109 cells/mL and accordingly serially diluted in LB or THB broth to 
104 cells/mL.  Two hundred µL of the final dilution were aliquoted into wells of a 96-well plate.  
Peptides were diluted serially so that adding 5 µL of the dilution to 200 µL of culture would 
produce a range of final concentrations from 1-250 µM.  M. smegmatis MICs were performed in 
1 mL cultures with final concentrations ranging from 30-7.5 µM.  Plates containing gradients of 
each peptide alongside identical dilutions of the peptide solvents in cultures of the different 
species were then incubated in a GeneMachines HiGro® 96-well plate incubator from Digilab, 
Inc. (Holliston, MA) at 37 oC and 500 rpm for 16 hours.  After incubation the plates were 
removed from the incubator and their optical densities were measure at 600 nm using a 
SpectraMax 190 from Molecular Devices, Inc. (Sunnyvale, CA).  The M. smegmatis cultures 
were incubated at 37 oC for 2 days when the culture with no peptide added had reached 
stationary phase growth.  The optical density at 600 nm of 700 µL aliquots of each culture was 
measured using a Spectronic® Genesys™ 20 spectrophotometer from Thermo Fisher Scientific, 
Inc. (Waltham, MA).  The minimum inhibitory concentration was selected as the smallest 
concentration of peptide required to completely inhibit growth of the culture. 
 
5.6.14  Synthetic Peptide Growth Curves 
 Cultures of both E. coli SM101 and S. aureus were incubated overnight in 3 mL of LB 
medium.  The cultures were diluted from 109 to 105 cells/mL in LB.  Two hundred µL of the 
dilutions were placed in wells of a 96-well plate and incubated at 37 oC and 500 rpm in a 
GeneMachines HiGro® 96-well plate incubator from Digilab, Inc. (Holliston, MA).  The optical 
densities of the cultures were monitored at 600 nm using a SpectraMax 190 from Molecular 
Devices, Inc. (Sunnyvale, CA).  When the cultures had reached mid-log growth phase, dilutions 
of either peptide 84 or 84 Pro- were added to make a gradient of final concentrations ranging 
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from 125 to 0 µM.  Incubation of the cultures was continued and the optical density was 
measured periodically following the addition of the peptides.  In the final analysis, the optical 
density of uninoculated LB at 600 nm was subtracted from the measured values of each culture. 
 
5.6.15  Replication Dependence Assays 
 A culture of S. aureus in 3 mL of THB was started with an individual colony and 
incubated overnight at 37 oC with shaking.  The overnight culture was diluted 1/1000 by adding 
17 µL to 17 mL of fresh THB medium and incubated at 37 oC with shaking.  When the cells had 
achieved mid-log phase growth, the culture was centrifuged at 7,000 rpm for 5 minutes to pellet 
the cells.  The supernatant was removed and the pellet washed twice in 10 mL of HEPES-NaCl 
(HN) buffer pH 7.0 to remove all growth medium from the cells and stop replication.  The final 
pellet was resuspended in 11 mL of HN buffer and incubated at 37 oC with shaking for 30 
minutes to ensure the cessation of replication and growth.   
 Three 200 µL aliquots were placed in wells of a 96-well plate.  To each well one of the 
following was added:  peptide 84 or 84 Pro- to a final concentration of 60 µM, or replication-
dependent, bacteriolytic antibiotic ampicillin to a final concentration of 1480 µM.  The optical 
density at 600 nm was measured using a SpectraMax 190 from Molecular Devices, Inc. 
(Sunnyvale, CA) and samples of the cultures were removed for plating to determine the viable 
cell count.  Samples were plated on LB medium at various dilutions to get statistically significant 
counts.  The 96-well plate was incubated at 37 oC and 450 rpm in a GeneMachines HiGro® 96-
well plate incubator from Digilab, Inc. (Holliston, MA).  The optical density was monitored every 
15 minutes for 45 minutes and samples were removed for plating.  Twenty-one µL of 10x 
concentrated THB medium was added to each well to provide the necessary nutrients for 
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growth.  Incubation was continued with periodic optical density measurements and sample 
removal for plating.   
 The plates with various concentrations of culture were incubated overnight at 37 oC.  
Individual colonies were counted and the concentrations of viable cells in the cultures were 
calculated.  In final analysis, the optical densities of the cultures were subtracted by similar, 
uninoculated media (HN only or HN + 10x THB). 
 
5.6.16  Hemolytic Assays 
 Defibrinated sheep’s blood (38% PCV) obtained from HemoStat Laboratories (Dixon, 
CA) was washed twice and resuspended to a final concentration of 10% PCV in phosphate 
buffered saline (PBS) pH 7.4.  Two hundred µL aliquots of the defibrinated sheep’s blood 
suspension were distributed to microcentifuge tubes.  Serial dilutions of peptides 84 and 84 Pro- 
were prepared using PBS pH 7.4.  The peptide dilutions were added to the aliquots to a final 
concentration ranging from 250 to 1 µM.  Control aliquots of defbrinated sheep’s blood 
containing either PBS pH 7.4 only or 0.1% Triton X-100 were used as 0%  and 100% hemolysis 
benchmarks respectively as well as a gradient of peptide solvent, DMF.  The aliquots were 
incubated, with shaking at 37 oC for 18 hrs.  The aliquots were then centrifuged to pellet whole 
erythrocytes or cell debris from lysis.  The optical density at 570 nm of 50 µL of each samples’ 
supernatant was measured using a SpectraMax 190 from Molecular Devices, Inc. (Sunnyvale, 
CA) to calculate the amount of hemoglobin released by lysed erythrocytes.  The level of 
hemolysis of the PBS pH 7.4 only aliquot was subtracted from the peptide and DMF samples.  
Percent hemolysis was calculated by dividing the peptide and DMF sample values by the 0.1% 
Triton X-100 complete hemolysis sample and multiplied by 100. 
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5.6.17 Circular Dichroism of Synthetic Peptides 
 Three ~400 µM samples of both peptides 84 or 84 Pro- in PBS pH 7.0 were lyophilized 
for three days to remove any residual DMF in which the peptides were originally stored.  The 
solids (salts and peptide) of each tube was resuspended in 500 µL of one of the following 
solvents for each peptide:  dH2O, 25% 2,2,2-trifluoroethanol (TFE) / 75% dH2O or 50% TFE / 
50% dH2O.  Two hundred µL of each sample was placed into a 1 mm path length, quartz 
cuvette and it circular dichroism spectrum from 190-260 nm was recorded using a Chirascan™-
Plus circular dichroism spectrometer by Applied Photophysics (Surrey, UK) .  TFE was used to 
mimic the 84 Pro-‘s potential operating environment within the plasma membrane as it is a 
hydrophobic compound. 
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CHAPTER 6 
2ND GENERATION PEPTIDE DESIGN AND CHARACTERIZATION OF THE PEPTIDES 
GENERATED 
 
6.1 Abstract 
 Extrapolating from the amino acid distribution of the lytic peptides isolated from the pIVD 
system, we rationally designed and assayed a series of peptides.  Designed peptides EO2, VL1 
and VL2 caused lysis upon expression within E. coli cells.  The distribution of their amino acid 
sequences, similar to the lytic peptides they were derived from, is consistent with the formation 
of amphipathic α-helices. 
One peptide, EO1 (FAWLWSWWRARR), did not conform to the α-helical model that we 
have proposed previously and demonstrated bactericidal activity at low intracellular 
concentrations with a secondary lytic effect.  PhoA activity assays and cytoplasmic expression 
revealed that EO1’s activity is contingent upon its translocation to the periplasm.  Cell 
morphology studies, hypertonic growth curves and its bactericidal phenotype suggest it does not 
inhibit cell wall synthesis causing cell lysis.  However, its complete lysis of Gram-positive 
bacterium Staphylococcus aureus cultures, suggest that its activity may be related cell wall 
synthesis.  EO1’s activity against Gram-positive organisms including Staphylococcus aureus, 
Eneterococcus faecalis, Streptococcus salvarius, Bacillus subtilis, Micrococcus luteus, 
Corynebacterium minutissium and Mycobacterium smegmatis and its lack of hemolytic activity 
make it an attractive lead antimicrobial peptide. 
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6.2 Introduction 
 Two approaches were developed to isolate and optimize lytic peptides based on those 
isolated from the periplasmic peptide selection in Chapter 4.  The first method screened a 
constrained peptide library (Chapter 5) and had success in isolating lytic peptides based on 
position conservation in the bacteriolytic peptide pool.  The second approach characterizes and 
combines key sequence elements to rationally design new optimized lytic peptides (Figure 6.1). 
 
 
Figure 6.1:  Methods of antimicrobial development discussed within this dissertation.  Chapter 6 
focuses on rational design of lytic peptides by combining the sequence elements observed in 
the bacteriolytic peptides isolated from the periplasmic in vivo peptide selection in Chapter 4. 
 
The 94 lytic peptides isolated from the periplasmic selection in Chapter 4 can be 
grouped upon characteristics of their phenotypes observed in their induced growth curves 
(Figure 6.2).  Three such groups were defined: 1) early onset of cell lysis (Table 6.1, Figures 
6.3.A-C), 2) high rate of lysis (Table 6.2, Figures 6.4.A-C), and 3) low optical density end point 
444 
 
 
 
(Table 6.3, Figures 6.5.A-F).  The most strongly lytic peptides are those that begin lysing the 
host cells within one hour following induction with arabinose.  We designated these peptides as 
early onset (EO).  The high rate of lysis group is defined as having a greater decrease in optical 
density per unit time once lysis begins compared to the average of the general lytic peptide 
pool.  This correlates with a negative slope of the growth curve during lysis.  Finally, members of 
the low optical density endpoint produced the greatest amount of lysis as measured by the 
range of optical density from the onset of lysis until its completion when the optical density of the 
culture reaches a minimum (the endpoint).  The previous group definitions allow for particular 
peptides to belong to more than one group.  
 
Figure 6.2:  Phenotypic groups of bacteriolytic peptides isolated from the periplasmic in vivo 
display selection and the peptides rationally designed based on their sequence elements. 
 
 Of the 94 bacteriolytic peptides isolated from the periplasmic peptide selection a large 
portion demonstrate a pattern in their amino acid sequences.  When aligned as linear peptides, 
alternating pairs of basic and hydrophobic residues were non-randomly distributed (Table 6.4).  
By determining common patterns of amino acids in each phenotypic group and combining these 
common motifs, we hoped to isolate new, optimized peptides with enhanced lytic phenotypes.   
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Table 6.1:  Amino acid sequences of early onset of lysis peptides (EO) isolated from the 
periplasmic in vivo display selection of Chapter 4. 
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Figures 6.3.A-B:  Induced growth curves of the early onset of lysis peptides (EO) isolated from 
the periplsmic in vivo display selection.  Peptide NI001 represents the effects on E. coli growth 
of expression of a non-inhibitory, translocating peptide. 
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Figure 6.3.C:  Induced growth curves of the early onset of lysis peptides (EO) isolated from the 
periplsmic in vivo display selection.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide. 
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Table 6.2:  Amino acid sequences of high rate of lysis peptides (VL) isolated from the 
periplasmic in vivo display selection of Chapter 4. 
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Figures 6.4.A-B:  Induced growth curves of the high rate of lysis peptides (VL) isolated from the 
periplsmic in vivo display selection.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide. 
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Figure 6.4.C:  Induced growth curves of the high rate of lysis peptides (VL) isolated from the 
periplsmic in vivo display selection.  Peptide NI001 represents the effects on E. coli growth of 
expression of a non-inhibitory, translocating peptide. 
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Table 6.3:  Amino acid sequences of low optical density endpoint peptides (GD) isolated from 
the periplasmic in vivo display selection of Chapter 4. 
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Figures 6.5.A-B:  Induced growth curves of the low optical density endpoint peptides (GD) 
isolated from the periplsmic in vivo display selection.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide. 
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Figures 6.5.C-D:  Induced growth curves of the low optical density endpoint peptides (GD) 
isolated from the periplsmic in vivo display selection.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide. 
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Figures 6.5.E-F:  Induced growth curves of the low optical density endpoint peptides (GD) 
isolated from the periplsmic in vivo display selection.  Peptide NI001 represents the effects on 
E. coli growth of expression of a non-inhibitory, translocating peptide. 
455 
 
 
 
 
Table 6.4:  The distribution of basic residues arginine and lysine and hydrophobic residues 
leucine and tryptophan at each position among the bacteriolytic peptides isolated in the 
periplasmic selection.  Positions having ≥ 30% of either the basic or hydrophobic residues are 
highlighted in red. 
 
6.3 Objective of the Project 
 To rationally design peptides based on amino acid motifs of lytic peptides isolated from 
the periplasmic selection that have optimized lytic activity.   
 
6.4 Results 
6.4.1 Phenotypes of Designed Peptides 
 Two peptides were designed and evaluated from each phenotypic group.  EO1 and EO2 
were based on the sequences of the early onset of lysis pool.  EO3, a similar peptide, derived 
its sequence from the early onset of lysis pool isolated in the constrained peptide pool 
discussed in Chapter 5.  GD1, GD2 and VL1, VL2 were designed with the sequences of low 
optical density endpoint and high rate of lysis pools, respectively, in mind. 
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DNA sequences encoding each of the seven designed peptide sequences were cloned 
into pKan-PhoA1 (Figure 6.6), the construct used for screening the periplasmic peptide library.  
They were placed 3’ to the PhoA signal peptide and 5’ to the linker peptide and PhoA gene.  
The constructs were then transformed into electro-competent DH5α E. coli cells.  Cultures were 
then grown to early log phase and L-arabinose was added to one of two duplicates for each 
clone to induce expression of the peptide-PhoA fusion.  The growth of each culture was 
monitored by measuring the optical density at 600 nm. 
 
Figure 6.6:  pKan-PhoA1 is derived from plasmid pKan-EmGH.  The gene encoding EmGFP 
was replaced with phoA, encoding periplasmic display protein alkaline phosphatase (PhoA), a 
native enzyme of E. coli.  Expression of PhoA is inducible by the addition of L-arabinose to the 
growth medium. 
 
 Low optical density endpoint  Peptides GD1 and GD2 were designed based on the 30 
lytic peptides from the periplasmic, bacteriolytic peptide selection demonstrating low optical 
density endpoints following the completion of lysis.  Residues at each position were selected 
based on perceived preferences or estimations based on the limited size of the population 
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(Table 6.5).  GD1 is composed of alternating hydrophobic and basic residues with Ws at 
positions 1, 3, 7 and 8 and L at position 4.  Rs were placed at positions 2, 5, 6, 8, 9 and 12.  
Position 11 demonstrated no bias for basic or hydrophobic residues, thus a hypothesized 
benign alanine was placed there.  GD2 is similar to GD1 with the substitution of alanine 
residues at positions 1, 2 and 9.  A second L was substituted at position 7.  Finally, an R 
replaced the W at position 3.  Unfortunately, neither peptide had any effect on the growth of 
their host cells when induced (Figure 6.7).   
 
 
 
Table 6.5:  Distribution of common amino acids among the low optical density endpoint 
peptides (GD) used in the design of peptides GD1 and GD2. 
 
458 
 
 
 
 
Figure 6.7:  Induced growth curves of rationally designed peptides GD1 and GD2 based on the 
sequence elements of the low optical density endpoint peptides (GD). 
 
High rate of lysis  The 14 peptides exhibiting a high rate of lysis following induction were 
used to produce two peptides, VL1 and VL2.   Residues at each position were selected by their 
prevalence among the 14 peptides (Table 6.6).  A leucine was placed at position 4 for both 
peptides.  Arginines were placed at positions 6, 9, 10 and 12 for both peptides with VL1 also 
having one at positions 2 and 7 and VL2 with one at position 3.  Tryptophan and alanine were 
distributed at the remaining positions.  Both VL1 and VL2 were lytic, but no more so than the 
peptides from which they were derived (Figure 6.8).   
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Table 6.6:  Distribution of common amino acids among the high rate of lysis peptides (VL) used 
in the design of peptides VL1 and VL2. 
 
Early onset of lysis  Only 12 peptides from the periplasmic selection exhibited an early 
onset of lysis within 1 hour of induction.  The sequences of these peptides were used in 
designing the amino acid sequences of peptides EO1 and EO2 (Table 6.7).  Both peptides have 
a phenyalanine at the first position.  EO1 is the only designed peptide to have a serine, which is 
located at position 6.  A C-terminal tail of three arginines at positions 9, 11, and 12 with an 
alanine at position 10 was included in EO1.  EO2 contains three additional arginines at positions 
3, 5 and 6.  Position 2 was fixed as alanine for both peptides and position 4 was locked as 
leucine as with previous peptides due to the preference of the pool of lytic peptides.  The 
remaining positions were filled with tryptophan.  EO2 had a similar effect as VL1 and VL2, being 
bacteriolytic, but no more so than the peptides from which was derived (Figure 6.9).  EO1, 
however, was highly antimicrobial, with an early onset of lysis.  Cultures expressing EO1 begin 
to decrease in optical density within 60 minutes of induction. 
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Figure 6.8:  Induced growth curves of rationally designed peptides VL1 and VL2 based on the 
sequence elements of the high rate of lysis peptides (VL). 
 
 
Table 6.7:   Distribution of common amino acids among the early onset of lysis peptides (EO) 
used in the design of peptides EO1 and EO2. 
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Figure 6.9:  Induced growth curves of rationally designed peptides EO1 and EO2 based on the 
sequence elements of the early onset of lysis peptides (EO). 
 
A third peptide, EO3, was designed based on the 22 early onset of lysis peptides 
isolated from the constrained peptide screen (Chapter 5, Section 5.4.3.1) (Figure 6.10).  Our 
predominant concern was stressing incorporation of residues not used in the design of EO1 and 
EO2 peptides (Table 6.8).  This includes isoleucine at position 1, methionine at position 5, 
valine at position 11 and finally threonine at position 12.  Unfortunately, EO3 was not lytic, but 
weakly inhibitory (Figure 6.11).   
One explanation for the EO phenotype observed with peptide EO1, is that EO peptides 
are active at low concentrations, a characteristic that is important for the development of new 
antimicrobial drugs.  Thus, a series of experiments were carried out to further characterize EO1 
and its antimicrobial activity.   
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Figure 6.10:  Phenotypic groups of bacteriolytic peptides isolated from the constrained peptide 
library screen from Chapter 5 and the peptide, EO3, rationally designed based on the sequence 
elements of the early onset of lysis peptide group (EO2). 
 
 
Table 6.8:  Distribution of common amino acids among the early onset of lysis peptides isolated 
from the constrained peptide library (EO2) used in the design of peptide EO3. 
463 
 
 
 
 
Figure 6.11:  Induced growth curves of rationally designed peptide EO3 based on the sequence 
elements of the early onset of lysis peptides isolated from the constrained library peptide screen 
(EO2). 
 
To determine the effect of the physiological state of the culture on EO1’s antimicrobial 
activity, EO1 was induced at different stages of the E. coli growth curve.  Separate cultures 
were grown and induced either at 0 minutes (early lag phase), 150 minutes (late lag phase), 210 
minutes (early log phase), 240 minutes (early log phase), 300 minutes (mid-log phase) and 360 
minutes (late log phase).  The optical densities of each culture were measured at 600 nm.  All 
cultures, upon induction showed identical growth curves (Figure 6.12).  The optical density of 
the cultures decreased gradually, unlike previously isolated bacteriolytic peptides.  It appears 
the peptide affects growth quickly after induction, implying only a small amount is necessary, but 
the lytic endpoint of EO1 is not as low as some of the other cultures suggesting that the lytic 
behavior of EO1 is not the determinant of its antimicrobial activity, but a secondary effect 
caused by its activity.  The cultures induced at 0 and 150 minutes curiously appear to achieve 
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log phase growth before EO1 begins to have its effect on the cell.  This may be determined by 
the rate of transcription/translation of pKan-PhoAEO1 encoding EO1 which is insignificant until 
log phase growth or EO1’s phenotype is dependent on a process occurring only during log 
phase growth. 
 
 
 
Figure 6.12:  Induced growth curves of rationally designed peptide EO1.  Induction points were 
varied chronologically by adding L-arabinose to the cultures at different points during E. coli’s 
growth.  Arrows and corresponding numbers indicate the minutes after inoculation of the culture 
that induction occurred. 
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Figure 6.13.A-B:  Induced growth curve of rationally designed peptide EO1 measuring the 
optical density of the culture (A600) at five minute intervals following the addition of L-arabinose 
to delineate the time needed for EO1’s activity to affect growth.  Figure B is the same growth 
curve as A, focusing on the time span around the point of induction. 
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To more thoroughly characterize the EO phenotype of EO1, a culture of E. coli DH5α 
cells hosting pKan-PhoAEO1 encoding the EO1 peptide was grown to late log phase.  The 
culture was induced with the addition of L-arabinose and the optical density at 600 nm was 
measured at increments of 5 minutes.  After 10 minutes of induction, the optical density of the 
induced culture begins to deviate from that of the uninduced culture (Figures 6.13.A-B).  The 
lytic trajectory was biphasic with a short period of rapid lysis 10 minutes long followed by a long 
period of gradual cell lysis. 
Finally, to determine the phenotype of EO1, cell viability was measured at several time 
points following induction.  A culture harboring EO1-encoding pKan-PhoAEO1 was incubated 
until achieving late log phase growth.  L-arabinose was added to induce EO1-PhoA fusion 
expression.  At time intervals prior to and following induction, the optical density was measured 
at 600 nm and samples of the culture were removed, diluted and plated on LB agar plates 
containing D-glucose to repress EO1’s expression.  The plates were incubated overnight and 
the colonies counted.  The optical density curve was identical to those performed earlier (Figure 
6.14).  The viable cell count, plotted on a logarithmic scale, belies a characteristic not observed 
using the culture’s optical density.  Within 60 minutes of induction, cell death in the culture had 
reached a plateau.  In that time span there was a reduction in the amount of viable cells by 
99.86%.  Clearly, the decrease in viability is not reflected in the optical density of the culture, 
suggesting that cell death is not due to lysis, but instead that lysis occurs as an indirect result of 
cell death in a portion of the population. 
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Figure 6.14:  Cell viability assay in comparison to an induced growth curve performed on the 
same culture of E. coli DH5α cells expressing EO1-PhoA fusions.  A logarithmic y-axis was 
used for the viable cell count. 
 
6.4.2 Resistance to EO1 and the PBAD Promoter 
 In the viable cell count curve above, two additional observations concerning the efficacy 
of EO1 are worth noting: 1) Not all of the cells in the culture died (~0.14%) and 2) the viable cell 
count increases for the last two points of the curve.  EO1 resistance in these cultures is not due 
to loss of the pKan-PhoAEO1 plasmid (data not shown).  Hypotheses for the observed recovery 
of induced EO1 cultures include: 1) heterologous induction among members of the population 
due to autocatalysis554; 603; 604 2) mutations that disrupt EO1-PhoA expression409; 505; 506 and 3) 
mutations in genes, other than those involved in EO1 expression, which confer resistance to 
EO1.   
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 To determine if the observed recovery of EO1 induced cultures is due to mutations or 
autocatalysis in the PBAD expression system, a second construct, pAmp-PhoAEO1B2 (Figure 
6.15), was produced for co-transformation with the original EO1 construct and that of the 
resistant clone.  Modifications were made to pKan-PhoAEO1 encoding EO1 including replacing 
neo gene with the bla gene for ampicillin resistance to select for maintenance of both plasmids 
in the same host cell and replacing the p15A replication origin with that of pMB1 for plasmid 
compatibility.  The PBAD promoter was also replaced with the PLac promoter for induced 
expression upon the addition of IPTG.  pAmp-PhoAEO1B2 was transformed into fresh DH5α 
cells, cells containing the original EO1 construct and cells derived from the resistant clone 
(Figures 6.16-17).  Induced growth curves were carried out on each of the clones containing 
solo constructs (original EO1, resistant clone of EO1 and EO1 B2) (Figure 6.18) and dual 
constructs (original EO1 + EO1 B2, resistant clone of EO1 + EO1 B2) (Figure 6.19).   
 The cultures containing only one construct performed as expected.  The original EO1 
construct was lethal when induced with the addition of L-arabinose, but when it was left to 
incubate overnight the culture recovered to a high optical density indicating resistant clones had 
been selected for and had taken over the culture.  The resistant clone of EO1 grew as if it were 
left uninduced upon the addition of L-arabinose.  Both EO1 B2 cultures were lethal.  The 
uninduced culture showed lysis at a level less than that observed previously.  The PLac promoter 
is known to be leakier than the PBAD promoter406 (this was the primary reason we did not use if 
for selecting peptides) coupled with a replication origin (pMB1)503; 605 that has a higher copy 
number enough EO1 was produced to lyse the host cell.  The induced culture of EO1 B2 
showed a more intense level of cell lysis than the uninduced culture or the original EO1 
construct due to reasons listed above.  However, both cultures recovered after overnight 
incubation revealing the resistance mechanism is not unique to the original construct. 
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Figure 6.15: pAmp-EO1B2, a derivative of pKan-EmGH, via daughter plasmid pAmp EmGHB2.  
There are changes to its replication origin (pMB1), selection marker (bla), and promoter (PLac) to 
ensure plasmid compatibility with pKan-EO1A1 and independent induction of expression. 
 
 
Figure 6.16:  Single plasmid transformants of the EO1 resistance assay.  Induced cultures 
either were not affected by EO1 expression (resistant pKan-EO1A1) or lytic with a recovery of 
full growth following an overnight incubation (pKan-EO1A1, pAmp-EO1B2). 
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Figure 6.17:  Double plasmid transformants of the EO1 resistance assay.  Induced cultures 
were either lytic, but had a subsequent recovery following an overnight incubation (resistant 
pKan-EO1A1 & pAmp-EO1B2) or lytic with no recovery after overnight incubation (pKan-EO1A1 
& pAmp-EO1B2). 
 
 
Figure 6.18:  Induced growth curves of single plasmid transformants of the EO1 resistance 
assay.  The final point follows an overnight incubation. 
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Figure 6.19:  Induced growth curves of double plasmid transformants of the EO1 resistance 
assay.  The final point follows an overnight incubation. 
 
 Both dual constructs exhibited lethality.  First, the resistant clone of EO1 co-transformed 
with pAmp-PhoAEO1B2 showed a recovery of EO1 lethality with the addition of IPTG to induce 
EO1-PhoA expression from pAmp-PhoAEO1B2.  The lethality, however, did not last as 
overnight incubation saw the selection of resistance.  This is comparable to the pAmp-
PhoAEO1B2 solo construct culture described above.  The culture containing the original lethal 
EO1 clone co-transformed with EO1 B2 demonstrated a lasting lethality.  The culture was 
unable to recover growth during overnight incubation.  This indicates that mutations are 
occurring within the promoters of both PLac and PBAD which account for solo construct cultures 
recovering.  The probability of mutations occurring in both the PLac and PBAD promoter in the 
same cell however are low enough that it does not happen in the dual construct cultures and 
therefore there is no selection for resistance.   
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 A final assay linking resistance to the plasmid was performed.  Plasmid DNA was 
isolated from the EO1 resistant clone based on its molecular weight in an agarose gel.  This 
DNA was then transformed into fresh DH5α cells.  Clones containing the plasmid from the 
resistant clone were plated on to both repression medium containing D-glucose and on 
induction medium containing L-arabinose (Figure 6.20).  The original EO1 construct and the 
resistant EO1 clone that the plasmid was isolated from were also plated on the two media.  All 
of the colonies plated on repression medium grew.  On the induction plate, however, only cells 
containing plasmid isolated from the EO1 resistant cultures grew while cells expressing WT 
EO1 were inhibited.  Thus, the resistance was carried over by the plasmid DNA further 
indicating that mutations affecting EO1 expression are the cause if the resistance. 
 
 
 
Figure 6.20:  Plating of pKan-EO1A1 plasmid from resistant clones transformed into fresh E. 
coli DH5α cells compared to ‘WT’ pKan-EO1A1 containing cells and resistant pKan-EO1A1 
containing cells on induction medium supplemented with L-arabinose.  Only the ‘WT’ pKan-
EO1A1 containing cells failed to grow. 
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6.4.3 Characterization of the EO1 Peptide 
6.4.3.1  Alanine Scan 
 Alanine scanning is a genetic method of determining the contribution of each residue to 
the overall function of a peptide.606  Site-directed mutagenesis was used to make 10 constructs 
(positions 2 and 10 are alanine in EO1) where each one has an alanine substituted for the 
original residue (Table 6.9).  Alanine is characterized by having a methyl group bound to the α-
carbon.  It is used in assaying the importance of the residues that it replaces due to its 
chemically inert nature and small size.  No studies were undertaken to examine the importance 
of the alanine residues originally part of the peptide at positions 2 and 10. 
Each mutant was placed within the original pKan-PhoA1 plasmid and transformed into 
separate DH5α cells.  Induced growth curves were carried out in parallel and compared with the 
original EO1 construct.  Cultures were grown to early log phase and then L-arabinose was 
added to induce expression of the EO1-PhoA fusion mutants.  The optical density of the 
cultures at 600 nm was monitored to determine the effect of each residue’s and position’s 
importance concerning EO1’s function (Figures 6.21.A-B). 
The induced growth curves closely mimicked the behavior of the original EO1 construct 
except for the alanine substitution at position 4.  Replacing the leucine at position 4 with an 
alanine residue completely negated any inhibitory function of the peptide.  Leucine is 
characterized by an isobutyl side group which is both more hydrophobic and larger than that of 
alanine.  A large preference for leucine at position 4 was also observed in the original 
bacteriolytic peptide pool (Chapter 4, Section 4.4.3.2, Figure 4.15.D and Tables 4.9.A, 4.10).  
The other positions of EO1 contained residues of greater divergence from alanine including 
tryptophan and phenylalanine (large and hydrophobic), serine (hydrophilic) and arginine (large 
and basic) yet the replacement of these residues had no effect on function.  It is possible that 
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Table 6.9:  Amino acid sequences of the EO1 alanine scan mutants and their effect on EO1’s 
growth phenotype. 
 
 
Figure 6.21.A:  Induced growth curves of alanine scan mutants.  Each clone had one position, 
except for positions 2 and 10, substituting an alanine for the original residue.  The cultures were 
compared to an induced growth curve of the non-mutated EO1 clone. 
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Figure 6.21.B:  Induced growth curves of alanine scan mutants.  Each clone had one position, 
except for positions 2 and 10, substituting an alanine for the original residue.  The cultures were 
compared to an induced growth curve of the non-mutated EO1 clone. 
 
EO1’s function arises from a cumulative effect of all residues and that the replacement of one of 
them, besides the position 4 leucine, has no effect on the overall structure or other determining 
characteristic.  Position 4, however, is important for its individual contribution. 
 
6.4.3.2  Position 4 Mutants 
 The alanine scan pinpointed leucine at position 4 as the only residue which could not be 
replaced by an alanine and maintain EO1’s characteristic phenotype.  To further analyze what 
replacements are tolerated at position 4, a series of constructs were made using site-directed 
mutagenesis to incorporate a variety of residues at the position (Table 6.10).  The loss of 
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function by alanine suggests size of the side group may be important.  Therefore, a number of 
hydrophobic residues of increasing size were substituted including valine, isoleucine, 
phenylalanine and tyrosine.  To study the necessity of a hydrophobic residue at the position, 
constructs incorporating the hydrophilic residue asparagine, the acidic residue aspartic acid and 
the basic residue lysine were also made.  All constructs were cloned in pKan-PhoA1 as an N-
terminal fusion to PhoA.  The plasmids were then transformed into E. coli DH5α cells.  Cultures 
were grown to early log phase and L-arabinose was added to induce expression of the EO1-
PhoA position 4 mutants.  The optical densities of the cultures at 600 nm were measured to 
determine the effect of each residue on the bacteriolytic phenotype of EO1 (Figures 6.22.A-B). 
None of the substitutions, except those most closely resembling the original leucine, 
maintained the original EO1 phenotype.  Peptides containing valine and isoleucine, which share 
similar size and hydrophobicity,607 were as antimicrobial as EO1.  These data imply that the size 
of the residue at position 4 is a critical factor affecting the antimicrobial activity of EO1.  The L4D 
mutation also prevented lysis, suggesting, that charge also plays an important role since leucine 
and aspartic acid are similar in size.  Lysine’s size and charge both differ from leucine, making it 
hard to distinguish which had the dominating effect in negating function.  Finally, the L4N mutant 
demonstrated no lysis as well, presumably because asparagine is both larger and more 
hydrophilic than leucine. 
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Table 6.10:  Amino acid sequences of the EO1 position 4 mutants and their effect on EO1’s 
growth phenotype. 
 
 
 
Figure 6.22.A:  Induced growth curves of EO1 position 4 mutants substituting residues of 
increasing dissimilarity for the leucine in the original EO1 sequence.  The cultures were 
compared to an induced growth curve of the non-mutated EO1 clone. 
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Figure 6.22.B:  Induced growth curves of EO1 position 4 mutants substituting residues of 
increasing dissimilarity for the leucine in the original EO1 sequence.  The cultures were 
compared to an induced growth curve of the non-mutated EO1 clone. 
 
6.4.3.3  Solubility Mutants 
 EO1 was not soluble in aqueous solvents.  In an attempt to increase EO1’s solubility and 
maintain its lytic activity, a number of mutants were produced (Table 6.11).  The design of the 
mutants sought to replace large, hydrophobic residues such as phenylalanine and tryptophan 
with alanine or serine residues.607  One mutant reduced the total number of residues to 11 by 
deleting the initial phenylalanine.  Another two mutants were produced that examined the 
importance of the C-terminal arginine tail (RARR) that may have been causing solubility 
problems as well.  In one mutant, the final arginine residue was replaced with a glutamic acid 
residue, swapping a basic for an acidic charge and thus lowering the peptide’s overall charge  
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Table 6.11:  Amino acid sequences of the EO1 solubility mutants and their effect on EO1’s 
growth phenotype. 
 
from +3 to +1.  The second mutant replaced the alanine of the arginine tail with a second 
glutamic acid (RERE) making the overall charge of the peptide neutral. 
 Site-directed mutagenesis was used to incorporate the desired mutations.  These were 
then cloned into pKan-PhoA1 at the N-terminus of PhoA.  E. coli DH5α cells were transformed 
with each plasmid and grown to early log phase.  The optical densities at 600 nm were 
measured and compared to that of the original EO1 construct to determine their effect on EO1’s 
lethality. 
 Of the four peptides designed to minimize the effects of hydrophobicity on EO1’s 
solubility, only EO1-1 maintained lethality (Figure 6.23).  Substitutions of alanine residues at 
positions 1 and 8, replacing phenylalanine and tryptophan respectively, reduced the activity of 
EO1-1 to weakly bacteriostatic/bactericidal.  Approximately 2 hours after induction with L-
arabinose, the optical density of the EO1-1 culture begins to gradually decrease.  As opposed to 
the results seen in the alanine scan previously, substituting multiple alanine residues can greatly 
diminish function whereas one substitution has no effect.  Overall the mutants suggest that the 
overall hydrophobicity of the peptide is crucial for its lethality. 
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Figure 6.23:  Induced growth curves of EO1 solubility mutants lowering the overall 
hydrophobicity of the original EO1 peptide.  The cultures were compared to an induced growth 
curve of the non-mutated EO1 clone. 
 
 Mutants of the arginine tail retained more lytic activity (Figure 6.24).  Replacing the final 
arginine residue with glutamic acid lowered the bacteriolytic nature of the peptide but not the 
onset of lethality.  EO1-5 is best described as a bacteriostatic/bactericidal peptide.  EO1-6 
lowered the overall charge of the peptide to neutral.  Upon induction the growth rate of cultures 
expressing EO1-6 decreased and 150 minutes after induction the growth rate slowed 
significantly, nearly stopping.  Taken together, these results suggest that the overall charge of 
the peptide or placement of arginine residues appears to be important for lysis but not growth 
inhibition. 
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Figure 6.24:  Induced growth curves of EO1 solubility mutants lowering the overall charge of 
the original EO1 peptide by modifying the C-terminal, arginine tail.  The cultures were compared 
to an induced growth curve of the non-mutated EO1 clone. 
 
6.4.3.4  Expression & Translocation Analysis of EO1 and its Derivatives 
 Alkaline phosphatase (PhoA), the display protein used in the periplasmic selection and 
in these studies, can also serve to report the successful transcription, translation and 
translocation of the peptide-PhoA fusion.  PhoA is only capable of folding properly once it has 
translocated into the periplasm where the environment is highly oxidizing.501  Once folded, PhoA 
has the ability to hydrolyze 5-bromo-4-chloro-3-indoxyl-phosphate (X-Phos) to form a blue 
precipitate.499; 500  The designed peptides and all of EO1’s derivatives discussed thus far were 
assayed for PhoA activity (Table 6.12). 
Of the designed peptides (EO1, 2, and 3; GD1, 2; VL1, 2), only EO1 had PhoA activity.  
Compared to the NI001 clone, which encodes a non-inhibitory peptide that translocates, EO1 
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exhibited high PhoA activity.  High PhoA activity only occurs when a large amount of PhoA is 
correctly translocated, but as all growth curves and viable counts indicate, EO1 kills its host cell 
shortly after induction.  It is, therefore, unlikely that large amounts of PhoA are accumulating in 
the periplasm before cell death.  PhoA activity has also been correlated to a peptide’s ability to 
pass through the membrane.  The bacteriolytic, amphipathic, α-helical model peptides are 
presumed to have no PhoA activity as being inserted into and staying in the membrane or 
secretion machinery, preventing translocation, is part of their function.  When EO1’s sequence 
is projected on an Edmundson wheel515 (Figures 6.25) the resultant helix does not form distinct 
basic and hydrophobic interfaces as seen with pore-forming peptides in nature such as 
magainin 2516 or the bacteriolytic peptide pool from the periplasmic selection (Figure 6.26).  The 
fact that EO1 does have strong PhoA activity along with its gradual rate of host cell lysis during 
the induced growth curve and its inability to form an amphipathic α-helix suggest that it operates 
by a different mechanism than the previously characterized α-helical model peptides. 
 All of the alanine scan mutants translocated to varying degrees.  The position 4 mutant 
which had an alanine instead of leucine and was the sole mutant without function translocated 
weakly.  Conservative position 4 substitutions including residues valine and isoleucine had high 
PhoA activity.  This was not surprising given that both mutations maintained full lytic activity.  
The aspartic acid mutant that had no lytic activity, however, had NI001-comparable PhoA 
activity.  The majority of the solubility mutants did not translocate and those that did performed 
weakly.  Mutations exhibiting no PhoA activity indicate a disruption of translocation or upstream 
processes such as misfolding of PhoA.  Mutations that do have PhoA, but no lytic activity 
suggest the substitutions inhibit EO1 from binding its target. 
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Table 6.12:  PhoA activity of the designed peptides and mutants of EO1.  Amino acid 
sequences as they would appear in an α-helix demonstrate that designed peptides, other than 
EO1, have basic and hydrophobic interfaces implying that they form amphipathic α-helices. 
*Weakly inhibitory ^Bacteriostatic/bactericidal 
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Figure 6.25:  Edmundson wheel projections of bacteriolytic, designed peptides EO1, EO2, VL1, 
and VL2 demonstrating that EO1 does not form an amphipathic α-helix like the other three 
peptides. 
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Figure 6.26:  Edmundson wheel projection of the amino acid group distribution of the 
bacteriolytic peptides isolated from the periplasmic peptide library selection from Chapter 4.  
The number within each circle indicates the position in the linear peptide sequence.  Colors 
represent the amino acid groups based on side chain characteristics and the size of the circle is 
proportional to the frequency of the group observed. 
 
6.4.3.5  Expression of Free EO1 Peptide 
 Periplasmic expression  Within the peptide-PhoA fusion there are potential contextual 
effects caused by the presence of PhoA and the peptide linker that may determine the activity of 
the peptide.  First, the initial residues of PhoA and/or linker, at the C-terminus of the peptide, 
may contribute to a motif necessary for the peptide’s function.  Also, the peptide may bind to a 
site on a target that does not lead to cell death, but the large, globular structure of PhoA may, 
through steric hindrance, inhibit the normal function of the target.  To characterize the 
functionality of EO1 in the absence of the display protein, PhoA, it was cloned into the same 
construct used in Chapter 4 and 5 to study free peptide expression, pKan-Solo (Figure 6.27).  
Plasmid pKan-Solo is an identical vector to pKan-PhoA1, the vector used in both the 
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periplasmic selection and constrained peptide screen, except that PhoA gene and linker 
sequence at the 3’ end of the peptide sequence has been removed.  Within a host cell, the 
vector, when induced, expresses a hybrid peptide composed of the PhoA signal peptide and the 
EO1 peptide.  As before, the signal peptide enables translocation of the peptide into the 
periplasm (Figure 6.28). 
 
 
Figure 6.27:  pKan-Solo was derived from the plasmid pKan-PhoA1.  The DNA encoding PhoA 
was removed leaving a gene product comprised of the signal peptide and the peptide of 
interest. 
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The construct was transformed into E. coli DH5α cells and grown to early log phase.  L-
arabinose was added to induce expression of the peptide and the optical density at 600 nm was 
measured to monitor the growth of the culture.  An uninduced culture was monitored in parallel 
and then the growth curves were compared.  EO1 preserved function within the free peptide 
construct, appearing to elicit host cell lysis faster than the EO1-PhoA construct (Figure 6.29).  
This is observation is likely due to the extra time necessary for the translation and translocation 
of PhoA. 
 
 
Figure 6.28:  Induction of pKan-Solo cultures produces a fusion of the PhoA signal peptide and 
the peptide of interest.  Following translocation, a peptidase cleaves off the signal peptide 
permitting the peptide of interest to be free of contextual effects. 
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Figure 6.29:  Free peptide expression of peptide EO1 in the periplasm.  Optical density (A600) 
was measured at different time intervals following the addition of L-arabinose. 
 
 
Cytoplasmic expression  To determine the effect of location on EO1’s activity, we moved 
the peptide into the construct pAmp-SoloTEV (Figure 6.30), a derivative of pKan-EmGH.  
pAmp-SoloTEV has been modified in several ways to accommodate co-transformation with 
pZS4int-TetR and pRK603440 for the in vivo expression of TEV protease.  The original p15A 
replication origin was replaced with pMB1 while the PLac promoter was substituted for the 
original PBAD promoter.  The selection marker bla was inserted in place of neo to enable 
selection of all three plasmids (pRK603 has neo).  The DNA sequence encoding EO1 was 
placed 3’ to the TEV protease recognition sequence and 5’ to a stop codon.  Upon the addition 
of isopropyl β-D-1-thiogalactopyranoside (IPTG) a hybrid peptide is expressed under the power 
of the PLac promoter.  This hybrid peptide is composed of three parts (Figure 6.31): 1) the N-
terminal sequence of EmGFP which is efficiently transcribed and translated (Chapter 2, Figure 
2.11), 2) the TEV recognition and cleavage sequence,440 and 3) the EO1 peptide.  When 
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induced in a host cell containing pZS4int-tetR and pRK603 with the addition of 
anhydrotetracycline (ATC), the induced TEV protease binds to its recognition sequence and 
cleaves the hybrid peptide releasing the EO1 peptide (Figure 6.32).  The system was 
constructed for free peptide expression in the cytoplasm only.  With the PhoA signal peptide 
absent, EO1 should be unable to translocate into the periplasm. 
 The construct was co-transformed with pZS4int-tetR and pRK603 into E. coli EPI301 
cells.  Three cultures were incubated until late lag phase when ATC was added to induce TEV 
protease expression.  Incubation continued until early log phase when IPTG was added to 
induce expression of the hybrid EO1 peptide.  The optical densities of the cultures at 600 nm 
were measured to monitor their growth rates.  The cultures induced either with L-arabinose or L-
arabinose and ATC showed only minor deviations in growth rate as compared to the uninduced 
culture (Figure 6.33).  EO1, while lethal as a free peptide in the periplasm, has no activity in the 
cytoplasm.  Again, EO1 differs from the α-helical model peptides whereas peptide 84 Pro- 
showed some activity in the cytoplasm.  Most likely the α-helical model peptides have access to 
their purported targets, the inner membrane or Sec pathway, from the cytoplasm.  The lowered 
level of lethality may arise from the lack of being forced to interact with the membrane via the 
PhoA signal peptide versus having to randomly interact with the membrane while floating in the 
cytoplasm.  EO1 having no activity in the cytoplasm indicates that its target is in the periplasm, 
either as a free-floating target, the cell wall or at the periplasmic interface of the membrane. 
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Figure 6.30:  pAmp-SoloTEV was constructed for the solo expression of peptides in the 
cytoplasm.  It is a derivative of pKan5-T1T2 with changes to the replication origin (pMB1), 
selection marker (bla) and promoter (PLac) to insure plasmid compatibility with pRK603 and 
pZS4int-tetR. 
 
 
 
 
 
 
Figure 6.31:  Hybrid peptide generated by inducing pAmp-SoloTEV with the addition of L-
arabinose to the growth medium comprised of the leader peptide, TEV protease recognition 
sequence and the peptide EO1 
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Figure 6.32:  In vivo TEV protease processing of hybrid peptide expressed from pAmp SoloTEV 
results in non-fused, free EO1 peptide in the cytoplasm. 
 
 
Figure 6.33:  Growth curve of peptide EO1 expressed as a free peptide in the cytoplasm only.  
Optical density was measured at different time intervals following the addition of ATC (TEV 
protease induction) and L-arabinose (peptide induction). 
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6.4.3.6  Morphological Effects of Free Peptide Expression 
 EO1’s activity in the periplasm and its bactericidal phenotype indicate that its function 
possibly involves inhibition of the cell wall directly or indirectly by interrupting its synthesis.  This 
should have adverse effects on the cell morphology of the host cell.  E. coli DH5α cells 
containing the pKan-SoloEO1 construct encoding the EO1 peptide were grown to mid-log 
phase.  As a control, a culture of pKan-Solo84Pro-, encoding the 84 Pro- peptide and 
supplemented with D-glucose to suppress expression during growth, was grown in parallel.  L-
arabinose was added to the culture to induce EO1 peptide’s expression.  At time intervals 
following induction, samples of each culture were viewed under differential interference contrast 
(DIC) microscopy.  This procedure obviates the need for staining the cells to make them visible 
and potentially altering the cell morphology.  Ethidium bromide (EtBr) was added to the samples 
at a low concentration (~5.7 ng/mL).  EtBr helps in the assessment of cell viability without 
changing cell morphology.  Dead cells or cells whose membrane has increased membrane 
permeability due to disruption have increased uptake of EtBr.552; 553  When viewing the cells 
under a TRITC filter on a fluorescent microscope the amount of EtBr uptake by each cell is 
observable, using the DIC field as a comparison we can differentiate viable and dead cells. 
 The control culture, with repressed 84 Pro- peptide expression, shows healthy rod-
shaped cells of varying length at the point of induction (Figure 6.34).  After 120 minutes of 
further incubation the control culture cells maintain the same morphology (Figure 6.35).  The 
addition of EtBr to the sample showed that only a small minority of the population of the cells 
are capable of EtBr uptake, consistent with healthy cells. Approximately 15 minutes after 
induction with the addition of L-arabinose, a majority of cells in the EO1-expressing culture 
exhibit ample uptake of EtBr (Figure 6.36).  Approximately 60 minutes after induction a 
segment of the population develops small, black circles or lesions on their surfaces (Figure 
6.37).  When viewed under the TRITC filter, the lesions correlate with regions of cells that lack 
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uptake of EtBr, likely due to lysis.  These cells also tend to be elongated compared to WT cells.  
The appearance of elongated cells with lesions continued through the completion of the 
experiment (Figures 6.38-39).  The cell morphologies observed are similar to those of 84 Pro- 
(Chapter 5, Section 5.4.3.5), a representative of the α-helical model peptides, being expressed 
from a free peptide construct, but not as common.  The observed morphological changes may 
only result from cells producing larger amounts of EO1 as a secondary effect of EO1’s activity.  
Cells expressing smaller amounts would only exhibit more permeable membranes via EtBr 
uptake.  The induced growth curves of EO1 where the optical densities decreased gradually 
indicate a majority of the population does not lyse. 
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Figure 6.34:  DIC photomicrographs of E. coli DH5α cells with plasmid pKan-Solo84Pro- in LB 
growth medium supplemented with 0.2% glucose to repress 84 Pro- expression.  Photos were 
taken when the cultures were entering mid-log phase growth, simultaneous with the addition of 
L-arabinose to induce test cultures. 
 
495 
 
 
 
 
Figure 6.35:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-Solo84Pro- in LB growth medium supplemented with 0.2% glucose to repress 84 Pro- 
expression.  Photos were taken 120 minutes following the addition of L-arabinose to induce test 
cultures.  DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the 
right column (D, E, F) observing EtBr uptake using a TRITC filter. 
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Figure 6.36:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-SoloEO1 in LB growth medium supplemented with 0.3% arabinose to induce EO1 
expression.  Photos were taken 15 minutes following induction with the addition of L-arabinose..  
DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the right 
column (D, E, F) observing EtBr uptake using a TRITC filter. 
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Figure 6.37:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-SoloEO1 in LB growth medium supplemented with 0.3% arabinose to induce EO1 
expression.  Photos were taken 60 minutes following induction with the addition of L-arabinose.  
DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the right 
column (D, E, F) observing EtBr uptake using a TRITC filter. 
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Figure 6.38:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-SoloEO1 in LB growth medium supplemented with 0.3% arabinose to induce EO1 
expression.  Photos were taken 120 minutes following induction with the addition of L-
arabinose.  DIC photos in the left column (A, B) correspond with the fluorescent photos in the 
right column (D, E) observing EtBr uptake using a TRITC filter. 
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Figure 6.39:  DIC and fluorescent (TRITC) photomicrographs of E. coli DH5α cells with plasmid 
pKan-SoloEO1 in LB growth medium supplemented with 0.3% arabinose to induce EO1 
expression.  Photos were taken 150 minutes following induction with the addition of L-
arabinose.  DIC photos in the left column (A, B, C) correspond with the fluorescent photos in the 
right column (D, E, F) observing EtBr uptake using a TRITC filter. 
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6.4.3.7  EO1’s Effect on Cell Osmolarity 
 The cell viability assay indicated that the small amount of cell lysis observed during EO1 
induced growth curves was a secondary effect of the peptide’s bactericidal activity.  Free 
peptide expression in the cytoplasm and PhoA activity assays also indicate that EO1 only has 
activity when localized to the periplasm, a cellular compartment critical for the synthesis of the 
cell wall.  Therefore, stabilization of the cell with the use of an hypertonic growth medium may 
negate EO1’s effect on cell wall synthesis. 
 To examine the mechanism of EO1 we expressed its PhoA fusion from the pKan-
PhoAEO1 plasmid in Luria-Bertani (LB) growth media442; 443 supplemented with various 
concentrations of sucrose and MgSO4 to produce hypertonic solutions.  Cultures were incubated 
until early log phase growth, then EO1-PhoA fusions were induced and the growth of the culture 
was monitored to detect if EO1 maintained its lethality and/or lytic activity.  Samples of the 
cultures were removed at time intervals following induction to observe changes in cell 
morphology using differential interference contrast (DIC) microscopy. 
 Expression of EO1 in a isotonic growth medium (LB) causes cell death, as seen in the 
cell viability assay, and causes a percentage of the population to lyse within 30 minutes of 
induction (Figure 6.40).  The addition of various concentrations of sucrose, which correlated 
with a decrease in the growth rate of uninduced cultures, and MgSO4 did not negate the 
bactericidal activity of EO1.  The induced cultures in hypertonic growth media, however, did not 
decrease in optical density in contrast to the culture grown in LB.  This substantiates the results 
of the cell viability assay indicating that cell lysis caused by EO1 is a secondary effect not 
necessary for its bactericidal activity.  Photomicrographs of cells expressing EO1 in the LB 
supplemented with 0.5 M sucrose or 0.5 M sucrose + 16.6 mM MgSO4 were similar to 
uninduced cells containing the plasmid encoding 84 Pro-, pKan-PhoA84Pro- (Figure 6.41).  
501 
 
 
 
This contrasts with the cell morphologies observed in Section 6.4.3.6 where EO1 induced cells 
in LB medium exhibited a lesioned, elongated cell phenotype following induction.  This suggests 
that this phenotype is associated with the secondary lytic effect and not the primary bactericidal 
effect.   
The phenotype is also dissimilar to that exhibited by pore-forming AMPs according to 
previous studies541; 555 and the peptidoglycan-inhibiting and cell-lysing antibiotic ampicillin.556; 557  
An identical growth curve of cells containing the plasmid pKan-PhoA84Pro- in LB supplemented 
with 0.5 M sucrose + 16.6 mM MgSO4 negated ampicillin’s lytic effect (Figure 6.42), but by a 
mechanism not observed with EO1, through the formation of spheroplasts (Figure 6.43). 
 
 
Figure 6.40:  Induced growth curves of E. coli DH5α cells expressing EO1-PhoA fusions in 
various hypertonic growth media supplemented with L-arabinose. 
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Figure 6.41:  DIC photomicrographs of E. coli DH5α cells containing plasmid pKan-PhoA1 
encoding EO1-PhoA fusions in LB medium supplemented with various additives to produce a 
hypertonic solution.  Photos were taken 160 mins after induction with the addition of 0.2% 
arabinose.  A) 84 Pro-, 0.5 M sucrose, 16.6 mM MgSO4, uninduced; B) EO1, 0.5 M sucrose, 
0.2% arabinose; C) EO1, 0.5 M sucrose, 16.6 mM MgSO4, 0.2% arabinose. 
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Figure 6.42:  Growth curves of E. coli DH5α containing plasmid pKan-PhoA1 encoding 84 Pro- 
peptide-PhoA fusions in various hypertonic growth media supplemented with the bacteriolytic 
antibiotic ampicillin. 
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Figure 6.43:  DIC photomicrographs of E. coli DH5α cells containing plasmid pKan-PhoA1 
encoding 84 Pro- peptide-PhoA fusions in LB medium supplemented with 0.5 M sucrose and 
16.6 mM MgSO4.  Photos were taken after the addition of 250 ng/mL ampicillin: A) 160 mins 
after, B) 200 mins after.  Arrows indicate spheroplast formation. 
 
6.4.4 Antimicrobial Activity of Synthetic Peptide EO1 
6.4.4.1  Determination of Minimum Inhibitory Concentrations 
EO1 peptide was synthesized at ~95% purity for further in vitro analysis.  It was 
dissolved in either dimethyl formamide (DMF) or dimethyl sulfoxide (DMSO) and used to 
calculate minimum inhibitory concentrations (MICs) employing the broth dilution method.441   
A number of organisms were analyzed to delineate EO1’s spectrum of activity.  Gram-
negative organisms included ‘WT’ W3110 and SM101, a permeable lpxA mutant,444 Escherichia 
coli strains, Pseudomonas aeruginosa, Klebsiella pneumoniae and Enterobacter aerogenes.  
None of the Gram-negative organisms had susceptibility at concentration ≤ 250 µM (Table 
6.13).  Given that E. coli DH5α cells producing EO1 were highly susceptible, this indicates 
permeability issues.402  Optimizing EO1 for permeability or attaching a carrier molecule that is 
permeable could recover lethality of EO1 when introduced exogenously. 
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EO1 had more success against Gram-positive organisms, including Staphylococcus 
aureus, Enterococcus faecalis, Streptococcus salivarius, Bacillus subtilis, Micrococcus luteus, 
Corynebacterium minutissimum and Mycobacterium smegmatis.  Growth conditions had to be 
changed to accommodate several of the fastidious Gram-positive organisms.  Growth media for 
E. faecalis, S. salivarius and C. minutissimum was Todd Hewitt Broth (THB), for M. smegmatis it 
was 7H9 broth while S. aureus, B. subtilis and M. luteus demonstrated the same growth and 
MIC in both LB and THB.  M. luteus’ calculated MIC of 3.9 µM was the lowest compared to 10 
µM for S. aureus, 15.6 µM for both E. faecalis and B. subtilis, 7.8 µM for S. salivarius and C. 
minutissimum and 30 µM for M. smegmatis.  The inhibition of all Gram-positive organisms 
studied at low concentrations further suggests that EO1 suffers permeability issues against 
Gram-negative organisms. 
 The MIC of eukaryote Saccharomyces cerevisiae was also determined.  It is not unusual 
that antimicrobial peptides found or derived from nature have activity against bacteria, yeasts559 
and even viruses.560  Theoretically, the basic charge of EO1 should decrease its activity against 
eukaryotes such as S. cerevisiae or mammalian cells due to their neutrally charged 
membranes.520  Further, earlier studies suggest EO1 is not a pore-forming peptide like the α-
helical model peptides and their counterparts in nature.  The same procedure was used as 
above substituting YPD medium561 for the growth of S. cerevisiae BY4742.  EO1 did show 
activity at a greatly reduced MIC of 250 µM compared to the bacterial species assayed.  This 
suggests EO1 would have less toxicity against higher eukaryotes due to their greater 
divergence in membrane and cell wall composition.562 
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Table 6.13:  MICs of peptide EO1 against various organisms.  A value of ‘> 250’ indicates no 
MIC was determined. 
 
 Both peptides EO1 and 84 Pro- have bacteriolytic effects on S. aureus and share 
common phenotypes as observed with microscopy (Section 6.4.3.6 and Chapter 5 Section 
5.4.3.5), their reliance on replication (Section 6.4.4.3 and Chapter 5 Section 5.4.4.3), and their 
hemolytic activities (Section 6.4.4.4 and Chapter 5 Section 5.4.4.4).  Their sequences and 
structures, however, differ.  We have proposed that peptide 84 Pro- forms an amphipathic α-
helix that is a determinant for its lytic activity.  EO1 does not conform to this secondary 
structure.  This suggests that the peptides may be acting by two different mechanisms.  It is also 
possible that the peptides have the same target and their activities result in similar outcomes or 
that their activities are synergistic.  To determine their relationship, we performed an MIC with 
both peptides on S. aureus.  Three MICs were determined: EO1, 84 Pro- and a combination of 
both peptides (Table 6.14) using the methods outlined above.  The combination of 6 µM of both 
EO1 and 84 Pro- was inhibitory whereas the peptides alone had an MIC of 10 µM and 9 µM 
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respectively.  If the peptides functioned by identical mechanisms we would expect that the 
combination of the peptides would produce an MIC half of the individual peptides.  If, however, 
the peptides had separate mechanisms and were not synergistic, the MIC would be that of the 
most active peptide (9 µM, 84 Pro-).  The observed MIC of both peptides satisfies neither 
scenario.  A lowered MIC of 6 µM may indicate synergy between the peptides.   
 
Table 6.14:  MIC of a combination of synthetic peptides EO1 and 84 Pro- against S. aureus 
compared to their MICs as individual peptides.   
*In combination, each peptide’s MIC was lowered to 6 µM 
 
6.4.4.2  The Effect of EO1 on the Growth of Staphylococcus aureus 
 To observe the phenotypic effect of the peptide exogenously, growth curves using S. 
aureus were performed with varying concentrations of peptide EO1.  EO1 was added to growing 
cultures of S. aureus at concentrations varying from 62.5 to 0 µM.  The optical density of the 
cultures was then monitored at short time intervals following the peptide’s addition. 
 Cultures with concentrations of 3.9 up to 62.5 µM showed immediate decreases in 
optical density upon addition of the peptide (Figure 6.44).  The 15.6, 31.3, and 62.5 µM cultures 
had long periods of cell lysis that attained low optical densities.  This is contrary to what was 
observed when expressing EO1 within E. coli DH5α cells.  The more complex cell wall of Gram-
negative cells may provide some deterrent to full cell lysis even though the cell is still dead.  
Similar to the growth curves carried out using peptide 84 Pro- in Chapter 5 (Section 5.4.4.2), 
recovery of cultures initially lysing was observed at concentrations of 31.3, 15.6, 7.8 and 3.9 µM.  
To determine if resistance to EO1 peptide accounted for the recovery of growth in the cultures a 
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small volume of the 15.6 µM culture that had recovered was plated on LB medium.   An isolated 
colony was then subjected to an MIC assay and found to have a maximum MIC of 15.6 µM.  
This indicates that no resistance to the peptide arose, but that there was not enough peptide to 
lyse the entire culture or the peptide was proteolytically degraded before all cells were lysed.   
 The efficiency of EO1’s lethality versus higher density cultures exceeds what was 
expected.  An MIC value of 10 µM was calculated based on starting inoculum of 104 cells/mL.  If 
we assume that an optical density of 0.14 at 600 nm is ~1.2 x 108, then the mid-log phase 
culture to which EO1 was added had a cell density of ~2.8 x 108 cells/mL amounting to a 2.7 x 
104 fold difference in cell density.  However, the effective MIC over 450 minute period increased 
only 6.25 fold.  Udekwu et al., demonstrated that commonly used antibiotics such as 
vancomycin, linezolid and oxacillin demonstrated decreased effectiveness versus high-density 
cultures of S. aureus at elevated concentrations of 20x their original MICs.608 
 
Figure 6.44:  Growth curves of S. aureus, supplemented with synthetic EO1 peptide at various 
concentrations. 
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6.4.4.3  Replication Dependence of EO1 Activity 
 Antimicrobial peptides whose function involves pore-formation or other general 
membrane disruption mechanisms have been shown to be effective at killing persister563 or 
stationary phase cells.564  These mechanisms, unlike those of more traditional antibiotics such 
as penicillin, do not require replicating or metabolically active cells.  This proves advantageous 
when dealing with biofilms built upon non-replicating persister cells or slow-growing, intracellular 
pathogens such as Mycobacterium tuberculosis.609  We performed an assay to characterize the 
behavior of EO1 in the presence on non-replicating cells.  
 A culture of S. aureus was grown to mid-log phase and then washed resuspended in 
HEPES-NaCl (HN) buffer.  To aliquots of suspended cells, EO1 peptide at a concentration of 60 
µM, ampicillin at a concentration of 1480 µM and non-inhibitory peptide 84 (Chapter 5, Section 
5.4.4.3) from the constrained peptide screen at a concentration of 60 µM were added.  The cell 
suspensions were then incubated with shaking at 37 oC.  The optical densities of each 
suspension were measured at 600 nm to monitor lysis of the cells.  After 45 minutes 10x 
concentrated THB was added to each suspension to resume growth conditions.  The optical 
density was measured at time intervals during the subsequent incubation.   
 The addition of peptide 84 had no effect on the optical density or viable cell count on the 
cells in either the HN buffer or the THB supplemented buffer (Figure 6.45).  The cells resumed 
growth shortly after the addition of medium to the cell suspensions.  The optical density and 
viable cell count of the ampicillin culture did not change in the HN buffer (Figure 6.46).  Once 
THB was added, the optical density did not increase while the amount of viable cells decreased 
toward zero.  The viable cell count of the aliquot containing EO1 decreased by ~88.3% in the 
HN buffer (Figure 6.47.A), however, a more dramatic decrease was observed once THB was 
added and the cells were able to resume growth.  The log-scale chart better reflects this 
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decrease after THB was added (Figure 6.47.B).  The optical density remained largely 
unchanged.  After the addition of THB the viable cell count decreased by an additional 99.99%.  
While a large decrease was observed during the non-replicating phase, a much larger decrease 
when growth medium was introduced demonstrates a preference for growth to have an effect.  
The immediate onset of lysis once THB was added may indicate uptake of EO1 was increased 
in the presence of nutrients. 
 The replication assay suggests that EO1 has activity against non-replicating cells, but 
that this activity is diminished compared to cells actively growing.   Nutrient uptake by the cells 
may increase the intracellular concentration of EO1, increasing its antimicrobial activity. 
 
 
Figure 6.45:  Replication dependence assay monitoring the effects of synthetic peptide 84 on 
the viable count and optical density (A600) of non-replicating and replicating S. aureus cells in 
HN buffer or HN buffer supplemented with Todd Hewitt Broth. 
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Figure 6.46:  Replication dependence assay monitoring the effects of bacteriolytic antibiotic 
ampicillin on the viable count and optical density (A600) of non-replicating and replicating S. 
aureus cells in HN buffer or HN buffer supplemented with Todd Hewitt Broth. 
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Figures 6.47.A-B:  Replication dependence assay monitoring the effects of synthetic peptide 
EO1 on the viable count and optical density (A600) of non-replicating and replicating S. aureus 
cells in HN buffer or HN buffer supplemented with Todd Hewitt Broth.  A) Standard scale, B) 
logarithmic scale for viable count y-axis. 
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6.4.4.4  Hemolytic Activity of Peptide EO1 
 Bacteriolytic peptides in nature tend to be membrane perturbers through the formation of 
holes that result in cell lysis.  Unfortunately, this mechanism also lyses erythrocytes or red blood 
cells, decreasing or nullifying the therapeutic value of the antimicrobial.527; 528  We performed a 
sheep red blood cell (SRBC) hemolysis assay to determine if EO1 was hemolytic.529 
 The SRBCs were washed and resuspended in phosphate buffered saline (PBS) solution 
at pH 7.4.  Peptides EO1 or 84 were serially diluted and added to the cell suspensions at a 
range of concentrations from 1 to 250 µM.  All SRBC/peptide mixtures were incubated at 37 oC 
for 18 hours with shaking for a stringent examination of EO1’s hemolytic activity.  The longer 
incubation used properly reflects the clearance of the peptide if it were to be present in the 
blood.529  After the incubation the samples were centrifuged to remove whole, unlysed 
erythrocytes.  The optical density of the supernatants at 570 nm was measured to quantify the 
amount of hemoglobin that was released from lysed erythrocytes.  Background hemolysis was 
approximated by the 0% hemolytic control containing only PBS and subtracted from the values 
of the other samples. 
 The 250 µM sample of EO1 had the highest hemolytic value at 2.28% hemolysis 
compared to the completely lysed 0.1% Triton X-100 sample (Table 6.15).  Therefore, EO1 has 
no appreciable hemolytic activity, according to this assay, well above its MIC against S. aureus 
of 10 µM.  EO1 shares a similar primary sequence with natural antimicrobial peptides and 
peptide 84 Pro-, but likely does not conform to their secondary structure or the hemolytic nature 
of the former.  The antimicrobial activity of EO1 against Gram-positive bacteria and its lack of 
hemolytic activity may make it a viable lead for anti-infective development. 
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Table 6.15:  Hemolytic activity of peptide EO1 at various concentrations against sheep red 
blood cells calculated as a percentage of the amount of hemolysis observed with 0.1% of 
detergent Triton X-100. 
 
6.5 Discussion 
 For the isolation of more peptides and understanding the sequence requirements of the 
α-helical model peptides, the linear amino acid sequences of the 94 lytic peptides, isolated 
using the pIVD system (Chapter 4, Table 4.1), were used for the rational design of 6 peptides 
(Figure 6.2).  Two peptides each were designed from three groups based on phenotypic 
characteristics of the lytic peptides 1) early onset of lysis (Table 6.1, Figures 6.3.A-C), 2) high 
rate of lysis (Table 6.2, Figures 6.4.A-C), and 3) low optical density endpoint (Table 6.3, 
Figures 6.5.A-F).  The peptides based on the low optical density endpoint group, GD1 and GD2 
(Table 6.5), were non-inhibitory (Figure 6.7) despite their seeming conformation to the 
amphipathic α-helix with large basic interfaces containing arginines (Figure 6.48).  This 
indicates that although there are numerous instances of variation in the size of the interfaces 
and position of residues, there may be strict requirements for particular positions.  In contrast, 
designed peptides VL1, VL2 and EO2 (Tables 6.6-7) were all lytic (Figures 6.8-9), lacked PhoA 
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activity (Table 6.12), and their sequences conformed to the model of an amphipathic α-helix 
(Figure 6.25).  The isolation of these three peptides demonstrates that the design of lytic 
peptides based on the distribution of amino acids of the lytic peptides isolated from the pIVD 
system is possible and obviates the need to screen large libraries for continued isolation of 
peptides of similar sequence and mechanism.  
 
Figure 6.48:  Edmundson wheel projections of designed peptides GD1 and GD2.  Neither 
peptide exhibited growth inhibiting phenotypes despite the suggestion that they are capable of 
forming amphipathic α-helices. 
 
The peptide EO1 (Table 6.7) was designed based on the same parameters as EO2, VL1 
and VL2, its sequence, however, does not conform to an amphipathic α-helix when wrapped 
around an Edmundson wheel projection515 (Figure 6.25).  The dissimilarity of EO1’s structure 
compared to the α-helical model peptides, in addition to its efficient translation and 
translocation, as seen in the PhoA activity assays (Table 6.12), strongly implies that EO1 has a 
distinct mechanism than the α-helical model peptides despite sharing a similar amino acid 
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composition.  The growth phenotype of EO1 also differs radically from the other lytic peptides.  
Induced growth curves of EO1 demonstrated an early onset of growth inhibition within 10 
minutes of induction with a gradual reduction of the culture’s optical density (Figures 6.9, 6.12).  
The induced culture undergoes a rapid rate of lysis in the first 10 minutes of growth inhibition but 
decreases to a gradual rate for the remainder of the growth curve (Figures 6.13.A-B).  If we 
assume that time following induction has a linear correlation with the accumulation of EO1 
peptide in the periplasm, then a low intracellular concentration of the peptide is sufficient for the 
inhibition of growth.  Further examination revealed a marked decrease in the viable cells in the 
culture during induction not correlating to the amount of lysis observed suggesting EO1’s activity 
is bactericidal (Figure 6.14).  Induction of EO1 expression in hypertonic growth medium further 
indicated the lysis observed previously was a secondary effect of EO1’s bactericidal activity 
(Figure 6.40) and not necessary for growth inhibition.  The amount and rate of lysis was 
diminished in the presence various concentrations of solutes, sucrose and MgSO4, suggesting 
EO1’s activity cascades, decreasing the integrity of the cell wall causing a portion of the cell 
population to lyse in isotonic LB growth medium. 
Free peptide expression of EO1 had an effect on cell morphology producing a black 
circle or lesioned phenotype on the surfaces of elongated cells (Figures 6.37-39) suggesting 
that the peptide may be most effective against replicating cells.  Similar to peptide 84 Pro- 
(Chapter 5, Section 5.4.3.6), longer incubation times in the presence of inducer also produced 
the black circle/lesion phenotype in non-elongated or non-replicating cells (Figure 6.38).  This 
may be because actively replicating cells are sensitive at lower concentrations of the peptide 
than cells not actively replicating.  These data are supported by experiments showing a small 
reduction in the viability of Staphylococcus aureus cells suspended in HN buffer (Figures 
6.47.A-B), possibly because some cells were still metabolically active, with a larger decrease in 
viability upon the subsequent addition of nutrients, initiating growth and replication. 
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Like peptide 84 Pro-, free peptide expression in the periplasm was lethal, producing the 
same growth phenotype as the EO1-PhoA fusion (Figure 6.29).  Free peptide expression in the 
cytoplasm, however, did not affect the growth of E. coli (Figure 6.33).  Whereas, peptide 84 
Pro- slowed growth of host cells upon cytoplasmic expression, EOI required translocation to the 
periplasm to have activity. Data presented in Chapters 4 and 6 suggest that peptide 84 Pro- and 
related α-helical peptides target the inner membrane or Sec pathway, both of which are 
accessible from the cytoplasm.  This suggests that EO1 does not target the inner membrane or 
the Sec pathway but a target located solely in the periplasm.  The synthesis of peptidoglycan, 
an integral component of the cell wall, is one potential target of an exclusively periplasmic-acitve 
peptide.  Photomicrographs of EO1 induced cells growing in hypertonic growth medium (Figure 
6.41), however, showed no visible effects on the cell wall in comparison to uninduced (Figure 
6.41), 84 Pro- induced (Chapter 5, Figure 5.38), and ampicillin treated cells (Figure 6.43), yet 
expression was still lethal (Figure 6.40).  The lack of defective cell wall phenotype similar to 
peptidoglycan-synthesis inhibiting antibiotic, ampicillin (Figure 6.43), suggests that EO1 does 
not inhibit this process.  Therefore, EO1’s target is located in the periplasm but is likely not the 
inner membrane, peptidoglycan synthesis or the Sec pathway.  Experiments in which both 
peptide 84 Pro- and EO1 were added to the same culture of S. aureus (Table 6.14) showed that 
while the combined toxicity of the two peptides was greater than either of the individual 
peptides, the effects were not precisely additive.  If the peptides were not acting by the same 
mechanism we might expect their MICs to not be affected by the presence of the other peptide. 
Since the PhoA activity, hypertonic growth curves, and spectrum of activity (Table 6.13, Chapter 
5, Table 5.17) data suggest EO1 has a distinct mechanism from 84 Pro-, this ambiguous result 
implies that one of the peptides may enhance the activity of the other.  For instance, if peptide 
84 Pro- inhibits translocation through the Sec pathway this could limit the concentration of 
EO1’s target in the periplasm and thus require a smaller concentration of EO1 to elicit cell 
death. 
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Several mutants of EO1 were generated to examine their effect on EO1’s activity.  
Alanine scanning was used to determine which residues were critical for function606 (Table 6.9).  
The only mutation that affected the antimicrobial activity of the peptide was the replacement of 
the leucine at position 4 with an alanine (Figures 6.21.A-B).  PhoA activity of the mutant was 
diminished compared to EO1, comparable to other alanine mutants that were still lethal (Table 
6.12).  Assuming the conservative leucine to alanine mutation does not affect solubility, folding 
or degradation of the EO1-fusion,610; 611 this suggests that the alanine mutant was defective in 
target binding.  Strangely, leucine is not a reactive amino acid and would not be expected to 
have a critical role in binding to a target.  A series of EO1 mutants replacing the leucine at 
position 4 with residues of increasingly different side groups were produced (Table 6.10) and 
tested for lethality (Figures 6.22.A-B) and PhoA activity (Table 6.12).  Isoleucine and valine 
mutants, whose side groups are characteristically similar in size and hydrophobicity to leucine, 
were the only mutants to maintain the original EO1’s lethality indicating strict position 
requirements.  Larger amino acids, including phenyalanine, tyrosine, asparagine and lysine had 
no antimicrobial or PhoA activity possibly due to their misfolding of PhoA, inhibition of translation 
or their inability to translocate to the periplasm.  As the encoding DNA of the mutants and the 
original EO1 are the same except for the mutated codon it is difficult to imagine that the lack of 
activity is due to misfolding by the mRNA or protein from single and largely conservative 
mutations.  Therefore, it is possible that phenylalanine and tyrosine mutants are too large and 
hydrophobic (EO1 is mostly comprised of large residues including F, W, and R) too pass 
through the exit channel of the ribosome stalling its own translation.612  Substitution of 
asparagine for leucine, given EO1’s similarity to typical conserved elements in signal peptides, 
may inhibit translocation.613  Similarly, a high concentration of basic residues C-terminal to a 
signal peptide, as is the case with a lysine substitution in EO1 and supported by the α-helical 
model peptides of Chapters 4 and 5, can prevent translocation into the periplasm resulting in 
cytoplasmic accumulation.614  This, however, cannot explain the lysine mutant’s lack of lytic 
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activity.  Finally, the aspartic acid mutant acted similar to the position 4 alanine scan mutant and 
was able to produce PhoA activity, supporting the premise that small residues do not prevent 
EO1’s translocation or upstream processes, but did not exhibit lethality.  Unfortunately, the 
inability of the large side groups to translocate impairs study of the requirements at position 4 
within the pIVD system, necessitating the use of in vitro methods that bypass inner membrane 
permeability concerns.  
Concerns with EO1’s solubility prior to its synthesis prompted the production of a series 
of mutants to lower either its hydrophobicity or the concentration of basic residues at the C-
terminus (Table 6.11).  To address the hydrophobicity reduction, four mutants altering positions 
1 and 8 were generated.607  In all of the mutants, the initial phenylalanine was replaced with an 
alanine (EO1-1), deleted (EO1-2), or replaced with a small, hydrophilic serine residue (EO1-3, 
4).  The tryptophan at position 8 was replaced with an alanine in EO1-1 and EO1-3 and a serine 
in EO1-4.  Oddly, while the alanine scan showed that only position 4 was critical for function and 
that all the alanine mutants were efficiently translocated, mutants EO1-2, 3, and 4 demonstrated 
no PhoA activity (Table 6.12).  However, mutant EO1-1 was able to translocate but had a late 
onset of bacteriostatic/bactericidal activity distinct from the original EO1 peptide (Figure 6.23).  
Therefore, while no one position, besides position 4, had a critical effect on the activity of EO1 
the replacement of two large amino acids, F and W, by small amino acids negated PhoA 
activity.  This is contrary to what was observed at position 4 where large amino acids tend to 
inhibit active PhoA.  While mutants EO1-2, 3 and 4 offer no insights on EO1’s interaction with its 
target, EO1-1 demonstrates a significant reduction in activity with two alanine mutations.  Single 
alanine mutations have no effect on EO1, but coordination of two alanine mutations can reduce 
its activity. 
A second set of mutations modified the composition of the arginine-rich C-terminus of 
EO1 (Table 6.11).  The placement of glutamic acid at position 12 in mutant EO1-5, replaced a 
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basic arginine and lowered the overall charge of the peptide to +1.  Further, EO1-6 replaced the 
alanine at position 10 with a second glutamic acid to produce a neutrally charged peptide.  In 
comparison to the original EO1 construct’s growth curve, EO1-5 initiates cell death nearly 
simultaneously but does not exhibit the gradual reduction in optical density (Figure 6.24).  As 
our data suggest that cell lysis is a secondary effect of EO1’s activity, this implies that the 
positive charge of the arginine tail is responsible for this effect.  However, further reduction of 
the charge, making the peptide neutral, results in a delay in the onset of cell death but does not 
negate activity.  Therefore, the arginine tail increases function of EO1 but is not necessary for its 
activity. 
EO1 demonstrated a different spectrum of activity than either peptides PL098 (Chapter 
4, Table 4.17) or 84 Pro- (Chapter 5, Table 5.17).  Surprisingly, EO1 had no activity against E. 
coli when introduced exogenously (Table 6.13).  It was also not effective against other Gram-
negative organisms including Pseudomonas aeruginosa, Klebsiella pneumoniae, and 
Enterobacter aerogenes indicating EO1 may not be able to penetrate the more complex Gram-
negative cell wall402 (Chapter 5, Figures 5.49.A-B).  Cell permeability problems can be 
addressed by the incorporation of peptides or molecules that increase permeability403  or the 
use of nanoparticle vectors for intracellular delivery.404  However, EO1 had activity against all 
Gram-positive organisms assayed including Streptococcus salivarius (7.8 µM), a contributor of 
dental caries584 and potential opportunistic pathogen,585 Enterococcus faecalis (15.6 µM), which 
can cause meningitis,586 endocarditis,587 and bacteremia588 and is a notable hospital acquired 
infection,589 and S. aureus (10 µM), which causes extensive ailments including pneumonia,590 
meningitis,591 bacteremia,592 toxic shock syndrome,593 and a number of skin conditions.594  E. 
faecalis and S. aureus represent strains exhibiting antibiotic resistance, especially vancomycin-
resistant Enterococcus (VRE)595 and methicillin-resistant S. aureus (MRSA).596  The sensitivity 
of Mycobacterium smegmatis (30 µM) indicates that EO1 might also have activity against the 
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Mycobacterium tuberculosis597 the typical causative agent of tuberculosis and increasingly 
antibiotic resistant.598; 599 
Interestingly, growth curves of S. aureus supplemented with EO1 (Figure 6.44) had a 
similar lytic profile to that of peptide 84 Pro- (Chapter 5, Figure 5.39) instead of the bisphasic, 
gradual lysis observed within E. coli, suggesting a possible inhibition more intimately tied to cell 
wall synthesis.  Unfortunately, without a similar study of E. coli’s response to exogenous EO1, 
incomplete due to a lack of permeability in Gram-negative bacteria, it cannot be concluded if this 
is an effect EO1 has on all bacteria when introduced exogenously instead of in vivo or 
endogenously.  The S. aureus growth curves also demonstrated EO1’s resilient activity against 
mid-log phase cells with an MIC of 62.5 µM, a 6.25-fold increase compared to orders of 
magnitude increase in the amount of cells.  This indicates that EO1 has a low therapeutic 
concentration.   
Natural, lytic antimicrobial peptides (AMPs) form amphipathic, α-helices with basic 
interfaces and have activity against a variety of microorganisms.  Unfortunately, several of the 
peptides, including melittin527 and magainin 2,528 also exhibit hemolytic activity, diminishing their 
value as therapeutic agents.  To thoroughly examine the hemolytic activity of EO1, which shares 
common sequence elements with the lytic AMPs, we incubated sheep red blood cells with the 
peptide in a non-isotonic solution for 18 hours at 37 oC to properly reflect therapeutic 
conditions.529  All concentrations of EO1 up to 250 µM, 25-times the MIC of S. aureus, 
demonstrated negligible hemolysis (Table 6.15).  EO1’s lack of hemolytic activity and its low 
MICs against medically pertinent pathogens, such as S. aureus and E. faecalis, make it an 
attractive candidate for antimicrobial use and development.  
 Studies of EO1 revealed that the pIVD and other IVD systems could be improved.  
Mutations in the PBAD promoter system have been shown to give rise to unresponsive mutants 
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during induced growth curves (Figures 6.18-19), similar mutations have been observed in 
previous studies.409; 505; 506  Such mutants have complicated the study of peptide phenotypes and 
differentiation of bacteriostatic and bactericidal phenotypes.  Construction of a tandem promoter 
system may obviate this problem.  The inclusion of a second inducible promoter, such as PTet or 
PLac, would decrease the chances of mutations occurring in both promoters permitting reliable 
expression of the peptide-display protein fusion during selection or subsequent studies. 
 EO1 also illustrates the strengths of the IVD systems.  Through rational design and 
implementation within the pIVD system we were able to isolate an antimicrobial peptide that 
probably would not have been isolated by traditional methods.  High-throughput screens for cell 
viability in medium containing exogenous peptide using Gram-negative bacteria, such as E. coli, 
would have failed to isolate EO1 due to its inability to penetrate their complex cell walls.402  
Likewise, traditional in vitro peptide screening methods require prior identification and 
purification of EO1’s target in its pertinent conformation.  Further, it is unlikely that peptides such 
as EO1 would have been isolated in a phage display peptide screen because its antimicrobial 
activity would have precluded the production of viable recombinant phage.  These experiments 
provide solid proof of principle that the pIVD system is effective for the design and isolation of 
de novo antimicrobial peptides.  The efficacy of these peptides suggests that they may have 
utility as therapeutic antimicrobial agents in their current form as topical anti-infectives and 
further, provide a molecular framework upon which non-peptide antimicrobial derivatives may be 
produced. 
 
 
 
 
523 
 
 
 
6.6 Materials & Methods 
6.6.1 Bacterial Strains & Media 
 All experiments, unless otherwise indicated, were carried out in E. coli DH5α (fhuA2, 
Δ(argF-lacZ)U169, phoA, glnV44, Φ80, Δ(lacZ)M15, gyrA96, recA1, endA1, thi-1, hsdR17).  
Clones were grown and maintained in Luria-Bertani (LB) medium containing 30 µg/mL 
kanamycin (LB-Kan30).  To induce peptide-PhoA fusions from the PBAD promoter L-arabinose 
was added to the culture at a final concentration of 0.2%.  Induction times are indicated in the 
individual methods outlined later.  Clones encoding suspected lethal peptide-PhoA fusions were 
propagated in LB-Kan30 medium with 0.2% D-glucose to repress expression from the PBAD 
promoter.  Transformations were carried out via electroporation at 2.44 kV with electro-
competent cells prepared beforehand and stored at -80 oC.  Transformed cells were recovered 
in SOC medium for 1 hour without antibiotics prior to either plating on solid media or assaying. 
 
6.6.2 Enzymes & Reagents 
 Restriction enzymes and T4 DNA ligase were purchase from New England Biolabs Inc. 
(Ipswich, MA).  Restriction enzymes were also ordered from Fermentas (a division of Thermo 
Fisher Scientific, Inc., (Glen Burnie, MD).  Oligonucleotides, for use as primers in polymerase 
chain reactions (PCRs) or in the formation of DNA duplexes, were purchased from Integrated 
DNA Technologies Inc. (Coralville, IA).  Choice-Taq™ DNA polymerase and PCR reagents 
were obtained from Denville Scientific, Inc. (Metuchen, NJ).  Pfu polymerase, derived from 
Pyrococcus furiosus and having 3’ to 5’ exonuclease proofreading activity, was obtained from 
the Chow Laboratory in the Wayne State University Chemistry Department.  DNA polymerase, 
dideoxynucleotide mixtures and sequencing buffers (SequiTherm Excel™ II DNA sequencing 
kit) were obtained from Epicentre Biotechnologies (a division of Illumina, Inc., Madison, WI).  
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Sequencing primers for use with the LI-COR Biosciences Sequencer 4000L, oligonucleotides 
bound at the 5’ end to either 700 or 800 IRDye®, were ordered from either LI-COR (Lincoln, NE) 
or Integrated DNA Technologies Inc. (Coralville, IA).  5-bromo-4-chloro-3-indoxyl-phosphate (X-
Phos) was obtained from Denville Scientific, Inc. for assaying alkaline phosphatase (PhoA) 
activity. 
 
6.6.3 Rational Design of Peptides & Vector Construction 
 Peptides of the bacteriolytic peptide pool isolated from the perimplasmic selection 
discussed in Chapter 4 were characterized and grouped based on their phenotypes into three 
groups:  early onset of cell lysis, high rate of cell lysis and large decrease in the optical density 
or low optical density endpoint.  Peptides from the pool may be represented in more than one 
category.  Two peptides were designed based on the linear, amino acid, consensus sequence 
of each bacteriolytic peptide category:  EO1, EO2 from the early onset pool, VL1 and VL2 from 
the high rate of cell lysis pool and GD1 and GD2 from the low optical density endpoint pool.  
Peptide EO3 was designed based on the consensus sequence of the early onset of cell lysis 
peptides of the bacteriolytic peptide pool isolated from the constrained peptide pool discussed in 
Chapter 5. 
 To clone the designed peptides the oligonucleotide PerF was paired with 
oligonucleotides encoding a particular designed peptide: EO1b and EO2b for peptides EO1 and 
EO2, VL1b and VL2b for peptides VL1 and VL2, GD1b and GD2b for peptides GD1 and GD2 
and EO3 for peptide EO3 (Table 6.16).  PerF is complimentary to the paired oligonucleotide and 
a duplex is produced upon primer extension with Pfu polymerase.  The DNA duplexes were 
isolated and purified via gel electrophoresis and then digested with restriction enzymes BsrGI  
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and KasI.  Plasmid pKan-PhoA1 was similarly digested.  All digestion products were isolated 
and cleaned using gel electrophoresis.  Individual digested duplexes were ligated into the 
digested vector to produce constructs for expressing the designed peptides at the N-terminus of 
PhoA, C-terminal to the PhoA signal peptide.  Each clone was verified by DNA sequencing.  
Each construct was transformed into E. coli DH5α via electroporation. 
 
6.6.4 DNA Sequencing 
 Isolated clones were sequenced using a two-step process.   Overnight cultures were 
grown in LB-Kan30 + 0.2% D-glucose.  One µL of culture was used as template in an initial 
PCR including primers arapromseqF and Per12R (Table 6.16).  The primers are complimentary 
to sequences on either side of the randomized region.  ArapromseqF has a 5’ tail not 
complimentary to any region in pKan-PhoA1, but has been selected for complementarity with a 
third oligonucleotide, JSLF (Table 6.16).  The product of the first reaction incorporates the 
JSLF-complimentary tail using Taq polymerase.  The 25 µL product is then diluted in 170 µL 
dH2O and used as a template in a sequencing reaction employing dideoxynucleotide mixes and 
a 5’ IRDye®-labeled primer, JSLF.  The labeled primer binds the tail sequence permitting high-
throughput sequencing. 
 
6.6.5 Induced Growth Curves & Viable Cell Count of pKan-PhoAEO1 
 A culture of each clone, started with an individual colony, was incubated overnight at 37 
oC in 3 mL LB-Kan30 + 0.2% D-glucose.  The overnights were diluted 1/1000 by moving 17 µL 
into 17 mL LB-Kan30 and incubated until early log phase (~210 minutes).  L-arabinose was 
added to the culture to a final concentration of 0.2%.  The optical density of a 700 µL sample of 
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the cultures at 600 nm was measured periodically at the point of induction and at 30 or 60 
minute intervals following induction using Spectronic® Genesys™ 20 spectrophotometer from 
Thermo Fisher Scientific, Inc. (Waltham, MA).  In the final analysis, the optical density of 
uninoculated LB broth was subtracted from the values of each clone’s culture at every time 
point.  For the induced growth curve of designed peptide EO1 demonstrating the peptide’s effect 
on growth at different growth phases, induction by the addition of L-arabinose to a final 
concentration of 0.2%, was delayed until growth phases were achieved in separate, 17 mL LB-
Kan30 cultures of cells containing pKan-PhoAEO1.  The high-resolution, induced growth of EO1 
expressing cells used an identical procedure, increasing the number of times the optical density 
at 600 nm was measured following induction of the EO1-PhoA fusion. 
 A similar method was used to produce the viable cell count of E. coli DH5α cells 
expressing designed peptide EO1.  During the induced growth curve procedure, samples of the 
culture were removed from the flask, diluted with LB medium and plated on LB-Kan30 + 0.2% 
D-glucose solid media.  The plates were incubated overnight at 37 oC.  Individual colonies were 
counted and used to estimate the concentration of viable cells in the induced culture. 
 
6.6.6 pAmp-PhoAEO1B2 Construction 
 pAmp-PhoAEO1 was generated as a derivative of pAmp-EmGHB2, itself a derivative of 
lab plasmid pKan-EmGH.  The construction of this plasmid is outlined in the Material & Methods 
section of chapter 2.  A plasmid that could be co-transformed with pKan-PhoAEO1 needs a 
different replication origin, antibiotic selection marker and promoter.  pAmp-EmGHB2 contains 
all of these.  The pMB1 replication origin has replaced that of p15A for plasmid compatibility, the 
neo marker was replaced with bla for ampicillin resistance and the PBAD promoter was replaced 
with the IPTG-inducible PLac promoter.  Both plasmids, pAmp-EmGHB2 and pKan-PhoAEO1, 
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were digested with restriction enzymes PstI and NotI.  The desired DNA fragments from the 
digestion were isolated and cleaned via gel electrophoresis.  The fragments were ligated to form 
plasmid pAmp-PhoAEO1B2.  The clone was verified by restriction analysis and replica plating 
onto LB-Amp100 + 0.2% D-glucose and LB-Amp100 + 1 mM IPTG plates and selecting for 
death on the latter induction plate. 
 
6.6.7 EO1-Resistant Induced Growth Curves 
 Plasmid pAmp-PhoAEOB2 was transformed into E. coli DH5α cells containing pKan-
PhoAEO1, a resistant isolate containing pKan-PhoAEO1, and DH5α cells containing no prior 
constructs.  Each clone was propagated in 3 mL LB + 0.2% D-glucose overnight at 37 oC with 
shaking with the appropriate antibiotic; Kan30 for pKan-PhoAEOI clones, Amp100 for the pAmp-
PhoAEO1B2 clone, and Kan30Amp100 for the dual pKan-PhoAEO1 and pAmp-PhoAEO1B2 
clones.  The overnight cultures were diluted 1/1000 by adding 17 µL to two flasks of 17 mL LB 
with the appropriate antibiotics for plasmid selection.  The flasks were incubated at 37 oC with 
shaking.  During incubation, 700 µL samples were removed and their optical densities at 600 
nm were measured using Spectronic® Genesys™ 20 spectrophotometer from Thermo Fisher 
Scientific, Inc. (Waltham, MA).  When mid-log phase growth was reached (5 hours) the 
appropriate inducers were added to one flask of each clone.  L-arabinose, IPTG or both were 
added to a final concentration of 0.2% and 1 mM respectively.  Incubation was continued with 
periodic sample removal for the measurement of the optical density.  Cultures were incubated 
overnight to observe mutant recover over an extended period of time. 
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6.6.8 EO1 Alanine Scan, Position 4 & Solubility Mutants Construction 
 To produce the EO1 modified clones oligonucleotide PerF was paired with an 
oligonucleotide encoding the modified EO1 peptide.  These paired oligonucleotides include: 
EO1bAla1, 2, 4, 5, 6, 7, 8, 9, 11 ,12 (Table 6.16) for the construction of the alanine scan clones 
whereas the number indicates which position in the EO1 peptide sequence is replaced with an 
alanine residue; EO1bLY, V, N, K, I, F, D (Table 6.16) for the construction of position 4 mutants 
whereas the letter indicates the amino acid substituted for the original leucine; and EO1b1, 2, 3, 
4, 5, and 6 (Table 6.16) for the construction of the solubility mutants.  PerF is complimentary to 
the 3’ end of the paired oligonucleotide allowing the production of a DNA duplex upon primer 
extension using Pfu polymerase and isolated and cleaned using gel electrophoresis.  Primer 
extension products were digested with restriction enzymes BsrGI and KasI.  The plasmid pKan-
PhoA1 was similarly digested.  All digestion products were run on agarose gels to purify the 
desired DNA fragments.  Each digested duplex was individually ligated into the digested pKan-
PhoA1 to form a plasmid encoding the desired EO1 mutant.  Each clone was verified by DNA 
sequencing. 
 
6.6.9 Peptide-PhoA Expression Assays 
 Individual colonies of each clone were placed on solid LB-Kan30 + 0.2% D-glucose 
medium atop a 0.45 µm nylon transfer membrane and incubated at 37 oC for 20 hours.  The 
membranes allow for the diffusion of nutrients and inducers through the pores but also permit 
the transfer of colonies to fresh media.  The presence of the membranes slows growth such that 
after 20 hours of incubation the colonies are still small and in exponential phase growth.  The 
colonies were transferred to solid LB-Kan30 + 50 µg/mL X-Phos + 0.2% L-arabinose medium 
and incubated at 37 oC for 2 hours.  The use of solid medium with X-Phos localizes the 
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generation of the precipitant making visualization easier, especially if the peptide is bacteriolytic 
and kills its host cell soon after its induction.  The color of the colonies, determined by the 
amount of PhoA activity, was recorded in comparison to the non-inhibitory clone NI001 that 
demonstrates high PhoA activity. 
 
6.6.10  Free EO1 Peptide Expression Constructs 
6.6.10.1  pKan-SoloEO1 Construction 
 pKan-Solo was generated as a derivative of pKan-PhoA1 for free peptide expression in 
the periplasm.  The oligonucleotide PerisoloF was paired with an oligonucleotide encoding the 
EO1 peptide, EO1bsoloR (Table 6.16).  PerisoloF has complimentary to the paired primer and 
forms a duplex DNA upon primer extension using Pfu polymerase.  The products were cleaned 
and digested with restriction enzymes BsrGI and XbaI.  Plasmid pKan-PhoA1 was similarly 
digested.  The digestion products were cleaned via gel electrophoresis and ligated to form a 
free peptide expressing derivative of the original pKan-PhoAEO1.  Identical to the previous 
method, the linker sequence and PhoA gene had been removed and a stop codon placed at the 
immediate 3’ end of the peptide without disturbing the 5’ signal peptide.  The clone was verified 
by DNA sequencing. 
 
6.7.10.2  pAmp-SoloTEVEO1 Construction 
 pAmp-SoloTev was generated as a derivative of pAmp-EmGHB2, itself a derivative of 
lab plasmid pKan-EmGH, for free peptide expression in the cytoplasm.  The construction of this 
plasmid is outlined in the Material & Methods section of Chapter 2.  Oligonucleotide 
EO1bsoloTEV, encoding EO1 to be freely expressed in the cytoplasm, was paired with 
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UniTevG-F (Table 6.16) in a primer extension reaction.  The resulting DNA duplex encoded the 
TEV protease recognition sequence followed by the desired peptide sequence and a stop 
codon.  Two restriction enzyme recognition sequences, NheI and XbaI, were included at either 
end of the product.  The DNA duplex and pAmp-EmGHB2 were then digested with NheI and 
XbaI.  The digestion product of the duplex was ligated to the digested pAmp-EmGHB2 vector.  
The final construct, pAmp-SoloTEVEO1, replaces the EmGFP gene with a DNA sequence 
encoding a hybrid peptide with a TEV protease recognition sequence and EO1.  The clone was 
verified by DNA sequencing and transformed into E. coli EPI301 cells containing plasmids 
pRK603 (addgene plasmid 8831) and pZS4int-tetR for TEV protease expression via 
electroporation. 
 
6.6.11  Free EO1 Peptide Induced Growth Curves 
 For EO1 free peptide expression in the periplasm, the induced growth curve procedure 
was identical to that outlined in section 6.6.5.  To study the effect of EO1 free peptide 
expression in the cytoplasm, E. coli EPI301 cells containing plasmids pAmp-SoloTEVEO1, 
pRK603 and pZS4int-tetR were cultured from an individual colony in 3 mL LB-
Amp100Kan30Spec50 + 0.2% D-glucose and incubated overnight at 37 oC with shaking.  The 
overnight culture was diluted 1/1000 by adding 17 µL to 3 flasks of 17 mL of LB-
Amp100Kan30Spec50.  All flasks were incubated at 37 oC with shaking until late lag phase 
growth was achieved (~210 minutes).  To measure the optical density at 600 nm 700 µL 
samples of each culture were analyzed using Spectronic® Genesys™ 20 spectrophotometer 
from Thermo Fisher Scientific, Inc. (Waltham, MA).   Anhydrotetracycline (ATC) was added to 
one flask to a final concentration of 250 ng/µL to induce TEV protease expression.  Incubation 
was continued until early log phase growth (~270 minutes).  IPTG was added to a final 
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concentration of 1 mM to two of the flasks, including the one previously induced for TEV 
protease, to induce EO1 hybrid peptide expression.  Incubation was resumed and the optical 
density monitored until the cultures entered stationary phase growth. 
 
6.6.12  Microscopy of E. coli Cells Expressing Free EO1 Peptide 
 E. coli DH5α cells containing plasmids pKan-SoloEO1 or pKan-Solo84Pro- were grown 
in 3 mL LB-Kan30 + 0.2% D-glucose overnight at 37 oC with shaking.  The overnight cultures 
were diluted 1/1000 by adding 17 µL into flasks of 17 mL of fresh LB-Kan30 medium, 0.2% D-
glucose was added to the pKan-Solo84Pro- culture to repress expression of the peptide to 
serve as a normal E. coli cell morphology control.  The cultures were incubated at 37 oC with 
shaking until mid-log phase growth was achieved (~5 hours).  Two hundred µL samples of both 
cultures were removed and mixed gently in a microcentrifuge tube with 12 µL of 100 ng/mL 
ethidium bromide (EtBr) to stain dead or permeable cells.  The tubes were incubated for 1 min 
at room temperature. One to 5 µL, depending on the concentration of cells in the culture, was 
placed on a microscope slide.  A coverslip was added atop to which a drop of immersion oil was 
added for increased resolution.  The samples were viewed under differential interference 
contrast (DIC) to observe cell morphology and a tetramethylrhodamine isothiocyanate (TRITC) 
filter to observe EtBr staining on an Olympus BX51 fluorescent microscope using an Olympus 
DP30BW camera from Olympus Imaging America Inc. (Center Valley, PA).  L-arabinose was 
added to the culture containing pKan-SoloEO1 to a final concentration of 0.3%.  Incubation of 
the cultures was continued and samples were removed periodically to observe cell morphology 
and EtBr staining. 
 
 
533 
 
 
 
6.6.13  Cell Osmolarity Assays 
 E. coli DH5α cells containing either plasmid pKan-PhoAEO1 or pKan-PhoA84Pro- were 
grown in 3 mL LB-Kan30 + 0.2% D-glucose + 0.3 M sucrose overnight at 37 oC with shaking.  
The overnight culture of pKan-PhoAEO1 was diluted 1/1000 by adding 17 µL into two flasks of 
17 mL of fresh LB-Kan30 + 0.3 M sucrose medium, one flask of fresh LB-Kan30 + 0.5 M 
sucrose + 16.6 mM MgSO4 medium, one flask of fresh LB-Kan30 + 0.5 M sucrose and one flask 
of fresh LB-Kan30.  The overnight culture of pKan-PhoA84Pro- was diluted 1/1000 by adding 17 
µL into one flask of 17 mL of fresh LB-Kan30 + 0.3 M sucrose medium, two flasks of fresh LB-
Kan30 + 0.5 M sucrose + 16.6 mM MgSO4 medium, one flask of fresh LB-Kan30 + 0.5 M 
sucrose and one flask of fresh LB-Kan30.  The cultures were incubated at 37 oC with shaking 
until an optical density of A600 of ~0.3 was achieved.  Ampicillin was added to a final 
concentration of 250 ng/mL to one of each of the following growth media containing pKan-
PhoA84Pro-: 0.5 M sucrose, 0.5 M sucrose + 16.6 mM MgSO4, 0.3 M sucrose and plain LB-
Kan30.  Arabinose was added to a final concentration of 0.2% to one of each of the growth 
media containing pKan-PhoAEO1: 0.5 M sucrose, 0.5 M sucrose + 16.6 mM MgSO4, 0.3 M 
sucrose, and plain LB-Kan30.  One flask of pKan-PhoAEO1 in LB-Kan30 + 0.3 M sucrose and 
one flask of pKan-PhoA84Pro- in LB-Kan30 + 0.5 M sucrose + 16.6 mM MgSO4 were left 
uninduced and without the addition of ampicillin.  Incubation of cultures continued.  Periodically 
700 µL samples were removed for the measurement of optical density at A600.  After 400 
minutes of incubation, 200 µL samples were removed from the cultures each hour.  Two µL of 
each sample was placed on a microscope slide, a coverslip was added atop to which a drop of 
immersion oil was added for increased resolution.  The samples were viewed under a 
differential interference contrast (DIC) to observe cell morphology on an Olympus BX51 
fluorescent microscope using an Olympus DP30BW camera from Olympus Imaging America 
Inc. (Center Valley, PA). 
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6.6.14  Determination of Minimum Inhibitory Concentrations 
 EO1 peptide was purchased from Selleck Chemicals (Houston, TX) at 95% purity.  
Dimethylformamide (DMF) was used to dissolve the peptide to 10 mM stock concentrations and 
stored at -20 oC in aliquots for use in the calculation of its minimum inhibitory concentrations 
(MICs) for various organisms. 
E. coli strains W3110 (F-, λ-, rph-1, INV(rrnD, rrnE))  and SM101 (F-, thr-1, araC14, 
lpxA2(ts), tsx-78, Δ(galK-attLAM)99, hisG4, rfbC1, rpsL136, xylA5, mtl-1, thi-1) and various 
other organisms including Gram-negative bacteria Enterobacter aerogenes, Pseudomonas 
aeruginosa, Klebsiella pneumonia and Gram-positive bacteria Staphylococcus aureus, Bacillus 
subtilis, Micrococcus luteus and were streaked on solid LB medium to get individual colonies.  
Further MIC studies of Gram-positive bacteria Enterococcus faecalis and Streptococcus 
salivarius, Corynebacterium minutissimum substituted Todd Hewitt Broth (THB)523, a rich 
medium for fastidious organisms for LB.  Mycobacterium smegmatis required 7H9 medium for 
growth.  Cultures were started in 3 mL LB, THB or 7H9 broth using one colony and incubated 
overnight at 37 oC, or three days for M. smegmatis.  Overnight cultures were estimated to be 
109 cells/mL and accordingly serially diluted in LB or THB broth to 104 cells/mL.  Two hundred 
µL of the final dilution were aliquoted into wells of a 96-well plate.  Peptides were diluted serially 
so that adding 5 µL of the dilution to 200 µL of culture would produce a range of final 
concentrations from 250-1 µM.  M. smegmatis MICs were performed in 1 mL cultures with final 
concentrations ranging from 30-7.5 µM.  Plates containing gradients of each peptide alongside 
identical dilutions of the peptide solvents in cultures of the different species were then incubated 
in a GeneMachines HiGro® 96-well plate incubator from Digilab, Inc. (Holliston, MA) at 37 oC 
and 500 rpm for 16 hours.  After incubation the plates were removed from the incubator and 
their optical densities were measured at 600 nm using a SpectraMax 190 from Molecular 
Devices, Inc. (Sunnyvale, CA).  The M. smegmatis cultures were incubated at 37 oC for 2 days 
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when the culture with no peptide added had reached stationary phase growth.  The optical 
density at 600 nm of 700 µL aliquots of each culture was measured using a Spectronic® 
Genesys™ 20 spectrophotometer from Thermo Fisher Scientific, Inc. (Waltham, MA).  The 
minimum inhibitory concentration was selected as the smallest concentration of peptide required 
to completely inhibit growth of the culture. 
 
6.6.15  Synthetic EO1 Peptide Growth Curves 
 A culture S. aureus was incubated overnight in 3 mL of LB medium.  The cultures were 
diluted from 109 to 105 cells/mL in LB.  Two hundred µL aliquots of the dilution were placed in 
wells of a 96-well plate and incubated at 37 oC and 500 rpm in a GeneMachines HiGro® 96-well 
plate incubator from Digilab, Inc. (Holliston, MA).  The optical densities of the cultures were 
monitored at 600 nm using a SpectraMax 190 from Molecular Devices, Inc. (Sunnyvale, CA).  
When the cultures had reached mid-log growth phase, serial dilutions of EO1 peptide were 
added to make a gradient of final concentrations ranging from 62.5 to 0 µM.  Incubation 
continued and the optical density was measured periodically following the addition of the 
peptide.  In the final analysis, the optical density of uninoculated LB at 600 nm was subtracted 
from the measured values of each culture. 
 
6.6.16  Replication Dependence Assays 
 A culture of S. aureus in 3 mL of THB was started with an individual colony and 
incubated overnight at 37 oC with shaking.  The overnight culture was diluted 1/1000 by adding 
17 µL to 17 mL of fresh THB medium and incubated at 37 oC with shaking.  When the cells had 
achieved mid-log phase growth, the culture was centrifuged at 7,000 rpm for 5 minutes to pellet 
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the cells.  The supernatant was removed and the pellet washed twice in 10 mL of HEPES-NaCl 
(HN) buffer pH 7.0 to remove all growth medium from the cells and stop replication.  The final 
pellet was resuspended in 11 mL of HN buffer and incubated at 37 oC with shaking for 30 
minutes to ensure the cessation of replication and growth.   
 Three 200 µL aliquots were placed in wells of a 96-well plate.  To each well one of the 
following was added:  peptide 84, a non-inhibitory peptide, or EO1 to a final concentration of 60 
µM, or replication-dependent, bacteriolytic antibiotic ampicillin to a final concentration of 1480 
µM.  The optical density at 600 nm was measured using a SpectraMax 190 from Molecular 
Devices, Inc. (Sunnyvale, CA) and samples of the cultures were removed for plating to 
determine the viable cell count.  Samples were plated on LB medium at various dilutions to get 
statistically significant counts.  The 96-well plate was incubated at 37 oC and 450 rpm in a 
GeneMachines HiGro® 96-well plate incubator from Digilab, Inc. (Holliston, MA).  The optical 
density was monitored every 15 minutes for 45 minutes and samples were removed for plating.  
Twenty-one µL of 10x concentrated THB medium was added to each well to provide the 
necessary nutrients for growth.  Incubation was continued with periodic optical density 
measurements and sample removal for plating.   
 The plates with various concentrations of culture were incubated overnight at 37 oC.  
Individual colonies were counted and the concentrations of viable cells in the cultures were 
calculated.  In final analysis, the optical densities of the cultures were subtracted by similar, 
uninoculated media (HN only or HN + 10x THB). 
 
6.6.17  EO1 Hemolytic Assays 
 Defibrinated sheep’s blood (38% PCV) obtained from HemoStat Laboratories (Dixon, 
CA) was washed twice and resuspended to a final concentration of 10% PCV in phosphate 
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buffered saline (PBS) pH 7.4.  Two hundred µL aliquots of the defibrinated sheep’s blood 
suspension were distributed to microcentifuge tubes.  Serial dilutions of peptide EO1 were 
prepared using PBS pH 7.4.  The peptide dilutions were added to the aliquots to a final 
concentration ranging from 250 to 1 µM.  Control aliquots of defbrinated sheep’s blood 
containing either PBS pH 7.4 only or 0.1% Triton X-100 were used as 0%  and 100% hemolysis 
benchmarks respectively as well as a gradient of peptide solvent DMF.  The aliquots were 
incubated, with shaking at 37 oC for 18 hrs.  The aliquots were then centrifuged to pellet whole 
erythrocytes or cell debris from lysis.  The optical density at 570 nm of 50 µL of each sample’s 
supernatant was measured using a SpectraMax 190 from Molecular Devices, Inc. (Sunnyvale, 
CA) to calculate the amount of hemoglobin released by lysed erythrocytes.  The level of 
hemolysis of the PBS pH 7.4 only aliquot was subtracted from the peptide and DMF samples.  
Percent hemolysis was calculated by dividing the peptide and DMF sample values by the 0.1% 
Triton X-100 complete hemolysis sample and multiplied by 100. 
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CHAPTER 7 
SINGLE MUTATIONS THAT DISRUPT THE FUNCTION OF THE 16S RIBOSOMAL SUBUNIT 
 
7.1 Abstract 
 The rise of antibiotic resistance among opportunistic pathogenic bacteria has 
necessitated the development of new antimicrobials.  The ribosome presents an established 
target, the focus of several antibiotic classes such as the aminoglycosides, tetracyclines and 
MLS antibiotics used medically.   
 A genetic system for studying the function of the 16S ribosomal subunit of the bacterial 
ribosome has been adapted to identify key bases whose identity is critical for function, termed 
‘instant evolution’.  Through this method it is possible to identify bases that are essential for 
ribosome function and therefore are viable targets for antimicrobials with reduced susceptibility 
to the development of drug resistance through mutation. 
 We used a negative selection to identify single base mutations that are deleterious to the 
function of the ribosome.   Using this method we identified 24 mutations located throughout the 
16S rRNA that virtually negate ribosomal function.  A number of these mutations occur at highly 
conserved bases known to be involved in essential processes of translation such as the 
decoding region including G527A, G529A, A533G, A1492G, and A1493G.  Others, such as 
A607G, A608G, A609G, G1015A, and U1126C, are variously conserved among Bacteria but 
absent or not conserved in Eukarya, making them attractive targets for antimicrobial 
development. 
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7.2 Introduction 
 The peptide selections employed in the previous chapters represent one method of 
producing antimicrobial leads and the discovery of new, viable targets in the development of de 
novo antimicrobials.  A second, more established approach utilizes targets of known 
antimicrobial value as demonstrated by natural antibiotics and discovering new binding sites on 
the target that inhibit its function.  The ribosome is one such target,615 and we have developed a 
selection to identify single bases that are important for ribosome function and present potential 
antimicrobial binding sites (Figure 7.1). 
 
Figure 7.1:  Methods of antimicrobial development discussed within this dissertation.  Chapter 7 
focuses on the identification of single mutants deleterious to ribosome function and discover 
potential target sites for new antimicrobials. 
 
7.2.1 Ribosome 
The production of functional entities from a stored database of information is the 
cornerstone of the life.  In the central dogma of biology, information stored in DNA is transcribed 
to the intermediary, RNA, which is then translated to produce protein.616  The ribosome is a 
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complex of RNA and protein responsible for translating mRNA and is one of the most conserved 
complexes known in biology.617  The 70S ribosome is composed of two RNA subunits and an 
assortment of associated proteins.  In bacteria this includes the large 50S subunit responsible 
for peptide bond formation, and the small 30S subunit involved in decoding the mRNA 
sequence into protein.618  The 50S subunit is composed of two RNA elements, the 23S of 2904 
nucleotides and the 5S of 120 nucleotides.  Thirty-four ribosomal proteins (L1-L34) interact with 
the two RNAs to form the complete 50S subunit during the subunit assembly.619  The 30S 
subunit has one RNA component, the 16S, 1542 nucleotides in length.  Twenty-one ribosomal 
proteins (S1-S21) bind to complete the subunit (Figure 7.2).  The 16S rRNA is further divided 
into four domains characterized by their independent secondary structure including the 5’, 
central, 3’ major and 3’ minor domains620 (Figure 7.3). 
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Figure 7.3:  Secondary structure of the 16S rRNA of E. coli and its domains.621  
543 
 
 
 
7.2.2 Translation 
During translation initiation, the 30S subunit binds to the mRNA sequence via the Shine-
Dalgarno sequence622 located upstream of the mRNA’s start codon to the complimentary anti-
Shine-Dalgarno sequence located at the 3’ end of the 16S rRNA.  This is followed by the 
association of the two subunits to complete the 70S ribosome.623  During elongation, charged 
tRNAs bind to the codon located at the A site of the 30S subunit and a peptide bond is formed 
between the peptide bound to the tRNA in the P site and the amino acid bound to the tRNA in 
the A site.624  The deacetylated tRNA then moves to the E-site and the tRNA conveying the 
nascent peptide moves into the P site.625  This process is repeated for each codon in the mRNA 
as the ribosome moves towards the 3’ end of the mRNA.  Once a stop codon enters the A site, 
a release factor, RF1 or RF2, binds the mRNA.626 Peptide bond formation is stopped and the 
fully translated protein is released.  RF3, a third release factor displaces the initial release factor 
and destabilizes ribosome association, separating the subunits.627  The subunits are recycled 
and can initiate additional rounds of translation.628 
 
7.2.3 Antibiotics 
 The critical importance of the ribosome to life and the conservation of its sequence make 
it the most popular target of antibiotics.615  Ribosome-targeting antibiotics can be classified on 
whether they bind the 30S or 50S subunit.  Chloramphenicol,20 the marcolides, lincosaminides, 
streptogramins (MLS antibiotics),24 and the synthetic oxazolidinones28 all bind the 23S rRNA.  
Chloramphenicol binds near and obstructs the peptidyl-transferase center of the 23S rRNA 
inhibiting peptide elongation during translation. The MLS antibiotics have dissimilar chemical 
structures but bind in a cluster around the peptidyl-transferase center.  Lincosaminides and 
marcolides, similar to chloramphenicol, disrupt elongation of the nascent peptide by inhibiting 
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peptide bond formation.  Streptogramins, however, inhibit translation by blocking the tunnel 
through which the nascent peptide exits the ribosome, stalling the ribosome and blocking growth 
of the cell.  Oxazolidinones are a synthetic class of antibiotics developed in 1978.27  While they 
bind the ribosome at a similar location as the previously described antibiotics, it appears that 
they sterically inhibit the association of the 30S and 50S ribosomal subunits during initiation 
preventing the formation of the 70S ribosome. 
 The 30S subunit is targeted by two classes of antibiotics encompassing a large amount 
of molecules, the aminoglycosides and tetracyclines.  The aminoglycosides include common 
antibiotics such as streptomycin, kanamycin and tobramycin.  They bind to the A site of the 16S 
rRNA that acts as the tRNA receptor during translation.  This interaction increases the rate of 
translation causing a higher error rate of amino acid incorporation.  This leads to critically 
mistranslated membrane proteins that increase the permeability of the membrane resulting in 
cell death18.  The tetracyclines also bind at the A site interacting with helices 31 and 34 of the 
16S rRNA.  When bound, they prevent the binding of charged tRNAs to the A site.14 
 The ribosome remains a viable target for the production of new antimicrobials.  
Aminoglycosides,108; 349 tetracyclines,348 oxazolidinones629 and MLS630; 631; 632 classes have been 
chemically or biologically modified to circumvent existing resistance mechanisms.  With the 
elucidation of the crystal structure of E. coli’s ribosome, it has become easier to engineer new 
antibiotics in silico or find de novo molecules that can bind and possibly inhibit key positions of 
the ribosome.20; 350; 351  While some critical parts of the ribosome, such as the A site in the 16S 
rRNA and the peptidyl-transferase center in the 23S rRNA, have already been identified, it is 
likely that other, previously unidentified, critical nucleotides in the ribosomal RNA exist. 
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7.2.4 Genetic System for 16S Functional Analysis 
A genetic system isolating the 16S rRNA within an E. coli bacterium was developed by 
the Cunningham laboratory633 (Figure 7.4).  The centerpiece of the system is a plasmid 
encoding a copy of the rrnB operon from E. coli’s genome.  PCR mutagenesis was used to alter 
the 3’ end of the 16S gene.  This resulted in an anti-Shine-Dalgarno (ASD) sequence that was 
incompatible with genomic mRNAs.  Two genes also encoded by the plasmid and under the 
control of a constitutive trp promoter, gfp (green fluorescent protein) and cam (chloramphenicol 
acetyltransferase) were also altered at the 5’ end to make their Shine-Dalgarno sequences 
complimentary to the mutant ASD of the plasmid-encoded 16S rRNA.634  This creates a second 
population of ribosomes in the host cell allowing the genetic manipulation of the plasmid 
encoded 16S rRNA without affecting the health of the host cell.  The functional importance of a 
base or series of bases can be determined by first incorporation of mutations via a mutagenic 
polymerase chain reaction and then cloning the fragment into the vector pRNA123 that contains 
the genetic system.  Because the level of chloramphenicol resistance and GFP fluorescence is 
dependent on the level of specialized ribosome activity, this system can be used to both 
positively and negatively select mutations that affect ribosome function in vivo without affecting 
the protein synthesis activities of the wild-type cellular ribosomes.  The effects of 16S rRNA 
mutations on ribosome function can be quantified by measuring either CAT activity of GFP 
fluorescence.  
 This system was used successfully to identify regions of the 16S gene that cannot be 
mutated and maintain functionality.  Dr. Ashesh Saraiya of the Cunningham Lab randomly 
mutated the entire 16S gene using a manganese supplemented PCR that increases the error 
rate of the DNA polymerase’s base insertion.635  A selection using chloramphenicol was 
undertaken to recover 2593 rRNA mutants that retained ribosome function.  These were then 
sequenced and aligned to show what regions of the ribosome were critical for ribosome 
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function.  Clusters of bases distributed within each of the domains of the 16S rRNA including 5’, 
central and 3’ were identified that were conserved among the functional mutant ribosomes.  
These clusters of bases are possible targets for the development of new anti-infectives.  A 
common mechanism for resistance against antibiotics includes altering of the target site which 
can be accomplished by simply changing the nucleotide base in the case of RNA.67  This, 
however, possibly incurs a fitness cost on the host organism.636; 637  If a mutation that prevents 
binding of an antibiotic also disrupts ribosome function significantly then the cell dies or its 
growth rate is reduced to a level that can be outcompeted by other bacteria or eliminated by the 
host’s immune system.  Positions in the 16S rRNA, such as this, present a viable target for anti-
infective leads, trapping the bacteria by the functionality of its own ribosomes. 
 
Figure 7.4:  Genetic lab system developed for the analysis of the 16S rRNA.  Plasmid 
pRNA123 encodes the rrnB operon under the control of the lacUV5 promoter.  The incorporated 
16S rDNA has a mutated anti-Shine-Dalgarno sequence that matches the mutated Shine-
Dalgarno sequences of the GFP and CAT genes transcribed constitutively from the trpc 
promoter. 
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7.3 Objective of the Project 
 Isolate single mutants in the 16S rRNA that block ribosomal activity.  Quantify the effect 
of each mutation on protein synthesis and propose possible mechanisms responsible for loss of 
function via crystal structures and prior studies.  Evaluate the suitability of using these positions 
as target for antimicrobials by their conservation among human and other higher order 
eukaryotes. 
 
7.4 Results 
7.4.1 Library Construction 
 We have devised a scheme for isolating deleterious, single mutations in 16S rDNA to 
identify potential antimicrobial targets in the 30S subunit of bacterial ribosomes.  This system 
utilizes the genetic system developed by the Cunningham laboratory for mutational analysis of 
16S rRNA function.633 
pRNA228 (Figure 7.5) has the E. coli rrnB ribosome operon under the control of the 
lacUV5 promoter, which is inducible with the gratuitous inducer isopropyl β-D-1-
thiogalactopyranoside (IPTG).  The ASD of the plasmid-encoded 16S rRNA has been mutated 
and is not complimentary to genomic mRNAs.  Likewise the Shine-Dalgarno sequences of 
mRNAs of plasmid encoded reporter proteins CAT and GFP have been modified to be 
complimentary to the new, mutated ASD of the plasmid-encoded 16S rRNA, but not 
complimentary to genomic derived ribosomes.634 
To get the desired amount of random mutations in the 16S rDNA, a mutatgenic PCR 
was carried out.  Taq polymerase, lacking a 3’ to 5’ proofreading function and incorporating 1 
mismatched base per 9,000 bases, was used to amplify the 16S rRNA gene of pWK122638 
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(Figure 7.6).   The resulting amplicon was gel purified, digested with BclI and BstEII and cloned 
into pRNA228. 
 
Figure 7.5:  pRNA228 is a derivative of pRNA123 used in this study. 
 
 
Figure 7.6:  pWK122 is a derivative of the pUC19 plasmid with the 16S rDNA inserted for the 
subcloning of the mutant library. 
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7.4.2 Non-functional Mutant Selection 
 pRNA228 plasmids harboring mutated 16S rDNA were transformed into E. coli DH5 cells 
and plated on solid media, containing ampicillin to select for plasmid transformation.  The 
transformants were replicated on Luria-Bertani medium442; 443 containing 70 µg/mL 
chloramphenicol and chloramphenicol sensitive colonies were retained for further study.  A 
concentration of 70 µg/mL chloramphenicol inhibits the growth of clones whose ribosomes are ≤ 
10% of WT function.  Approximately 500 chloramphenicol sensitive clones were isolated and 
sequenced to identify mutations in the 16S rRNA gene.   
A total of 24 unique, single, point mutations were identified (Table 7.1).  Mutations were 
present in all four domains of the 16S rRNA (Figures 7.7-8).  Of the 24 mutations, 22 were 
transitions comprising 13 A→G, 6 G→A, 1 C→U and 2 U→C mutations.  Only two mutations 
involved transversions, 1 A→U and 1 G→U mutation.  The mutations were subcloned into wild-
type pRNA228 to eliminate the possibility that mutations outside the 16S rRNA gene were 
contributing to the phenotype.  The ribosome activity of each single mutant was assayed in vivo 
by measuring the amount of GFP produced from the mutated-SD GFP mRNA compared to cells 
expressing wild-type ribosomes. 
The 5’ domain contained 5 mutations (Figure 7.9), two in helix 15 (A374G and A389G) 
and three in helix 18 (G527A, G529A and A533G).  The helix 18 mutants are involved in the 
decoding region of the 30S subunit and their identity is critical for function.639  Here, they serve 
to as a positive control for our selection.  Two clusters of mutants comprising 5 mutations and 
one non-clustered mutant were isolated in the central domain (Figure 7.10).  The first cluster, 
located in helix 21, includes three adenine transitions to guanine (A607G, A608G, and A609G) 
within the internal loop of helix 21.  The second cluster of two mutations (C897U and G903A)  
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Table 7.1:  Single-base mutations of the 16S rRNA that are deleterious to the function of the 
ribosome.  The function of each mutant, as a percentage of WT 16S rRNA activity, was 
determined by GFP assays. 
 
form adjacent base-pairing interactions in the stem-loop of helix 27 forming the conserved 900 
loop implicated in formation of an intersubunit bridge640 and a pseudoknot with helix 24.641  
Position A787, mutated to a G, is located in the conserved 790 loop of helix 24a, has also been 
previously identified as critical for ribosome function.633  Eight mutations are scattered 
throughout the 3’ major domain (Figure 7.11), not forming clusters of neighboring bases with 
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the exception of A914G and A918G.  These two bases form the central pseudoknot, an 
essential linkage of the 3’ major and 5’ domains.642; 643  Mutations A978G, G1015A, and U1126C 
are located in unstructured portions of the domain including hairpin and internal loops in helices 
32, 33b, and 39, respectively.  The remaining mutations, G1104, A1163U and G1241U 
participate in base-pairing interactions in the stems of helices 35, 40 and 41, respectively.  Five 
mutations were isolated in the 3’ minor domain (Figure 7.12), U1406C, A1492G, A1493G, 
G1497A and A1502G, all of which are clustered in the decoding region of helix 44 and highly 
conserved.644 
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Figure 7.8:  The isolated single mutants with deleterious effects on the function of E. coli’s 
ribosome as they appear in the 16S rRNA secondary structure.621 
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Figure 7.9:  Single mutants located in the 5’ domain of the 16S rRNA including A374G and 
A389G of helix 15; and G527A, G529A and A533G of helix 18.621 
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Figure 7.10:  Single mutants located in the central domain of the 16S rRNA including A607G, 
A608G, and A609G of helix 21; and C897U and G903A of helix 27.621 
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Figure 7.11:  Single mutants located in the 3’ major domain of the 16S rRNA including A914G 
and A918G of helix 28; A978G of helix 32; G1015A of helix 33b; G1104A of helix 35; U1126C of 
helix 39; A1163U of helix 40; and G1241U of helix 41.621 
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Figure 7.12:  Single mutants located in the 3’ minor domain of the 16S rRNA including U1406C, 
A1492G, A1493G, G1497A, and A1502G of helix 44.621 
 
7.5 Discussion 
 The single base mutants isolated from the chloramphenicol acetyltransferase (CAT) 
activity selections were dispersed throughout the 16S rRNA with a concentration around the 
decoding region of the A site.645  Several of the mutations represent regions previously known to 
be important for function including the A site, with mutations in the 530 loop646 and helix 44,647 
the 790 loop633 and the 970 loop.648  These results confirm the efficacy of the selection in 
isolating nucleotides that are important for ribosome function.  To understand why these 
mutations have deleterious effects on ribosome function and if they present viable targets for 
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antimicrobial development, their phylogenetic conservation and location, structure and 
interactions determined by crystal structures and previous studies have been analyzed. 
 
7.5.1 A374G 
 Residue A374 is located in helix 15 of the 5’ domain.  It is highly conserved across all 
three domains of life and organelles.644  Eukaryotic 18S phylogenetic data show a tolerance for 
C but a transversion to G is not observed.  The crystal structure shows a cis base pair between 
A374’s Watson-Crick side and the sugar edge of U390 (Figure 7.13).649  A374’s sugar interacts 
with R70 of ribosomal protein S16.650  A transversion to G at position 374 would disrupt the base 
pairing with U390 that may position A374 for proper interaction with S16.  As a secondary-
binding protein, S16 has been shown to bind helices 15 and 17 and facilitate the folding of 
remote helix 3 during assembly.651  S16 is essential for growth and the loss of critical positioning 
of the rprotein by A374 may result in the complete loss of function in the A374G mutant. 
 
7.5.2 A389G 
 Residue A389 is nearly directly opposite of A374, which base pairs with adjacent base 
U390, in helix 15 of the 5’ domain and base pairs through its Watson-Crick edge with U375.  
Phylogenetically, A389 is highly conserved in all three domains of life and the organelles.644  
This stresses the importance of the internal loop of helix 15 in Escherichia coli’s 16S rRNA 
secondary structure.  Similar to A374, U375 interacts with protein S16 (Figure 7.14).649  The 
crystal structure shows there are three interactions between residues of S16 and the backbone 
and sugar of U375.  The carboxyl oxygen of the amide bond of L6 interacts with the 2’ OH of 
U375’s ribose via a hydrogen bond.  The OH of Y17 hydrogen bonds with the ring oxygen and 
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R70’s guanidinium group closely interacts with U375’s phosphate backbone.  A389’s base-
pairing with U375 may be critical for its positioning to interact with S16 and facilitate its 
conformational change on the 16S rRNA.  This makes U375 of similar importance to A374 and 
most likely could be isolated as a single mutant with no ribosome function in our selection. 
 
 
 
 
Figure 7.13:  A374 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
A374 forms a cWS base-pairing with U390.  Its sugar also lies within 3 Å of R70 of rprotein S16. 
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Figure 7.14:  A389 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
A389 forms a Watson-Crick base pair with U375 proximal to A374 possibly stabilizing 
interactions between U375 and S16. 
 
7.5.3 m7G527A, G529A & A533G 
 All three bases are located in the highly conserved 530 loop644 that has a role in the A 
site near the junction of the mRNA codon and tRNA anti-codon, a critical interaction for 
decoding of the mRNA.639  As with the majority of the single mutations isolated in our selection, 
the mutations are transversions; replacing a large, guanidine purine base with the other purine, 
adenine or vice versa.  m7G527 makes two base interactions according to the E. coli crystal 
structure (Figure 7.15),649 a canonical Watson-Crick base pair with C522 and a sugar/Watson-
Crick pair with N1 of A535. The aminoglycoside antibiotic, streptomycin, is known to bind the 
phosphate backbone of m7G527 reinforcing its importance in ribosome function.652  m7G527 is 
one of 11 modified bases in the 16S rRNA.  It is methylated by 7-methylguanosine 
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methyltransferase (RsmG) at the 7’ nitrogen.653  Deletion of RsmG (GidB) results in no 
methylation at G527, but has no effect on growth and confers resistance to streptomycin.654  
S12, a tertiary binding protein, involved in subunit association and translocation, interacts with 
m7G527.  In the E. coli crystal structure, the side chain amino group of N45 in S12 is within 3.0 
Å of m7G527’s O6 that hydrogen bonds to C522 (Figure 7.15).  N45’s and m7G527’s hydrogen 
bond may be transient and necessary for translocation to occur.  The mutation m7G527A 
removes the possibility of base pairing with C522 and interacting with N45. 
 
 
Figure 7.15:  m7G527 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 
2I2P).649  The base forms a Watson-Crick base pair with C522, a sugar/Watson-Crick pair with 
A535 and a possible interaction with N45 of rprotein S12. 
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Residue G529 is located near the bottom of the Asite cleft.  It is flipped out of helix 18 
and forms a triplet stack with bases C518 and G530 facing the codon-anticodon junction 
between the A site tRNA and the mRNA in Thermus thermophilus’ crystal structure (Figure 
7.16).655  It also forms a sugar/Hoogsteen base pair with A520.  Unlike m7G527 and A533, G529 
is protected from chemical probes by the binding of A site tRNA indicating close proximity.639  
The G529U mutant is error-prone resulting in a loss of cell viability perhaps due to the 
destabilization of the stacking interaction and removing the proof-reading ability of G530.656  The 
G529A mutation isolated in our selection would not destabilize a stacking interaction but may 
stabilize a conformation through base pairing that inhibits the binding of EF-Tu or the transient 
interaction of the A site tRNA, notably the fMettRNA, and thus inhibiting translation initiation.  The 
Watson-Crick edge of G529 forms two hydrogen bonds with amino acid S50 of protein S12.  As 
previously noted, S12 is important for the proper folding of 16S RNA and a G529A mutation 
would disrupt the interaction with the S50 carboxyl and amine groups of the peptide bond.  
Chemical probe studies by Xu, et al. suggest that the change in reactivity by the probes during 
translocation could indicate G529’s importance lies in transient interactions.657  
 Residue A533 forms a number of weak H-bond interactions forming a kinked-turn658 
likely positioning G530 and its neighboring bases in the decoding region.  It forms a 
Hoogsten/Watson-Crick base pair with Ψ516 which in turn forms a sugar/Watson-Crick base 
pair with C519 (Figure 7.17).655  A520 is in close proximity to A533 and may form a transient H-
bond between their Watson-Crick edges.  G517 appears to form two H-bonds with the 
phosphate backbone of A533.  These five bases serve to produce a strong interaction to hold 
together the 530 loop permitting bases in the decoding region to flip out.  A533 and Ψ516 make 
up the most critical of the bases considering the number of bonds formed.  Ψ516 is 
pseudouridylated by RsuA, pseudouridine synthetase.659  rsuA- strains grow at rates similar to 
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WT.660  Mutants of Ψ516 including A and T had no function while C, which closely resembles Ψ 
has 60% function.661  This argues that the O4 is important for preserving bonding and function 
which is not present in A533G, Ψ516G and Ψ516A.  The A533G mutation would disrupt the H-
bond formed between A533’s N6 and Ψ516’s O4.  The interaction with A520 would also be 
disrupted. 
 
 
Figure 7.16:  G529 in the crystal structure of T. thermophilus’ 30S ribosomal subunit with three 
bound tRNAs (PDB ID: 3I8G).655  G529 bookends a triple stacking interaction that is critical to 
the decoding region.  It also lies in close proximity to base A520 and S50 of rprotein S12. 
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Figure 7.17:  A533 in the crystal structure of T. thermophilus’ 30S ribosomal subunit with three 
bound tRNAs (PDB ID: 3I8G).655  The base forms interactions critical for the formation of the 
decoding region with bases A520 and Ψ516 (a uridine in T. thermophilus) on its Hoogsteen 
edge and G517 with its phosphate backbone. 
 
7.5.4 A607G, A608G & A609G 
The string of three A’s located in the internal loop of helix 21 of the central domain are 
conserved among bacteria, but not conserved in mitochondrial ribosomes.  There is no 
corresponding helix in eukaryotic 18S RNA making the nucleotides appropriate targets for the 
development of new anti-infectives.644  All three bases flip out of helix 21 and form a triple 
stacking interaction with each other with their collective backbone facing the ribosomal protein 
S16 (Figure 7.18).655  Residues A607 and A609 do not base pair in crystal structures pre- or 
post-translocation but may serve to position A608 to Watson-Crick/sugar edge base pair with 
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G292, which is highly conserved except for eukaryotic 18S ribosomes.  G292 forms a second 
base pair with C308 by standard Watson-Crick H-bonds.  Both G292 base pairs position the 
base for a stacking interaction with G309.  Footprinting assays using chemical probes show that 
the three bases, A607-A609, have base-specific interactions with S16.662  Previous mutants, 
A374G and A389G, demonstrate the importance of S16 interactions with the 16S rRNA 
suggesting that other S16-RNA contacts are viable targets for antimicrobials.  Crystal structures 
of post-translocation and with RF1-bound conformations demonstrate the transience of the 
bonds between these bases.  Contact between A607 and G309 through their Watson-
Crick/sugar edges is established when RF1 is bound (Figure 7.19).663  The triple stack of A607, 
A608 and A609 is maintained.  The bonding partners of the triplets changes, but the stacking 
interaction is crucial.  This may suggest a necessity for purines at these positions and the H-
bond donors and acceptors unique to adenosine may be required for a myriad of H-bonds that 
are made and broken during translation, possibly to accommodate binding of protein S16.  
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Figure 7.18:  A607, A608 and A609 in the crystal structure of T. thermophilus’ 30S ribosomal 
subunit with three bound tRNAs (PDB ID: 3I8G).655  The three bases form a triple stack, flipping 
out from helix 21 and positioning A608 to interact in a triple base pair with G292 and C308. 
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Figure 7.19:  A607, A608 and A609 in the crystal structure of T. thermophilus’ post-
translocational intermediate 30S ribosomal subunit (PDB ID: 2XUY).663  The triple stack of the 
three bases is preserved but moves A608 out of position to interact with G292 and C308, 
positioning A607 for an interaction with the sugar of G309. 
 
7.5.5 A787G 
    Residue A787 is located in helix 24a of the central domain in the highly conserved 790 
loop.  The base itself is conserved in all domains of life and the organelles.644  In the crystal 
structure of T. thermophilus, A787 makes a weak base pair with C795 through their Watson-
Crick edges (Figure 7.20).649  Site-direct mutagenesis of the 790 loop by Lee, et al. show base 
substitutions at  position 787 that form strong base pairs with C795, such as A787G, have no 
ribosome function.633  The weak H-bond likely allows necessary motility in the 790 loop for 
ribosome function. 
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Figure 7.20:  A787 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
Although universally conserved, the base, part of the highly conserved 790 loop, forms only a 
weak and possibly transient pairing with C795. 
 
7.5.6 C897U & G903A 
 Residues C897 and G903 are found in the stem of helix 27 of the 3’ major domain.  They 
form the closing base pairs of the 900 tetraloop.  The tertaloop maintains several functions 
critical for ribosome function including formation of an intersubunit bridge with helix 67 of the 
23S rRNA,640 and a pseudoknot with helix 24, important in eliciting a conformational change 
crucial for the decoding the mRNA.641  C897 and G903 form classic, Watson-Crick base pairs 
with G902 and C896 respectively (Figure 7.21).649  C897 is highly conserved in all domains of 
life.644  G903 however shows tolerance for A substitutions.644  Phylogenetic data for C896 show 
a variance tolerating U substitutions that suggest a base pair is necessary for function at both 
stem positions.644  The preservation of a closing G-C pair at positions C897 and G902 indicates 
a strong closing interaction to maintain rigidity in the 900 tetraloop is essential. 
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Figure 7.21:  C897 and G903 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 
2I2P).649  The form adjacent base pairs with bases G902 and C896 respectively, closing the 900 
tetraloop. 
 
7.5.7 A914G & A918G 
 Residues A914 and A918 are located in helix 2 of the 3’ major domain and are integral 
to the formation of the central pseudoknot of 16S rRNA.  Their identity is highly conserved 
across all domains of life.644  A914 forms a type II sheared base pair along its Hoogsteen edge 
with G21’s sugar edge (Figure 7.22)649 and A918 forms a canonical Watson-Crick base pair 
with U17 (Figure 7.23).649  These interactions form helix 2, bringing the 3’ major and 5’ domain 
together.  DMS reactivity assays in T. thermophilus have demonstrated that A914G mutants 
have a considerably more accessible local conformation compared to the WT conformation.664  
Complimentary base pairing and not base identity are conserved at positions 918 and 17 in site-
directed mutagenesis studies.665  The same is likely true of positions 918 and 21.  Therefore 
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antimicrobials based on disrupting helix 2 may become ineffective upon two, complimentary 
mutations.  This would also suggest that U17 and G21 are locations of single mutants whose 
ribosomes would have no function. 
 
 
 
Figure 7.22:  A914 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
A914 forms a sheared base pair with G21 as part of the central pseudoknot. 
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Figure 7.23:  A918 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
As part of the central pseudoknot, A918 forms a base pair with U17. 
 
7.5.8 A978G 
 Residue A978 is universally conserved among all three domains of life.644  It is located in 
helix 32, in close proximity to helix 31 and the 970 loop.  It forms a twisted Hoogsteen/Watson-
Crick base pair with A1360 which resides in the loop of helix 43 (Figure 7.24).649  A1360 has 
been, through cross-linking studies, associated with the spacer sequence between the Shine-
Dalgarno and start codon of the decoding mRNA.666  A978 inserts itself between bases A1318 
and A1319 producing a triple stacking interaction with their backbones facing the secondary 
ribosomal protein S19.  G1361 makes an H-bond on its Watson-Crick edge with the phosphate  
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Figure 7.24:  A978 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
A978 comprises part of a complex series of interactions among six bases.  A1318 and A1319 
bookend A978 in a triple stacking interaction positioning the base to pair on its Hoogsteen edge 
with A1360. 
 
backbone of A978.  A1360 makes contacts with tertiary ribosomal protein S14, including residue 
S57.  Positioning of the triple stack is preserved by the Hoogsteen/Watson-Crick base pairing 
between triplet member A1319 and U1315.  Several non-canonical interactions position A978 
for base pairing with A1360 to form a pseudoknot with two ribosomal proteins and the 970 loop 
in close proximity.  The mutant A978G would be incapable of forming H-bonds with A1360 and 
possibly shifting the 970 loop and disrupting IF3 binding and translation initiation. 
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7.5.9 G1015A 
 Residue G1015 is weakly conserved among eubacteria and not present in eukaryotic 
and mitochondrial ribosomes making it an interesting candidate for antimicrobial 
development.644  Helix 33b of the 3’ major domain is proximal to A978 and the 970 loop, 
discussed previously.  Ribosomal proteins S14 and S19 interact with the phosphate backbone 
of helix 35, but only residue H13 of S19 is within 3 Å of G1015 (Figure 7.25).649  Together with 
adjacent bases, A1014 and A1016, G1015 forms a triple stack that forms the loop of helix 33b.  
All three bases flip out and interact with the backbone of Watson-Crick pairing bases G987 and 
G988 in helix 32.  On its Watson-Crick edge, A1014 forms an H-bond with the ring oxygen of 
G988’s sugar.  A1016’s Watson-Crick edge forms a single H-bond with G988’s sugar as well at 
the 2’OH.  G1015 forms a close interaction of 2.5 Å with the O2 atom of C1218 which actively 
base pairs with G987.  A1014 forms close contacts with S19, the protein associated with 
intersubunit bridges B1a667 and B1b.619  Studies observing the effects of depurination at position 
1014, either due to ricin668 or Mirabilis antiviral protein,669 demonstrate a loss of subunit 
association.  If A1014 and its contacts with S19 are important for the formation of an 
intersubunit bridge, then the disruption of G1015’s H-bond with C1218 in the G1015A mutant 
may also disrupt the bridge.  It is also possible that G1015A forms a more stable local 
conformation that is incompatible with the mobility required at the bridge site. 
 
7.5.10  G1104A 
 Residue G1104 is a universally conserved base in all three domains of life.644  It is 
located in helix 35 of the 3’ major domain which interacts heavily with protein S2.  G1104 forms 
a canonical Watson-Crick base pair with C1071 (Figure 7.26).649  This brings the backbone of 
G1104 into close contact with S2, notably residues T105, Q108, S109 and R111, all of which 
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are hydrophilic and can form interactions with the base.  C1071 makes a second, single H-bond 
with U1085 with its N4 atom, already H-bonding to G1104, and U1085’s O4.  G1094 is tilted 
towards this bond, but does not appear to interact with either base.  It is, however, highly 
conserved in eubacteria and archaea but not in eukaryotic 18S where a U is highly 
conserved.644  Similarly, C is conserved in eubacteria at position 1071 but eukarya maintain G.  
The RNA fold produced by the three-way base pair of G1104, C1071 and U1085 produces a 
junction encapsulated by ribosomal proteins S2, S3 and S5.  G1104A would necessarily abolish 
the base-pairing with C1071, perhaps having greater conformation implications for S2, S3 and 
S5 binding due to the lack of position of both bases and U1085 and G1094. 
 
Figure 7.25:  G1015 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
G1015 forms a triple stacking interaction with A1014 and A1016 in the loop of helix 33b.  The 
three bases flip out and pair with the backbones of G987 and G988 of helix 32.  The phosphate 
backbone of G1015 also interacts with H13 of S19. 
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Figure 7.26:  G1104 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
G1104 forms a Watson-Crick base pair with C1071 as part of a three member base-pairing 
interaction including U1085.  The G1104’s helix lies in proximity to three rproteins; S2, S3 and 
S5 suggesting its base-pairing is important for neighboring RNA-protein interactions. 
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Figure 7.27:  U1126 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
U1126 forms a weak stacking interaction with C1281 possibly stabilizing a local conformation for 
S9 and S10 binding. 
 
7.5.11  U1126C 
 Residue U1126 is part of the internal bulge in helix 39 in the 3’ major domain.  It is highly 
conserved in eubacteria and deleted in eukarya,644 making it an appropriate target for 
antimicrobial development.  U1126 has been found to cross-link with C1281 of helix 41.670  In 
the crystal structure of E. coli’s 16S subunit (Figure 7.27),649 the two bases form a non-planar, 
stacking interaction that does not appear to be particularly stable.  Ribosomal proteins S9 and 
S10 span both helices possibly stabilizing the interaction.  S10 appears to accomplish this 
through two arginine residues, R37 and R47 that interact with either helix.  In the crystal 
structure of T. thermophilus with all three tRNAs bound (Figure 7.28),655 a stronger and more 
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Figure 7.28:  U1126 in the crystal structure of T. thermophilus’ 30S ribosomal subunit with three 
bound tRNAs (PDB ID: 3I8G).655  Unlike in the E. coli structure, U1126 forms a stonger 
interaction with U1281 (C1281 in E. coli) as part of a series of interactions with adjacent bases 
and rprotein S10. 
 
complex interaction ties the helices together.  U1126 forms H-bonds along its Watson-Crick 
edge at O4 and N3 with a perpendicular U1281, C1281 in E. coli, at its N3 and O2 atoms 
respectively.  Base A1280, along its Hoogsteen edge, interacts with the phosphate backbone of 
U1126 with N6 and N7 atoms.  This produces a knot, tying the two helices together.  Adjacent 
base, U1125, is flipped out of helix 39 and positioned by the preceding interactions to form an 
H-bond on its O4 with the R5 residue of S10.  Residue K7 of S10 forms an H-bond with the O4 
atom of U1281, likely possible due to positioning by the base pairing with U1126.  All three 
uracils are highly conserved;644 E. coli is one of 5% of bacterial 16S rRNAs with C1281, except 
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for the 18S of eukaryotes where each is deleted.  The mutation U1126C would completely 
disrupt the base-pairing with U1281, breaking the pseudoknot between helix 39 and 41.  What 
occurs in E. coli is difficult to discern given that 1281 is C, not U, as in T. thermophilus. 
 
7.5.12  A1163U 
 Residue A1163 is located in the stem of helix 40 and is entirely exposed at the soluble 
surface of the 16S subunit.  There is moderate conservation for G across all domains of life, but 
E. coli is among 10.8% of eubacteria with an A.644  A1163 forms a canonical Watson-Crick base 
pair with its opposing base in the helix, U1173 (Figure 7.29).649  A similar base pair is observed 
in T. thermophilus with a G-C pair.655  A1163 does not appear to make contact with any other 
molecules.  U1173’s phosphate backbone makes a distant contact with residue R4 of S7, 
perhaps its only contact with helix 40.  The loop of helix 40 forms a triple stack among 
adenosines 1167, 1169 and 1170 with U1168 flipped out away from the ribosome.  A1169 of the 
triple stack appears to form an H-bond with the phosphate backbone of G1089 of helix 37 along 
its Watson-Crick edge.  U1159 is flipped out of helix 40 prior to the A1163-U1173 base pair and 
juts towards U1173 without forming any interaction.  U1159 has been indicated as a tetracycline 
binder671 within the pairing of bases C1162-G1164 and G1172-G1174 in the midst of which is 
A1163.  The stem and loop of helix 40 may serve some greater function not yet fully 
understood, but due to the variation seen, especially in T. thermophilus, leads one to the 
conclusion that base-pairing between 1163 and 1173 is preserved and not the identity of the 
bases.  A1163U likely impartially disrupts this base pair, perhaps making S7’s binding site 
inaccessible or shifting the helix 40 loop away from its contact with helix 37. 
 
579 
 
 
 
 
Figure 7.29:  A1163 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
A1163 Watson-Crick base pairs with U1173 as one of the closing base pairs of the loop of helix 
40, the bases of which, A1167, A1169 and A1170, flip out forming a triple stacking interaction 
and a possible interaction with helix 37.  Base-pairing partner U1173 may also interact with R4 
of S7. 
 
7.5.13  G1241U 
 Residue G1241 is universally conserved among all three domains of life.644  It resides at 
the base of the stem of helix 41 in the 3’ major domain.  G1241 forms a canonical Watson-Crick 
base pair with C1296 forming the closing base pair of helix 41 (Figure 7.30).649  The base of 
helix 41 is beset on either side with ribosomal proteins, S7 and S13.  C1296’s phosphate 
backbone makes a possible H-bond with the ring nitrogen of H13 of S13.  The base adjacent to 
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G1241 in the internal loop that spawns helices 29, 30, 41, and 42, U1240, is flipped out from the 
loop.  The base is buried in a pocket formed by protein S7 with numerous potential contacts.  
The dissolution of the closing base pair of helix 41, as in the mutant G1241U, could greatly 
impact the local conformation.  The ramifications include the disruption of C1296’s contact with 
S13 and shifting of U1240 out of the S7 pocket.  The phylogenetic data indicates the identity of 
G1241 is preserved,644 but it may be possible to maintain the interaction with a C-G, A-U, or U-A 
base pair at positions 1241 and 1296. 
 
 
Figure 7.30:  G1241 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
The base forms a Watson-Crick base pair with C1296 possibly positioning it and G1241’s 
adjacent base, U1240, for protein interactions with S13 and S7, respectively 
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7.5.14  U1406C 
 Residue U1406 lies in the highly conserved helix 44 that plays a critical role in the 
formation of the decoding region where A site tRNA binds to codons of the mRNA being 
translated.  The base itself is also universally conserved.644  With tRNAs bound at all sites of the 
T. Thermophilus ribosome, U1406 makes one H-bond between its O4 atom and opposing base 
U1495’s N3 atom (Figure 7.31).655  This makes U1406’s backbone face the A and P site tRNAs.  
U1406 has been indicated as a target for antibiotic aminoglycoside binding672 and the mutant 
U1406A in cell viability and aminoglycoside resistance.673  The viability of a U1406A mutant 
indicates that a stronger base pairing interaction does not impair ribosome function.674  Cytosine 
in the U1406C mutant would make similar H-bonds as adenosine, but this interaction may 
require a shift in the base provided by the greater size of the purine. 
 
Figure 7.31:  U1406 in the crystal structure of T. thermophilus’ 30S ribosomal subunit with three 
bound tRNAs (PDB ID: 3I8G).655  U1406 forms a weak base pair with U1495 in an interaction 
universally conserved and critical for the decoding region. 
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7.5.15  A1492G & A1493G 
 The importance of bases A1492 and A1493 in decoding the mRNA in conjunction with 
the 530 loop is well documented.  In the study demonstrating the proofreading mechanism of 
both adenines at positions 1492 and 1493, mutations to guanines were detrimental.675  These 
effects were overcome by the modification of the mRNA backbone with 2’ fluorine substitutions.  
Both bases form transient H-bonds with the bases involved in the codon-anticodon base pairing 
at sites other than their Watson- Crick edge (Figure 7.32).655  If the incorrect or non-cognate 
tRNA binds to the A site codon, the geometry of the mRNA’s backbone does not present the 
correct hydrogen bond donor and acceptors to satisfy interactions with bases G530, A1492 and 
A1493.676  In this scenario the tRNA is rejected and a subsequent tRNA is allowed to bind.  The 
proofreading function, via hydrogen bonds is continued until the correct, cognate pair is 
achieved at which point translation proceeds.  A1492G and A1493G mutants are unable to 
properly bond with the codon during decoding, preventing translation from initiating. 
 
583 
 
 
 
 
Figure 7.32:  A1492 and A1493 in the crystal structure of T. thermophilus’ 30S ribosomal 
subunit with three bound tRNAs (PDB ID: 3I8G)655 with mRNA bases highlighted in black.  Both 
bases are universally conserved and form critically important interactions with bases of the 
mRNA, proofreading the interaction between the mRNA and incoming A site tRNAs. 
 
7.5.16  G1497A 
 Residue G1497 is also located in helix 44 close to the decoding region.  It is universally 
conserved in all domains of life.644  G1497 makes a canonical Watson-Crick base pair with base 
C1404 (Figure 7.33).649  Prior studies have suggested that preservation of the base pair and not 
identity of the bases is important for ribosome function.677  The sugar of G1497 appears to make 
H-bonds with both bases G791 and m62A1518 (Figure 7.34).655  G791 is part of the highly 
conserved 790 loop that makes a series of interactions along the backbone of helix 44 in the 
vicinity of G1497.  m62A1518 is one of two, universally conserved, dimethyl adenine modified 
bases that have not been demonstrated to be essential for ribosome function.678  Studies 
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suggest more interactions for G1497 due to protection of its N7 atom upon binding of tRNA639 
and mRNA679 and positioning near the mRNA in an E. coli crystal structure.649  This may be 
related to the base’s proximity to the P site tRNA, as seen in the crystal structure of T. 
thermophilus.655  A correctly positioned G1497 is necessary for the localization of helix 31 
(G791) and 43 (m62A1518).  G1497A would produce an A-C interaction which would deposition 
1497 and subsequently G791 and m62A1518. 
 
 
Figure 7.33:  A1497 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
The universally conserved base forms a Watson-Crick base pair with C1404 as a critical part of 
the decoding region.  Its sugar’s proximity to G791 and m62A1518 indicate potential, interactions 
dependent on positioning through the base pair with C1404. 
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Figure 7.34:  A1497 in the crystal structure of T. thermophilus’ 30S ribosomal subunit with three 
bound tRNAs (PDB ID: 3I8G).655  A1497’s sugar’s proximity to G791 and m62A1518 indicates 
potential interactions dependent on positioning through the base pair with C1404.. 
 
7.5.17  A1502G 
 Residue A1502 is located near the decoding region of the 16S subunit in helix 44 of the 
3’ minor domain and is universally conserved.644  The base forms one hydrogen bond on its 
Hoogsteen edge with G1505’s Watson-Crick interface (Figure 7.35).649  This is part of a triple 
base pair wherein G1505 forms a second H-bond with G1504.  G1504 also makes a canonical 
Watson-Crick base pair with C1399 allowing adjacent base C1400 to flip out and form a critical 
interaction with the anticodon of the A site tRNA.  Other, neighboring interactions include the 
stacking of G1505 and G926 and the Hoogsteen-sugar single H-bond between A1502 adjacent 
base, A1503, and G927.  Together these interactions form a knot localizing helix 28 to the 
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decoding region.  The single hydrogen bond of A1502 with G1505 indicates a need for mobility 
among the bases supported by the importance of C1400’s interaction with the P/E hybrid state 
tRNA.680  The mutation A1502G would not disrupt the interaction with G1505 on its Hoogsteen 
edge, but may reposition C1400 or A1503 by forming a more stable bond that freezes the local 
conformation when mobility is necessary. 
 
Figure 7.35:  A1502 in the crystal structure of E. coli’s 30S ribosomal subunit (PDB ID: 2I2P).649  
A1502, with its adjacent bases, forms a series of interactions critical for formation of the 
decoding region leading to an interaction with G926. 
 
7.5.18  Conclusion 
Of the 24 isolated non-functional mutants isolated, A607G, A608G, A609G, G1015A, 
U1126C, and A1163U have identified potential targets for the development of anti-infectives 
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based on their lack of conservation or deletion in eukaryotic 18S RNAs.  By designing 
molecules that can bind to elements of these six bases it may be possible to selectively disrupt 
bacterial translation similar to the aminoglycoside and tetracycline antibiotics.  However, a 
common resistance mechanism of ribosome-targeting antibiotics employs mutations of reduced 
ribosome function with a lowered binding affinity for the antibiotic.67  In the presence of the 
antibiotic these reduced-function mutants would be able to grow and possibly develop or adapt 
more efficient resistance mechanisms.681; 682  Thus, it is important to note that these mutations 
represent only one possible mutation out of three, the mutant A607G was isolated as a non-
functional mutant but this does not necessarily mean that A607U or A607C are likewise non-
functional.  The goal of this selection was to identify non-functional mutants of the 16S RNA, but 
previous studies using the Cunningham laboratory system have emphasized ‘instant 
evolution’633; 683; 684; 685; 686 or the identification of nucleotides whose identity is critical for 
ribosome function.  Therefore, further site-directed mutagenesis studies of the six bases 
identified is necessary to determine if the two other possible mutations (ex. A607C and A607U) 
are not functional as well before fully assessing the value of the nucleotides as anti-infective 
targets. 
 
7.6 Materials & Methods 
7.6.1 Bacterial Strains & Media 
 All experiments were carried out in E. coli DH5 (supE44, hsdR17, recA1, endA1, gyrA96, 
thi-1, relA1).  For the isolation of unmethylated plasmid DNA, E. coli ER2925 cells (ara-14, 
leuB6, fhuA31, lacY1, tsx78, glnV44, galK2, galT22, mcrA, dcm-6, hisG4, rfbD1, 
R(zgb210::Tn10)TetS, endA1, rpsL136, dam13::Tn9, xylA-5, mtl-1, thi-1, mcrB1, hsdR2), 
obtained from New England BioLabs, Inc. (Ipswich, MA) were employed.  Clones were grown 
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and maintained in Luria-Bertani (LB) medium containing 100 µg/mL ampicillin (LB-Amp100).  To 
induce plasmid-encoded ribosomes from the PLac promoter isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to the culture at a final concentration of 1 mM.  
Induction times are indicated in the individual methods outlined later.  Transformations were 
carried out via electroporation at 2.44 kV with electro-competent cells prepared beforehand and 
stored at -80 oC.  Transformed cells were recovered in SOC medium for 1 hour without 
antibiotics prior to either plating on solid media or selection. 
 
7.6.2 Enzymes & Reagents 
 Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs Inc. 
(Ipswich, MA).  Restriction enzymes were also ordered from Fermentas (a division of Thermo 
Fisher Scientific Inc., Glen Burnie, MD).  Oligonucleotides, for use as primers in polymerase 
chain reactions (PCRs) were purchased from Integrated DNA Technologies Inc. (Coralville, IA).  
Choice-Taq™ DNA polymerase and PCR reagents were obtained from Denville Scientific Inc 
(Metuchen, NJ).  DNA polymerase, dideoxynucleotide mixtures and sequencing buffers 
(SequiTherm Excel™ II DNA sequencing kit) were obtained from Epicentre Biotechnologies (a 
division of Illumina, Inc., Madison, WI).  Sequencing primers for use with the LI-COR 
Biosciences Sequencer 4000L, oligonucleotides bound at the 5’ end to either 700 or 800 
IRDye®, were ordered from Integrated DNA Technologies Inc. (Coralville, IA).   
 
7.6.3 Mutant 16S rDNA Library Construction 
 Purified pWK122, a laboratory plasmid containing 16S rDNA, was used as a template in 
a PCR reaction with oligonucleotides 16SR and 16SF (Table 7.2).  The primers are 
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complimentary to DNA at either end of the 16S rDNA including native, restriction enzyme 
recognition sequences BclI and BstEII (Fermentas: Eco911).  Taq polymerase, which lacks 3’ to 
5’ proofreading ability resulting in a nucleotide mis-incorporation rate of 1 per 9,000 bases, was 
used for the production of the 16S rDNA mutant pool.  Ninety-six, 5 µL reactions were carried 
out in wells of a 96-well plate to limit early mutations from dominating the mutant pool.  The 
reactions were pooled and purified via gel electrophoresis.  The products and the plasmid 
pRNA228 were digested with restriction enzymes BclI and BstEII.  The desired DNA fragments 
were isolated and cleaned using gel electrophoresis and ligated to form a mutant 16S rDNA 
library in pRNA228. 
 
7.6.4 Non-Functional 16S rRNA Mutant Selection Procedure 
 pRNA228 plasmids containing the mutant 16S rDNA pool were transformed into E. coli 
DH5 electro-competent cells via electroporation.  The cells were recovered in 1 mL of SOC 
medium for 15 minutes and plated on solid LB-Amp100 media, appropriately diluted to get 
isolated colonies, and incubated at 37 oC overnight.  Colonies were replica plated onto solid LB-
Amp100 + 1 mM IPTG and incubated at 37 oC for 6 hours to allow for induction of plasmid-
encoded ribosomes and subsequent production of chloramphenicol acetyltransferase (CAT).  
The colonies were replica plated a second time onto solid LB-Amp100 + 1 mM IPTG, 75 µg/mL 
chloramphenicol and LB-Amp100 plates and incubated overnight at 37 oC.  The concentration of 
chloramphenicol (75 µg/mL) was selected based on assays of 16S mutants of known function 
based on GFP assays for the selection of mutants with 0-10% function compared to WT.  
Colonies that failed to grow or grew weakly on LB-Amp100 + 1 mM IPTG, 75 µg/mL plates were 
selected for further analysis. 
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7.6.5 DNA Sequencing 
 Isolated clones were sequenced using a two-step process.   Overnight cultures were 
grown in 3 mL of LB-Amp100.  Plasmid DNA was purified from the culture by a standard 
alkaline lysis miniprep procedure.  The purified plasmid DNA was used as a template in a series 
of initial PCR reactions using one of two groups of oligonucleotides as primers whose products 
encompassed the entire 16S rDNA (Figure 7.36).  The first group of oligonucleotides required 
four separate PCR reactions for each clone comprising 4 pairs of primers.  The pairs included: 
16Set 1A JSL2 800/16Set 1B JSL 700, 16Set 3A JSL2 800/16Set 2B JSL 700, 16Set 5A JSL2 
800/16Set 4.3B JSL 700, and 16Set 6A JSL2 800/16Set 6B JSL 700 (Table 7.2). A second 
group of oligonucleotides encompassing four pairs also generated products spanning the 
 
Figure 7.36:  Sequencing primers used in the sequencing of the entire 16S rDNA of isolated 
mutated clones and their relative positions. 
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entire 16S rDNA and were used as confirmation of DNA sequences obtained using the former 
group of primers.  These included:  P1A 16S pRNA228 800/P1B 16S pRNA228 700, P2A 16S 
pRNA228 800/P2B 16S pRNA228 700, P3A 16S pRNA288 800/P3B 16S pRNA228 700 (Table 
7.2).  Primers labeled 700 or 800 have a 5’ end that is complimentary to 5’ IRDye®-labeled 
primers JSL or JSL2 (Table 7.2), respectively.   
The products of the initial reactions were incorporated with JSLF and JSL2-
complimentary tails on either end using Taq polymerase.  The 25 µL product was then diluted in 
170 µL dH2O and used as a template in a sequencing reaction employing dideoxynucleotide 
mixes and 5’ IRDye®-labeled primers, JSLF and JSL2 (Table 7.2).  The labeled primers bind 
their respective complimentary tail sequences permitting high-throughput sequencing. 
 
 
Table 7.2:  DNA sequences of the oligonucleotides used in this study. 
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7.6.6 GFP Assays of 16S Mutants 
 Two procedures were used for assaying the function of mutant ribosomes via the 
production of green fluorescent protein (GFP).  When low function mutants, according to 
chloramphenicol sensitivity, were initially isolated, a high-throughput method employing 96-well 
plates was utilized.  Clones were incubated at 37 oC overnight with shaking in 200 µL of LB-
Amp100 in a GeneMachines HiGro® 96-well plate incubator from Digilab, Inc. (Holliston, MA).  
Cultures were diluted 1 to 100 by adding 2 µL to 200 µL of fresh LB-Amp100 + 1 mM IPTG 
medium.  These cultures were incubated at 37 oC for 24 hours.  The 96-well plate was 
centrifuged at 2000 x g to pellet the cells.  The supernatant was removed, and the cells were 
washed twice in 200 µL of HEPES-NaCl (HN) buffer (20 mM HEPES, 150 mM NaCl pH 7.4).  
The cells were resuspended in 200 µL of HN buffer and 200 µL aliquots were assayed for the 
amount of GFP produced using a SpectraMax Gemini XPS 96-well plate fluorometer (excitation: 
395 nm, emission: 509 nm).  To normalize GFP levels to other clones, the fluorescence of each 
clone was divided by the optical density at 600 nm as measured by a SpectraMax 190 from 
Molecular Devices, Inc. (Sunnyvale, CA).  The percent function of each mutant was 
approximated by comparison to WT 16S rDNA in a non-mutated pRNA228 clone. 
 During clone confirmation, GFP assays were repeated using larger culture volumes.  
Cultures of each clone were incubated overnight in 3 mL of LB-Amp100 media.  The cultures 
were diluted 1 to 100 by adding 30 µL to 3 mL of fresh LB-Amp100 + 1 mM IPTG and incubated 
at 37 oC with shaking for 24 hours.  Five hundred µL samples of each clone were centrifuged at 
11,000 rpm to pellet the cells.  The supernatant was removed and the cells were washed twice 
with 500 µL of HN buffer.  The cell were resuspended in 500 µL of HN buffer and 200 µL were 
assayed for optical density at 600 nm, on a SpectraMax 190 from Molecular Devices, Inc. 
(Sunnyvale, CA), and GFP fluorescence, on a SpectraMax Gemini XPS (excitation: 395 nm, 
emission: 509 nm) 96-well plate fluorometer.  To normalize GFP values across the clones, the 
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fluorescence was divided by the optical density.  Percent function of each clone was 
approximated by comparison to a WT 16S rDNA clone represented by pRNA228. 
 
7.6.7 Clone Confirmation 
 The isolation of false negatives is a possibility during the use of a negative selection 
scheme.  Clones that lack ribosome function may arise due to mutation of the CAT gene or PLac 
promoter or the incorporation of the WT Shine-Dalgarno sequence in the plasmid-encoded 16S 
rDNA instead of the mutated one used in the Cunningham laboratory system.  To confirm that 
the lack of function arises from mutations solely in the 16S rDNA, each 16S gene for the 
isolated clones was removed and placed into fresh pRNA228 vectors with no mutations.  This 
was accomplished by moving purified plasmid DNA of each clone into E. coli ER2925 (dam-, 
dcm-) cells via chemical transformation.  Cultures of each clone were grown overnight in 3 mL 
LB-Amp100 at 37 oC with shaking.  Plasmid DNA was purified from each culture using a 
standard alkaline lysis miniprep procedure.  Purified plasmid was digested with restriction 
enzymes BclI and BstEII to excise the 16S rDNA from the original plasmids.  The plasmid 
pRNA228 was similarly digested.  All digestion products were run on agarose gels to clean and 
isolate the desired DNA fragments.  Mutant 16S rDNAs were then ligated into fresh pRNA228 
vector and confirmed by DNA sequencing.  Each clone was re-assayed for ribosome function by 
quantifying the amount of GFP produced. 
594 
 
 
 
CONCLUSION 
We have successfully implemented a high-throughput, in vivo screen for the 
identification of antimicrobial peptides, IVD, without prior knowledge of relevant targets, by 
isolating a total of 333 antimicrobial peptides.  Each IVD derivative system has yielded 
antimicrobial peptides of varying amino acid sequence including, 39 peptides from cIVD 
(Chapter 2), 5 peptides from nIVD (Chapter 3), 191 peptides from pIVD (Chapter 4); and from 
the subsequent, periplasmic peptide isolations, 82 peptides were isolated via the constrained 
peptide screen (Chapter 5) and 16 peptides were rationally designed or derived from peptide 
EO1 (Chapter 6). 
 Three peptides isolated from the pIVD system and its derivatives, PL098, 84 Pro- and 
EO1, were further characterized to elucidate their antimicrobial mechanisms and activity.  
Peptide 84 Pro-, a representative of the α-helical model peptides, has a dissimilar distribution of 
hydrophobic and basic residues in comparison to PL098 and EO1.  Analysis of 84 Pro-‘s activity 
in the cytoplasm, lack of PhoA activity, suggesting it does not translocate into the periplasm, 
and the negation of its activity in hypertonic growth medium suggest that it targets the Sec 
pathway, inhibiting the translocation of essential periplasmic proteins, resulting in cell lysis.  
Peptide EO1, however, differed in several respects.  It demonstrated PhoA activity, as did 
peptide PL098.  It is bactericidal with a secondary lytic effect, but fully lysed a growing culture of 
the Gram-positive bacterium, S. aureus.  Peptide EO1 is not inhibitory when expressed in the 
cytoplasm, suggesting a periplasmic target, not the inner membrane or the Sec pathway, and 
growth in hypertonic growth medium did not negate its bactericidal activity.  These data suggest 
peptide EO1’s target is involved with cell wall integrity.  Comparison of the spectra of activity 
against a number of microbes, including Gram-negative and Gram-positive bacteria and the 
eukaryote, S. cerevisiae, show significant differences in activity, strongly suggesting each of the 
three peptides have distinct mechanisms of inhibition.  Therefore, the peptides isolated using 
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IVD, besides the α-helical model peptides, are characteristically dissimilar, indicating the 
method has the potential to aid in the discovery of numerous de novo antimicrobial lead 
compounds. 
 However, these isolated peptides represent only a small portion of the potential peptides 
yet to be isolated using our in vivo display method.  The largest library we produced for 
selecting peptides, pIVD, encompassed ~1 x 109 theoretically unique peptides comprising only a 
minute fraction of a potential library of 2012 peptides for 12 randomized positions.  Thus by 
sampling a small portion of the potential sequence space we isolated 191 antimicrobial 
peptides, suggesting myriads of antimicrobial peptides, and in the case of the α-helical model 
peptides, more active peptides are yet to be isolated.  Our mutagenic ribosome assays have 
elucidated such targets that have not previously been exploited for the development of novel 
antimicrobials.  Further, size of the peptide library can be expanded beyond 12 positions to 
select for antimicrobial peptides with more complex secondary structures, exponentially 
increasing the vastness of the potential peptides to screen for activity. 
 Modifications of IVD, other than those previously described in this work, can offer new 
pools of biomolecules that have not been targeted by our libraries.  Selecting for antimicrobial 
activity in rich growth medium omits a number of metabolic pathways that are repressed.  By 
screening for activity in modified growth environments, such as minimal growth medium or 
oxygen restriction, more accurately mimicking the environment at the site of an infection,  we 
can increase the number of targets available.  It is also possible to produce IVD systems within 
other host species such as S. aureus or M. smegmatis.  While screens in these hosts would 
suffer reduced screening rates due to lower transformation efficiencies, they would expose more 
targets not screened against in E. coli, possibly resulting in antimicrobial leads with medically 
relevant activities against phylogentically distinct Gram-positive pathogens or the causative 
agent of tuberculosis, M. tuberculosis. 
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 While the isolation of antimicrobial peptides was the goal of IVD’s conception, it is 
possible to harness it for the optimization of the peptides isolated thus far.  Through a 
combination of IVD and mutagenesis, mutagenic libraries of individual peptides, such as PL098, 
84 Pro- and EO1, could be produced and screened in vivo, optimizing their activity.  This would 
be especially pertinent for peptide optimization in bacteria other than E. coli, such as S. aureus 
or M. smegmatis, to produce narrow spectrum derivatives of the peptides.  This scheme could 
also be used to increase membrane permeability of a peptide lacking exogenous activity.  A 
peptide, isolated from the cytoplasmic selections, would be placed C or N-terminal to a 
randomized region and inserted into the pIVD system for free peptide expression in the 
periplasm.  IVD could then be used to identify C or N-terminal amino acid sequences that 
facilitate the peptide’s passage back into the cytoplasm, killing the cell. 
 The problem of cell penetration and solubility could also be addressed by testing 
mutagenic derivatives of the peptides, replacing hydrophobic residues with polar residues to 
increase solubility or through the incorporation of additional residues at either terminus.  Another 
remedy is the production of hybrid peptides, covalently joining a peptide lacking exogenous 
activity to either a peptide demonstrating cell penetration and solubility, such as 84 Pro-, or a 
natural, antimicrobial peptide known to penetrate bacterial cells.  The utilization of hybrid 
peptides would not only address permeability concerns, but also decrease the likely hood of 
resistance by requiring a particular cell to have resistance to both peptide moieties to survive. 
 The development of antimicrobial leads from our isolated peptides requires further 
characterization.  Toxicity of the peptides against higher-order eukaryotic cells can be achieved 
by assaying activity against human cell lines or in animal models.  If a peptide is found to have 
undesirable toxic effects it is possible to produce mutagenic variants and re-assay for activity in 
bacterial and eukaryotic species.  Understanding the potential of a peptide as a lead compound 
can be furthered by identification of its target and examining the target’s conservation among 
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eukaryotes.  Ultimately, our goal is to produce lead compounds that can be used commercially 
for the reduction of bacterial populations, regardless of narrow or broad-spectrum activity.  
Peptides having suitable antimicrobial activity, but undesirable toxicity may find use in industrial 
or non-human settings.  Peptides with reduced toxicity may be utilized for medical purposes 
depending on both their pharmacological characteristics and our ability to mitigate them.  
Peptides with poor absorption or toxicity could be developed as topical antimicrobials after 
determining that they do not elicit strong immunogenic responses.  Developing the peptides for 
use in the treatment of systemic infections would likely necessitate peptidomimetics to limit 
adverse effects such as, clearing of the peptide, tissue permeability, immunogenic responses 
and proteolytic degradation.  Minimization of peptide size to the antimicrobial motif can lower 
conflicts with the immune system and incorporation of D-analog amino acids, modified peptide 
backbones and chemical modifications can decrease degradation.  It is also possible to develop 
small molecule analogs based on the peptide’s molecular characteristics, but this process would 
require identification of the target and how it interacts with the peptide. 
 As a nascent technology, IVD has thus far proven to be successful in the discovery of 
antimicrobial peptides with numerous, potential pathways for further development.  Future 
selections will yield exponentially more antimicrobial leads, but its ultimate success will rely on 
the development of current potential leads, such as PL098, 84 Pro- and EO1, as commercially-
viable antimicrobials. 
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ABSTRACT 
IN VIVO DISPLAY:  A SELECTION AND ITS DERIVATIVES FOR ANTIMICROBIAL PEPTIDE 
LEAD IDENTIFICATION. 
by 
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August 2012 
Advisor: Dr. Philip R. Cunningham 
Major:  Biological Sciences 
Degree: Doctor of Philosophy 
The rise of antibiotic resistance necessitates new approaches for the isolation of new 
antimicrobials with novel inhibitory mechanisms, bypassing the development of rapid resistance 
by modification of pre-existing resistance mechanisms.  In response, we have developed a 
series of systems for the rapid isolation and identification of peptides that inhibit the growth of 
Escherichia coli and other bacteria, termed in vivo display (IVD).   
 IVD harnesses the cellular processes of E. coli for the expression of a library of random 
peptides at the terminus of a display protein.  A library of 12-amino acid random peptide 
sequences was added to either the C- or N-terminus of Emerald Green Fluorescent Protein 
(EmGFP) for the isolation of peptides active in the cytoplasm or the N-terminus of Alkaline 
Phosphatase (PhoA) for the isolation of peptides active in the periplasm.  The peptide-display 
protein fusions were encoded behind an inducible promoter on plasmid vectors.  A high-
throughput method was implemented to select for peptides that inhibit bacterial growth followed 
by replica plating to confirm their efficacy. 
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 To date, we have isolated 322 peptides that inhibit the growth of E. coli, exhibiting a 
number of growth phenotypes including bacteriolytic, bacteriostatic, bactericidal and growth rate 
reducing or weakly inhibitory.  The cytoplasmic selection, in which the peptide library is fused to 
the C-terminus (cIVD) or the N-terminus (nIVD) of EmGFP produced 39 and 5 peptides, 
respectively.  Of the 39 peptides isolated using the cIVD system, one is bacteriolytic, 18 are 
bacteriostatic/bactericidal and 20 are weakly inhibitory.  Similarly, two of the peptides isolated 
using the nIVD system are bacteriostatic/bactericidal and three are weakly inhibitory.  The 
periplasmic in vivo display (pIVD) system yielded a total of 192 growth-inhibiting peptides, 
including 53 bacteriostatic/bactericidal, 44 weakly inhibitory and 95 bacteriolytic peptides.  
Further characterization of the isolated bacteriolytic peptides revealed that 75 of them share 
common sequence elements, suggesting that they share a common target.  Based on the 
amino acid distribution of all the bacteriolytic peptides isolated using pIVD, a constrained 
peptide library enriched for the observed sequence elements was generated and screened 
isolating nine bacteriostatic/bactericidal, four weakly inhibitory and 68 bacteriolytic peptides.  
Further, using a rational approach, we successfully designed a series of peptides based on the 
phenotypic groupings of the bacteriolytic peptides yielding one weakly inhibitory and four 
bacteriolytic peptides. 
 Select peptides were analyzed for activity against a variety of micro-organisms including 
Gram-negative and Gram-positive bacteria and yeast when added exogenously to live cultures.  
Three of the peptides, PL098, 84 Pro- and EO1, exhibit different spectra of activity, suggesting 
distinct targets and/or antimicrobial mechanisms that were examined by comparing cell 
morphologies, growth in hypertonic growth media and PhoA activity assays.  The ultimate 
isolation of antimicrobial peptides from IVD and its derivatives demonstrates proof of principle 
that IVD is an efficient method of the further isolation of antimicrobial peptides and their 
characterization for the development of therapeutic anti-infectives.  
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